"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtAU_IN","meanArtPer_AU_IN_FIRST","meanArtPer_AU_IN_LAST","meanArtPer_AU_IN_CORR","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","InternCoauthorship","AffCoauthorship","meanCitationTrend","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","medianAltmetricScore","altmetric_score_mean_top25AltmScore","altmetric_score_min_top25AltmScore","altmetric_score_max_top25AltmScore","cited_by_accounts_count_mean_top25AltmScore","cited_by_accounts_count_min_top25AltmScore","cited_by_accounts_count_max_top25AltmScore","cited_by_fbwalls_count_mean_top25AltmScore","cited_by_fbwalls_count_min_top25AltmScore","cited_by_fbwalls_count_max_top25AltmScore","cited_by_feeds_count_mean_top25AltmScore","cited_by_feeds_count_min_top25AltmScore","cited_by_feeds_count_max_top25AltmScore","cited_by_gplus_count_mean_top25AltmScore","cited_by_gplus_count_min_top25AltmScore","cited_by_gplus_count_max_top25AltmScore","cited_by_msm_count_mean_top25AltmScore","cited_by_msm_count_min_top25AltmScore","cited_by_msm_count_max_top25AltmScore","cited_by_patents_count_mean_top25AltmScore","cited_by_patents_count_min_top25AltmScore","cited_by_patents_count_max_top25AltmScore","cited_by_peer_review_sites_count_mean_top25AltmScore","cited_by_peer_review_sites_count_min_top25AltmScore","cited_by_peer_review_sites_count_max_top25AltmScore","cited_by_policies_count_mean_top25AltmScore","cited_by_policies_count_min_top25AltmScore","cited_by_policies_count_max_top25AltmScore","cited_by_posts_count_mean_top25AltmScore","cited_by_posts_count_min_top25AltmScore","cited_by_posts_count_max_top25AltmScore","cited_by_rdts_count_mean_top25AltmScore","cited_by_rdts_count_min_top25AltmScore","cited_by_rdts_count_max_top25AltmScore","cited_by_rh_count_mean_top25AltmScore","cited_by_rh_count_min_top25AltmScore","cited_by_rh_count_max_top25AltmScore","cited_by_tweeters_count_mean_top25AltmScore","cited_by_tweeters_count_min_top25AltmScore","cited_by_tweeters_count_max_top25AltmScore","cited_by_videos_count_mean_top25AltmScore","cited_by_videos_count_min_top25AltmScore","cited_by_videos_count_max_top25AltmScore","cited_by_wikipedia_count_mean_top25AltmScore","cited_by_wikipedia_count_min_top25AltmScore","cited_by_wikipedia_count_max_top25AltmScore","cohorts.com_mean_top25AltmScore","cohorts.com_min_top25AltmScore","cohorts.com_max_top25AltmScore","cohorts.doc_mean_top25AltmScore","cohorts.doc_min_top25AltmScore","cohorts.doc_max_top25AltmScore","cohorts.pub_mean_top25AltmScore","cohorts.pub_min_top25AltmScore","cohorts.pub_max_top25AltmScore","cohorts.sci_mean_top25AltmScore","cohorts.sci_min_top25AltmScore","cohorts.sci_max_top25AltmScore","readers.citeulike_mean_top25AltmScore","readers.citeulike_min_top25AltmScore","readers.citeulike_max_top25AltmScore","readers.connotea_mean_top25AltmScore","readers.connotea_min_top25AltmScore","readers.connotea_max_top25AltmScore","readers.mendeley_mean_top25AltmScore","readers.mendeley_min_top25AltmScore","readers.mendeley_max_top25AltmScore","readers_count_mean_top25AltmScore","readers_count_min_top25AltmScore","readers_count_max_top25AltmScore","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internazionali","avg_ResultingPublications_per_grant","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","nClTrial_w_AltmScore","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n"
"IRCCS_CAGRANDA",2000,194,6.79896907216495,2.34020618556701,0.427312775330396,0.396907216494845,0.391752577319588,0.134020618556701,0.144329896907216,14,85,23,7,68,0.44,0.12,0.04,0.35,39.89,0.88001085948512,0.180412371134021,0.907216494845361,0,0.409507382798573,0.339961802044714,0.386973180076628,0.344615384615385,"MARIA DOMENICA CAPPELLINI;LUCA BALDINI;FABIO PARAZZINI;GIACOMO P. COMI;FLORA PEYVANDI;PIER MANNUCCIO MANNUCCI;G. SCARLATO;G. FIORELLI;DARIO TAVAZZI;ALBERTO ZANCHETTI;PAOLO PELOSI;ELIO SCARPINI;ALBERTO ZANELLA;G. FAGLIA;ANTONINO NERI;NEREO BRESOLIN;SILVIA FARGION;LUCIANO GATTINONI;ANNA TERESA MAIOLO;M. LANDONI","9;8;6;6;6;6;6;6;5;5;4;4;4;4;4;4;4;4;4;3","FLORA PEYVANDI;PIER MANNUCCIO MANNUCCI;MARIA DOMENICA CAPPELLINI;ALBERTO ZANCHETTI;BRUNO PINAMONTI;ELENA SANTAGOSTINO;ANNA LUDOVICA FRACANZANI;CARLO VERGANI;R. CAPUTO;ALBERTO ZANELLA;ALBERTO TERZI;MARCO LOCATELLI;CITIC HEAVY;STEFAN PIZZI;PIER MANNUCCIO MANUCCI;DARIO LAQUINTANA;CARLO AGOSTONI;A.C. ALTAMURA;G. FIORELLI;DARIO TAVAZZI","1.91;1.82;1.5;1.48;1.33;1.25;1.24;1.1;1.03;1.01;1;1;1;1;1;1;1;1;0.95;0.85","MARIA DOMENICA CAPPELLINI;LUCA BALDINI;FABIO PARAZZINI;GIACOMO P. COMI;FLORA PEYVANDI;PIER MANNUCCIO MANNUCCI;G. SCARLATO;ALBERTO ZANCHETTI;PAOLO PELOSI;ELIO SCARPINI;ALBERTO ZANELLA;G. FAGLIA;ANTONINO NERI;NEREO BRESOLIN;SILVIA FARGION;LUCIANO GATTINONI;ANNA TERESA MAIOLO;GIULIANA MUTI;NICOLA BOTTINO;ANNA LUDOVICA FRACANZANI","9;8;6;6;6;6;6;5;4;4;4;4;4;4;4;4;4;3;3;3","FLORA PEYVANDI;PIER MANNUCCIO MANNUCCI;MARIA DOMENICA CAPPELLINI;ALBERTO ZANCHETTI;BRUNO PINAMONTI;ELENA SANTAGOSTINO;ANNA LUDOVICA FRACANZANI;CARLO VERGANI;ALBERTO ZANELLA;ALBERTO TERZI;MARCO LOCATELLI;CITIC HEAVY;STEFAN PIZZI;PIER MANNUCCIO MANUCCI;DARIO LAQUINTANA;CARLO AGOSTONI;A.C. ALTAMURA;LUCA BALDINI;G. FAGLIA;LUCIANO GATTINONI","1.91;1.82;1.5;1.48;1.33;1.25;1.24;1.1;1.01;1;1;1;1;1;1;1;1;0.78;0.77;0.76","GIACOMO P. COMI;FABIO PARAZZINI;AIJA KYTTÄLÄ;ANU SUOMALAINEN;JUKKA K. JUSELIUS;JYRKI KAUKONEN;LEENA PELTONEN;MASSIMO ZEVIANI;SIRKKA KERÄNEN;VALERIA TIRANTI;ANGELA BORTOLOTTI;ENRICO COLLI;M LAVEZZARI;M. LANDONI;FRANCESCO RODEGHIERO;ALOK SRIVASTAVA;DAVID GINSBURG;DOMINIQUE MEYER;ERIK BERNTORP;I. R. PEAKE","884;845;620;620;620;620;620;620;620;620;603;603;603;603;572;563;490;490;490;490","GIACOMO P. COMI;FABIO PARAZZINI;P.M. MANNUCCI;PIER MANNUCCIO MANNUCCI;LUCIANO GATTINONI;A. PEDOTTI;ANDRÉA ALIVERTI;DAVIDE CHIUMELLO;PAOLO PELOSI;RAFFAELE L. DELLACÁ;ALBERTO ZANCHETTI;LUCA BALDINI;NEREO BRESOLIN;ANDREA ROSSI;A. MAROCCHI;GIANNI CASELLA;L PRENCIPE;MARTA LANZANI;SERGIO ARLATI;SERGIO BRENNA","884;845;490;399;343;296;296;296;296;296;295;293;262;253;230;230;230;230;230;230","MARIA DOMENICA CAPPELLINI;LUCA BALDINI;PIER MANNUCCIO MANNUCCI;GIACOMO P. COMI;FABIO PARAZZINI;NEREO BRESOLIN;ALBERTO ZANCHETTI;ELIO SCARPINI;G. SCARLATO;LUCIANO GATTINONI;SILVIA FARGION;ELENA SANTAGOSTINO;FLORA PEYVANDI;NICOLA BOTTINO;ANNA LUDOVICA FRACANZANI;ANTONINO NERI;LORENA DUCA;A. CAPPELLARI;A. TEDESCHI;ALESSANDRA BARDONI","9;7;7;6;6;4;4;4;4;4;4;3;3;3;3;3;3;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PSYCHOLOGY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY;ART;BUSINESS;MATERIALS SCIENCE;PHILOSOPHY;ECONOMICS;GEOGRAPHY;HISTORY","174;62;21;17;15;11;10;8;4;3;2;2;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;GENETICS;IMMUNOLOGY;PATHOLOGY;ENDOCRINOLOGY;BIOCHEMISTRY;CARDIOLOGY;GASTROENTEROLOGY;ANESTHESIA;PSYCHIATRY;RADIOLOGY;MOLECULAR BIOLOGY;INTENSIVE CARE MEDICINE;DERMATOLOGY;ENVIRONMENTAL HEALTH;ANATOMY;CANCER RESEARCH;PEDIATRICS;MECHANICAL ENGINEERING","121;46;44;41;39;29;23;23;22;17;17;16;15;13;11;11;10;10;9;8","GENE;DISEASE;PLATELET;ANTIBODY;TRANSPLANTATION;CANCER;POPULATION;HORMONE;BLOOD PRESSURE;LUNG;LYMPHOMA;RESPIRATORY SYSTEM;THROMBOSIS;CHEMOTHERAPY;CORONARY ARTERY DISEASE;DIABETES MELLITUS;INSULIN;RECEPTOR;ALTERNATIVE MEDICINE;BONE MARROW;HUMAN IMMUNODEFICIENCY VIRUS (HIV);INCIDENCE (GEOMETRY);MECHANICAL VENTILATION;MULTIPLE MYELOMA;MYOCARDIAL INFARCTION;RISK FACTOR;VIRUS","36;15;13;11;11;10;10;9;8;8;8;8;8;7;7;7;7;7;6;6;6;6;6;6;6;6;6","MUTATION;ALLELE;EXON;VON WILLEBRAND FACTOR;GENOTYPE;TIDAL VOLUME;BASAL (MEDICINE);EJECTION FRACTION;FETUS;SEROLOGY;SPLENECTOMY;CD34;DYSTROPHIN;FACTOR V;GROWTH HORMONE;HEART RATE;HEPATITIS B VIRUS;INSULIN RESISTANCE;INTRON;LEFT VENTRICULAR HYPERTROPHY;METASTASIS;MUTANT;NEURORADIOLOGY;PLACEBO;SPIROMETRY;VIRAL DISEASE;WARFARIN","16;9;8;6;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","MISSENSE MUTATION;VON WILLEBRAND DISEASE;ORAL ANTICOAGULANT;PROBAND;ACROMEGALY;ALLELE FREQUENCY;ANTIRETROVIRAL THERAPY;COMPOUND HETEROZYGOSITY;CONNECTIVE TISSUE DISEASE;DESMIN;FRAMESHIFT MUTATION;GERMLINE MUTATION;GROWTH HORMONE DEFICIENCY;HAPLOTYPE;HBSAG;HETEROZYGOTE ADVANTAGE;LEUKAPHERESIS;LOSS OF HETEROZYGOSITY;MICROSATELLITE;POLYCYSTIC OVARY;RIGHT CORONARY ARTERY;SERINE PROTEASE;TUMOR SUPPRESSOR GENE","5;5;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;MALE;FEMALE;MIDDLE AGED;ADULT;AGED;;ITALY;ADOLESCENT;CHILD;SKIN NEOPLASMS;HYPERTENSION;MUTATION;IMMUNOSUPPRESSIVE AGENTS;VON WILLEBRAND DISEASES;CARCINOMA, SQUAMOUS CELL;AGED, 80 AND OVER;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;TIME FACTORS;CHILD, PRESCHOOL","137;95;82;72;70;54;53;34;32;20;17;16;16;14;14;13;12;12;12;11","MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;PLATELET DISORDERS AND THROMBOSIS MECHANISMS;LYMPHOID NEOPLASMS;THROMBOSIS AND COAGULATION DISORDERS;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;MECHANOSENSITIVE ION CHANNELS IN PHYSIOLOGY AND DISEASE;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;MOLECULAR MECHANISMS OF HEME BIOSYNTHESIS AND RELATED DISORDERS;MOLECULAR MECHANISMS OF MUSCLE REGENERATION AND ATROPHY;NEUROENDOCRINE REGULATION OF APPETITE AND BODY WEIGHT;RECOMMENDATIONS FOR CARDIAC CHAMBER QUANTIFICATION BY ECHOCARDIOGRAPHY;ACUTE MYELOID LEUKEMIA;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;ATRIAL FIBRILLATION;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;EATING DISORDERS AND BODY IMAGE CONCERNS;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF SEXUAL DYSFUNCTION","8;6;5;5;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2","POSITIVE END-EXPIRATORY PRESSURE;MECHANICAL VENTILATION;TREATMENT;VON WILLEBRAND DISEASE;BASAL (MEDICINE);HYPERTENSION;NONINVASIVE VENTILATION;RECOMBINANT FACTOR VIIA;REGIMEN;VENTILATOR-INDUCED LUNG INJURY;DYSTROPHIN;ETIOLOGY;FACTOR V;FACTOR V LEIDEN;FECAL INCONTINENCE;HEPATITIS C;INTERNATIONAL MYELOMA WORKING GROUP;NEURORADIOLOGY;ORAL ANTICOAGULANT;POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE","7;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","BONE MARROW;FACTOR VII;VON WILLEBRAND;WILLEBRAND DISEASE;ACUTE RESPIRATORY;ADULT PATIENTS;HORMONE DEFICIENCY;HUMAN FACTOR;MARROW TRANSPLANTATION;MULTIPLE MYELOMA;NON-TRANSFERRIN-BOUND IRON;PROTHROMBIN TIME;REPLACEMENT THERAPY;RISK FACTORS;ACUTE INTERMITTENT;ARTERY DISEASE;BASE PAIR;BLOOD STEM;CASE-CONTROL STUDY;CELL CARCINOMA;CLINICAL CHARACTERISTICS;COMBINED TREATMENT;CORONARY ARTERY;DISORDERS REPORT;DISTRESS SYNDROME;ERECTILE DYSFUNCTION;GLOBAL AMNESIA;GROWTH HORMONE;HEART FAILURE;HEPATOCELLULAR CARCINOMA","5;5;5;5;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","LEFT VENTRICULAR;ANGIOTENSIN II;LEPTIN CONCENTRATIONS;GASTRIC RELAXATION;ACROMEGALIC PATIENTS;CORONARY FLOW;CUSHINGS DISEASE;GASTRIC TONE;HORMONE LEVELS;MM HG;PROP- GENE;ADVERSE REACTIONS;CARDIAC SYMPATHETIC;CLINIC-HOME DIFFERENCES;CORONARY ARTERY;ELDERLY PATIENTS;FLOW VELOCITY;GUT HORMONE;HEART RATE;NMOLL NA;PLASMA GUT;PLASMA LEPTIN;PMOLL NA;PTLD DEVELOPED;SEVERE DEFECT;VENTRICULAR HYPERTROPHY;ADENYLATE CYCLASE;ADVERSE EVENTS;BLOOD PRESSURE;COLOR DOPPLER","9;7;7;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3",13,0.07,3,5,4,6,4.25,2,11,0,0,0,0,0,0,0,0,0,0,0,0,4,1,9,0,0,0,0,0,0,4.25,2,11,0,0,0,0,0,0,1,1,1,0,0,0,1.5,1,2,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0,48.75,28,78,48.75,28,78,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CAGRANDA",2001,189,7.25396825396825,2.92592592592593,0.341772151898734,0.44973544973545,0.46031746031746,0.137566137566138,0.238095238095238,14,72,43,12,50,0.38,0.23,0.06,0.26,75.61,1.65472633490169,0.201058201058201,0.920634920634921,0,0.446442179463424,0.379313349599164,0.435119047619048,0.467213114754098,"G. SCARLATO;GIACOMO P. COMI;NEREO BRESOLIN;BRUNO MARIO CESANA;ALBERTO ZANCHETTI;P. BECK‐PECCOZ;FABIO PARAZZINI;PAOLO PELOSI;EDUARDO NOBILE‐ORAZIO;MANUELA SIRONI;S. ALLARIA;LUCA PERSANI;MAURIZIO MOGGIO;LUCIANO GATTINONI;A. PRELLE;RACHELE CAGLIANI;G. FAGLIA;GIORGIO LA NASA;PIETRO CAIRONI;M. CARPO","16;12;9;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4","FABIO PARAZZINI;G. SCARLATO;NEREO BRESOLIN;ALBERTO ZANCHETTI;P. BECK‐PECCOZ;C. GELMETTI;GIACOMO P. COMI;LUIGI BERGAMASCHINI;A. SPADA;LUCA PERSANI;FEDERICO LOMBARDI;G MACCA;E. BALLARE;M. MARCONI;CARLO CIVARDI;CARLO GELMETTI;GRUPPO ITALIANO PER LO STUDIO DELL'ENDOMETRIOSI;ALBERTO ZANCHETTI;BRUNO MARIO CESANA;EDUARDO NOBILE‐ORAZIO","2.32;2.12;1.83;1.49;1.28;1.25;1.23;1.11;1.11;1.06;1;1;1;1;1;1;1;1;0.99;0.93","G. SCARLATO;GIACOMO P. COMI;NEREO BRESOLIN;BRUNO MARIO CESANA;ALBERTO ZANCHETTI;P. BECK‐PECCOZ;FABIO PARAZZINI;PAOLO PELOSI;EDUARDO NOBILE‐ORAZIO;S. ALLARIA;LUCA PERSANI;MAURIZIO MOGGIO;LUCIANO GATTINONI;A. PRELLE;RACHELE CAGLIANI;G. FAGLIA;GIORGIO LA NASA;PIETRO CAIRONI;M. CARPO;LUIGI BONAVINA","16;12;9;6;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;3","FABIO PARAZZINI;G. SCARLATO;NEREO BRESOLIN;ALBERTO ZANCHETTI;P. BECK‐PECCOZ;C. GELMETTI;GIACOMO P. COMI;LUIGI BERGAMASCHINI;A. SPADA;LUCA PERSANI;FEDERICO LOMBARDI;G MACCA;E. BALLARE;M. MARCONI;CARLO CIVARDI;CARLO GELMETTI;GRUPPO ITALIANO PER LO STUDIO DELL'ENDOMETRIOSI;ALBERTO ZANCHETTI;BRUNO MARIO CESANA;EDUARDO NOBILE‐ORAZIO","2.32;2.12;1.83;1.49;1.28;1.25;1.23;1.11;1.11;1.06;1;1;1;1;1;1;1;1;0.99;0.93","MASSIMO COLOMBO;ANDREW K. BURROUGHS;ERIK CHRISTENSEN;JORDI BRUIX;JOSEP M. LLOVET;JUAN RODÉS;LUIGI PAGLIARO;MICHEL BEAUGRAND;MORRIS SHERMAN;RICCARDO LENCIONI;PAOLO PELOSI;LUCIANO GATTINONI;D. MASCHERONI;ANDREA CIAMMOLA;BLAIR R. LEAVITT;CHIARA ZUCCATO;DONATO GOFFREDO;DOROTEA RIGAMONTI;ELENA CATTANEO;LUCIANO CONTI","4076;4056;4056;4056;4056;4056;4056;4056;4056;4056;2396;2354;1782;1291;1291;1291;1291;1291;1291;1291","MASSIMO COLOMBO;LUCIANO GATTINONI;PAOLO PELOSI;D. MASCHERONI;ANDREA CIAMMOLA;VINCENZO SILANI;LUCA BRAZZI;PAOLO TACCONE;PIETRO CAIRONI;JOHN J. MARINI;G. SCARLATO;GIULIO RONZONI;MICHELE MONDINO;STEFANIA CROTTI;ALEX B. ADAMS;ANDREW MCKIBBEN;G ECCHER;M GOLDNER;SABINA LOSAPPIO;GIACOMO P. COMI","4076;2354;2332;1782;1291;1291;1275;1275;1121;1057;575;549;549;549;508;508;508;508;508;500","G. SCARLATO;GIACOMO P. COMI;NEREO BRESOLIN;PIER MANNUCCIO MANNUCCI;ALBERTO ZANCHETTI;P. BECK‐PECCOZ;PAOLO BECK‐PECCOZ;EDUARDO NOBILE‐ORAZIO;FABIO PARAZZINI;LUCIANO GATTINONI;MAURIZIO MOGGIO;S. ALLARIA;BRUNO MARIO CESANA;M. CARPO;PAOLO PELOSI;PIETRO CAIRONI;G. FAGLIA;FRANCESCO FORTUNATO;A. PRELLE;ALBERTO PERACCHIA","15;12;8;6;6;6;5;5;5;5;5;5;5;4;4;4;4;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;ENGINEERING;COMPUTER SCIENCE;MATHEMATICS;PSYCHOLOGY;ECONOMICS;PHILOSOPHY;MATERIALS SCIENCE;SOCIOLOGY;BUSINESS","165;75;22;14;7;5;5;5;4;4;3;3;2","INTERNAL MEDICINE;GENETICS;ENDOCRINOLOGY;PATHOLOGY;SURGERY;IMMUNOLOGY;BIOCHEMISTRY;CARDIOLOGY;ANESTHESIA;GASTROENTEROLOGY;CELL BIOLOGY;RADIOLOGY;CANCER RESEARCH;PSYCHIATRY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;MOLECULAR BIOLOGY;PEDIATRICS;DERMATOLOGY;OPTICS","117;43;38;38;37;34;26;23;16;16;13;13;12;12;11;10;10;9;8;8","GENE;HORMONE;BLOOD PRESSURE;DISEASE;ANTIBODY;POPULATION;ENZYME;CANCER;CONFIDENCE INTERVAL;IN VITRO;RECEPTOR;ALTERNATIVE MEDICINE;INCIDENCE (GEOMETRY);MYOCARDIAL INFARCTION;RANDOMIZED CONTROLLED TRIAL;VIRUS;COMPLICATION;LESION;PREGNANCY;RADIATION THERAPY;RISK FACTOR;THYROID","37;19;17;16;11;11;10;8;8;8;8;7;7;7;7;7;6;6;6;6;6;6","MUTATION;HEART RATE;RELATIVE RISK;ALLELE;MITOCHONDRIAL DNA;VIRAL DISEASE;BASAL CELL CARCINOMA;ENDOCRINE SYSTEM;GENOTYPE;GROWTH HORMONE;NEURORADIOLOGY;ANGIOTENSIN-CONVERTING ENZYME;ARDS;CELL CYCLE;CHROMOSOMAL TRANSLOCATION;DIASTOLE;HAEMATOPOIESIS;HEPATITIS C VIRUS;LUTEINIZING HORMONE;MONOCLONAL ANTIBODY;MUTANT;PLACEBO;POLYMERASE CHAIN REACTION;PORTAL HYPERTENSION;PROGRAMMED CELL DEATH;TITER;TRANSCRIPTION FACTOR;VARICES","10;6;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","MISSENSE MUTATION;ENALAPRIL;ESOPHAGEAL VARICES;HERPESVIRIDAE;MITOCHONDRIAL MYOPATHY;ONCOGENE;ACROMEGALY;ANTIRETROVIRAL THERAPY;BREAKPOINT;CARBOPLATIN;CYTOGENETICS;FACTOR V LEIDEN;FOLLICLE-STIMULATING HORMONE;GERMLINE MUTATION;GONADOTROPIN-RELEASING HORMONE;HORMONE ANTAGONIST;MITOCHONDRIAL DISEASE;MONOCLONAL;OVULATION INDUCTION;SILENT PERIOD;TORQUE TENO VIRUS;TRANSFERRIN SATURATION","4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;;AGED;ADOLESCENT;CHILD;MUSCLE, SKELETAL;RNA, MESSENGER;HYPERTENSION;MUTATION;BRAIN NEOPLASMS;BLOOD PRESSURE;SKIN NEOPLASMS;THYROTROPIN;MYOCARDIAL INFARCTION;ANIMALS;ITALY","137;87;87;59;58;46;39;20;19;19;19;18;18;16;15;15;15;13;12;12","MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;GUILLAIN-BARRÉ SYNDROME AND RELATED NEUROPATHIES;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;THROMBOSIS AND COAGULATION DISORDERS;DIAGNOSIS AND MANAGEMENT OF POLYCYSTIC OVARY SYNDROME;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;INSULIN-LIKE GROWTH FACTORS IN HEALTH AND DISEASE;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION;MOLECULAR MECHANISMS OF MUSCLE REGENERATION AND ATROPHY;THYROID DISEASE AND HORMONE REGULATION;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;BLOOD RHEOLOGY AND COAGULATION MECHANISMS;EPIDEMIOLOGY AND MANAGEMENT OF FUNGAL SKIN INFECTIONS;EPIDEMIOLOGY AND MANAGEMENT OF SKIN CANCER;MANAGEMENT AND EPIDEMIOLOGY OF PNEUMONIA;MANAGEMENT OF VALVULAR HEART DISEASE","8;6;5;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2","HYPERTENSION;HYPERTHYROIDISM;HYPOTHYROIDISM;PATHOGENESIS;NEURORADIOLOGY;POSITIVE END-EXPIRATORY PRESSURE;THYROID HORMONE;TREATMENT;CONCOMITANT;CYTOMEGALOVIRUS;DYSTROPHIN;FACTOR V LEIDEN;KAPOSI'S SARCOMA;NONMELANOMA SKIN CANCER;SKIN CANCERS;TRANSCRANIAL MAGNETIC STIMULATION;ACROMEGALY;AEROBIC EXERCISE;BARRETT'S ESOPHAGUS;BASAL CELL CARCINOMA","9;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2","ACUTE RESPIRATORY;BLOOD PRESSURE;HYPERTENSIVE PATIENTS;RISK FACTORS;HYPERTENSION OPTIMAL;MULTIPLE LETTERS;MYOCARDIAL INFARCTION;OPTIMAL TREATMENT;RANDOMIZED CONTROLLED;RESPIRATORY FAILURE;TREATED HYPERTENSIVE;ALCOHOL ABUSERS;BASAL CELL;BONE MARROW;CELL CARCINOMA;CELL PROLIFERATION;CORD BLOOD;CUSHINGS DISEASE;DISTRESS SYNDROME;DYSTROPHIN GENE;FACTOR VII;GERMLINE MUTATIONS;HUNTINGTONS DISEASE;INDIVIDUAL RISK;KAPOSIS SARCOMA;LEFT VENTRICULAR;LIPID TRANSFER;LIVER TRANSPLANTATION;MITRAL REGURGITATION;NATURAL KILLER","4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BLOOD PRESSURE;NK CELLS;MM HG;OSPEDALE MAGGIORE;ENDOCRINE SCIENCES;MICROGL NA;MILAN OSPEDALE;PYRUVATE KINASE;SCIENCES UNIVERSITY;SERUM TSH;SHEEHANS SYNDROME;GNRH ANALOGUE;IGFI LEVELS;MEMORY REACTIVATION;SLEEP DEPRIVATION;BIOLOGICAL ACTIVITY;DNA MOTIFS;ERYTHROCYTE PYRUVATE;FT LEVELS;GH LEVELS;GNRH ANTAGONIST;HEALTHY CHILDREN;HUMAN ERYTHROCYTE;LUTEAL PHASE;MAGGIORE IRCCSSEARCH;MEDICINE OSPEDALE;MICROGL HOURS;NASOPHARYNGEAL CARRIAGE;NM NA;NM RANGE","9;8;7;7;6;6;6;6;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4",24,0.13,3,15.82,9,31.85,28.83,5,90,0,0,0,2,2,2,0,0,0,2,1,3,29.4,1,90,0,0,0,1,1,1,29,5,90,0,0,0,0,0,0,2,1,3,0,0,0,3.75,1,7,0,0,0,0,0,0,1.5,1,2,1,1,1,0.83,0,3,0.33,0,1,273.5,60,595,274.67,61,596,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CAGRANDA",2002,178,7.2247191011236,2.58988764044944,0.386117136659436,0.382022471910112,0.393258426966292,0.134831460674157,0.219101123595506,11,68,31,6,63,0.38,0.17,0.03,0.35,58.48,1.06007817692033,0.213483146067416,0.949438202247191,0,0.478788424925018,0.313103448275862,0.454,0.378109452736318,"GIACOMO P. COMI;NEREO BRESOLIN;G. SCARLATO;ALBERTO ZANCHETTI;PIER MANNUCCIO MANNUCCI;ROBERTO PENAGINI;FLORA PEYVANDI;PAOLO BECK‐PECCOZ;ROBERTO DEL BO;A. PRELLE;M. MANGANO;GIUSEPPE BASELLI;ALESSANDRA BARDONI;RACHELE CAGLIANI;MANUELA SIRONI;LAURA FUGAZZOLA;ALBERTO MALLIANI;MARIA DOMENICA CAPPELLINI;MAURIZIO MOGGIO;FEDERICO LOMBARDI","12;11;9;7;7;5;5;5;5;4;4;4;4;4;4;4;4;4;4;3","NEREO BRESOLIN;ALBERTO ZANCHETTI;FRANCESCO BLASI;LAURA FUGAZZOLA;GIACOMO P. COMI;PIER MANNUCCIO MANNUCCI;GIOVANNA MANTOVANI;MAURIZIO MOGGIO;ROBERTO PENAGINI;ELIO SCARPINI;ALBERTO EDEFONTI;G. SCARLATO;M. MANGANO;ALBERTO TERZI;PIETRO LUIGI GARAVELLI;MARCO LADETTO;RICCI MG;ALBERTO MALLIANI;FLORA PEYVANDI;M. CACCIALANZA","1.64;1.6;1.45;1.42;1.35;1.32;1.31;1.28;1.2;1.14;1.14;1.1;1.03;1;1;1;1;0.88;0.87;0.77","GIACOMO P. COMI;NEREO BRESOLIN;G. SCARLATO;ALBERTO ZANCHETTI;PIER MANNUCCIO MANNUCCI;ROBERTO PENAGINI;FLORA PEYVANDI;PAOLO BECK‐PECCOZ;ROBERTO DEL BO;A. PRELLE;M. MANGANO;LAURA FUGAZZOLA;MARIA DOMENICA CAPPELLINI;MAURIZIO MOGGIO;FEDERICO LOMBARDI;FRANCESCO BLASI;FABIO MAGRINI;MONICA SCIACCO;ANDREINA BORDONI;NICOLA MONTANO","12;11;9;7;7;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3","NEREO BRESOLIN;ALBERTO ZANCHETTI;FRANCESCO BLASI;LAURA FUGAZZOLA;GIACOMO P. COMI;PIER MANNUCCIO MANNUCCI;GIOVANNA MANTOVANI;MAURIZIO MOGGIO;ROBERTO PENAGINI;ELIO SCARPINI;ALBERTO EDEFONTI;G. SCARLATO;M. MANGANO;ALBERTO TERZI;PIETRO LUIGI GARAVELLI;MARCO LADETTO;RICCI MG;FLORA PEYVANDI;M. CACCIALANZA;NICOLA MONTANO","1.64;1.6;1.45;1.42;1.35;1.32;1.31;1.28;1.2;1.14;1.14;1.1;1.03;1;1;1;1;0.87;0.77;0.75","EMANUELA TAIOLI;G. SIRCHIA;DANIELE PRATI;MASSIMO COLOMBO;ALBERTO ZANELLA;DARIO CONTE;EMANUELA DEL VECCHIO;EMANUELA DELLA TORRE;F ZANUSO;FULVIO MOZZI;LUCIANA VIANELLO;SILVANO MILANI;SONIA BUTELLI;CARLA GIUSTETTO;CARLO NAPOLITANO;CARLO PAPPONE;E RONCHETTI;GIOVANNA FAGGIANO;JANNÌ NASTOLI;MASSIMILIANO GRILLO","1650;1457;1422;1422;1406;1406;1406;1406;1406;1406;1406;1406;1406;1042;1042;1042;1042;1042;1042;1042","MASSIMO COLOMBO;ALBERTO ZANELLA;DANIELE PRATI;DARIO CONTE;EMANUELA DEL VECCHIO;EMANUELA DELLA TORRE;EMANUELA TAIOLI;F ZANUSO;FULVIO MOZZI;G. SIRCHIA;LUCIANA VIANELLO;SILVANO MILANI;SONIA BUTELLI;CARLA GIUSTETTO;CARLO NAPOLITANO;CARLO PAPPONE;E RONCHETTI;GIOVANNA FAGGIANO;JANNÌ NASTOLI;MASSIMILIANO GRILLO","1422;1406;1406;1406;1406;1406;1406;1406;1406;1406;1406;1406;1406;1042;1042;1042;1042;1042;1042;1042","GIACOMO P. COMI;NEREO BRESOLIN;G. SCARLATO;PIER MANNUCCIO MANNUCCI;ALBERTO ZANCHETTI;ROBERTO DEL BO;A. PRELLE;FLORA PEYVANDI;MARIA DOMENICA CAPPELLINI;MAURIZIO MOGGIO;ROBERTO PENAGINI;NICOLA MONTANO;P. BECK‐PECCOZ;ANDREINA BORDONI;FABIO MAGRINI;FEDERICA LOCATELLI;FRANCESCO BLASI;GIOVANNA MANTOVANI;LAURA FUGAZZOLA;LENNART HANSSON","12;11;9;7;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;PSYCHOLOGY;ART;POLITICAL SCIENCE;PHILOSOPHY;ECONOMICS;SOCIOLOGY","152;63;24;15;9;8;6;6;4;3;2;1;1","INTERNAL MEDICINE;GENETICS;ENDOCRINOLOGY;PATHOLOGY;IMMUNOLOGY;BIOCHEMISTRY;SURGERY;GASTROENTEROLOGY;CARDIOLOGY;MOLECULAR BIOLOGY;ANESTHESIA;DERMATOLOGY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;CELL BIOLOGY;ONCOLOGY;CANCER RESEARCH;PSYCHIATRY;RADIOLOGY;MECHANICAL ENGINEERING;PEDIATRICS;UROLOGY","113;41;35;35;33;28;26;23;16;14;13;11;11;11;9;8;7;7;7;6;6;6","GENE;DISEASE;ANTIBODY;BLOOD PRESSURE;CANCER;POPULATION;ENZYME;HORMONE;TRANSPLANTATION;PREGNANCY;IMMUNOHISTOCHEMISTRY;RECEPTOR;THYROID;CHEMOTHERAPY;INFLAMMATION;MYOCARDIAL INFARCTION;BONE MARROW;CARCINOMA;DIALYSIS;INSULIN;LYMPHOMA;MULTIVARIATE ANALYSIS;RANDOMIZED CONTROLLED TRIAL","35;16;12;12;12;11;10;10;10;9;8;8;7;6;6;6;5;5;5;5;5;5;5","MUTATION;EXON;ALLELE;GENOTYPE;PHENOTYPE;BASAL (MEDICINE);DYSTROPHIN;INSULIN RESISTANCE;MITOCHONDRIAL DNA;REFLUX;UNIVARIATE ANALYSIS;ACUTE INTERMITTENT PORPHYRIA;AGONIST;ANGIOTENSIN-CONVERTING ENZYME;ANTAGONIST;BREAST CANCER;GENE EXPRESSION;GESTATION;GOITER;HEART RATE;KIDNEY TRANSPLANTATION;PLACEBO;POLYMERASE CHAIN REACTION;THYROID CANCER;VIRAL LOAD","16;6;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","MISSENSE MUTATION;COMPOUND HETEROZYGOSITY;POINT MUTATION;PROBAND;ABCIXIMAB;ACE INHIBITOR;ACROMEGALY;AZOOSPERMIA;CHLAMYDOPHILA PNEUMONIAE;CREB;ESOPHAGEAL SPHINCTER;EXTERNAL OPHTHALMOPLEGIA;GENE MUTATION;HORMONE RECEPTOR;JUNB;LACIDIPINE;MITOCHONDRIAL MYOPATHY;POLYCYSTIC OVARY;PROMOTER;RNA SPLICING;UROPORPHYRINOGEN III DECARBOXYLASE;VINCRISTINE","7;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;MALE;FEMALE;ADULT;MIDDLE AGED;AGED;;HYPERTENSION;ADOLESCENT;CHILD;ITALY;AGED, 80 AND OVER;ANIMALS;KIDNEY;FOLLOW-UP STUDIES;TREATMENT OUTCOME;CHILD, PRESCHOOL;RECOMBINANT PROTEINS;RISK FACTORS;ANTIHYPERTENSIVE AGENTS","139;94;91;64;64;41;32;24;23;21;20;15;15;15;14;14;13;13;12;11","MOLECULAR MECHANISMS OF MUSCLE REGENERATION AND ATROPHY;DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE;LYMPHOID NEOPLASMS;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;ACUTE MYELOID LEUKEMIA;MANAGEMENT AND TREATMENT OF HEMOPHILIA;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION;MOLECULAR MECHANISMS OF CARDIAC ARRHYTHMIAS;MOLECULAR MECHANISMS OF HEME BIOSYNTHESIS AND RELATED DISORDERS;THROMBOSIS AND COAGULATION DISORDERS;THYROID DISEASE AND HORMONE REGULATION;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;EPIDEMIOLOGY, CLASSIFICATION, AND CLINICAL FEATURES OF INFLAMMATORY MYOPATHIES;HEMATOPOIETIC STEM CELL BIOLOGY;HEPATITIS B INFECTION AND TREATMENT;HEPATOCELLULAR CARCINOMA;HEREDITARY ANGIOEDEMA: MOLECULAR MECHANISMS AND CLINICAL MANAGEMENT;KIDNEY TRANSPLANTATION","6;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","HYPERTENSION;HYPERTHYROIDISM;TREATMENT;BASAL (MEDICINE);DIAGNOSIS;DYSTROPHIN;HEART RATE VARIABILITY;THYROID HORMONE;UNIVARIATE ANALYSIS;COMPOUND HETEROZYGOSITY;FACTOR VIII;HYPOTHYROIDISM;INBORN ERRORS OF METABOLISM;MYELOID NEOPLASMS;NONINVASIVE VENTILATION;PATHOGENESIS;PATHOPHYSIOLOGY;PROBAND;THYROID ANTIBODIES;ABCIXIMAB","7;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;2","MULTIPLE LETTERS;BONE MARROW;GENE MUTATIONS;THYROID HORMONE;TRANSCRIPTION FACTOR;ADRENAL HYPOPLASIA;APPARENT REMISSION;BLOOD PROTHROMBIN;C-FOS ACTIVATION;CHLAMYDIA PNEUMONIAE;CIRCULATING THYROGLOBULIN;CLINICAL SUBTYPES;CONCERTED ACTION;COWS MILK;CREB TRANSCRIPTION;DIFFERENTIATED THYROID;DYSTROPHIN GENE;ELDERLY PATIENTS;EUROPEAN CONCERTED;EXTERNAL OPHTHALMOPLEGIA;FOLLOW-UP STUDY;GUGLIELMO SCARLATO;HDL CHOLESTEROL;HEMODIALYSIS PATIENTS;HIGHLY SENSITIVE;HYPERTENSION GUIDELINES;HYPOGONADOTROPIC HYPOGONADISM;HYPOPLASIA CONGENITA;KILLER CELLS;LATE-ONSET X-LINKED","4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MILANO ITALYSEARCH;HS-BASAL TG;TG TESTING;OSPEDALE MAGGIORE;CENTRO STUDIO;CLINICAL EVALUATION;DEL FEGATO;DI MILANO;DIPARTIMENTO MEDICINA;FEGATO OSPEDALE;INTERNA CENTRO;IRCCS MILANO;MAGGIORE IRCCS;MALATTIE METABOLICHE;MD DIPARTIMENTO;MEDICINA INTERNA;METABOLICHE DEL;MILANO MILANO;MILANO UNIVERSITÀ;STUDIO MALATTIE;UNIVERSITÀ DI;MG QD;BORZIO MD;TG MRNA;ACROMEGALIC PATIENTS;ADRENAL FAILURE;CARDIOVASCULAR EVENTS;MM HG;SERUM TG;TELOMERASE ACTIVITY","16;12;12;11;10;10;10;10;10;10;10;10;10;10;10;10;10;10;10;10;10;9;8;8;7;6;6;6;6;6",23,0.13,3,8.88,6,19,5.88,1,17,0,0,0,0,0,0,0,0,0,1,1,1,5.5,1,15,0,0,0,2,1,3,6.75,1,17,0,0,0,0,0,0,0,0,0,0,0,0,2,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0.12,0,1,0.12,0,1,106.88,10,257,107.12,10,258,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CAGRANDA",2003,221,7.09049773755656,2.46606334841629,0.405504587155963,0.420814479638009,0.434389140271493,0.14027149321267,0.226244343891403,16,86,27,17,80,0.39,0.12,0.08,0.36,56.71,1.07146524618988,0.230769230769231,0.936651583710407,0,0.481857818932874,0.343996931338703,0.425621118012422,0.41016333938294,"NEREO BRESOLIN;GIACOMO P. COMI;PIER MANNUCCIO MANNUCCI;FLORA PEYVANDI;MAURIZIO MOGGIO;ROBERTO DEL BO;P. BECK‐PECCOZ;R. CAPUTO;A. PRELLE;SARA GALBIATI;VINCENZO CAPPIELLO;MONICA SCIACCO;ANDREINA BORDONI;ALBERTO ZANCHETTI;R. PICCINNO;NINO STOCCHETTI;MAURA AROSIO;MARCO CRIMI;M. CACCIALANZA;SUSANNA ESPOSITO","12;11;11;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;4","ALBERTO ZANCHETTI;STEFANO BORIANI;PIER MANNUCCIO MANNUCCI;R. CAPUTO;CARLO AGOSTONI;ROBERTO DEL BO;SUSANNA ESPOSITO;R. PICCINNO;M. CACCIALANZA;FABIO TRIULZI;NEREO BRESOLIN;GIACOMO P. COMI;ALBERTO PRIORI;FLORA PEYVANDI;ALBERTO GIANNINI;ROMANA NEGRI;RATAN K. CHAUDHURI;RICCARDO BIGI;LUCA BATTISTINI;ELVIRA VERDUCI","2.38;2.33;2.14;2.03;2;1.6;1.45;1.45;1.45;1.39;1.34;1.16;1.12;1.09;1.03;1;1;1;1;1","NEREO BRESOLIN;GIACOMO P. COMI;PIER MANNUCCIO MANNUCCI;FLORA PEYVANDI;MAURIZIO MOGGIO;ROBERTO DEL BO;P. BECK‐PECCOZ;R. CAPUTO;A. PRELLE;SARA GALBIATI;VINCENZO CAPPIELLO;MONICA SCIACCO;ANDREINA BORDONI;ALBERTO ZANCHETTI;R. PICCINNO;NINO STOCCHETTI;MAURA AROSIO;MARCO CRIMI;M. CACCIALANZA;SUSANNA ESPOSITO","12;11;11;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;4","ALBERTO ZANCHETTI;STEFANO BORIANI;PIER MANNUCCIO MANNUCCI;R. CAPUTO;CARLO AGOSTONI;ROBERTO DEL BO;SUSANNA ESPOSITO;R. PICCINNO;M. CACCIALANZA;FABIO TRIULZI;NEREO BRESOLIN;GIACOMO P. COMI;ALBERTO PRIORI;FLORA PEYVANDI;ALBERTO GIANNINI;ROMANA NEGRI;RATAN K. CHAUDHURI;RICCARDO BIGI;ENRICO RINO BREGANI;P. BECK‐PECCOZ","2.38;2.33;2.14;2.03;2;1.6;1.45;1.45;1.45;1.39;1.34;1.16;1.12;1.09;1.03;1;1;1;1;0.96","NEREO BRESOLIN;C. MANGIONI;GIORGIO BOLIS;IGNACE VERGOTE;J. BAPTIST TRIMBOS;PIER MANNUCCIO MANNUCCI;ELIO SCARPINI;HOWARD FELDMAN;PHILIP SCHELTERNS;C. COENS;C. MADROÑAL;G. SCARFONE;GERARDO ZANETTA;J. B. VERMORKEN;L. GIURGEA;MASSIMO PIERGIUSEPPE FRANCHI;P.J. TIMMERS;S. PECORELLI;SAVERIO TATEO;A INNOCENZI","1099;1074;1074;1074;1074;962;710;697;697;643;643;643;643;643;643;643;643;643;643;620","GIORGIO BOLIS;NEREO BRESOLIN;PIER MANNUCCIO MANNUCCI;ELIO SCARPINI;HOWARD FELDMAN;PHILIP SCHELTERNS;G. SCARFONE;A INNOCENZI;GIULIO COSSU;GIUSEPPE D’ANTONA;KEVIN P. CAMPBELL;MARIA ANTONIETTA PELLEGRINO;MARIA GABRIELLA CUSELLA DE ANGELIS;MAURILIO SAMPAOLESI;RITA BARRESI;ROBERTO BOTTINELLI;ROSSANA TONLORENZI;YVAN TORRENTE;ALBERTO PRIORI;R SCORZA","1074;1070;799;710;697;697;643;620;620;620;620;620;620;620;620;620;620;620;510;499","GIACOMO P. COMI;NEREO BRESOLIN;PIER MANNUCCIO MANNUCCI;ROBERTO DEL BO;FLORA PEYVANDI;MAURIZIO MOGGIO;MARCO CRIMI;MONICA SCIACCO;A. PRELLE;ALBERTO ZANCHETTI;DAVIDE CHIUMELLO;FABIO MAGRINI;FABIO MOSCA;FABIO TRIULZI;M. CACCIALANZA;MAURA AROSIO;NINO STOCCHETTI;PAOLO BECK‐PECCOZ;R. PICCINNO;SUSANNA ESPOSITO","11;11;9;6;6;6;5;5;4;4;4;4;4;4;4;4;4;4;4;4","MEDICINE;BIOLOGY;CHEMISTRY;PSYCHOLOGY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;POLITICAL SCIENCE;MATHEMATICS;ECONOMICS;PHILOSOPHY;SOCIOLOGY;ART;ENVIRONMENTAL SCIENCE;GEOGRAPHY;HISTORY","198;85;26;13;12;10;7;5;4;3;2;2;1;1;1;1","INTERNAL MEDICINE;GENETICS;SURGERY;PATHOLOGY;ENDOCRINOLOGY;IMMUNOLOGY;BIOCHEMISTRY;GASTROENTEROLOGY;INTENSIVE CARE MEDICINE;RADIOLOGY;PEDIATRICS;ANESTHESIA;CARDIOLOGY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;DERMATOLOGY;NEUROSCIENCE;ANATOMY;MOLECULAR BIOLOGY;PHARMACOLOGY;PSYCHIATRY","144;51;45;42;40;39;34;24;22;21;19;18;17;15;15;14;14;11;11;11;11","GENE;DISEASE;CANCER;HORMONE;POPULATION;PREGNANCY;RECEPTOR;IN VITRO;PLATELET;ANTIBODY;CHEMOTHERAPY;MYOCARDIAL INFARCTION;THROMBOSIS;ASYMPTOMATIC;BLOOD PRESSURE;CENTRAL NERVOUS SYSTEM;ENZYME;KIDNEY;LUNG;MUSCULAR DYSTROPHY;OBESITY;STIMULATION;VIRUS","42;31;16;15;12;11;11;8;8;7;7;7;7;6;6;6;6;6;6;6;6;6;6","MUTATION;GENOTYPE;PHENOTYPE;VON WILLEBRAND FACTOR;DYSTROPHIN;FETUS;GROWTH HORMONE;MITOCHONDRIAL DNA;ALLELE;EXON;THROMBOTIC THROMBOCYTOPENIC PURPURA;VIRAL DISEASE;AGONIST;BASAL GANGLIA;BONE MINERAL;BREAST CANCER;DYSFERLIN;GESTATIONAL AGE;GHRELIN;HAZARD RATIO;HYDRONEPHROSIS;INTRON;LEFT VENTRICULAR HYPERTROPHY;LEPTIN;MELANOCYTE-STIMULATING HORMONE;MESSENGER RNA;METALLOPROTEINASE;MUTANT;OVARIAN CANCER;PARKINSON'S DISEASE;POLYMERASE CHAIN REACTION;PROTEIN KINASE A;REFLUX;RNA","14;7;7;6;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","MISSENSE MUTATION;ACROMEGALY;DEEP BRAIN STIMULATION;HAPLOTYPE;HETEROPLASMY;LIMB-GIRDLE MUSCULAR DYSTROPHY;MITOCHONDRIAL DISEASE;MITOCHONDRIAL MYOPATHY;POINT MUTATION;PRENATAL DIAGNOSIS;THROMBOSPONDIN;VON WILLEBRAND DISEASE;ANTIRETROVIRAL THERAPY;COMPOUND HETEROZYGOSITY;CONNECTIVE TISSUE DISEASE;GENOTYPING;IN UTERO;LMNA;MICROANGIOPATHIC HEMOLYTIC ANEMIA;MUTANT PROTEIN;OVARIAN CARCINOMA;POLYMORPHISM (COMPUTER SCIENCE);REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;URETEROPELVIC JUNCTION","6;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;AGED;;ADOLESCENT;CHILD;ITALY;CHILD, PRESCHOOL;TREATMENT OUTCOME;ANIMALS;AGED, 80 AND OVER;BRAIN;OVARIAN NEOPLASMS;PARKINSON DISEASE;FOLLOW-UP STUDIES;MUSCLE, SKELETAL;HYPERTROPHY, LEFT VENTRICULAR","173;110;104;71;67;53;39;37;30;22;18;18;17;16;16;16;16;15;15;14","INSULIN-LIKE GROWTH FACTORS IN HEALTH AND DISEASE;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;DEEP BRAIN STIMULATION FOR NEUROLOGICAL DISORDERS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;NEUROENDOCRINE REGULATION OF APPETITE AND BODY WEIGHT;ROLE OF COMPLEMENT SYSTEM IN IMMUNE RESPONSE;ROLE OF HOMOCYSTEINE IN HEALTH AND DISEASE;SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;MOLECULAR MECHANISMS OF MUSCLE REGENERATION AND ATROPHY;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;PEDIATRIC URINARY TRACT INFECTIONS;PLATELET DISORDERS AND THROMBOSIS MECHANISMS;BLOOD RHEOLOGY AND COAGULATION MECHANISMS;CLASSIFICATION AND TREATMENT OF HISTIOCYTIC DISORDERS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DEVELOPMENTAL ORIGINS OF ADULT HEALTH AND DISEASE;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE","6;6;5;5;4;4;4;4;4;4;3;3;3;3;3;2;2;2;2;2","TREATMENT;HYPERTENSION;NEUROINFLAMMATION;PRESENTATION (OBSTETRICS);VON WILLEBRAND DISEASE;DEEP BRAIN STIMULATION;DYSTROPHIN;LIVER DISEASE;NEUROMODULATION;PATHOGENESIS;ADAMTS;ADAMTS13;CLINICAL PRACTICE;DYSFERLIN;ENDOVENOUS TREATMENT;GHRELIN;HETEROPLASMY;LIMB-GIRDLE MUSCULAR DYSTROPHY;MELANOCYTE-STIMULATING HORMONE;METABOLISM","6;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","INTENSIVE CARE;VON WILLEBRAND;MULTIPLE LETTERS;OVARIAN CARCINOMA;PULMONARY EMBOLISM;ADJUVANT CHEMOTHERAPY;CHRONIC HEPATITIS;CLEAVING PROTEASE;FACTOR CLEAVING;GLIOMA GROWTH;LUPUS ERYTHEMATOSUS;MULTIPLE SCLEROSIS;NEOPLASM TRIAL;OVARIAN NEOPLASM;WILLEBRAND FACTOR;AC GENE;ACUTE CORONARY;ALZHEIMERS DISEASE;BODY MASS;BONE MARROW;BRAIN INJURY;BRAIN STIMULATION;BREAD WHEAT;CARE UNITS;CELL MODEL;CHRONIC RENAL;CORONARY SYNDROMES;CYSTIC FIBROSIS;DEEP BRAIN;EARLY-STAGE OVARIAN","5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ADJUVANT CHEMOTHERAPY;LOWER OESOPHAGEAL;OESOPHAGEAL SPHINCTER;RECURRENCE-FREE SURVIVAL;EARLY-STAGE OVARIAN;GHRELIN LEVELS;HIV-INFECTED CHILDREN;HR CI;HZ RHYTHM;OVARIAN CANCER;CONFIDENCE INTERVAL;EXTENT SCORE;GEP NETS;LUNG CANCER;MUSCULAR DYSTROPHY;STATISTICALLY SIGNIFICANT;TRANSIENT LOWER;CGA LEVELS;INTERVAL CI;IUGR FETUSES;LEISHMANIA DNA;ODDS RATIO;SPHINCTER PRESSURE;SPHINCTER RELAXATION;VEIN THROMBOSIS;ALBERTO ZANCHETTI;BASAL GANGLIA;BLOOD PRESSURE;CD CELLS;CEREBRAL VEIN","15;10;10;8;7;7;7;7;7;7;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4",27,0.12,6,14.67,9,25,9.88,2,33,0,0,0,1,1,1,0,0,0,1.5,1,3,12,1,33,1,1,1,2.5,1,4,10.62,2,33,0,0,0,1,1,1,1,1,1,1,1,1,1.5,1,2,0,0,0,0,0,0,1,1,1,0,0,0,0.12,0,1,0,0,0,199.75,14,532,199.88,14,532,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CAGRANDA",2004,212,7.00471698113208,2.90566037735849,0.344155844155844,0.429245283018868,0.476415094339623,0.117924528301887,0.212264150943396,8,101,36,11,54,0.48,0.17,0.05,0.25,50.87,1.08116334130324,0.188679245283019,0.966981132075472,0,0.443721035449472,0.368130081300813,0.403998519067012,0.392465753424658,"ALBERTO ZANCHETTI;GIACOMO P. COMI;NEREO BRESOLIN;PAOLO BECK‐PECCOZ;PIER MANNUCCIO MANNUCCI;FABIO MAGRINI;VINCENZO CAPPIELLO;CRISTINA L. RONCHI;FLORA PEYVANDI;MAURA AROSIO;PIER ALBERTO BERTAZZI;STEFANO FERRERO;FRANCESCO FORTUNATO;G. LUNGHI;SILVANO BÒSARI;ANNA SPADA;BRUNO MARIO CESANA;CLAUDIA GIAVOLI;GIOVANNA MANTOVANI;ELVIO ALESSI","11;9;9;9;8;7;6;6;6;6;5;5;5;5;5;5;4;4;4;4","FRANCESCO BLASI;C. GELMETTI;MAURÍZIO BATTAGLIA PARODI;PAOLA TORELLI;FRANCO FERRARIO;MARIA PIA RASTALDI;CLAUDIA GIAVOLI;PAOLO BECK‐PECCOZ;PIER ALBERTO BERTAZZI;PIER MANNUCCIO MANNUCCI;ALBERTO ZANCHETTI;ELVIO ALESSI;GIACOMO P. COMI;FLORA PEYVANDI;CLAUDIO RUSSO;ALBERTO TERZI;G. C. MANZONI;MAURIZIO BOARON;NEREO BRESOLIN;G. LUNGHI","2.5;1.62;1.5;1.5;1.5;1.5;1.38;1.31;1.29;1.25;1.15;1.12;1.08;1.06;1;1;1;1;0.95;0.92","ALBERTO ZANCHETTI;GIACOMO P. COMI;NEREO BRESOLIN;PAOLO BECK‐PECCOZ;PIER MANNUCCIO MANNUCCI;FABIO MAGRINI;VINCENZO CAPPIELLO;CRISTINA L. RONCHI;FLORA PEYVANDI;MAURA AROSIO;PIER ALBERTO BERTAZZI;STEFANO FERRERO;FRANCESCO FORTUNATO;G. LUNGHI;SILVANO BÒSARI;ANNA SPADA;CLAUDIA GIAVOLI;GIOVANNA MANTOVANI;ELVIO ALESSI;STEFANIA CORTI","11;9;9;9;8;7;6;6;6;6;5;5;5;5;5;5;4;4;4;4","FRANCESCO BLASI;C. GELMETTI;MAURÍZIO BATTAGLIA PARODI;PAOLA TORELLI;MARIA PIA RASTALDI;CLAUDIA GIAVOLI;PAOLO BECK‐PECCOZ;PIER ALBERTO BERTAZZI;PIER MANNUCCIO MANNUCCI;ALBERTO ZANCHETTI;ELVIO ALESSI;GIACOMO P. COMI;FLORA PEYVANDI;CLAUDIO RUSSO;ALBERTO TERZI;G. C. MANZONI;MAURIZIO BOARON;NEREO BRESOLIN;G. LUNGHI;ROBERTO PENAGINI","2.5;1.62;1.5;1.5;1.5;1.38;1.31;1.29;1.25;1.15;1.12;1.08;1.06;1;1;1;1;0.95;0.92;0.84","ALBERTO ZANCHETTI;BEVERLY A. SMITH;FRANCIS PLAT;GORDON T. MCINNES;HANS R. BRUNNER;JOHN H. LARAGH;LADA MITCHELL;LENNART HANSSON;MICHAEL A. WEBER;STEFFAN EKMAN;STEVO JULIUS;SVERRE E. KJELDSEN;TSUSHUNG A. HUA;ANTHONY SCHORK;M. ANTHONY SCHORK;GIACOMO P. COMI;NEREO BRESOLIN;PAOLO BECK‐PECCOZ;FLORA PEYVANDI;PIER MANNUCCIO MANNUCCI","3953;3163;3163;3163;3163;3163;3163;3163;3163;3163;3163;3163;3163;2562;601;537;527;526;421;414","ALBERTO ZANCHETTI;GIACOMO P. COMI;NEREO BRESOLIN;FLORA PEYVANDI;PIER MANNUCCIO MANNUCCI;FABIO MAGRINI;ANTONIO MANARI;MONICA REPETTO;FRANCESCO FORTUNATO;STEFANIA CORTI;STEFANO FERRERO;ROBERTO DEL BO;MAURA AROSIO;GIUSEPPE MANCIA;FABIO TRIULZI;PAOLO BECK‐PECCOZ;ROSSELLA LIBÉ;GASTONE LEONETTI;P BOCCASANTA;PAOLO EPAMINONDA","3708;537;453;421;405;361;321;321;302;282;267;245;236;233;221;217;199;189;189;182","GIACOMO P. COMI;ALBERTO ZANCHETTI;NEREO BRESOLIN;PIER MANNUCCIO MANNUCCI;FABIO MAGRINI;FLORA PEYVANDI;CRISTINA L. RONCHI;FRANCESCO FORTUNATO;G. LUNGHI;PAOLO BECK‐PECCOZ;PIER ALBERTO BERTAZZI;VINCENZO CAPPIELLO;MAURA AROSIO;STEFANO FERRERO;STEFANIA CORTI;FABIO MOSCA;SILVANO BÒSARI;CLAUDIA GIAVOLI;ELVIO ALESSI;FABIO TRIULZI","9;8;8;7;6;6;5;5;5;5;5;5;5;5;4;4;4;4;3;3","MEDICINE;BIOLOGY;CHEMISTRY;ENGINEERING;COMPUTER SCIENCE;PHYSICS;PSYCHOLOGY;SOCIOLOGY;MATERIALS SCIENCE;MATHEMATICS;PHILOSOPHY;BUSINESS;ECONOMICS;GEOGRAPHY;ART;ENVIRONMENTAL SCIENCE;POLITICAL SCIENCE","195;79;21;13;12;11;8;5;4;4;4;3;3;2;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;ENDOCRINOLOGY;GENETICS;PATHOLOGY;SURGERY;CARDIOLOGY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;RADIOLOGY;CELL BIOLOGY;DERMATOLOGY;ANESTHESIA;MOLECULAR BIOLOGY;PSYCHIATRY;PEDIATRICS;PHARMACOLOGY;UROLOGY;ANATOMY;CANCER RESEARCH;MECHANICAL ENGINEERING","135;46;43;43;41;41;32;25;24;21;18;15;14;13;13;13;12;11;10;9;9;9","GENE;DISEASE;POPULATION;BLOOD PRESSURE;HORMONE;ANTIBODY;CANCER;DIABETES MELLITUS;PREGNANCY;INSULIN;TRANSPLANTATION;VIRUS;CONFIDENCE INTERVAL;MYOCARDIAL INFARCTION;PLATELET;ALTERNATIVE MEDICINE;HEART FAILURE;LESION;RANDOMIZED CONTROLLED TRIAL;RECEPTOR","31;24;19;16;15;12;11;11;10;9;9;9;8;8;8;7;7;7;7;7","GENOTYPE;INSULIN RESISTANCE;MUTATION;EXON;GROWTH HORMONE;GENE EXPRESSION;VON WILLEBRAND FACTOR;AMBULATORY BLOOD PRESSURE;BASAL (MEDICINE);ESSENTIAL HYPERTENSION;HAEMATOPOIESIS;HEPATITIS C VIRUS;LEFT VENTRICULAR HYPERTROPHY;PLACEBO;RECOMBINANT DNA;RESTENOSIS;ALLELE;ANGIOTENSIN-CONVERTING ENZYME;BAROSTAT;BREAST CANCER;FETUS;GHRELIN;GLOMERULONEPHRITIS;HAZARD RATIO;KIDNEY TRANSPLANTATION;LIVER BIOPSY;LIVER TRANSPLANTATION;MICROALBUMINURIA;PITUITARY ADENOMA;REFLUX;TOLERABILITY;TYPE 2 DIABETES","8;8;8;7;7;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","ACROMEGALY;ADIPONECTIN;MISSENSE MUTATION;ADAMTS13;ALTERNATIVE SPLICING;BREAKPOINT;ESOPHAGEAL SPHINCTER;HBSAG;INSULIN SENSITIVITY;MIGRAINE WITH AURA;MULTIFOCAL MOTOR NEUROPATHY;OXALIPLATIN;PRENATAL DIAGNOSIS;RNA SPLICING;THROMBOMODULIN;THROMBOSPONDIN;VON WILLEBRAND DISEASE;ABCIXIMAB;ACE INHIBITOR;ACUTE GLOMERULONEPHRITIS;ADENINE NUCLEOTIDE;ADULT STEM CELL;AMNIOTIC FLUID;ANTIGEN-PRESENTING CELL;ANTIRETROVIRAL THERAPY;APOMORPHINE;ARTIFICIAL VENTILATION;BASAL CELL NEVUS SYNDROME;BASILIXIMAB;BIOPHYSICAL PROFILE;BRIDGE TO TRANSPLANTATION;CANDESARTAN;CARBIMAZOLE;CARDIAC INDEX;CAUDATE LOBE;CD40;CERVICAL INTRAEPITHELIAL NEOPLASIA;COMPOUND HETEROZYGOSITY;CONFORMATIONAL EPITOPE;CORONARY STENT;CORONAVIRUS DISEASE 2019 (COVID-19);CUTANEOUS LUPUS ERYTHEMATOSUS;CYP2C9;CYSTECTOMY;DEEP BRAIN STIMULATION;DEOXYCYTIDINE;DESMIN;DESTINATION THERAPY;DNA METHYLATION;ENALAPRIL;ENDOANAL ULTRASOUND;ENDOMYSIUM;ENDOTHELIAL PROTEIN C RECEPTOR;ENHANCER;ENZYME KINETICS;EPITOPE MAPPING;ESTROGEN RECEPTOR;EXTRAMEDULLARY HEMATOPOIESIS;FLUCYTOSINE;FLUORESCENCE IN SITU HYBRIDIZATION;FOSINOPRIL;GENOTYPING;GERD;GITELMAN SYNDROME;GLOMERULAR BASEMENT MEMBRANE;GLUCOSE HOMEOSTASIS;GLYCOPROTEIN IB;GROWTH HORMONE DEFICIENCY;HAPLOINSUFFICIENCY;HAPLOTYPE;HEART RATE VARIABILITY;HETEROPLASMY;HORMONE THERAPY;HUMAN GROWTH HORMONE;HYPERINSULINEMIA;IMMUNOGLOBULIN A;IN SITU HYBRIDIZATION;INDOCYANINE GREEN ANGIOGRAPHY;INFANT NUTRITION;INJURY SEVERITY SCORE;INTERLEUKIN 12;INTERLEUKIN 15;INTERLEUKIN 21;KIDNEY GLOMERULUS;LACIDIPINE;LEIGH DISEASE;LIMB-GIRDLE MUSCULAR DYSTROPHY;LYMPHOVASCULAR INVASION;MALE INFERTILITY;MHC CLASS I;MICROANGIOPATHIC HEMOLYTIC ANEMIA;MICROMETASTASIS;MITOCHONDRIAL MYOPATHY;MITRAL ANNULUS;MONOCHORIONIC TWINS;MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION;MULTIPOTENT STEM CELL;MYOD;NATURAL KILLER CELL;NATURAL KILLER T CELL;NEOVASCULAR GLAUCOMA;NEVOID BASAL-CELL CARCINOMA SYNDROME;ONCOGENE;PANCREATIC POLYPEPTIDE;PNEUMOCOCCAL VACCINATION;POINT MUTATION;POLYCYSTIC OVARY;POLYHYDRAMNIOS;POLYMORPHISM (COMPUTER SCIENCE);PORPHOBILINOGEN DEAMINASE;PROBAND;PROMOTER;PROSTATECTOMY;PSEUDOHYPOPARATHYROIDISM;RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS;RESTRICTION FRAGMENT LENGTH POLYMORPHISM;RETEPLASE;RETINOBLASTOMA PROTEIN;RISTOCETIN;RNA EXTRACTION;SCORAD;SIDA;SINGLE-NUCLEOTIDE POLYMORPHISM;SOMATOSTATIN ANALOGUE;SOMATOTROPIC CELL;STEATOHEPATITIS;SUBVENTRICULAR ZONE;SUMATRIPTAN;TANDEM EXON DUPLICATION;TARGET LESION;THIAZOLIDINEDIONE;THROMBASTHENIA;THYROTROPIN RECEPTOR;TOTAL PANCREATECTOMY;TOXICOGENOMICS;TRANSSPHENOIDAL SURGERY;TRANSVERSION;TRH STIMULATION TEST;VANCOMYCIN;VATS LOBECTOMY;VERTEPORFIN;WILD TYPE;WOLFF–CHAIKOFF EFFECT","5;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;ADULT;AGED;HYPERTENSION;;ITALY;ADOLESCENT;MYOCARDIAL INFARCTION;ADENOMA;HEPATITIS C;ANIMALS;BLOOD PRESSURE;RISK FACTORS;TIME FACTORS;TREATMENT OUTCOME;OCCUPATIONAL DISEASES;ANTIHYPERTENSIVE AGENTS","172;109;108;75;73;51;36;34;28;24;22;21;19;18;18;18;18;18;16;15","MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;HEPATITIS C INFECTION AND TREATMENT;INSULIN-LIKE GROWTH FACTORS IN HEALTH AND DISEASE;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;GENOTOXICITY AND CARCINOGENESIS MECHANISMS;ROLE OF COMPLEMENT SYSTEM IN IMMUNE RESPONSE;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;MANAGEMENT AND EPIDEMIOLOGY OF PNEUMONIA;METABOLISM AND FUNCTIONS OF COENZYME Q;MOLECULAR MECHANISMS OF MUSCLE REGENERATION AND ATROPHY;MULTIPOTENT MESENCHYMAL STEM CELLS;PATHOPHYSIOLOGY OF GLOMERULAR DISEASES AND NEPHROTIC SYNDROMES;THE EXPOSOME IN ENVIRONMENTAL HEALTH RESEARCH;AGE-RELATED MACULAR DEGENERATION RESEARCH;ATOPIC DERMATITIS AND SKIN MICROBIOME;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE","9;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2","HYPERTENSION;HEPATITIS C;STROKE (ENGINE);METABOLISM;PRENATAL DIAGNOSIS;TREATMENT;BASAL (MEDICINE);ESSENTIAL HYPERTENSION;HEART RATE VARIABILITY;NEPHROLOGY;ACROMEGALY;BAROSTAT;BLOOD PRESSURE;CORONARY STENTS;LIVER DISEASE;MICROALBUMINURIA;REFRACTORY (PLANETARY SCIENCE);REGIMEN;TOLERABILITY;VON WILLEBRAND DISEASE","12;6;6;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3","BLOOD PRESSURE;BONE MARROW;CELL CARCINOMA;CUSHINGS DISEASE;ESSENTIAL HYPERTENSIVES;GROWTH HORMONE;HISTOPATHOLOGICAL ATLAS;HORMONE THERAPY;LIVER DISEASE;PROXIMAL STOMACH;RECOMBINANT HUMAN;RISK ASSESSMENT;RISK FACTORS;SKELETAL MUSCLE;SPHINCTER RELAXATION;STEM CELLS;TRANSIENT LOWER;ACTIVE ANTIRETROVIRAL;ADIPONECTIN LEVELS;ANTIHYPERTENSIVE TREATMENT;ANTIRETROVIRAL THERAPY;ATHEROSCLEROTIC PLAQUES;ATOPIC DERMATITIS;BASAL CELL;BIOLOGICAL MONITORING;CARDIOVASCULAR RISK;CELIAC DISEASE;CLINICAL MANAGEMENT;COMMUNITY-ACQUIRED PNEUMONIA;CONTINUOUS POSITIVE","4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;DE CRISTOFARO;PULMONARY EMBOLISM;ΔK THROMBIN;ACROMEGALIC PATIENTS;MANNUCCI PM;PROTEIN SCI;SCI -CROSSREF;HAEMOST -CROSSREF;SJ THROMB;THROMB HAEMOST;LOS RELAXATIONS;POSTOBSTRUCTED KIDNEY;PREVIOUSLY REPORTED;RISK FACTORS;SIGNIFICANTLY LOWER;TRANSIENT LOS;AMINO ACID;BIOCHEMISTRY -CROSSREF;BIOL CHEM;BLOOD PRESSURE;CHEM -ABSTRACT;IDIOPATHIC PULMONARY;JENKINS PV;LEFT VENTRICULAR;MAZZUCCONI MG;MG ROCINO;MOLECULAR DYNAMICS;PERKINS SJ","47;42;16;11;11;9;9;9;9;8;8;8;7;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6;6;6",26,0.12,3,13.68,6,46.5,5.5,2,15,1,1,1,1,1,1,0,0,0,3,1,5,3.5,1,9,0,0,0,1.67,1,3,6.2,2,18,0,0,0,0,0,0,4,3,5,4,4,4,1.33,1,2,0,0,0,2,2,2,2.5,2,3,1,1,1,0.3,0,3,0.2,0,1,108.1,17,408,108.6,17,412,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CAGRANDA",2005,243,8.30041152263374,2.69135802469136,0.371559633027523,0.403292181069959,0.395061728395062,0.123456790123457,0.320987654320988,7,121,38,24,52,0.5,0.16,0.1,0.21,49.99,0.944243460669382,0.238683127572016,0.975308641975309,0,0.422806152615907,0.383236834849738,0.446428571428571,0.424552429667519,"NEREO BRESOLIN;ALBERTO ZANCHETTI;GIORGIO LA NASA;GIACOMO P. COMI;A. SPADA;P. BECK‐PECCOZ;ANDREA LANIA;ELIO SCARPINI;VERONICA FUSI;GIOVANNA MANTOVANI;EMANUELA TAIOLI;AGOSTINO CORTELEZZI;CESARE CUSPIDI;DANIELA GALIMBERTI;PAOLO BECK‐PECCOZ;STEFANO MEANI;ERALDO OCCHETTA;SEYMOUR GARTE;PIER MANNUCCIO MANNUCCI;ALBERTO PRIORI","17;14;8;7;7;7;6;6;6;6;6;6;6;6;6;6;5;5;5;5","ALBERTO ZANCHETTI;NEREO BRESOLIN;MARIA PIA RASTALDI;GUGLIELMO FOFFANI;FRANCO FERRARIO;FEDERICO SCHENA;RENATA DE MARIA;GIUSEPPE LANDONIO;E. DOLFINI;A. SPADA;P. BECK‐PECCOZ;ALBERTO PRIORI;GIORGIO LA NASA;FEDERICA DI BERARDINO;PAOLO BECK‐PECCOZ;ANDREA LANIA;ERALDO OCCHETTA;GIACOMO P. COMI;EMANUELA TAIOLI;GIOVANNA MANTOVANI","4.41;1.75;1.62;1.53;1.5;1.12;1;1;1;0.98;0.98;0.98;0.91;0.87;0.8;0.77;0.77;0.76;0.73;0.73","NEREO BRESOLIN;ALBERTO ZANCHETTI;GIORGIO LA NASA;GIACOMO P. COMI;A. SPADA;P. BECK‐PECCOZ;ANDREA LANIA;ELIO SCARPINI;VERONICA FUSI;GIOVANNA MANTOVANI;EMANUELA TAIOLI;AGOSTINO CORTELEZZI;CESARE CUSPIDI;DANIELA GALIMBERTI;PAOLO BECK‐PECCOZ;STEFANO MEANI;ERALDO OCCHETTA;PIER MANNUCCIO MANNUCCI;ALBERTO PRIORI;CHIARA FENOGLIO","17;14;8;7;7;7;6;6;6;6;6;6;6;6;6;6;5;5;5;5","ALBERTO ZANCHETTI;NEREO BRESOLIN;MARIA PIA RASTALDI;GUGLIELMO FOFFANI;FEDERICO SCHENA;RENATA DE MARIA;A. SPADA;P. BECK‐PECCOZ;ALBERTO PRIORI;GIORGIO LA NASA;FEDERICA DI BERARDINO;PAOLO BECK‐PECCOZ;ANDREA LANIA;ERALDO OCCHETTA;GIACOMO P. COMI;EMANUELA TAIOLI;GIOVANNA MANTOVANI;SERGIO GENTILLI;PIER MANNUCCIO MANNUCCI;GIANNI CASELLA","4.41;1.75;1.62;1.53;1.12;1;0.98;0.98;0.98;0.91;0.87;0.8;0.77;0.77;0.76;0.73;0.73;0.7;0.66;0.66","RITA FACCHETTI;ROBERTO SEGA;GIUSEPPE MANCIA;NEREO BRESOLIN;GUIDO GRASSI;MICHELE BOMBELLI;GIANCARLO CESANA;GIOVANNI CORRAO;ALBERTO PRIORI;ALESSIO DI FONZO;BEN A. OOSTRA;EGBERTO REIS BARBOSA;FABRIZIO STOCCHI;G. MECO;GUIDO J. BREEDVELD;HSIN FEN CHIEN;JOAQUIM J. FERREIRA;STEFANO GOLDWURM;VINCENZO BONIFATI;GIACOMO P. COMI","1246;1246;1108;1094;1086;1086;980;980;772;710;710;710;710;710;710;710;710;710;710;677","GIUSEPPE MANCIA;GUIDO GRASSI;MICHELE BOMBELLI;RITA FACCHETTI;ROBERTO SEGA;NEREO BRESOLIN;GIANCARLO CESANA;GIOVANNI CORRAO;ALBERTO PRIORI;ALESSIO DI FONZO;GIACOMO P. COMI;GIANLUCA ARDOLINO;B. BOSSI;ELIO SCARPINI;ROBERTO DEL BO;LAURA FUGAZZOLA;SERGIO BARBIERI;EMILIO BERTI;DANIELA GALIMBERTI;ALBERTO ZANCHETTI","1086;1086;1086;1086;1086;1050;980;980;772;710;677;542;512;503;493;474;436;435;434;432","NEREO BRESOLIN;ALBERTO ZANCHETTI;GIACOMO P. COMI;GIORGIO LA NASA;PAOLO BECK‐PECCOZ;ALBERTO PRIORI;A. SPADA;CESARE CUSPIDI;PIER MANNUCCIO MANNUCCI;STEFANO MEANI;VERONICA FUSI;AGOSTINO CORTELEZZI;EDGARDO SOMIGLIANA;EMANUELA TAIOLI;FEDERICO SCHENA;FLORA PEYVANDI;GIOVANNA MANTOVANI;GUGLIELMO FOFFANI;LAURA FUGAZZOLA;NICOLA MONTANO","14;9;7;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;PSYCHOLOGY;ENGINEERING;MATHEMATICS;MATERIALS SCIENCE;POLITICAL SCIENCE;ECONOMICS;SOCIOLOGY;PHILOSOPHY;ENVIRONMENTAL SCIENCE;GEOLOGY;BUSINESS;GEOGRAPHY;HISTORY","219;100;28;15;14;13;9;8;7;7;5;5;4;3;3;1;1;1","INTERNAL MEDICINE;GENETICS;ENDOCRINOLOGY;PATHOLOGY;SURGERY;IMMUNOLOGY;CARDIOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;RADIOLOGY;ANATOMY;CELL BIOLOGY;CANCER RESEARCH;MOLECULAR BIOLOGY;PSYCHIATRY;ONCOLOGY;UROLOGY;ANESTHESIA;NEUROSCIENCE;PEDIATRICS","164;61;46;44;43;41;40;30;25;20;16;15;15;14;14;13;12;11;10;10;10","GENE;DISEASE;POPULATION;BLOOD PRESSURE;CANCER;HEART FAILURE;KIDNEY;RECEPTOR;PREGNANCY;ANTIBODY;IMMUNOHISTOCHEMISTRY;MYOCARDIAL INFARCTION;TRANSPLANTATION;DIABETES MELLITUS;HEMODYNAMICS;HORMONE;IN VITRO;INSULIN;VIRUS;PATHOGENESIS","52;27;21;19;14;13;13;13;11;10;10;10;10;9;9;9;9;8;8;7","GENOTYPE;MUTATION;ALLELE;GENE EXPRESSION;CARCINOGENESIS;HEART RATE;INSULIN RESISTANCE;PARKINSON'S DISEASE;ALZHEIMER'S DISEASE;AMBULATORY BLOOD PRESSURE;CARDIOMYOPATHY;LIVER TRANSPLANTATION;MUTANT;PHENOTYPE;DOBUTAMINE;INFERTILITY;REVASCULARIZATION;TRANSCRIPTION FACTOR;ANTAGONIST;BASAL GANGLIA;CELL CYCLE;CHRONIC LYMPHOCYTIC LEUKEMIA;CYTOTOXIC T CELL;DEEP VEIN;DIASTOLE;EJECTION FRACTION;ESSENTIAL HYPERTENSION;EXON;GENETIC PREDISPOSITION;GENOME;HAZARD RATIO;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HEPATITIS B VIRUS;HEPATITIS C VIRUS;KIDNEY TRANSPLANTATION;LOCUS (GENETICS);PERCUTANEOUS CORONARY INTERVENTION;PLACEBO;POLYMERASE CHAIN REACTION;RESTENOSIS;RNA;SINUS RHYTHM;VASCULAR ENDOTHELIAL GROWTH FACTOR","13;11;8;7;6;6;6;6;5;5;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","SINGLE-NUCLEOTIDE POLYMORPHISM;DEEP BRAIN STIMULATION;MISSENSE MUTATION;COMPOUND HETEROZYGOSITY;GENE EXPRESSION PROFILING;HEART RATE VARIABILITY;HETEROZYGOTE ADVANTAGE;LOSS OF HETEROZYGOSITY;ADIPONECTIN;ALTERNATIVE SPLICING;BK VIRUS;CERVICAL INTRAEPITHELIAL NEOPLASIA;CONSERVED SEQUENCE;CYCLIN D1;DNA MICROARRAY;HAPLOTYPE;ISCHEMIC CARDIOMYOPATHY;LAMIVUDINE;LRRK2;MITOCHONDRIAL MYOPATHY;MONOCLONAL;MUTANT PROTEIN;NUCLEAR PROTEIN;POINT MUTATION;POLYCYSTIC OVARY;POLYMORPHISM (COMPUTER SCIENCE);PROBAND;RETINOID;RNA SPLICING;SCANNING LASER POLARIMETRY;WILD TYPE","5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;MALE;FEMALE;MIDDLE AGED;ADULT;AGED;ITALY;;HYPERTENSION;ADOLESCENT;TREATMENT OUTCOME;AGED, 80 AND OVER;RNA, MESSENGER;MYOCARDIAL INFARCTION;SKIN NEOPLASMS;BIOMARKERS;RETROSPECTIVE STUDIES;TIME FACTORS;AUTOIMMUNE DISEASES;BLOOD PRESSURE","192;125;115;94;90;77;43;42;41;24;23;22;21;18;17;16;16;16;15;15","MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DEEP BRAIN STIMULATION FOR NEUROLOGICAL DISORDERS;HEPATITIS C INFECTION AND TREATMENT;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HEPATOCELLULAR CARCINOMA;MOLECULAR PHYSIOLOGY OF PURINERGIC SIGNALLING;PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;PELVIC FLOOR DISORDERS;POLYOMAVIRUS-ASSOCIATED CARCINOGENESIS AND CLINICAL MANIFESTATIONS;THYROID DISEASE AND HORMONE REGULATION;ACUTE MYELOID LEUKEMIA;ATRIAL FIBRILLATION;CHEMISTRY AND APPLICATIONS OF ANTIMICROBIAL POLYMERS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT","10;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2","HYPERTENSION;BLOOD PRESSURE;PATHOGENESIS;TREATMENT;DEEP BRAIN STIMULATION;CARDIAC IMAGING;CARDIOVASCULAR RISK ASSESSMENT;DEEP VEIN THROMBOSIS;DOBUTAMINE;HEART RATE VARIABILITY;HEPATITIS C;REGIMEN;SUBTHALAMIC NUCLEUS;ADENOSINE RECEPTORS;B-CELL RECEPTOR SIGNALING;CARDIAC PACING;COMPOUND HETEROZYGOSITY;CORONARY STENTS;DRUG-ELUTING STENTS;ENDOTHELIAL CELL BEHAVIOR","11;8;7;7;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3","BLOOD PRESSURE;PARKINSONS DISEASE;AMBULATORY BLOOD;MULTIPLE SCLEROSIS;CHRONIC LYMPHOCYTIC;HYPERTENSIVE PATIENTS;LYMPHOCYTIC LEUKEMIA;METABOLIC SYNDROME;MYOCARDIAL INFARCTION;ACUTE MYOCARDIAL;ALZHEIMERS DISEASE;ASSISTED REPRODUCTION;B-CELL CHRONIC;CELL LYMPHOMA;CELL TRANSPLANTATION;CERVICAL CANCER;CERVICAL INTRAEPITHELIAL;COGNITIVE IMPAIRMENT;CORONARY ARTERY;CUTANEOUS T-CELL;DIABETIC PATIENTS;ENDOTHELIAL CELLS;ESSENTIAL HYPERTENSION;EXPRESSION PROFILING;FACTOR VII;FEMALE SUI;GENE MUTATION;GENETIC SUSCEPTIBILITY;GROWTH FACTOR;HEART FAILURE","9;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;BLOOD PRESSURE;RISK FACTORS;RCC CELLS;ANTI-EPCR AUTOANTIBODIES;BRUSSELS BELGIUM;ERASME BRUSSELS;SCIENCEGOOGLE SCHOLAR;BIOL CHEM;HYPERTENS ORIGINAL;ORIGINAL PAPER;BRUXELLES CAMPUS;CAMPUS ERASME;DE BRUXELLES;IRIBHM UNIVERSITÉ;LIBRE DE;UNIVERSITÉ LIBRE;CHEM -ABSTRACT;IGA ANTI-EPCR;PHARMACOL -CROSSREF;ADENOSINE RECEPTOR;IGM ANTI-EPCR;INFLAMMATORY BOWEL;CELL PROLIFERATION;ALBUMINCREATININE RATIO;BELGIUM SEARCH;FREDHOLM BB;HEART RATE;HYPERTENS REVIEW","88;62;38;32;26;24;22;22;22;19;19;19;18;18;18;18;18;18;17;17;15;14;14;14;13;12;12;12;12;12",42,0.17,3,8.64,6,21.08,5.17,2,22,0,0,0,1,1,1,0,0,0,1.5,1,2,6,2,21,0,0,0,1,1,1,5.25,2,22,0,0,0,0,0,0,1,1,1,0,0,0,2,1,3,0,0,0,0,0,0,1,1,1,0,0,0,0.08,0,1,0.17,0,2,82.83,11,226,83.08,11,226,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CAGRANDA",2006,293,8.68941979522184,2.84641638225256,0.351318944844125,0.382252559726962,0.406143344709898,0.180887372013652,0.26962457337884,9,120,44,35,75,0.41,0.15,0.12,0.26,41.9,0.820330747764434,0.242320819112628,0.9419795221843,0,0.447992374370337,0.34232723326592,0.383906432748538,0.33046902971715,"NEREO BRESOLIN;ELIO SCARPINI;DANIELA GALIMBERTI;PAOLO BECK‐PECCOZ;E. VENTURELLI;GIACOMO P. COMI;CARLO LOVATI;CHIARA FENOGLIO;LUCA PERSANI;CLAUDIO MARIANI;ANGELO VALERIO MARZANO;GIORGIO LA NASA;UMBERTO GIANELLI;MARIA DOMENICA CAPPELLINI;PIER MANNUCCIO MANNUCCI;AGOSTINO CORTELEZZI;SILVANO BÒSARI;GIANLUIGI FORLONI;EMILIO BERTI;ANNA SPADA","13;11;10;9;8;7;6;6;6;6;5;5;5;5;5;5;5;5;5;5","MARIA DOMENICA CAPPELLINI;PIER MANNUCCIO MANNUCCI;FRANCESCO BLASI;NINO STOCCHETTI;PIER ALBERTO BERTAZZI;A. CARLO ALTAMURA;FRANCESCO ONIDA;NEREO BRESOLIN;CARLO AGOSTONI;MARIA PIA RASTALDI;ELIO SCARPINI;SERENA PERCIVALLE;R. PICCINNO;FRANCO FERRARIO;M. CACCIALANZA;FRANCESCO ROCCO;G. COSTA;PAOLO BECK‐PECCOZ;ALBERTO ZANCHETTI;DANIELA GALIMBERTI","2.51;1.72;1.53;1.4;1.33;1.25;1.18;1.15;1.09;1.07;1.01;1;1;1;1;1;1;0.98;0.94;0.91","NEREO BRESOLIN;ELIO SCARPINI;DANIELA GALIMBERTI;PAOLO BECK‐PECCOZ;E. VENTURELLI;GIACOMO P. COMI;CHIARA FENOGLIO;LUCA PERSANI;ANGELO VALERIO MARZANO;GIORGIO LA NASA;UMBERTO GIANELLI;MARIA DOMENICA CAPPELLINI;PIER MANNUCCIO MANNUCCI;AGOSTINO CORTELEZZI;SILVANO BÒSARI;EMILIO BERTI;ANNA SPADA;P. BECK‐PECCOZ;FERRUCCIO BONINO;D. SCALABRINI","13;11;10;9;8;7;6;6;5;5;5;5;5;5;5;5;5;5;4;4","MARIA DOMENICA CAPPELLINI;PIER MANNUCCIO MANNUCCI;FRANCESCO BLASI;NINO STOCCHETTI;PIER ALBERTO BERTAZZI;A. CARLO ALTAMURA;FRANCESCO ONIDA;NEREO BRESOLIN;CARLO AGOSTONI;MARIA PIA RASTALDI;ELIO SCARPINI;R. PICCINNO;M. CACCIALANZA;FRANCESCO ROCCO;G. COSTA;PAOLO BECK‐PECCOZ;ALBERTO ZANCHETTI;DANIELA GALIMBERTI;ANGELO VALERIO MARZANO;CAROLINA MENSI","2.51;1.72;1.53;1.4;1.33;1.25;1.18;1.15;1.09;1.07;1.01;1;1;1;1;0.98;0.94;0.91;0.89;0.83","YVAN TORRENTE;A INNOCENZI;BEATRIZ G. GÁLVEZ;CHIARA RINALDI;CLAUDIO BORDIGNON;GIULIO COSSU;GIUSEPPE D’ANTONA;INÈS BARTHÉLÉMY;JEAN-LAUREN THIBAUD;LAURA PERANI;MARIA GABRIELLA CUSELLA DE ANGELIS;MARIA GUTTINGER;MAURILIO SAMPAOLESI;NICOLAS GRANGER;ORIETTA PANSARASA;PAOLO MOGNOL;ROBERTO BOTTINELLI;ROSSANA TONLORENZI;SARA MANTERO;STÉPHANE BLOT","852;749;749;749;749;749;749;749;749;749;749;749;749;749;749;749;749;749;749;749","YVAN TORRENTE;PAOLO BECK‐PECCOZ;ROLANDO CIMAZ;DANIELA GALIMBERTI;NEREO BRESOLIN;STEFANO BORIANI;DAVIDE SOLIGO;MARIA DOMENICA CAPPELLINI;ANNA SPADA;GIOVANNI MONTINI;GIACOMO GAZZANO;MARIA PIA RASTALDI;AGOSTINO CORTELEZZI;GIACOMO P. COMI;MONICA FUMAGALLI;EMILIO BERTI;GIANLUCA TADINI;STEFANIA ROSSI;C. ANNALORO;ANTONIO NICOLINI","852;619;618;456;409;400;376;359;355;326;325;294;293;275;246;240;237;233;225;216","NEREO BRESOLIN;DANIELA GALIMBERTI;ELIO SCARPINI;PAOLO BECK‐PECCOZ;E. VENTURELLI;GIACOMO P. COMI;MARIA DOMENICA CAPPELLINI;SILVANO BÒSARI;UMBERTO GIANELLI;AGOSTINO CORTELEZZI;ANGELO VALERIO MARZANO;PIER MANNUCCIO MANNUCCI;A. CARLO ALTAMURA;CHIARA FENOGLIO;DARIO CONSONNI;EMILIO BERTI;GIORGIO LA NASA;LUCA PERSANI;M. CACCIALANZA;NINO STOCCHETTI","11;9;9;8;7;7;5;5;5;5;5;5;4;4;4;4;4;4;4;4","MEDICINE;BIOLOGY;PSYCHOLOGY;CHEMISTRY;PHYSICS;ENGINEERING;COMPUTER SCIENCE;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY;MATERIALS SCIENCE;BUSINESS;ECONOMICS;GEOLOGY;PHILOSOPHY;GEOGRAPHY","273;104;30;27;14;13;9;8;8;8;7;5;3;3;3;1","INTERNAL MEDICINE;PATHOLOGY;GENETICS;SURGERY;IMMUNOLOGY;GASTROENTEROLOGY;ENDOCRINOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;CARDIOLOGY;PSYCHIATRY;ANESTHESIA;INTENSIVE CARE MEDICINE;RADIOLOGY;CELL BIOLOGY;PEDIATRICS;MOLECULAR BIOLOGY;CANCER RESEARCH;DERMATOLOGY;ONCOLOGY","190;67;66;60;55;39;36;29;29;25;21;20;18;18;17;17;15;14;14;13","GENE;DISEASE;POPULATION;VIRUS;CANCER;TRANSPLANTATION;PREGNANCY;MYOCARDIAL INFARCTION;RECEPTOR;ANTIBODY;BLOOD PRESSURE;IMMUNE SYSTEM;INCIDENCE (GEOMETRY);LYMPHOMA;THYROID;BONE MARROW;CHEMOTHERAPY;CIRRHOSIS;COHORT;LUNG;ODDS RATIO;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY;STEM CELL;STIMULATION","52;36;22;17;15;15;13;12;12;10;10;10;10;10;9;8;8;8;8;8;8;8;8;8;8","MUTATION;GENOTYPE;ALLELE;ALZHEIMER'S DISEASE;HEPATITIS C VIRUS;GENE EXPRESSION;PHENOTYPE;CHEMOKINE;EXON;HEPATITIS B VIRUS;INFERTILITY;LOCUS (GENETICS);CD34;CHRONIC HEPATITIS;CYCLOPHOSPHAMIDE;DEMENTIA;LIVER TRANSPLANTATION;MYCOSIS FUNGOIDES;OCCUPATIONAL MEDICINE;PERCUTANEOUS CORONARY INTERVENTION;TOLERABILITY;UNIVARIATE ANALYSIS;VIRAL LOAD","15;14;13;9;9;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4","RIBAVIRIN;HAPLOTYPE;SINGLE-NUCLEOTIDE POLYMORPHISM;MISSENSE MUTATION;ANTIRETROVIRAL THERAPY;ASSISTED REPRODUCTIVE TECHNOLOGY;CXCL10;DEEP BRAIN STIMULATION;FLUDARABINE;LAMIVUDINE;PENETRANCE;POLYMORPHISM (COMPUTER SCIENCE);RADIOIODINE THERAPY;ALLELE FREQUENCY;ALPHA (FINANCE);AZOOSPERMIA;CARDIAC INDEX;CLINICAL GLOBAL IMPRESSION;COMPOUND HETEROZYGOSITY;CRYOGLOBULINEMIA;DNA METHYLATION;ENDOTHELIAL PROGENITOR CELL;FRONTOTEMPORAL DEMENTIA;GENE EXPRESSION PROFILING;GERMLINE MUTATION;GROWTH HORMONE DEFICIENCY;HBSAG;MACE;MANIA;MORBID OBESITY;OSTEOCALCIN;OSTEOPROTEGERIN;PENDRIN;PRESENILIN;REPRODUCTIVE TECHNOLOGY;SEMEN ANALYSIS;TIMI","7;6;6;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;MALE;FEMALE;MIDDLE AGED;ADULT;;AGED;ITALY;ADOLESCENT;ALZHEIMER DISEASE;TREATMENT OUTCOME;CHILD;HYPERTENSION;RETROSPECTIVE STUDIES;POSTOPERATIVE COMPLICATIONS;CHILD, PRESCHOOL;MUTATION;MYOCARDIAL INFARCTION;OCCUPATIONAL DISEASES;PROSPECTIVE STUDIES","212;147;141;105;102;76;73;41;35;28;25;24;23;19;18;17;17;16;16;16","HEPATITIS C INFECTION AND TREATMENT;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;MECHANISMS OF ALZHEIMER'S DISEASE;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;HEPATITIS B INFECTION AND TREATMENT;CARDIAC SURGERY AND BYPASS GRAFTING OUTCOMES;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;CLINICAL MANAGEMENT OF TRACHEAL AND AIRWAY DISORDERS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;EPIDEMIOLOGY AND MANAGEMENT OF SKIN CANCER;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS;MINERAL METABOLISM IN CHRONIC KIDNEY DISEASE;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;SCHIZOPHRENIA RESEARCH AND TREATMENT","9;6;6;5;5;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","TREATMENT;HYPERTENSION;PEGYLATED INTERFERON;ASBESTOS EXPOSURE;COMBINATION THERAPY;HEPATITIS C;NEURODEGENERATION;PATHOGENESIS;LINKAGE DISEQUILIBRIUM;OUTPATIENT CLINIC;PROTEIN MISFOLDING;SNP;TOLERABILITY;UNIVARIATE ANALYSIS;ANTIVIRAL THERAPY;ASSISTED REPRODUCTIVE TECHNOLOGY;BASAL CELL CARCINOMA;CORONARY STENTS;CUMULATIVE INCIDENCE;DEFERASIROX","7;6;6;5;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3","ALZHEIMERS DISEASE;CHRONIC HEPATITIS;ITALIAN STUDY;CHRONIC LYMPHOCYTIC;CYSTIC FIBROSIS;ITALIAN POPULATION;MYOCARDIAL INFARCTION;PROSPECTIVE RANDOMIZED;RETROSPECTIVE STUDY;RISK FACTORS;STEM CELL;ACUTE CORONARY;ACUTE MYOCARDIAL;ALLOGENEIC HEMATOPOIETIC;ALZHEIMER DISEASE;ANTIRETROVIRAL THERAPY;ASSESSING RESPONSES;ASSISTED REPRODUCTIVE;AUTOIMMUNE PHENOMENA;B-CELL CHRONIC;BASAL CELL;BONE MARROW;CARDIOVASCULAR RISK;CD T-CELL;CELL CARCINOMAS;CELL TRANSPLANTATION;CLINICAL EVALUATION;CLINICAL OUTCOMES;COGNITIVE IMPAIRMENT;COMPUTED TOMOGRAPHY","7;5;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","NATIVE LUNG;PUBMED SCOPUS;STEM CELLS;PULMONARY ARTERY;DEVELOPMENTAL COMPETENCE;ICSI PROCEDURE;PARTHENOGENETIC ACTIVATION;STATISTICALLY SIGNIFICANT;LUNG TRANSPLANTATION;MULTIVARIATE ANALYSIS;PAIN RELIEF;SIGNIFICANT DIFFERENCE;STEM CELL;ACR PEDIATRIC;ACTIVATED OOCYTES;ACTIVATION PROTOCOL;CANCER PATIENTS;CARDIOPULMONARY BYPASS;HR PLT;IVF MEDIUM;LOWER PERCENTAGE;NERIDRONATE TREATMENT;OOCYTE DEVELOPMENTAL;OPG LEVELS;PAGETS DISEASE;SERUM OPG;SINGLE LUNG;B-RAF VE;C-REACTIVE PROTEIN;CD STEM","16;11;11;10;9;9;9;9;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6;6;6;6;6;5;5;5",30,0.1,3,9.56,6,26.08,6,2,24,2,2,2,1,1,1,0,0,0,1,1,1,3.5,1,5,1,1,1,1.67,1,2,7.11,2,31,0,0,0,1,1,1,2,1,3,0,0,0,5.33,2,10,0,0,0,0,0,0,1.5,1,2,1,1,1,0.56,0,2,0.44,0,4,149.44,0,548,150.44,0,554,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,5,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"CRESPIATICO LORETTA;DRAGO FRANCESCA;ESPADAS DE ARIAS ALEJANDRO;POLI FRANCESCA;VILLA MARIA ANTONIETTA","1;1;1;1;1","INDIVIDUAL","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;49 MATHEMATICAL SCIENCES","1;1;1",NA,NA,NA,NA,"C12Q1/68","1","C12Q1/6881;C12Q2600/156","1;1",2,1018800,231300,3,4.5,3,0.5,5,"FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO;CANCER RESEARCH UK;CENTRO CARDIOLOGICO MONZINO;INSTITUTE OF PLANT GENETICS AND CROP PLANT RESEARCH;LEIDEN UNIVERSITY MEDICAL CENTER;NHS BLOOD AND TRANSPLANT;POLICLINICO SAN MATTEO FONDAZIONE;VALL D'HEBRON HOSPITAL UNIVERSITARI","2;1;1;1;1;1;1;1","EUROPEAN COMMISSION;TELETHON FOUNDATION","1;1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","FP6-2004-LIFESCIHEALTH-5 (CALL FOR PROPOSAL);FP6-LIFESCIHEALTH - LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH: THEMATIC PRIORITY 1 UNDER THE FOCUSING AND INTEGRATING COMMUNITY RESEARCH PROGRAMME 2002-2006. (PROGRAMME);STREP - SPECIFIC TARGETED RESEARCH PROJECT (FUNDING SCHEME);TELETHON GRANT PROJECTS - 2006 (PROGRAM)","1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3206 MEDICAL BIOTECHNOLOGY;3209 NEUROSCIENCES","2;1;1;1","REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN;TRANSPLANTATION;BIOTECHNOLOGY;CLINICAL RESEARCH;GENETICS;HEMATOLOGY;NEURODEGENERATIVE;NEUROSCIENCES;RARE DISEASES;STEM CELL RESEARCH - EMBRYONIC - HUMAN;STEM CELL RESEARCH - UMBILICAL CORD BLOOD/ PLACENTA;STEM CELL RESEARCH - UMBILICAL CORD BLOOD/ PLACENTA - HUMAN","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","NEUROLOGICAL","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.2 CELLULAR AND GENE THERAPIES","1;1","LEUKEMIA / LEUKAEMIA;MYELOMA;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER","1;1;1;1","5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","1","A01 CLINICAL MEDICINE;A04 PSYCHOLOGY, PSYCHIATRY AND NEUROSCIENCE","1;1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,5.55,198.5,2,19.36,0,0,1,0,5,0,2,6,0,8,3,0,0,0,0,0,0,13,1,0,10,3,0,1,0,0,0,0,0,0,"United States;Germany","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;52 PSYCHOLOGY;3206 MEDICAL BIOTECHNOLOGY;3213 PAEDIATRICS;3215 REPRODUCTIVE MEDICINE;47 LANGUAGE, COMMUNICATION AND CULTURE;5202 BIOLOGICAL PSYCHOLOGY;5203 CLINICAL AND HEALTH PSYCHOLOGY","13;6;5;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;RARE DISEASES;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;CANCER;LUNG;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;TRANSPLANTATION;ACUTE RESPIRATORY DISTRESS SYNDROME;BRAIN DISORDERS;LYMPHOMA;NEUROSCIENCES;PEDIATRIC;BIOENGINEERING;CONTRACEPTION/REPRODUCTION;INFANT MORTALITY;INFECTIOUS DISEASES;KIDNEY DISEASE","6;5;4;4;3;3;3;3;3;3;2;2;2;2;2;1;1;1;1;1","CANCER;REPRODUCTIVE HEALTH AND CHILDBIRTH;RENAL AND UROGENITAL;RESPIRATORY","3;2;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY","5;4;1","NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;MYELOMA;LUNG CANCER","3;2;2;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","3;1"
"IRCCS_CAGRANDA",2007,276,8.97101449275362,2.91666666666667,0.342857142857143,0.373188405797101,0.373188405797101,0.13768115942029,0.246376811594203,7,129,53,24,57,0.47,0.19,0.09,0.21,45,0.852591794302244,0.25,0.927536231884058,0,0.434914945830182,0.418849206349206,0.397822252894717,0.411102775693924,"NEREO BRESOLIN;YVAN TORRENTE;M. BELICCHI;MIRELLA MEREGALLI;SUSANNA ESPOSITO;ANDREA FARINI;DANIELA GALIMBERTI;MANUELA GAVINA;ELIO SCARPINI;ALBERTO ZANCHETTI;D. PAROLINI;SARA MARCEGLIA;LAURA PORRETTI;NICOLA PRINCIPI;ALBERTO PRIORI;CHIARA MARCHESI;FABIOLA B. SOZZI;GIACOMO P. COMI;ANTONINO NERI;ROBERTO BOTTINELLI","16;11;11;10;10;9;8;7;6;6;6;6;6;6;6;6;5;5;5;5","ALBERTO ZANCHETTI;PIER MANNUCCIO MANNUCCI;SUSANNA ESPOSITO;NEREO BRESOLIN;SARA MARCEGLIA;MARCO VITALE;NICOLA PRINCIPI;EMILIO MERLINI;ALBERTO PRIORI;LUCIANO GATTINONI;FOGAZZI GB;EMANUELE RONDONOTTI;G AZZALI;C. GELMETTI;YVAN TORRENTE;M. BELICCHI;MIRELLA MEREGALLI;ANDREA FARINI;ROBERTO DE CASTRO;FABIOLA B. SOZZI","1.9;1.59;1.57;1.53;1.24;1.23;1.17;1.03;1.02;1.01;1;1;1;1;0.98;0.98;0.95;0.88;0.83;0.74","NEREO BRESOLIN;YVAN TORRENTE;M. BELICCHI;MIRELLA MEREGALLI;SUSANNA ESPOSITO;ANDREA FARINI;DANIELA GALIMBERTI;MANUELA GAVINA;ELIO SCARPINI;ALBERTO ZANCHETTI;D. PAROLINI;SARA MARCEGLIA;LAURA PORRETTI;NICOLA PRINCIPI;ALBERTO PRIORI;CHIARA MARCHESI;FABIOLA B. SOZZI;GIACOMO P. COMI;ANTONINO NERI;M. BATTISTELLI","16;11;11;10;10;9;8;7;6;6;6;6;6;6;6;6;5;5;5;5","ALBERTO ZANCHETTI;PIER MANNUCCIO MANNUCCI;SUSANNA ESPOSITO;NEREO BRESOLIN;SARA MARCEGLIA;MARCO VITALE;NICOLA PRINCIPI;EMILIO MERLINI;ALBERTO PRIORI;LUCIANO GATTINONI;FOGAZZI GB;EMANUELE RONDONOTTI;C. GELMETTI;YVAN TORRENTE;M. BELICCHI;MIRELLA MEREGALLI;ANDREA FARINI;ROBERTO DE CASTRO;FABIOLA B. SOZZI;CAROLINA MENSI","1.9;1.59;1.57;1.53;1.24;1.23;1.17;1.03;1.02;1.01;1;1;1;0.98;0.98;0.95;0.88;0.83;0.74;0.74","NEREO BRESOLIN;ALBERTO PRIORI;MASSIMO COLOMBO;CRISTINA RIGAMONTI;D. CONTE;G. RONCHI;GIOVANNI CASAZZA;MARIA FRANCESCA DONATO;MIRELLA FRAQUELLI;M. BELICCHI;YVAN TORRENTE;F. COGIAMANIAN;G. DANELLI;GREGORY C. FANELLI;SARA MARCEGLIA;MARCO BACIARELLO;S. LEONE;SIMONE DI CIANNI;GIUSEPPE D’ANTONA;ROBERTO BOTTINELLI","1085;844;839;831;831;831;831;831;831;731;731;719;646;646;622;594;594;594;543;543","NEREO BRESOLIN;MASSIMO COLOMBO;D. CONTE;MARIA FRANCESCA DONATO;M. BELICCHI;YVAN TORRENTE;ALBERTO PRIORI;MIRELLA MEREGALLI;MANUELA GAVINA;MAURIZIO MOGGIO;PAOLO BECK‐PECCOZ;NICOLA MONTANO;ANDREA FARINI;CHIARA MARCHESI;M. BATTISTELLI;ELIO SCARPINI;FABIO TRIULZI;ALESSANDRO TAVANO;CHIARA GAGLIARDI;FRANCO FABBRO","1053;839;831;831;731;731;721;504;501;473;437;425;406;406;406;379;378;361;361;361","NEREO BRESOLIN;M. BELICCHI;YVAN TORRENTE;MIRELLA MEREGALLI;ANDREA FARINI;SUSANNA ESPOSITO;DANIELA GALIMBERTI;MANUELA GAVINA;CHIARA MARCHESI;D. PAROLINI;NICOLA PRINCIPI;MAURIZIO MOGGIO;ALBERTO PRIORI;ELIO SCARPINI;PAOLO BECK‐PECCOZ;M. BATTISTELLI;SARA MARCEGLIA;ALBERTO ZANCHETTI;ANNA LUDOVICA FRACANZANI;ANTONINO NERI","15;11;11;10;9;8;7;7;6;6;6;5;5;5;5;5;5;4;4;4","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;MATERIALS SCIENCE;MATHEMATICS;ECONOMICS;PHILOSOPHY;ART;BUSINESS;SOCIOLOGY;POLITICAL SCIENCE;GEOLOGY;HISTORY","247;102;23;23;20;17;11;9;9;7;6;3;3;3;2;1;1","INTERNAL MEDICINE;GENETICS;PATHOLOGY;SURGERY;IMMUNOLOGY;ENDOCRINOLOGY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;RADIOLOGY;CARDIOLOGY;BIOCHEMISTRY;PEDIATRICS;CELL BIOLOGY;MOLECULAR BIOLOGY;NEUROSCIENCE;INTENSIVE CARE MEDICINE;CANCER RESEARCH;PSYCHIATRY;ANESTHESIA;ANATOMY;OPTICS","153;62;60;51;48;37;32;27;27;26;23;20;17;16;16;15;14;13;12;11;11","GENE;DISEASE;CANCER;POPULATION;ANTIBODY;BLOOD PRESSURE;STEM CELL;DIABETES MELLITUS;RANDOMIZED CONTROLLED TRIAL;TRANSPLANTATION;ALTERNATIVE MEDICINE;BIOPSY;DUCHENNE MUSCULAR DYSTROPHY;FIBROSIS;INCIDENCE (GEOMETRY);OBESITY;PREGNANCY;RECEPTOR;ENZYME;MUSCULAR DYSTROPHY;MYOCARDIAL INFARCTION;VIRUS","50;33;24;19;17;12;11;10;9;9;8;8;8;8;8;8;8;8;7;7;7;7","GENOTYPE;MUTATION;ALLELE;PHENOTYPE;EXON;PARKINSON'S DISEASE;LOCUS (GENETICS);CARCINOGENESIS;CHROMOSOME;DYSTROPHIN;PLACEBO;PROSTATE CANCER;AUTOANTIBODY;CD34;CHEMOKINE;DEGENERATIVE DISEASE;ERYTHROPOIESIS;GENE EXPRESSION;GENOME;LIVER FIBROSIS;METABOLIC SYNDROME;MONOCLONAL ANTIBODY;MUTANT;PROGENITOR CELL;PROSTATE;RITUXIMAB","13;12;10;9;8;7;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4","SINGLE-NUCLEOTIDE POLYMORPHISM;COMPARATIVE GENOMIC HYBRIDIZATION;MISSENSE MUTATION;MONOCLONAL;PROSTATECTOMY;DEEP BRAIN STIMULATION;FLUORESCENCE IN SITU HYBRIDIZATION;FRAMESHIFT MUTATION;HAPLOTYPE;POINT MUTATION;ALLELE FREQUENCY;ALTERNATIVE SPLICING;ANDROGEN RECEPTOR;ANTI-NUCLEAR ANTIBODY;CHEMOKINE RECEPTOR;COMPOUND HETEROZYGOSITY;COPY-NUMBER VARIATION;CORTICOBASAL DEGENERATION;CXCR4;DIETHYLCARBAMAZINE;DUAL-ENERGY X-RAY ABSORPTIOMETRY;ERYTHROBLAST;FAS LIGAND;FRONTOTEMPORAL DEMENTIA;GENOME INSTABILITY;GERD;GLOMERULOSCLEROSIS;GRAVES' OPHTHALMOPATHY;LAMIVUDINE;MDX MOUSE;MEDULLARY THYROID CANCER;MICROFILARIA;PNEUMOCOCCAL CONJUGATE VACCINE;PODOCYTE;PRIMARY ANGIOPLASTY;PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS;TRAB;TRANSIENT ELASTOGRAPHY;TUMOR SUPPRESSOR GENE","8;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;MALE;FEMALE;MIDDLE AGED;ADULT;AGED;;ITALY;ADOLESCENT;CHILD;MUSCLE, SKELETAL;TREATMENT OUTCOME;ANIMALS;AGED, 80 AND OVER;BRAIN;RETROSPECTIVE STUDIES;BIOMARKERS;GENETIC PREDISPOSITION TO DISEASE;PARKINSON DISEASE;FOLLOW-UP STUDIES","198;142;128;94;91;73;67;46;28;26;24;24;23;20;20;19;18;17;17;16","MOLECULAR MECHANISMS OF MUSCLE REGENERATION AND ATROPHY;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;PELVIC FLOOR DISORDERS;MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS;ROLE OF HOMOCYSTEINE IN HEALTH AND DISEASE;DEEP BRAIN STIMULATION FOR NEUROLOGICAL DISORDERS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;MANAGEMENT AND EPIDEMIOLOGY OF PNEUMONIA;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;PATHOPHYSIOLOGY OF GLOMERULAR DISEASES AND NEPHROTIC SYNDROMES;COCHLEAR NEUROPATHY AND HEARING LOSS MECHANISMS;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;HEPATITIS B INFECTION AND TREATMENT;HEPATOCELLULAR CARCINOMA;PARASITIC DISEASES AND TREATMENT STRATEGIES;PLATELET DISORDERS AND THROMBOSIS MECHANISMS;SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS","8;6;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;2","TREATMENT;SKELETAL MUSCLE ATROPHY;ASBESTOS EXPOSURE;DIAGNOSIS;METABOLIC SYNDROME;SNP;CARDIAC IMAGING;CARDIOVASCULAR RISK ASSESSMENT;COMPARATIVE GENOMIC HYBRIDIZATION;CYSTIC FIBROSIS;DEEP BRAIN STIMULATION;DYSTROPHIN;GRAVES' OPHTHALMOPATHY;INTERNATIONAL MYELOMA WORKING GROUP;MELANOMA;ROPIVACAINE;STROKE (ENGINE);DIABETES;DOBUTAMINE;ECHOCARDIOGRAPHY","10;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3","MUSCULAR DYSTROPHY;STEM CELLS;CYSTIC FIBROSIS;MULTIPLE MYELOMA;MULTIPLE SCLEROSIS;STRESS URINARY;URINARY INCONTINENCE;ADJUSTABLE CONTINENCE;ALZHEIMERS DISEASE;CONTINENCE THERAPY;DOBUTAMINE STRESS;DUCHENNE MUSCULAR;LIVER DISEASE;MAGNETIC RESONANCE;METABOLIC SYNDROME;PARKINSONS DISEASE;RANDOMIZED TRIAL;RISK FACTORS;ACUTE STROKE;ANTI-CD MONOCLONAL;ANTIBODY RITUXIMAB;BLOOD PRESSURE;BRAIN STIMULATION;C-CELL HYPERPLASIA;CARDIOVASCULAR RISK;CD CELLS;CENTRAL VENOUS;COELIAC DISEASE;COGNITIVE IMPAIRMENT;DAY SURGERY","5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","HBV DNA;CHRONIC HEPATITIS;PUBMED SCOPUS;CROSSREF PUBMED;HYPERTENS REVIEW;BLOOD PRESSURE;ADEFOVIR DIPIVOXIL;SERUM HBV;COMBINATION THERAPY;GENOTYPIC RESISTANCE;LMV-RESISTANT PATIENTS;PATIENTS TREATED;DEEP ENDOMETRIOSIS;DNA LEVEL;FEMORAL NERVE;SERUM SAMPLES;SHOULDER PAIN;ALADEFOVIR DIPIVOXIL;DNA LEVELS;NERVE STIMULATION;ADV RESISTANCE;IPSILATERAL SHOULDER;ML CI;SURFACE ANTIGEN;TRANSFERRIN SATURATION;VIROLOGIC BREAKTHROUGH;VIROLOGICAL RESPONSE;BODY MASS;CIRRHOTIC PATIENTS;CONJUGATE PNEUMOCOCCAL","46;45;43;28;19;16;14;14;13;13;13;11;10;10;10;10;10;9;9;9;8;8;8;8;8;8;8;7;7;7",42,0.15,3,10.11,6,19,5.62,2,16,0,0,0,1.33,1,2,0,0,0,1.25,1,2,5.91,2,15,0,0,0,1.33,1,2,5.81,2,17,0,0,0,1,1,1,1,1,1,0,0,0,1.67,1,3,0,0,0,0,0,0,1,1,1,0,0,0,0.06,0,1,0.25,0,2,139.31,38,392,139.62,38,393,2,1,1,0,0,0,0,0,0,0,0,0,2,0,0,0,4,1,0,0,2,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"CRESPIATICO LORETTA;DRAGO FRANCESCA;ESPADAS DE ARIAS ALEJANDRO;FOFFANI GUGLIELMO;POLI FRANCESCA;PRIORI ALBERTO;ROSSI LORENZO;VILLA MARIA ANTONIETTA","1;1;1;1;1;1;1;1","FONDAZIONE IRCCS OSPEDALE MAGGIORE POLICLINICO;INDIVIDUAL","1;1","40 ENGINEERING;32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;4003 BIOMEDICAL ENGINEERING;49 MATHEMATICAL SCIENCES","2;1;1;1;1","BRAIN DISORDERS;NEUROSCIENCES","1;1",NA,NA,"A61N1/34;A61N1/36;C12Q1/68","1;1;1","A61N1/3605;A61N1/36067;A61N1/36082;C12Q1/6881;C12Q2600/156","1;1;1;1;1",3,3786421.67,331512.62,4,9.33333333333333,4.66666666666667,1,166.5,"FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO;ALTA (ITALY);ALZHEIMER EUROPE;CASA SOLLIEVO DELLA SOFFERENZA;CEINGE BIOTECNOLOGIE AVANZATE (ITALY);ENTE OSPEDALIERO OSPEDALI GALLIERA;ERASMUS MC;EUROPEAN PARKINSONS DISEASE ASSOCIATION;GENETIC ALLIANCE UK (UNITED KINGDOM);GHENT UNIVERSITY;GLOBAL ALLIANCE OF MENTAL ILLNESS ADVOCACY NETWORKS-EUROPE;GOETHE UNIVERSITY FRANKFURT;IRBM SCIENCE PARK;ISTITUTI CLINICI DI PERFEZIONAMENTO;ISTITUTO GIANNINA GASLINI;NOVARTIS (ITALY);SAARLAND UNIVERSITY;UNIVERSITY OF BIRMINGHAM;UNIVERSITY OF GDAŃSK;UNIVERSITY OF MÜNSTER","3;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;TELETHON FOUNDATION","2;1","COALITION S;EC & ERC - EUROPEAN UNION","2;2","FP6-LIFESCIHEALTH - LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH: THEMATIC PRIORITY 1 UNDER THE FOCUSING AND INTEGRATING COMMUNITY RESEARCH PROGRAMME 2002-2006. (PROGRAMME);FP6-2004-LIFESCIHEALTH-5 (CALL FOR PROPOSAL);FP6-2005-LIFESCIHEALTH-6 (CALL FOR PROPOSAL);IP - INTEGRATED PROJECT (FUNDING SCHEME);NOE - NETWORK OF EXCELLENCE (FUNDING SCHEME);TELETHON NETWORK OF GENETIC BIOBANKS - 2007 (PROGRAM)","2;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","2;1;1;1;1;1;1","BIOTECHNOLOGY;CHRONIC LIVER DISEASE AND CIRRHOSIS;CLINICAL RESEARCH;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;GENETICS;HEPATITIS;HEPATITIS - C;HUMAN GENOME;IMMUNIZATION;INFECTIOUS DISEASES;LIVER DISEASE;PREVENTION;VACCINE RELATED","1;1;1;1;1;1;1;1;1;1;1;1;1;1","INFECTION","1","3.4 VACCINES;5.1 PHARMACEUTICALS","1;1","LIVER CANCER","1","2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;3.4 VACCINES;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","1;1;1","A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1;1","3 GOOD HEALTH AND WELL BEING","1",0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,5.12,265.88,1,24.64,0,0,2,0,4,0,2,3,0,7,2,0,0,0,0,0,0,11,0,0,9,2,0,0,0,0,0,0,0,0,"Belgium;Germany;Italy","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3213 PAEDIATRICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4207 SPORTS SCIENCE AND EXERCISE;49 MATHEMATICAL SCIENCES;52 PSYCHOLOGY;5203 CLINICAL AND HEALTH PSYCHOLOGY","11;3;3;3;2;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;HEMATOLOGY;CANCER;RARE DISEASES;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PREVENTION;BRAIN DISORDERS;INFECTIOUS DISEASES;LUNG;NEUROSCIENCES;ACUTE RESPIRATORY DISTRESS SYNDROME;ASSISTIVE TECHNOLOGY;BIOENGINEERING;BIOTECHNOLOGY;DIABETES;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;INFANT MORTALITY;LIVER DISEASE;LUNG CANCER","7;5;4;4;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CANCER;NEUROLOGICAL;CARDIOVASCULAR;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;METABOLIC AND ENDOCRINE;MUSCULOSKELETAL;RESPIRATORY","3;2;1;1;1;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","6;1;1","LEUKEMIA / LEUKAEMIA;LUNG CANCER;BLOOD CANCER;THYROID CANCER","3;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","4;1"
"IRCCS_CAGRANDA",2008,288,9.09722222222222,2.57291666666667,0.388663967611336,0.3125,0.388888888888889,0.0763888888888889,0.298611111111111,6,130,54,23,57,0.45,0.19,0.08,0.2,52.38,0.954496344727241,0.309027777777778,0.954861111111111,0,0.417600888460325,0.337711069418387,0.371184218740246,0.455411255411255,"MARIA DOMENICA CAPPELLINI;NEREO BRESOLIN;ELIO SCARPINI;DANIELA GALIMBERTI;ALESSIO AGHEMO;FLORA PEYVANDI;EDGARDO SOMIGLIANA;CHIARA FENOGLIO;MAURIZIO MOGGIO;SILVIA FUSTINONI;E. VENTURELLI;PIERGIORGIO MESSA;PIER MANNUCCIO MANNUCCI;ALBERTO PRIORI;MARIA GRAZIA RUMI;FABIO MOSCA;PAOLO BECK‐PECCOZ;FRANCESCO MONACO;MAURO VIGANÒ;ANNA LUDOVICA FRACANZANI","12;10;9;9;6;6;6;6;6;5;5;5;5;5;5;5;5;4;4;4","MARIA DOMENICA CAPPELLINI;PIER MANNUCCIO MANNUCCI;ELIO SCARPINI;DANIELA GALIMBERTI;STEFANO BORIANI;P. BECK‐PECCOZ;ROBERTO DE CASTRO;SUSANNA ESPOSITO;NICOLA PRINCIPI;UO EPATOLOGIA;GIOVANNI GAMBARO;AUGUSTO B. FEDERICI;ANDREA BARALDO;EDGARDO SOMIGLIANA;NEREO BRESOLIN;SILVIA FUSTINONI;ALESSIO AGHEMO;CHIARA FENOGLIO;MARIA GRAZIA RUMI;ALBERTO PRIORI","2.13;1.56;1.4;1.4;1.31;1.25;1.17;1.08;1.08;1;1;1;1;1;0.96;0.89;0.85;0.81;0.79;0.71","MARIA DOMENICA CAPPELLINI;NEREO BRESOLIN;ELIO SCARPINI;DANIELA GALIMBERTI;ALESSIO AGHEMO;FLORA PEYVANDI;EDGARDO SOMIGLIANA;CHIARA FENOGLIO;MAURIZIO MOGGIO;SILVIA FUSTINONI;E. VENTURELLI;PIERGIORGIO MESSA;PIER MANNUCCIO MANNUCCI;ALBERTO PRIORI;MARIA GRAZIA RUMI;FABIO MOSCA;PAOLO BECK‐PECCOZ;FRANCESCO MONACO;MAURO VIGANÒ;ANNA LUDOVICA FRACANZANI","12;10;9;9;6;6;6;6;6;5;5;5;5;5;5;5;5;4;4;4","MARIA DOMENICA CAPPELLINI;PIER MANNUCCIO MANNUCCI;ELIO SCARPINI;DANIELA GALIMBERTI;STEFANO BORIANI;P. BECK‐PECCOZ;ROBERTO DE CASTRO;SUSANNA ESPOSITO;NICOLA PRINCIPI;UO EPATOLOGIA;GIOVANNI GAMBARO;AUGUSTO B. FEDERICI;ANDREA BARALDO;EDGARDO SOMIGLIANA;NEREO BRESOLIN;SILVIA FUSTINONI;ALESSIO AGHEMO;CHIARA FENOGLIO;MARIA GRAZIA RUMI;ALBERTO PRIORI","2.13;1.56;1.4;1.4;1.31;1.25;1.17;1.08;1.08;1;1;1;1;1;0.96;0.89;0.85;0.81;0.79;0.71","BO ZHENG;BRIDGET M. DEASY;BRUNO PÉAULT;JOHNNY HUARD;LORENZA LAZZARI;MIHAELA CRISAN;BIN SUN;CHIEN‐WEN CHEN;CYRILLE NOROTTE;GABRIELLA ANDRIOLO;HANS‐JÖRG BÜHRING;JEAN‐PAUL GIACOBINO;JEREMY TRAAS;LI ZHANG;LOUIS CASTEILLA;MIRKO CORSELLI;PANG-NING TENG;REBECCA C. SCHUGAR;SOLOMON YAP;STEPHEN F. BADYLAK","3868;3868;3868;3868;3868;3868;3749;3749;3749;3749;3749;3749;3749;3749;3749;3749;3749;3749;3749;3749","LORENZA LAZZARI;GABRIELLA ANDRIOLO;ANGELO COLOMBO;FEDERICO POLLI;MASSIMO CRESSONI;F. COGIAMANIAN;ELIO SCARPINI;NEREO BRESOLIN;DANIELA GALIMBERTI;PIER MANNUCCIO MANNUCCI;MARIA DOMENICA CAPPELLINI;MAURIZIO VERGARI;MARIA PIA RASTALDI;SERGIO BARBIERI;ALBERTO ZANELLA;GIACOMO P. COMI;ROBERTO DE FRANCHIS;PIERGIORGIO MESSA;ROBERTA PALLA;STEFANO ZAGO","3868;3749;706;706;706;486;485;467;442;442;434;401;393;326;319;313;292;268;257;255","NEREO BRESOLIN;MARIA DOMENICA CAPPELLINI;ELIO SCARPINI;DANIELA GALIMBERTI;ALESSIO AGHEMO;MAURIZIO MOGGIO;CHIARA FENOGLIO;EDGARDO SOMIGLIANA;FLORA PEYVANDI;MARIA GRAZIA RUMI;PIERGIORGIO MESSA;PIER MANNUCCIO MANNUCCI;ALBERTO PRIORI;ALBERTO ZANELLA;E. VENTURELLI;F. COGIAMANIAN;FABIO MOSCA;M. COLOMBO;MASSIMO COLOMBO;MAURIZIO VERGARI","10;10;9;8;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4","MEDICINE;BIOLOGY;PSYCHOLOGY;CHEMISTRY;PHYSICS;MATHEMATICS;COMPUTER SCIENCE;ENGINEERING;ECONOMICS;POLITICAL SCIENCE;BUSINESS;PHILOSOPHY;ENVIRONMENTAL SCIENCE;MATERIALS SCIENCE;ART;HISTORY;SOCIOLOGY","266;97;22;20;20;17;15;12;10;8;6;6;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;GENETICS;PATHOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;CARDIOLOGY;ENDOCRINOLOGY;BIOCHEMISTRY;PEDIATRICS;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;PSYCHIATRY;RADIOLOGY;CELL BIOLOGY;ANESTHESIA;ONCOLOGY;DERMATOLOGY;NEUROSCIENCE;OPTICS","182;67;57;51;48;40;29;29;25;25;23;23;23;21;16;15;15;14;11;11","GENE;DISEASE;POPULATION;CANCER;PREGNANCY;STEM CELL;VIRUS;CONFIDENCE INTERVAL;ODDS RATIO;ANTIBODY;INCIDENCE (GEOMETRY);TRANSPLANTATION;BLOOD PRESSURE;CHEMOTHERAPY;CIRRHOSIS;DIABETES MELLITUS;HEART FAILURE;HEPATOCELLULAR CARCINOMA;ASYMPTOMATIC;IN VITRO;RECEPTOR;THALASSEMIA","44;43;17;16;14;12;12;11;11;10;10;10;9;9;9;8;8;8;7;7;7;7","GENOTYPE;ALLELE;MUTATION;EXON;CD34;PROGENITOR CELL;ALZHEIMER'S DISEASE;GENE EXPRESSION;HEPATITIS C VIRUS;INSULIN RESISTANCE;PHENOTYPE;CARDIOMYOPATHY;CHELATION THERAPY;CHRONIC HEPATITIS;DEMENTIA;ENDOTHELIAL STEM CELL;GESTATION;HAEMATOPOIESIS;HAZARD RATIO;PARKINSON'S DISEASE;RNA;THALIDOMIDE;UNIVARIATE ANALYSIS","12;11;11;7;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4","RIBAVIRIN;FRONTOTEMPORAL DEMENTIA;HAPLOTYPE;MISSENSE MUTATION;CD146;PERICYTE;RNA SPLICING;SINGLE-NUCLEOTIDE POLYMORPHISM;ADAMTS13;CARDIAC RESYNCHRONIZATION THERAPY;DNA METHYLATION;DRUG-ELUTING STENT;EPIRUBICIN;HBSAG;LAMIVUDINE;MULTIPOTENT STEM CELL;NONALCOHOLIC FATTY LIVER DISEASE;POINT MUTATION;POLYMORPHISM (COMPUTER SCIENCE);PROMOTER;TRANSFERRIN SATURATION;TRANSIENT ELASTOGRAPHY","5;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;MIDDLE AGED;;ADULT;AGED;ITALY;TREATMENT OUTCOME;ADOLESCENT;AGED, 80 AND OVER;FOLLOW-UP STUDIES;CHILD;RETROSPECTIVE STUDIES;RISK FACTORS;COHORT STUDIES;ANTINEOPLASTIC AGENTS;POSTOPERATIVE COMPLICATIONS;LIVER CIRRHOSIS;LIVER NEOPLASMS","197;127;124;97;82;81;69;41;33;28;27;23;22;21;19;18;17;17;16;16","GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;HEPATITIS C INFECTION AND TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;HEPATOCELLULAR CARCINOMA;MEDICAL EQUIPMENT MAINTENANCE AND MANAGEMENT;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;ATRIAL FIBRILLATION;EFFECTS OF BRAIN STIMULATION ON MOTOR CORTEX;HEPATITIS B INFECTION AND TREATMENT;MANAGEMENT AND TREATMENT OF HEMOPHILIA;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;MULTIPOTENT MESENCHYMAL STEM CELLS;PELVIC FLOOR DISORDERS;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;REGULATION OF IRON METABOLISM AND ANEMIA;ROLE OF COMPLEMENT SYSTEM IN IMMUNE RESPONSE;AGE-RELATED MACULAR DEGENERATION RESEARCH;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH","7;7;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;2;2","TREATMENT;HEPATITIS C;REGIMEN;SUBCLINICAL INFECTION;;CARDIAC IMAGING;CONCOMITANT;HEPATITIS B;LIVER BIOPSY;CHELATION THERAPY;ECHOCARDIOGRAPHY;HEPATOCELLULAR CARCINOMA;LIVER DISEASE;NEURODEGENERATION;TRANSCRANIAL DIRECT CURRENT STIMULATION;TRANSCRANIAL MAGNETIC STIMULATION;UNIVARIATE ANALYSIS;ADAMTS13;ANTICOAGULANT THERAPY;AUTOLOGOUS STEM-CELL TRANSPLANTATION","12;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3","HEPATOCELLULAR CARCINOMA;ALZHEIMERS DISEASE;CHRONIC HEPATITIS;MULTIPLE MYELOMA;MULTIPLE SCLEROSIS;PROSPECTIVE STUDY;DIRECT CURRENT;IRON OVERLOAD;CLINICAL OUTCOMES;COMMUNITY-ACQUIRED PNEUMONIA;CURRENT STIMULATION;DE NOVO;LEFT VENTRICULAR;LUNG CANCER;MUSCULAR DYSTROPHY;MYOCARDIAL INFARCTION;PATIENTS TREATED;STEM CELLS;THALASSEMIA MAJOR;ADEFOVIR MG;ATRIAL FIBRILLATION;BIOLOGICAL MONITORING;BLOOD PRESSURE;BONE MARROW;BREAST CANCER;CALF DEEP;CANCER PATIENTS;CARCINOMA HCC;CARDIAC DYSFUNCTION;CARDIAC RESYNCHRONIZATION","8;5;5;5;5;5;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","DIABETIC NEPHROPATHY;DI CARDIOLOGIA;ANTI-CYPE IGG;CONFIDENCE INTERVAL;NEURAL NETWORKS;THROMBOCYTOPENIC PURPURA;THROMBOTIC THROMBOCYTOPENIC;BONE MARROW;CONFORMATIONAL ANTI-CYPE;CONSECUTIVE PATIENTS;DIABETIC PATIENTS;GLUTATHIONYLATED HEMOGLOBIN;HEART DISEASE;NNO LEVELS;PPB IPI;PREMATURE TERMINATION;STEM CELLS;ADAMTS DEFICIENCY;ADIPOSE TISSUE;ARTIFICIAL NEURAL;COMMUNITY-ACQUIRED PNEUMONIA;DRUG-ELUTING STENTS;HEALTHY CHILDREN;HOST GENES;HR CI;IMMUNE EFFECTS;INTERVENTRICULAR SEPTUM;LEFT VENTRICULAR;MYOCARDIAL PERFORMANCE;PCD PATIENTS","12;10;8;7;7;7;7;6;6;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;5",34,0.12,5,12.72,6.5,31.192,10.78,1,52,1,1,1,1.67,1,2,0,0,0,1,1,1,10.57,2,48,1,1,1,1,1,1,12,1,53,0,0,0,1,1,1,2.25,1,6,0,0,0,1,1,1,0,0,0,0,0,0,2,1,5,1,1,1,0.67,0,4,0.44,0,1,371.89,23,2012,373,23,2014,6,2,6,0,0,0,0,0,0,0,0,0,8,0,0,14.3333333333333,2.75,1.125,2,1,3,0,2,2,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,7,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"PRIORI ALBERTO;COGIAMANIAN FILIPPO MARIA;DRAGO FRANCESCA;FOFFANI GUGLIELMO;POLI FRANCESCA;ROSSI LORENZO;CRISPIATICO LORETTA;ESPADAS DE ARIAS ALEJANDRO;KARPASITOU KATERINA;MARCEGLIA SARA RENATA FRANCESC","4;2;2;2;2;2;1;1;1;1","INDIVIDUAL;FONDAZIONE IRCCS ISTITUTO DI RICOVERO E CURA A CAR;UNIVERSITA DEGLI STUDI DI MILANO;FONDAZIONE D AMICO PER LA RICERCA SULLE MALATTIE RENALI","4;2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;40 ENGINEERING;42 HEALTH SCIENCES;3202 CLINICAL SCIENCES;4003 BIOMEDICAL ENGINEERING;4207 SPORTS SCIENCE AND EXERCISE;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3203 DENTISTRY;49 MATHEMATICAL SCIENCES","6;4;4;2;2;2;1;1;1;1","NEUROSCIENCES;BIOENGINEERING;BRAIN DISORDERS;REHABILITATION;ASSISTIVE TECHNOLOGY","3;2;2;2;1","6.7 PHYSICAL","2","C12Q1/68;A61N1/20;A61K31/165;A61K31/245;A61K31/70;A61K38/00;A61K38/18;A61N1/05;A61N1/34;A61N1/36","3;2;1;1;1;1;1;1;1;1","A61N1/20;A61N1/205;A61N1/3605;A61N1/36067;A61N1/36082;C12Q1/6881;C12Q2600/156;A61K31/165;A61K31/245;A61K38/185","2;2;2;2;2;2;2;1;1;1",1,148983,18622.88,2,8,1,1,25,"BAMBINO GESÙ CHILDREN'S HOSPITAL;CATHOLIC UNIVERSITY OF THE SACRED HEART;FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO;FONDAZIONE ISTITUTO NEUROLOGICO NAZIONALE CASIMIRO MONDINO;UNIVERSITY OF GENOA;UNIVERSITY OF MESSINA;UNIVERSITY OF PADUA;UNIVERSITY OF TURIN","1;1;1;1;1;1;1;1","TELETHON FOUNDATION","1",NA,NA,"TELETHON - UILDM CLINICAL GRANT PROJECTS - 2007 (PROGRAM)","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","1;1","BRAIN DISORDERS;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DUCHENNE/ BECKER MUSCULAR DYSTROPHY;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);MUSCULAR DYSTROPHY;PEDIATRIC;RARE DISEASES","1;1;1;1;1;1;1;1","MUSCULOSKELETAL","1",NA,NA,NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1",NA,NA,1,"PUBLIC LIBRARY OF SCIENCE","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3213 PAEDIATRICS;3215 REPRODUCTIVE MEDICINE;41 ENVIRONMENTAL SCIENCES","2;1;1;1","AGENT ORANGE & DIOXIN;CLINICAL RESEARCH;CONTRACEPTION/REPRODUCTION;PEDIATRIC;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD","1;1;1;1;1","METABOLIC AND ENDOCRINE;REPRODUCTIVE HEALTH AND CHILDBIRTH","1;1",NA,NA,"POPULATION & SOCIETY","1",NA,NA,NA,NA,"3 GOOD HEALTH AND WELL BEING","1",27,4.67,1162.7,8,28.33,1,1,7,0,8,0,0,10,0,18,6,0,0,0,0,0,0,24,1,2,23,3,0,1,0,0,0,0,0,0,"United Kingdom;Italy;Switzerland;United States","4;3;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3213 PAEDIATRICS;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;3210 NUTRITION AND DIETETICS;3211 ONCOLOGY AND CARCINOGENESIS;3215 REPRODUCTIVE MEDICINE;40 ENGINEERING;4012 FLUID MECHANICS AND THERMAL ENGINEERING;42 HEALTH SCIENCES;4206 PUBLIC HEALTH;44 HUMAN SOCIETY;4403 DEMOGRAPHY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","27;12;5;3;2;1;1;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;PEDIATRIC;CANCER;HEMATOLOGY;PATIENT SAFETY;PREVENTION;CARDIOVASCULAR;BRAIN DISORDERS;HEART DISEASE;INFECTIOUS DISEASES;LUNG;ATHEROSCLEROSIS;BIOENGINEERING;BIOTECHNOLOGY;DIABETES;INFANT MORTALITY;NEUROSCIENCES;NUTRITION","20;12;10;7;6;6;5;5;4;3;3;3;3;2;2;2;2;2;2;2","CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM;RESPIRATORY;CANCER;BLOOD;INFECTION;METABOLIC AND ENDOCRINE;MUSCULOSKELETAL;RENAL AND UROGENITAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;STROKE","4;4;4;3;2;2;1;1;1;1;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;3.4 VACCINES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES;6.2 CELLULAR AND GENE THERAPIES;6.3 MEDICAL DEVICES;6.4 SURGERY;6.7 PHYSICAL","12;1;1;1;1;1;1;1;1;1;1","LEUKEMIA / LEUKAEMIA;LUNG CANCER;COLON AND RECTAL CANCER;KAPOSI'S SARCOMA;LIVER CANCER;OVARIAN CANCER;SARCOMA","4;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","6;1;1;1;1"
"IRCCS_CAGRANDA",2009,303,9.28052805280528,2.72937293729373,0.366384522370012,0.343234323432343,0.399339933993399,0.194719471947195,0.306930693069307,10,141,67,31,52,0.47,0.22,0.1,0.17,46.52,1.00571218742282,0.273927392739274,0.930693069306931,0,0.442700105030531,0.460979042852674,0.442505315379164,0.422870436649964,"DANIELA GALIMBERTI;ELIO SCARPINI;NEREO BRESOLIN;MARIA DOMENICA CAPPELLINI;ANTONINO NERI;PAOLO BECK‐PECCOZ;AGOSTINO CORTELEZZI;LUCA BALDINI;BERNARDO DELL’OSSO;NICOLA PRINCIPI;SUSANNA ESPOSITO;YVAN TORRENTE;M. BELICCHI;P. BECK‐PECCOZ;GIORGIO LA NASA;E. VENTURELLI;ALFREDO SCILLITANI;CHIARA FENOGLIO;SILVIA FARGION;IACOPO CHIODINI","18;16;13;11;10;10;9;9;8;8;7;7;7;7;6;6;6;6;6;6","MARIA DOMENICA CAPPELLINI;CARLO AGOSTONI;DANIELA GALIMBERTI;ELIO SCARPINI;LUCIANO GATTINONI;AGOSTINO CORTELEZZI;BERNARDO DELL’OSSO;NEREO BRESOLIN;STEFANO VERALDI;PAOLO BECK‐PECCOZ;NICOLA PRINCIPI;A. CARLO ALTAMURA;FRANCESCO BLASI;DAVIDE CHIUMELLO;STEFFEN HÖDER;UO EPATOLOGIA;DOMENICO PANUCCIO;KURT BRAUNMÜLLER;SUSANNA ESPOSITO;PIER MANNUCCIO MANNUCCI","2.84;2.21;2.11;1.99;1.53;1.45;1.45;1.36;1.33;1.27;1.24;1.23;1.09;1.03;1;1;1;1;0.99;0.98","DANIELA GALIMBERTI;ELIO SCARPINI;NEREO BRESOLIN;MARIA DOMENICA CAPPELLINI;ANTONINO NERI;PAOLO BECK‐PECCOZ;AGOSTINO CORTELEZZI;LUCA BALDINI;BERNARDO DELL’OSSO;NICOLA PRINCIPI;SUSANNA ESPOSITO;YVAN TORRENTE;M. BELICCHI;P. BECK‐PECCOZ;GIORGIO LA NASA;E. VENTURELLI;CHIARA FENOGLIO;SILVIA FARGION;IACOPO CHIODINI;LUCIANO GATTINONI","18;16;13;11;10;10;9;9;8;8;7;7;7;7;6;6;6;6;6;6","MARIA DOMENICA CAPPELLINI;CARLO AGOSTONI;DANIELA GALIMBERTI;ELIO SCARPINI;LUCIANO GATTINONI;AGOSTINO CORTELEZZI;BERNARDO DELL’OSSO;NEREO BRESOLIN;STEFANO VERALDI;PAOLO BECK‐PECCOZ;NICOLA PRINCIPI;A. CARLO ALTAMURA;FRANCESCO BLASI;DAVIDE CHIUMELLO;STEFFEN HÖDER;UO EPATOLOGIA;DOMENICO PANUCCIO;KURT BRAUNMÜLLER;SUSANNA ESPOSITO;PIER MANNUCCIO MANNUCCI","2.84;2.21;2.11;1.99;1.53;1.45;1.45;1.36;1.33;1.27;1.24;1.23;1.09;1.03;1;1;1;1;0.99;0.98","DANIELA GALIMBERTI;MICHELANGELO MANCUSO;GIORGIO ANNONI;CORINNE LENDON;DIDIER HANNEQUIN;DOMINIQUE CAMPION;FLORENCE PASQUIER;JEAN‐CHARLES LAMBERT;PHILIPPE AMOUYEL;A. FRANCK;ANNICK ALPÉROVITCH;BENEDETTA NACMIAS;BÉATRICE TAVERNIER;CAROLE DUFOUIL;CHRISTINE VAN BROECKHOVEN;CHRISTOPHE TZOURIO;CLAUDINE BERR;CÉLINE JAILLARD;DAVIDE SERIPA;DIANA ZÉLÉNIKA","2450;2262;2188;2116;2116;2116;2116;2116;2116;2096;2096;2096;2096;2096;2096;2096;2096;2096;2096;2096","DANIELA GALIMBERTI;LUCIANO GATTINONI;ANGELO SELICORNI;LETIZIA TARANTINI;VALENTINA BOLLATI;PAOLO BECK‐PECCOZ;MARIA CRISTINA PIETROGRANDE;FEDERICO POLLI;LUCA A. RAMENGHI;MARIA DOMENICA CAPPELLINI;SILVIA FARGION;MASSIMO IAVARONE;SARA MASSIRONI;MIRELLA FRAQUELLI;A. SANGIOVANNI;LAURA FORZENIGO;M. COLOMBO;M.A. MANINI;PIERPAOLO BIONDETTI;R. ROMEO","2450;942;747;632;632;566;563;562;531;465;464;418;407;404;401;401;401;401;401;401","DANIELA GALIMBERTI;ELIO SCARPINI;NEREO BRESOLIN;LUCA BALDINI;ANTONINO NERI;MARIA DOMENICA CAPPELLINI;BERNARDO DELL’OSSO;NICOLA PRINCIPI;M. BELICCHI;P. BECK‐PECCOZ;YVAN TORRENTE;CHIARA FENOGLIO;LUCIANO GATTINONI;PAOLO BECK‐PECCOZ;SILVIA FARGION;E. VENTURELLI;A. CARLO ALTAMURA;FRANCESCO BLASI;GIACOMO P. COMI;GIORGIO LA NASA","18;16;12;9;9;9;8;8;7;6;6;6;6;6;6;5;5;5;5;5","MEDICINE;BIOLOGY;CHEMISTRY;PSYCHOLOGY;COMPUTER SCIENCE;PHYSICS;ENGINEERING;ECONOMICS;POLITICAL SCIENCE;MATHEMATICS;MATERIALS SCIENCE;PHILOSOPHY;SOCIOLOGY;ART;BUSINESS;GEOGRAPHY;ENVIRONMENTAL SCIENCE;GEOLOGY;HISTORY","276;119;23;20;19;19;14;9;9;8;7;6;6;4;2;2;1;1;1","INTERNAL MEDICINE;GENETICS;SURGERY;PATHOLOGY;IMMUNOLOGY;ENDOCRINOLOGY;GASTROENTEROLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;CANCER RESEARCH;CARDIOLOGY;ONCOLOGY;PEDIATRICS;CELL BIOLOGY;NEUROSCIENCE;RADIOLOGY;ANESTHESIA;INTENSIVE CARE MEDICINE;PSYCHIATRY;OPTICS;VIROLOGY","200;76;61;50;49;45;41;29;27;19;19;19;19;18;18;18;17;16;15;12;12","GENE;DISEASE;POPULATION;CANCER;HORMONE;RECEPTOR;STEM CELL;VIRUS;RANDOMIZED CONTROLLED TRIAL;CHEMOTHERAPY;ANTIBODY;DIABETES MELLITUS;IN VITRO;PREGNANCY;CONFIDENCE INTERVAL;INSULIN;LUNG;ODDS RATIO;TRANSPLANTATION;ADVERSE EFFECT;LYMPHOMA;THYROID","68;39;24;19;13;13;13;13;12;11;10;10;10;10;9;9;9;9;9;8;8;8","GENOTYPE;ALLELE;MUTATION;DEMENTIA;PHENOTYPE;CD34;GENE EXPRESSION;ALZHEIMER'S DISEASE;BASAL (MEDICINE);CHRONIC HEPATITIS;CHRONIC LYMPHOCYTIC LEUKEMIA;EXON;HAZARD RATIO;HEPATITIS B VIRUS;HEPATITIS C VIRUS;MYELODYSPLASTIC SYNDROMES;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MICRORNA;PERCUTANEOUS CORONARY INTERVENTION;PLACEBO;RITUXIMAB;TOLERABILITY","21;17;14;8;7;6;6;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4","SINGLE-NUCLEOTIDE POLYMORPHISM;FRONTOTEMPORAL DEMENTIA;MISSENSE MUTATION;POLYMORPHISM (COMPUTER SCIENCE);ALLELE FREQUENCY;HBSAG;MACE;RIBAVIRIN;ACROMEGALY;CD38;KRAS;MOLECULAR MEDICINE;PODOCYTE;CD146;COLONOSCOPY;COMPOUND HETEROZYGOSITY;DIFFUSE ALVEOLAR DAMAGE;DNA METHYLATION;DRUG-ELUTING STENT;FLUDARABINE;GENE MUTATION;GENOTYPING;GLOMERULAR BASEMENT MEMBRANE;HAPLOTYPE;HUMAN GENOME;KARYOTYPE;LAMIVUDINE;MONOCLONAL;MULTIPLEX POLYMERASE CHAIN REACTION;PARATHYROID NEOPLASM;PERICYTE;PROBAND;SEROTONIN TRANSPORTER;TARGET LESION;TRANSFERRIN SATURATION;TRANSIENT ELASTOGRAPHY;TREATMENT-RESISTANT DEPRESSION;VAGUS NERVE STIMULATION","11;6;5;5;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;MIDDLE AGED;;AGED;ADULT;ITALY;YOUNG ADULT;ADOLESCENT;CHILD;TREATMENT OUTCOME;RISK FACTORS;MULTIPLE MYELOMA;AGED, 80 AND OVER;GENOTYPE;POLYMORPHISM, SINGLE NUCLEOTIDE;BRAIN;MUTATION;BIOMARKERS","199;143;139;101;98;81;79;47;31;25;25;25;23;22;21;20;20;19;19;18","GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;HEPATITIS C INFECTION AND TREATMENT;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;MECHANISMS OF ALZHEIMER'S DISEASE;MOLECULAR MECHANISMS OF MUSCLE REGENERATION AND ATROPHY;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;THYROID DISEASE AND HORMONE REGULATION;ACUTE MYELOID LEUKEMIA;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;HEPATITIS B INFECTION AND TREATMENT;NEUROIMMUNE INTERACTION IN PSYCHIATRIC DISORDERS;ROLE OF COMPLEMENT SYSTEM IN IMMUNE RESPONSE;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;DENTAL IMPLANTOLOGY AND PERI-IMPLANT DISEASES;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;EPIDEMIOLOGY AND PATHOGENESIS OF RESPIRATORY VIRAL INFECTIONS","8;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;3;3;3;3","TREATMENT;DEPRESSION (ECONOMICS);FRONTOTEMPORAL LOBAR DEGENERATION;NEURODEGENERATION;SUBCLINICAL INFECTION;TRANSFUSION THERAPY;BASAL (MEDICINE);DRUG-ELUTING STENTS;HYPERTHYROIDISM;HYPOTHYROIDISM;PATHOGENESIS;POSITIVE END-EXPIRATORY PRESSURE;ANTICOAGULANT THERAPY;CONCOMITANT;CYSTIC FIBROSIS;DYSTROPHIN;GENETIC ASSOCIATION;HBV INFECTION;HEPATITIS B;LIVER BIOPSY","10;6;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4","ALZHEIMERS DISEASE;LUNG CANCER;MULTIPLE MYELOMA;STEM CELL;ASSOCIATION STUDY;CHRONIC HEPATITIS;CYSTIC FIBROSIS;FRONTOTEMPORAL LOBAR;LOBAR DEGENERATION;LYMPHOCYTIC LEUKEMIA;MUSCULAR DYSTROPHY;RESPIRATORY DISTRESS;ACUTE OTITIS;ACUTE RESPIRATORY;BARE METAL;CELL TRANSPLANTATION;CHRONIC LYMPHOCYTIC;COMMUNITY-ACQUIRED PNEUMONIA;DISTRESS SYNDROME;IRON OVERLOAD;LIVER DISEASE;METAL STENT;OTITIS MEDIA;PATIENTS AFFECTED;PRIMARY ANGIOPLASTY;STEM CELLS;ACROMEGALIC PATIENTS;ADULT HUMAN;ADULT PATIENTS;ALLOGENEIC STEM","10;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2","CD CELLS;PUBMED SCOPUS;CROSSREF PUBMED;PARATHYROID GLANDS;GENE EXPRESSION;HFE MUTATIONS;LUNG CANCER;PARATHYROID TUMORS;SCIENCEGOOGLE SCHOLAR;IRON ACCUMULATION;NORMAL PARATHYROID;STEM CELL;STEM CELLS;IRON OVERLOAD;SIGNIFICANTLY LOWER;TUMORAL PARATHYROID;UNIVERSITÀ DI;CANCER RISK;CONFIDENCE INTERVAL;HYPER-IGE SYNDROME;ODDS RATIO;PARATHYROID-DERIVED CD;ENDOTHELIAL CELLS;IRON STATUS;MRNA LEVELS;MULTIPLE MYELOMA;ALZHEIMERS DISEASE;BAS MODULATE;CELL CYCLE;CELL LINES","80;67;61;19;18;18;18;17;15;13;13;13;13;11;11;11;11;10;10;10;10;10;9;9;9;9;8;8;8;8",46,0.15,3,7.83,6,11,3.57,2,9,0,0,0,1,1,1,1,1,1,1,1,1,3.5,1,9,0,0,0,1.6,1,2,3.57,2,9,0,0,0,1,1,1,1,1,1,0,0,0,1,1,1,0,0,0,1,1,1,1,1,1,0,0,0,0.36,0,2,0.29,0,1,120.14,10,367,120.79,10,370,2,2,1,0,0,0,0,0,0,0,0,0,3,0,0,0,4.33333333333333,1,0,0,3,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"GIORDANO ROSARIA;LAZZARI LORENZA;MONTEMURRO TIZIANA;REBULLA PAOLO;SIRCHIA GIROLAMO;DRAGO FRANCESCA;KARPASITOU KATERINA;POLI FRANCESCA","2;2;2;2;2;1;1;1","FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO;INDIVIDUAL","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY","4;1;1","BIOTECHNOLOGY;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN","1;1;1;1",NA,NA,"A61K35/12;C12N5/073;C12N5/078;C12N5/00;C12N5/07;C12Q1/68","2;2;2;1;1;1","A61K2035/124;A61P19/10;A61P35/00;A61P35/02;A61P37/02;A61P7/06;C12N2501/125;C12N2501/145;C12N2501/23;C12N2501/26","2;2;2;2;2;2;2;2;2;2",5,791733.4,128832.7,2.2,7,1.8,0.6,12,"FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO;CATHOLIC UNIVERSITY OF THE SACRED HEART;UNIVERSITY OF MESSINA;UNIVERSITY OF PADUA;UNIVERSITY OF TURIN;UNIVERSITY OF VERONA;ALCIMED;BAMBINO GESÙ CHILDREN'S HOSPITAL;DÉLÉGATION PARIS 11;FONDAZIONE HUMANITAS PER LA RICERCA;FONDAZIONE ISTITUTO NEUROLOGICO NAZIONALE CASIMIRO MONDINO;FONDAZIONE SANTA LUCIA;FONDAZIONE STELLA MARIS;FRENCH NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;OTR3 (FRANCE);SAARLAND UNIVERSITY;UNIVERSITY HOSPITAL HEIDELBERG;UNIVERSITY OF CHIETI-PESCARA;UNIVERSITY OF MODENA AND REGGIO EMILIA;UNIVERSITY OF NAPLES FEDERICO II","5;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","TELETHON FOUNDATION;EUROPEAN COMMISSION","4;1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","TELETHON - UILDM CLINICAL GRANT PROJECTS - 2008 (PROGRAM);TELETHON GRANT PROJECTS - 2009 (PROGRAM);CP-FP - SMALL OR MEDIUM-SCALE FOCUSED RESEARCH PROJECT (FUNDING SCHEME);FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2007-B (CALL FOR PROPOSAL)","2;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY;31 BIOLOGICAL SCIENCES;3105 GENETICS;3209 NEUROSCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","5;3;2;2;1;1;1","GENETICS;PEDIATRIC;RARE DISEASES;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;BIOTECHNOLOGY;BRAIN DISORDERS;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);MUSCULAR DYSTROPHY;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN;TRANSPLANTATION;CLINICAL RESEARCH;CONGENITAL STRUCTURAL ANOMALIES;DUCHENNE/ BECKER MUSCULAR DYSTROPHY;FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY;GENE THERAPY;NEURODEGENERATIVE;NEUROSCIENCES;SPINAL MUSCULAR ATROPHY","3;3;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1","MUSCULOSKELETAL;GENERIC HEALTH RELEVANCE;NEUROLOGICAL","2;1;1","5.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.2 CELLULAR AND GENE THERAPIES","3;2;1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE;A04 PSYCHOLOGY, PSYCHIATRY AND NEUROSCIENCE;C21 SOCIOLOGY","3;1;1",NA,NA,6,"PUBLIC LIBRARY OF SCIENCE","6","42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3105 GENETICS;4202 EPIDEMIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","7;6;4;3;3;2","CANCER;GENETICS;LUNG;LUNG CANCER;TOBACCO;TOBACCO SMOKE AND HEALTH;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HUMAN GENOME;PREVENTION;RARE DISEASES;SUBSTANCE MISUSE","4;3;3;3;3;3;1;1;1;1;1;1","CANCER;RESPIRATORY","5;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1","BIOMEDICAL","1","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH","2;1","LUNG CANCER","4",NA,NA,21,3.62,818.59,3,50.57,0,0,2,1,8,0,2,8,0,12,6,0,0,0,0,0,0,15,3,3,16,3,0,1,1,0,0,0,0,0,"United States;Italy;Japan;Switzerland","3;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;52 PSYCHOLOGY;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3210 NUTRITION AND DIETETICS;3213 PAEDIATRICS;3215 REPRODUCTIVE MEDICINE;40 ENGINEERING;4014 MANUFACTURING ENGINEERING;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;5203 CLINICAL AND HEALTH PSYCHOLOGY","21;9;5;2;2;1;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;CANCER;HEMATOLOGY;PEDIATRIC;PREVENTION;LUNG;PATIENT SAFETY;AGING;ASSISTIVE TECHNOLOGY;BIOENGINEERING;CARDIOVASCULAR;HEART DISEASE;PROSTATE CANCER;UROLOGIC DISEASES;ACUTE RESPIRATORY DISTRESS SYNDROME;AUTOIMMUNE DISEASE;BEHAVIORAL AND SOCIAL SCIENCE;BRAIN DISORDERS","12;9;6;5;4;4;4;3;3;2;2;2;2;2;2;2;1;1;1;1","CANCER;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY;CARDIOVASCULAR;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;METABOLIC AND ENDOCRINE;MUSCULOSKELETAL","3;2;2;1;1;1;1;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;3.3 NUTRITION AND CHEMOPREVENTION;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.6 PSYCHOLOGICAL AND BEHAVIOURAL;7.1 INDIVIDUAL CARE NEEDS","9;2;1;1;1;1;1;1","PROSTATE CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;OVARIAN CANCER;PANCREATIC CANCER;PARATHYROID CANCER;PITUITARY TUMOR;STOMACH CANCER","2;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","4;1;1"
"IRCCS_CAGRANDA",2010,531,9.67043314500942,3.24858757062147,0.307826086956522,0.467043314500942,0.453860640301318,0.350282485875706,0.384180790960452,16,275,109,47,65,0.52,0.21,0.09,0.12,43.27,0.957526400323248,0.303201506591337,0.926553672316384,0,0.469713961474753,0.401654770782287,0.434969864714555,0.432198347107438,"DARIO CONSONNI;SUSANNA ESPOSITO;MARIA DOMENICA CAPPELLINI;GIORGIO LA NASA;DANIELA GALIMBERTI;ELIO SCARPINI;NICOLA PRINCIPI;ANTONINO NERI;AGOSTINO CORTELEZZI;NEREO BRESOLIN;SILVIA FARGION;PAOLO BECK‐PECCOZ;PIER ALBERTO BERTAZZI;PIER MANNUCCIO MANNUCCI;FABIO MOSCA;LUCIANO RIBOLDI;LUCA VALENTI;FRANCESCO ONIDA;ANDREA BACCARELLI;STELLA FORTI","17;16;16;15;15;13;13;12;12;12;11;11;10;10;10;9;9;9;9;8","DAVIDE CHIUMELLO;DANIELA GALIMBERTI;PIER MANNUCCIO MANNUCCI;PAOLO REBULLA;ELIO SCARPINI;GIOVANNI COSTA;ANGELA CECILIA PESATORI;FABIO MOSCA;NINO STOCCHETTI;DARIO CONSONNI;LUCIANO RIBOLDI;SUSANNA ESPOSITO;MARIA DOMENICA CAPPELLINI;ANDREA BACCARELLI;LORENZO PIGNATARO;LORENZO BERETTA;CARLO VERGANI;LUCA VALENTI;STELLA FORTI;PIER ALBERTO BERTAZZI","2.44;2.21;2.1;2.04;1.95;1.87;1.84;1.82;1.82;1.81;1.79;1.78;1.76;1.65;1.53;1.52;1.51;1.49;1.46;1.38","DARIO CONSONNI;SUSANNA ESPOSITO;MARIA DOMENICA CAPPELLINI;GIORGIO LA NASA;DANIELA GALIMBERTI;ELIO SCARPINI;NICOLA PRINCIPI;ANTONINO NERI;AGOSTINO CORTELEZZI;NEREO BRESOLIN;SILVIA FARGION;PAOLO BECK‐PECCOZ;PIER ALBERTO BERTAZZI;PIER MANNUCCIO MANNUCCI;FABIO MOSCA;LUCIANO RIBOLDI;LUCA VALENTI;FRANCESCO ONIDA;ANDREA BACCARELLI;STELLA FORTI","17;16;16;15;15;13;13;12;12;12;11;11;10;10;10;9;9;9;9;8","DAVIDE CHIUMELLO;DANIELA GALIMBERTI;PIER MANNUCCIO MANNUCCI;PAOLO REBULLA;ELIO SCARPINI;GIOVANNI COSTA;ANGELA CECILIA PESATORI;FABIO MOSCA;NINO STOCCHETTI;DARIO CONSONNI;LUCIANO RIBOLDI;SUSANNA ESPOSITO;MARIA DOMENICA CAPPELLINI;ANDREA BACCARELLI;LORENZO PIGNATARO;LORENZO BERETTA;CARLO VERGANI;LUCA VALENTI;STELLA FORTI;PIER ALBERTO BERTAZZI","2.44;2.21;2.1;2.04;1.95;1.87;1.84;1.82;1.82;1.81;1.79;1.78;1.76;1.65;1.53;1.52;1.51;1.49;1.46;1.38","ROBERTO DE FRANCHIS;ANDREA BACCARELLI;VALENTINA BOLLATI;SILVIA FARGION;GIOVANNI COSTA;MASSIMO COLOMBO;LUCA VALENTI;PIER MANNUCCIO MANNUCCI;LETIZIA TARANTINI;DARIO CONSONNI;ALBERTO PRIORI;KURT STRAÍF;ROEL VERMEULEN;PAOLO BECK‐PECCOZ;JOEL SCHWARTZ;PAOLA DONGIOVANNI;ANTONIO GRIECO;SERGIO BARBIERI;ERHARD HAUS;EVA SCHERNHAMMER","2277;1403;1229;1167;1126;919;905;834;825;820;819;756;756;753;745;736;735;717;592;592","ROBERTO DE FRANCHIS;ANDREA BACCARELLI;VALENTINA BOLLATI;GIOVANNI COSTA;SILVIA FARGION;LUCA VALENTI;ALBERTO PRIORI;LETIZIA TARANTINI;SERGIO BARBIERI;PAOLA DONGIOVANNI;PIER MANNUCCIO MANNUCCI;DARIO CONSONNI;PAOLO BECK‐PECCOZ;SUSANNA ESPOSITO;BENEDETTA DEL MENICO;E. GALMOZZI;PIER ALBERTO BERTAZZI;NICOLA PRINCIPI;ANNA LUDOVICA FRACANZANI;MASSIMO COLOMBO","2277;1346;1172;1126;1092;851;819;768;717;682;645;621;572;553;548;548;539;524;517;517","MARIA DOMENICA CAPPELLINI;SUSANNA ESPOSITO;DARIO CONSONNI;NICOLA PRINCIPI;GIORGIO LA NASA;DANIELA GALIMBERTI;ELIO SCARPINI;ANTONINO NERI;AGOSTINO CORTELEZZI;NEREO BRESOLIN;PIER ALBERTO BERTAZZI;FABIO MOSCA;FRANCESCO ONIDA;LORENZO BERETTA;SILVIA FARGION;CHIARA FENOGLIO;ALBERTO PRIORI;ANDREA BACCARELLI;LUCA VALENTI;PAOLO BECK‐PECCOZ","16;16;15;13;13;13;13;12;11;11;9;9;9;9;9;8;8;8;8;8","MEDICINE;BIOLOGY;CHEMISTRY;PSYCHOLOGY;COMPUTER SCIENCE;PHYSICS;ENGINEERING;MATHEMATICS;MATERIALS SCIENCE;POLITICAL SCIENCE;SOCIOLOGY;ECONOMICS;PHILOSOPHY;ENVIRONMENTAL SCIENCE;BUSINESS;ART;GEOGRAPHY;GEOLOGY;HISTORY","485;206;47;47;37;37;28;20;17;17;16;15;13;8;6;5;3;3;3","INTERNAL MEDICINE;GENETICS;PATHOLOGY;SURGERY;IMMUNOLOGY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;ENDOCRINOLOGY;BIOCHEMISTRY;PEDIATRICS;PSYCHIATRY;CARDIOLOGY;INTENSIVE CARE MEDICINE;CANCER RESEARCH;RADIOLOGY;ANESTHESIA;CELL BIOLOGY;MOLECULAR BIOLOGY;ONCOLOGY;PHYSICAL THERAPY","335;136;111;106;103;85;59;56;48;48;46;42;35;32;31;30;29;23;23;23","GENE;DISEASE;POPULATION;ANTIBODY;PREGNANCY;CANCER;BLOOD PRESSURE;STEM CELL;BONE MARROW;CONFIDENCE INTERVAL;VIRUS;RANDOMIZED CONTROLLED TRIAL;ANTIGEN;BODY MASS INDEX;TRANSPLANTATION;ADVERSE EFFECT;CIRRHOSIS;IN VITRO;INCIDENCE (GEOMETRY);LYMPHOMA;ODDS RATIO","98;78;51;27;27;26;22;21;20;20;20;18;17;17;17;16;16;15;15;15;15","GENOTYPE;MUTATION;ALLELE;GENE EXPRESSION;DEMENTIA;FETUS;GESTATIONAL AGE;RITUXIMAB;FATTY LIVER;HAEMATOPOIESIS;EPIGENETICS;EXON;PLACEBO;AUTOANTIBODY;CHRONIC LYMPHOCYTIC LEUKEMIA;HEART RATE;METHYLATION;TOLERABILITY;ALZHEIMER'S DISEASE;BIRTH WEIGHT;HUMAN LEUKOCYTE ANTIGEN;INFECTIOUS DISEASE (MEDICAL SPECIALTY);LIVER BIOPSY;PROGENITOR CELL","30;20;18;18;15;11;11;11;10;10;9;9;9;8;8;8;8;8;7;7;7;7;7;7","SINGLE-NUCLEOTIDE POLYMORPHISM;DNA METHYLATION;FRONTOTEMPORAL DEMENTIA;HAPLOTYPE;CORONAVIRUS DISEASE 2019 (COVID-19);COMPOUND HETEROZYGOSITY;MISSENSE MUTATION;NONALCOHOLIC FATTY LIVER DISEASE;GENE EXPRESSION PROFILING;ALLELE FREQUENCY;FLUDARABINE;INEFFECTIVE ERYTHROPOIESIS;PLACENTA;POINT MUTATION;POLYMORPHISM (COMPUTER SCIENCE);TRANSIENT ELASTOGRAPHY;CD38;DEEP BRAIN STIMULATION;DORSOLATERAL PREFRONTAL CORTEX;DRUG-ELUTING STENT;FACTOR V LEIDEN;IGHV@;OSTEOPENIA;PSEUDOHYPOPARATHYROIDISM;RIBAVIRIN;STEATOHEPATITIS","15;11;8;8;7;6;6;6;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","HUMANS;FEMALE;MALE;ADULT;;MIDDLE AGED;AGED;ITALY;YOUNG ADULT;ADOLESCENT;TREATMENT OUTCOME;CHILD;AGED, 80 AND OVER;LIVER CIRRHOSIS;FATTY LIVER;FOLLOW-UP STUDIES;CHILD, PRESCHOOL;RETROSPECTIVE STUDIES;INFANT;PROSPECTIVE STUDIES","368;253;240;157;154;152;111;90;55;51;50;49;48;43;37;35;32;32;30;30","EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HEALTH EFFECTS OF AIR POLLUTION;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;HEPATITIS C INFECTION AND TREATMENT;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;REGULATION OF IRON METABOLISM AND ANEMIA;SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME;INFLUENZA VIRUS RESEARCH AND EPIDEMIOLOGY;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;;EPIGENETIC MODIFICATIONS AND THEIR FUNCTIONAL IMPLICATIONS;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;ACUTE MYELOID LEUKEMIA;ATRIAL FIBRILLATION;DEEP BRAIN STIMULATION FOR NEUROLOGICAL DISORDERS","15;9;9;9;8;7;7;7;7;7;7;6;6;5;5;5;5;4;4;4","TREATMENT;DEPRESSION (ECONOMICS);EXPOSURE ASSESSMENT;LIVER DISEASE;NEURODEGENERATION;REGIMEN;SNP;STEATOSIS;COMPOUND HETEROZYGOSITY;FRONTOTEMPORAL LOBAR DEGENERATION;HYPERTENSION;POSITIVE END-EXPIRATORY PRESSURE;PRETERM INFANTS;STROKE (ENGINE);TOLERABILITY;BASAL (MEDICINE);CLINICAL ENDPOINT;CORD BLOOD;ETIOLOGY;GENETIC ASSOCIATION","20;8;8;8;8;8;8;8;7;7;7;7;7;7;7;6;6;6;6;6","CHRONIC HEPATITIS;SYSTEMIC SCLEROSIS;ALZHEIMERS DISEASE;FATTY LIVER;LEFT VENTRICULAR;LIVER DISEASE;BONE MARROW;CHRONIC LYMPHOCYTIC;CORD BLOOD;FRONTOTEMPORAL LOBAR;LOBAR DEGENERATION;LYMPHOCYTIC LEUKEMIA;BLOOD PRESSURE;CLINICAL OUTCOME;ESSENTIAL HYPERTENSION;LUNG CANCER;MULTICENTER STUDY;MULTIPLE MYELOMA;MULTIPLE SCLEROSIS;PRETERM INFANTS;AIRWAY PRESSURE;BASAL CELL;CIRRHOTIC PATIENTS;DNA METHYLATION;INTENSIVE CARE;ITALIAN STUDY;MAGNETIC RESONANCE;MYELODYSPLASTIC SYNDROMES;MYOCARDIAL INFARCTION;STEM CELL","9;8;7;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4","PUBMED SCOPUS;CROSSREF PUBMED;LUNG CANCER;DNA METHYLATION;CONFIDENCE INTERVAL;LIVER DISEASE;BONE MARROW;GROWTH FACTOR;RISK FACTORS;MYOCARDIAL INFARCTION;ODDS RATIO;STATISTICALLY SIGNIFICANT;CHOLESTEROL LEVELS;GENE EXPRESSION;IRON OVERLOAD;LDL CHOLESTEROL;TKI THERAPY;CELL LUNG;COPY GAIN;EGFR TKI;EPIDERMAL GROWTH;BLOOD PRESSURE;FACTOR RECEPTOR;FATTY LIVER;GESTATIONAL AGE;INCREASED RISK;NON-SMALL CELL;PRIMARY RESISTANCE;SIGNIFICANTLY LOWER;BODY COMPOSITION","86;65;35;24;22;21;19;19;19;17;17;16;15;15;15;15;15;13;13;13;13;12;12;12;12;12;12;12;12;11",92,0.17,3,20.03,7,216.25,6.72,1,37,2.33,1,5,1,1,1,0,0,0,3.6,1,26,3,1,12,0,0,0,2.17,1,4,7.48,1,37,2,2,2,1,1,1,5.4,1,29,1,1,1,1.4,1,3,2,2,2,1.8,1,4,3.5,1,21,2,2,2,0.24,0,3,0.12,0,2,168.12,2,615,168.48,2,615,5,0,4,0,1,2,0,0,1,1,0,0,7,2,0,2,4.22222222222222,1,0,0,5,0,1,3,0,1,3,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,2,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"DRAGO FRANCESCA;POLI FRANCESCA;GIORDANO ROSARIA;KARPASITOU KATERINA;LAZZARI LORENZA;MONTEMURRO TIZIANA;REBULLA PAOLO;SIRCHIA GIROLAMO;BONINO FERRUCCIO;CATANIA ANNA","3;3;2;2;2;2;2;2;1;1","FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO","9","32 BIOMEDICAL AND CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;33 BUILT ENVIRONMENT AND DESIGN;34 CHEMICAL SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;4207 SPORTS SCIENCE AND EXERCISE;49 MATHEMATICAL SCIENCES","13;4;3;2;1;1;1;1;1","REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN;BIOTECHNOLOGY;RARE DISEASES;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN","4;4;4;2;1;1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;5.1 PHARMACEUTICALS;6.7 PHYSICAL","1;1;1","A61K35/12;C12N5/073;C12N5/078;C12Q1/68;C12N5/00;C12N5/074;C12N5/0789;A61K35/28;A61K38/34;A61K48/00","4;4;4;3;2;2;2;1;1;1","A61K2035/124;A61P19/10;A61P35/00;A61P35/02;A61P37/02;A61P7/06;C12N2501/125;C12N2501/145;C12N2501/23;C12N2501/26","4;4;4;4;4;4;4;4;4;4",3,4183880,329753.17,3.33333333333333,10.6666666666667,3.33333333333333,0.666666666666667,51,"FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO;UNIVERSITY OF VERONA;ALCIMED;ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS;ATOMIC ENERGY AND ALTERNATIVE ENERGIES COMMISSION;AUTONOMOUS UNIVERSITY OF MADRID;BAMBINO GESÙ CHILDREN'S HOSPITAL;CATHOLIC UNIVERSITY OF THE SACRED HEART;CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES;CENTRE HOSPITALIER UNIVERSITAIRE DE TOURS;DÉLÉGATION PARIS 11;ISTITUTO GIANNINA GASLINI;ISTITUTO ORTOPEDICO RIZZOLI;KITOZYME (BELGIUM);MAX PLANCK SOCIETY;UNIVERSITAT POLITÈCNICA DE CATALUNYA;UNIVERSITY MEDICAL CENTER UTRECHT;UNIVERSITY OF BERGEN;UNIVERSITY OF BOLOGNA;UNIVERSITY OF LIÈGE","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","TELETHON FOUNDATION;EUROPEAN COMMISSION","2;1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CP-IP - LARGE-SCALE INTEGRATING PROJECT (FUNDING SCHEME);FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2009-SINGLE-STAGE (CALL FOR PROPOSAL);TELETHON - UILDM CLINICAL GRANT PROJECTS - 2009 (PROGRAM);TELETHON GRANT PROJECTS - 2010 (PROGRAM)","1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3203 DENTISTRY;3206 MEDICAL BIOTECHNOLOGY;3209 NEUROSCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","2;1;1;1;1;1;1;1","BIOTECHNOLOGY;REGENERATIVE MEDICINE;STEM CELL RESEARCH;TRANSPLANTATION;BIOENGINEERING;GENETICS;NEURODEGENERATIVE;NEUROSCIENCES;PEDIATRIC;RARE DISEASES;SPINAL MUSCULAR ATROPHY;STEM CELL RESEARCH - INDUCED PLURIPOTENT STEM CELL;STEM CELL RESEARCH - INDUCED PLURIPOTENT STEM CELL - HUMAN;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","GENERIC HEALTH RELEVANCE;MUSCULOSKELETAL;NEUROLOGICAL","1;1;1","5.2 CELLULAR AND GENE THERAPIES;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.2 CELLULAR AND GENE THERAPIES","2;1;1;1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE;A04 PSYCHOLOGY, PSYCHIATRY AND NEUROSCIENCE;A05 BIOLOGICAL SCIENCES","1;1;1",NA,NA,4,"PUBLIC LIBRARY OF SCIENCE","4","32 BIOMEDICAL AND CLINICAL SCIENCES;52 PSYCHOLOGY;49 MATHEMATICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;37 EARTH SCIENCES;3705 GEOLOGY;4905 STATISTICS;5202 BIOLOGICAL PSYCHOLOGY","5;3;2;1;1;1;1;1;1;1","BRAIN DISORDERS;CLINICAL RESEARCH;BIPOLAR DISORDER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DEPRESSION;MENTAL HEALTH;SCHIZOPHRENIA;SERIOUS MENTAL ILLNESS","2;2;1;1;1;1;1;1","MENTAL HEALTH","1","6.1 PHARMACEUTICALS","1","CLINICAL","2","CLINICAL MEDICINE AND SCIENCE","2",NA,NA,NA,NA,26,4.87,536.83,7,23.35,0,0,7,1,8,0,1,9,0,19,5,0,0,0,0,0,0,22,1,3,23,2,0,1,0,0,0,0,0,0,"United States;Italy;Germany;France;Japan;Poland","5;3;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3204 IMMUNOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;5202 BIOLOGICAL PSYCHOLOGY;5203 CLINICAL AND HEALTH PSYCHOLOGY","24;9;6;4;3;2;2;1;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;LUNG;PEDIATRIC;HEMATOLOGY;CANCER;DIGESTIVE DISEASES;ASSISTIVE TECHNOLOGY;BIOENGINEERING;PATIENT SAFETY;PREVENTION;AGING;BRAIN DISORDERS;CARDIOVASCULAR;INFECTIOUS DISEASES;LYMPHOMA;NEUROSCIENCES;NUTRITION;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD","16;10;8;6;6;5;4;4;3;3;3;3;2;2;2;2;2;2;2;2","CANCER;RESPIRATORY;INFECTION;NEUROLOGICAL;BLOOD;CARDIOVASCULAR;CONGENITAL;EYE;INJURIES AND ACCIDENTS;REPRODUCTIVE HEALTH AND CHILDBIRTH","4;3;2;2;1;1;1;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.3 MEDICAL DEVICES;6.4 SURGERY;6.7 PHYSICAL;7.1 INDIVIDUAL CARE NEEDS","10;2;2;1;1;1;1;1;1","LEUKEMIA / LEUKAEMIA;LIVER CANCER;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;STOMACH CANCER","3;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","3;1;1"
"IRCCS_CAGRANDA",2011,771,10.3631647211414,3.51232166018158,0.284711964549483,0.507133592736706,0.46822308690013,0.280155642023346,0.416342412451362,10,383,131,98,101,0.5,0.17,0.13,0.13,40.12,0.94313170269185,0.328145265888457,0.924773022049287,0,0.500324549242575,0.482478273058593,0.512698739200929,0.466575618171363,"PIER ALBERTO BERTAZZI;ELIO SCARPINI;NEREO BRESOLIN;SUSANNA ESPOSITO;DANIELA GALIMBERTI;DARIO CONSONNI;AGOSTINO CORTELEZZI;ANDREA BACCARELLI;NICOLA PRINCIPI;GIACOMO P. COMI;ANTONINO NERI;FRANCESCO BLASI;LORENZO PIGNATARO;MARIA DOMENICA CAPPELLINI;FABIO MOSCA;LUCA AGNELLI;PIER MANNUCCIO MANNUCCI;ANGELA CECILIA PESATORI;SILVIA FUSTINONI;STEFANO ALIBERTI","35;32;30;29;27;26;23;22;20;19;19;16;15;15;15;14;14;13;13;13","PIER ALBERTO BERTAZZI;SUSANNA ESPOSITO;ELIO SCARPINI;DANIELA GALIMBERTI;NICOLA PRINCIPI;DARIO CONSONNI;LORENZO PIGNATARO;PIER MANNUCCIO MANNUCCI;GIAMPIETRO FARRONATO;ANDREA BACCARELLI;NEREO BRESOLIN;DAVIDE CHIUMELLO;LUCIANO GATTINONI;SARA TORRETTA;LUIGI FEDELE;MARIA DOMENICA CAPPELLINI;AGOSTINO CORTELEZZI;FABIO MOSCA;FRANCESCO BLASI;FLORA PEYVANDI","4.44;4.35;3.75;3.2;3.13;3;2.81;2.51;2.5;2.38;2.37;2.22;2.2;2.13;2.09;2.04;2.01;1.98;1.82;1.75","PIER ALBERTO BERTAZZI;ELIO SCARPINI;NEREO BRESOLIN;SUSANNA ESPOSITO;DANIELA GALIMBERTI;DARIO CONSONNI;AGOSTINO CORTELEZZI;ANDREA BACCARELLI;NICOLA PRINCIPI;GIACOMO P. COMI;ANTONINO NERI;FRANCESCO BLASI;LORENZO PIGNATARO;MARIA DOMENICA CAPPELLINI;FABIO MOSCA;LUCA AGNELLI;PIER MANNUCCIO MANNUCCI;ANGELA CECILIA PESATORI;SILVIA FUSTINONI;STEFANO ALIBERTI","35;32;30;29;27;26;23;22;20;19;19;16;15;15;15;14;14;13;13;13","PIER ALBERTO BERTAZZI;SUSANNA ESPOSITO;ELIO SCARPINI;DANIELA GALIMBERTI;NICOLA PRINCIPI;DARIO CONSONNI;LORENZO PIGNATARO;PIER MANNUCCIO MANNUCCI;GIAMPIETRO FARRONATO;ANDREA BACCARELLI;NEREO BRESOLIN;DAVIDE CHIUMELLO;LUCIANO GATTINONI;SARA TORRETTA;LUIGI FEDELE;MARIA DOMENICA CAPPELLINI;AGOSTINO CORTELEZZI;FABIO MOSCA;FRANCESCO BLASI;FLORA PEYVANDI","4.44;4.35;3.75;3.2;3.13;3;2.81;2.51;2.5;2.38;2.37;2.22;2.2;2.13;2.09;2.04;2.01;1.98;1.82;1.75","ELIO SCARPINI;DANIELA GALIMBERTI;MARIA PIA RASTALDI;ALÌ TAHER;KHALED M. MUSALLAM;ALESSIA FORNONI;HANI TAMIM;STEFANO GATTI;TOBIAS B. HUBER;NEREO BRESOLIN;PIER MANNUCCIO MANNUCCI;FRITS R. ROSENDAAL;A HABBAL;ASSAAD SOWEID;DONAT R. SPAHN;FADI S. DAHDALEH;FAEK R. JAMALI;JAMAL J. HOBALLAH;KAIVAN KHAVANDI;MOHAMMAD KHREISS","2478;1922;1739;1395;1394;1284;1241;1211;1125;1094;1087;1079;1078;1078;1078;1078;1078;1078;1078;1078","ELIO SCARPINI;DANIELA GALIMBERTI;MARIA PIA RASTALDI;STEFANO GATTI;KHALED M. MUSALLAM;PIER MANNUCCIO MANNUCCI;SUSANNA ESPOSITO;NEREO BRESOLIN;DARIO CONSONNI;GIACOMO P. COMI;LUCIANO GATTINONI;MASSIMO COLOMBO;ANDREA SORDI;A. GRINGERI;MAURIZIO MOGGIO;PIER ALBERTO BERTAZZI;ALBERTO PRIORI;NICOLA PRINCIPI;MARIA DOMENICA CAPPELLINI;FRANCESCA CORTINI","2190;1826;1739;1211;1169;1087;881;880;844;837;819;788;753;733;703;678;654;644;601;600","PIER ALBERTO BERTAZZI;SUSANNA ESPOSITO;ELIO SCARPINI;NEREO BRESOLIN;DANIELA GALIMBERTI;DARIO CONSONNI;AGOSTINO CORTELEZZI;GIACOMO P. COMI;NICOLA PRINCIPI;ANTONINO NERI;MARIA DOMENICA CAPPELLINI;FRANCESCO BLASI;PIER MANNUCCIO MANNUCCI;LORENZO PIGNATARO;FABIO MOSCA;SILVIA FUSTINONI;MASSIMO COLOMBO;LUCA AGNELLI;STEFANIA CORTI;CHIARA FENOGLIO","31;28;28;27;26;25;22;19;19;16;15;14;14;13;13;13;13;12;12;11","MEDICINE;BIOLOGY;CHEMISTRY;PSYCHOLOGY;PHYSICS;COMPUTER SCIENCE;ECONOMICS;ENGINEERING;MATHEMATICS;SOCIOLOGY;POLITICAL SCIENCE;MATERIALS SCIENCE;BUSINESS;GEOGRAPHY;PHILOSOPHY;ENVIRONMENTAL SCIENCE;ART;GEOLOGY;HISTORY","706;321;66;60;54;36;27;25;24;22;17;11;9;9;9;6;5;2;1","INTERNAL MEDICINE;GENETICS;IMMUNOLOGY;PATHOLOGY;SURGERY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;PEDIATRICS;ENDOCRINOLOGY;CARDIOLOGY;PSYCHIATRY;BIOCHEMISTRY;INTENSIVE CARE MEDICINE;ONCOLOGY;RADIOLOGY;ANESTHESIA;CANCER RESEARCH;CELL BIOLOGY;PHARMACOLOGY;MOLECULAR BIOLOGY;NEUROSCIENCE;OPTICS","509;200;162;149;135;117;91;74;65;64;64;56;52;49;44;37;36;33;31;30;30;30","GENE;DISEASE;POPULATION;CANCER;VIRUS;CONFIDENCE INTERVAL;TRANSPLANTATION;PREGNANCY;ANTIBODY;COHORT;RECEPTOR;LUNG;INCIDENCE (GEOMETRY);ADVERSE EFFECT;BLOOD PRESSURE;ODDS RATIO;STEM CELL;LEUKEMIA;IMMUNE SYSTEM;PROSPECTIVE COHORT STUDY","145;98;94;54;41;38;38;37;34;33;29;28;27;26;26;26;26;25;24;23","GENOTYPE;GENE EXPRESSION;MUTATION;ALLELE;DEMENTIA;CHRONIC LYMPHOCYTIC LEUKEMIA;PHENOTYPE;GESTATIONAL AGE;METHYLATION;ALZHEIMER'S DISEASE;FETUS;CD34;HEPATITIS C VIRUS;GENOME;MICRORNA;CHRONIC HEPATITIS;INFECTIOUS DISEASE (MEDICAL SPECIALTY);INSULIN RESISTANCE;RESPIRATORY TRACT INFECTIONS;RITUXIMAB;TOLERABILITY","41;27;27;21;18;16;16;15;15;13;13;12;12;11;11;10;10;10;10;10;10","SINGLE-NUCLEOTIDE POLYMORPHISM;DNA METHYLATION;RIBAVIRIN;CORONAVIRUS DISEASE 2019 (COVID-19);FRONTOTEMPORAL DEMENTIA;MISSENSE MUTATION;GENE EXPRESSION PROFILING;HAPLOTYPE;PODOCYTE;INEFFECTIVE ERYTHROPOIESIS;CD38;COMPARATIVE GENOMIC HYBRIDIZATION;FLUDARABINE;IGHV@;PRENATAL DIAGNOSIS;ALLELE FREQUENCY;ANTIRETROVIRAL THERAPY;DIFFUSING CAPACITY;FLUORESCENCE IN SITU HYBRIDIZATION;LAMIVUDINE;MANIA;MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION;NONALCOHOLIC FATTY LIVER DISEASE;POINT MUTATION;PROMOTER;PROSTATECTOMY;SMALL FOR GESTATIONAL AGE;VON WILLEBRAND DISEASE","24;15;11;10;10;9;7;7;7;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4","HUMANS;FEMALE;MALE;;MIDDLE AGED;ADULT;AGED;ITALY;ADOLESCENT;YOUNG ADULT;CHILD;TREATMENT OUTCOME;AGED, 80 AND OVER;PROSPECTIVE STUDIES;CHILD, PRESCHOOL;RISK FACTORS;RETROSPECTIVE STUDIES;ANIMALS;FOLLOW-UP STUDIES;COHORT STUDIES","513;361;354;242;239;234;180;139;102;93;92;80;74;56;53;53;51;46;45;39","GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MANAGEMENT AND EPIDEMIOLOGY OF PNEUMONIA;MANAGEMENT AND TREATMENT OF HEMOPHILIA;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;HEALTH EFFECTS OF AIR POLLUTION;HEPATITIS C INFECTION AND TREATMENT;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;MECHANISMS OF ALZHEIMER'S DISEASE;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;INFLUENZA VIRUS RESEARCH AND EPIDEMIOLOGY;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;MOLECULAR MECHANISMS OF MUSCLE REGENERATION AND ATROPHY;EFFECTS OF BRAIN STIMULATION ON MOTOR CORTEX;MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA","18;16;15;12;11;11;11;11;11;11;11;11;10;10;9;8;7;7;6;6","TREATMENT;EXPOSURE ASSESSMENT;HEPATITIS C;PATHOGENESIS;GENETIC ASSOCIATION;TOLERABILITY;CONCOMITANT;ECHOCARDIOGRAPHY;FRONTOTEMPORAL LOBAR DEGENERATION;PRETERM INFANTS;ASBESTOS EXPOSURE;NEURODEGENERATION;PANDEMIC;DEPRESSION (ECONOMICS);DIAGNOSIS;GENOME-WIDE ASSOCIATION STUDY;LIVER FIBROSIS;REGIMEN;SNP;TRANSCRANIAL DIRECT CURRENT STIMULATION","23;15;14;12;11;11;10;10;10;10;9;9;9;8;8;8;8;8;8;8","LUNG CANCER;CHRONIC HEPATITIS;ALZHEIMERS DISEASE;SYSTEMIC SCLEROSIS;CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;STEM CELL;DNA METHYLATION;CYSTIC FIBROSIS;RISK FACTORS;COHORT STUDY;HEPATOCELLULAR CARCINOMA;BLOOD PRESSURE;CELL TRANSPLANTATION;COMMUNITY-ACQUIRED PNEUMONIA;MULTIPLE SCLEROSIS;PRETERM INFANTS;CANCER RISK;CELL CARCINOMA;CONTROLLED TRIAL;CURRENT STIMULATION;DIRECT CURRENT;HOSPITALIZED PATIENTS;RANDOMIZED CONTROLLED;RESPIRATORY TRACT;AMYOTROPHIC LATERAL;BIPOLAR DISORDER;FATTY LIVER;FRONTOTEMPORAL LOBAR;GENE EXPRESSION","15;14;13;13;12;12;11;10;9;9;8;8;7;7;7;7;7;6;6;6;6;6;6;6;6;5;5;5;5;5","PUBMED SCOPUS;CROSSREF PUBMED;LUNG CANCER;DNA METHYLATION;GENE EXPRESSION;CELL LINES;NEPHROL -CROSSREF;CONFIDENCE INTERVAL;INCREASED RISK;SOC NEPHROL;STATISTICALLY SIGNIFICANT;LE TC;PIR EXPRESSION;ODDS RATIO;LIVER FIBROSIS;AHN INFLUENZA;CELL POLARITY;GLOMERULAR FILTRATION;JM KIM;KIM SH;METABOTROPIC GLUTAMATE;TUMOR CELL;ALLEN PG;CELLULAR SENESCENCE;CHRONIC HEPATITIS;FONDAZIONE IRCCS;GENET -CROSSREF;MILAN ITALY;POLYMERASE CHAIN;Α-ACTININ--CLP COMPLEX","199;155;52;38;27;26;26;24;23;22;20;19;19;18;17;16;16;16;16;16;16;16;15;15;15;15;15;15;15;15",187,0.24,3,19.43,6,184,9.21,2,37,2.25,1,7,1.85,1,5,1,1,1,5.78,1,23,6.19,1,33,0,0,0,1.64,1,3,10.47,2,56,0,0,0,1,1,1,6,1,28,1,1,1,1.38,1,3,1.43,1,2,2.11,1,6,4.7,1,19,1.12,1,2,0.23,0,2,0.02,0,1,131.91,3,655,145.06,3,693,9,0,5,5,0,5,1,0,0,0,0,0,8,6,2,8.5,3.25,1.9375,3,5,7,0,0,7,0,0,2,1,1,0,1,0,3,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,3,3,1,2,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"DRAGO FRANCESCA;LAZZARI LORENZA;POLI FRANCESCA;REBULLA PAOLO;GREPPI NOEMI;KARPASITOU KATERINA;PARAZZI VALENTINA;SCORZA RAFFAELLA;BONINO FERRUCCIO;FOFFANI GUGLIELMO","4;4;4;4;3;3;3;3;2;2","FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO;FOND IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO;LAZZARI LORENZA;REBULLA PAOLO;UNIVERSITA DEGLI STUDI DI MILANO;ANDRIOLO GABRIELLA;BONINO FERRUCCIO;FRASCA STEFANIA;GIOVENTU SILVIA;GREPPI NOEMI","11;5;2;2;2;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;40 ENGINEERING;3203 DENTISTRY;4003 BIOMEDICAL ENGINEERING;52 PSYCHOLOGY;31 BIOLOGICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;33 BUILT ENVIRONMENT AND DESIGN;34 CHEMICAL SCIENCES","22;7;5;3;3;2;1;1;1;1","BIOENGINEERING;BRAIN DISORDERS;NEUROSCIENCES;REHABILITATION;ASSISTIVE TECHNOLOGY;DENTAL/ORAL AND CRANIOFACIAL DISEASE;GENETICS;KIDNEY DISEASE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN","2;2;2;2;1;1;1;1;1;1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS","1;1;1;1","C12Q1/68;A61K35/19;A61K31/245;A61K35/16;A61P17/02;A61P7/00;A61P9/00;A61P9/10;C12N5/02;A01N1/02","5;3;2;2;2;2;2;2;2;1","C12Q2600/156;C12Q1/6881;C12Q2600/16;A61K31/245;A61K35/19;A61P17/00;A61P17/02;A61P21/00;A61P29/00;A61P3/10","5;4;4;3;3;3;3;3;3;3",2,2970800,192248.21,3.5,11.5,3,1,21,"FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO;CF CONSULTING FINANZIAMENTI UNIONE EUROPEA;GERMAN RESEARCH CENTRE FOR ARTIFICIAL INTELLIGENCE;IMPERIAL COLLEGE LONDON;ISTITUTO NEUROLOGICO CARLO BESTA;ITALIAN INSTITUTE OF TECHNOLOGY;KARLSRUHE INSTITUTE OF TECHNOLOGY;KUKA (GERMANY);NATIONAL RESEARCH COUNCIL;OSPEDALE NIGUARDA CA' GRANDA;OSPEDALE SAN PAOLO;POLITECNICO DI MILANO;RENISHAW (IRELAND);TECHNICAL UNIVERSITY OF MUNICH;TECHNION – ISRAEL INSTITUTE OF TECHNOLOGY;TEL AVIV SOURASKY MEDICAL CENTER;UNIVERSITY OF CAMPANIA ""LUIGI VANVITELLI"";UNIVERSITY OF MESSINA;UNIVERSITY OF PADUA;UNIVERSITY OF PISA","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;TELETHON FOUNDATION","1;1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CP - COLLABORATIVE PROJECT (GENERIC) (FUNDING SCHEME);FP7-ICT - SPECIFIC PROGRAMME ""COOPERATION"": INFORMATION AND COMMUNICATION TECHNOLOGIES (PROGRAMME);FP7-ICT-2009-6 (CALL FOR PROPOSAL);TELETHON - UILDM CLINICAL GRANT PROJECTS - 2010 (PROGRAM)","1;1;1;1","31 BIOLOGICAL SCIENCES;3105 GENETICS;32 BIOMEDICAL AND CLINICAL SCIENCES;40 ENGINEERING;46 INFORMATION AND COMPUTING SCIENCES;4608 HUMAN-CENTRED COMPUTING","1;1;1;1;1;1","BIOENGINEERING;BIOTECHNOLOGY;BRAIN DISORDERS;CLINICAL RESEARCH;GENETIC TESTING;GENETICS;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);MUSCULAR DYSTROPHY;NEUROSCIENCES;RARE DISEASES","1;1;1;1;1;1;1;1;1;1",NA,NA,NA,NA,NA,NA,NA,NA,"A01 CLINICAL MEDICINE;B11 COMPUTER SCIENCE AND INFORMATICS","1;1","4 QUALITY EDUCATION","1",12,"PUBLIC LIBRARY OF SCIENCE;AMERICAN ASSOCIATION FOR CANCER RESEARCH","9;3","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;52 PSYCHOLOGY;3105 GENETICS;5202 BIOLOGICAL PSYCHOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3005 FISHERIES SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3203 DENTISTRY;49 MATHEMATICAL SCIENCES;4905 STATISTICS","10;9;5;3;3;2;1;1;1;1;1;1","CANCER;BIOTECHNOLOGY;CLINICAL RESEARCH;GENETICS;RARE DISEASES;AGING;BIOMEDICAL IMAGING;BRAIN DISORDERS;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;HEMATOLOGY;HUMAN GENOME;LIVER CANCER;LIVER DISEASE;NEURODEGENERATIVE;NEUROSCIENCES;PARKINSON'S DISEASE;PREVENTION;UROLOGIC DISEASES","3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;NEUROLOGICAL","5;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","2;2","BIOMEDICAL;CLINICAL","2;1","CLINICAL MEDICINE AND SCIENCE","6","MYELOMA;BLADDER CANCER;LIVER CANCER","3;1;1",NA,NA,36,5.19,245.07,9,46,4,1,4,1,11,0,4,11,0,23,8,0,0,0,0,0,0,33,2,1,30,5,0,1,0,0,0,0,0,0,"United States;Italy;Japan;United Kingdom;Austria;France;Germany;Poland","9;5;3;2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3213 PAEDIATRICS;3215 REPRODUCTIVE MEDICINE;4203 HEALTH SERVICES AND SYSTEMS","35;18;10;8;2;2;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;CANCER;HEMATOLOGY;DIGESTIVE DISEASES;LIVER DISEASE;LYMPHOMA;INFECTIOUS DISEASES;LIVER CANCER;LUNG;ORPHAN DRUG;TRANSPLANTATION;CHRONIC LIVER DISEASE AND CIRRHOSIS;EMERGING INFECTIOUS DISEASES;GENETICS;HEPATITIS;KIDNEY DISEASE;NEUROSCIENCES;PATIENT SAFETY","29;17;17;10;10;6;6;5;3;3;3;3;3;2;2;2;2;2;2;2","CANCER;INFECTION;BLOOD;CONGENITAL;RENAL AND UROGENITAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;CARDIOVASCULAR;EYE;INFLAMMATORY AND IMMUNE SYSTEM;METABOLIC AND ENDOCRINE;RESPIRATORY","5;4;2;2;2;2;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.4 SURGERY;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.2 CELLULAR AND GENE THERAPIES","22;6;3;3;2;1;1","LEUKEMIA / LEUKAEMIA;LIVER CANCER;NON-HODGKIN'S LYMPHOMA;HODGKIN'S DISEASE;LUNG CANCER;MYELOMA;NOT SITE-SPECIFIC CANCER;THYROID CANCER","5;5;5;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","10;1;1;1;1;1;1"
"IRCCS_CAGRANDA",2012,745,9.95973154362416,3.30738255033557,0.302353896103896,0.499328859060403,0.424161073825503,0.306040268456376,0.456375838926175,17,398,132,73,94,0.53,0.18,0.1,0.13,41.51,0.993913071519482,0.332885906040268,0.928859060402685,5.6374634960367,0.498278805717916,0.474824204771005,0.48358792618844,0.486845730027548,"SUSANNA ESPOSITO;DANIELA GALIMBERTI;ELIO SCARPINI;MARIA DOMENICA CAPPELLINI;NICOLA PRINCIPI;DARIO CONSONNI;AGOSTINO CORTELEZZI;NEREO BRESOLIN;FABIO MOSCA;GIACOMO P. COMI;ANTONINO NERI;FLORA PEYVANDI;BERNARDO DELL’OSSO;EDGARDO SOMIGLIANA;LUIGI FEDELE;PAOLO BECK‐PECCOZ;PIER ALBERTO BERTAZZI;KHALED M. MUSALLAM;ANDREA BACCARELLI;LUCIANO GATTINONI","29;24;23;21;21;20;20;19;19;18;17;17;15;15;15;14;13;13;13;13","SUSANNA ESPOSITO;NICOLA PRINCIPI;S. MANDOLFO;ALESSIO AGHEMO;DARIO CONSONNI;DANIELA GALIMBERTI;ELIO SCARPINI;MARIA DOMENICA CAPPELLINI;FLORA PEYVANDI;LUIGI FEDELE;FRANCESCO BLASI;PIER MANNUCCIO MANNUCCI;FABIO MOSCA;BERNARDO DELL’OSSO;EDGARDO SOMIGLIANA;KHALED M. MUSALLAM;GIOVANNA MANTOVANI;ANNA SPADA;LORENZO PIGNATARO;SARA TORRETTA","4.99;3.58;3;2.94;2.83;2.73;2.66;2.66;2.61;2.55;2.29;2.27;2.16;2.15;2.04;1.99;1.93;1.9;1.8;1.77","SUSANNA ESPOSITO;DANIELA GALIMBERTI;ELIO SCARPINI;MARIA DOMENICA CAPPELLINI;NICOLA PRINCIPI;DARIO CONSONNI;AGOSTINO CORTELEZZI;NEREO BRESOLIN;FABIO MOSCA;GIACOMO P. COMI;ANTONINO NERI;FLORA PEYVANDI;BERNARDO DELL’OSSO;EDGARDO SOMIGLIANA;LUIGI FEDELE;PAOLO BECK‐PECCOZ;PIER ALBERTO BERTAZZI;KHALED M. MUSALLAM;ANDREA BACCARELLI;LUCIANO GATTINONI","29;24;23;21;21;20;20;19;19;18;17;17;15;15;15;14;13;13;13;13","SUSANNA ESPOSITO;NICOLA PRINCIPI;S. MANDOLFO;ALESSIO AGHEMO;DARIO CONSONNI;DANIELA GALIMBERTI;ELIO SCARPINI;MARIA DOMENICA CAPPELLINI;FLORA PEYVANDI;LUIGI FEDELE;FRANCESCO BLASI;PIER MANNUCCIO MANNUCCI;FABIO MOSCA;BERNARDO DELL’OSSO;EDGARDO SOMIGLIANA;KHALED M. MUSALLAM;GIOVANNA MANTOVANI;ANNA SPADA;LORENZO PIGNATARO;SARA TORRETTA","4.99;3.58;3;2.94;2.83;2.73;2.66;2.66;2.61;2.55;2.29;2.27;2.16;2.15;2.04;1.99;1.93;1.9;1.8;1.77","MASSIMO COLOMBO;SUSANNA ESPOSITO;ANDREA BACCARELLI;ELIO SCARPINI;NEREO BRESOLIN;PELLEGRINO MUSTO;ANTONIO SPADEA;MONIA LUNGHI;PIETRO LAMPERTICO;FLORA PEYVANDI;ALBERTO MARTINI;ANDREA DORIA;ARGYRE STARRA;CARLOS VASCONCELOS;CAROLINE GORDON;CEES G. M. KALLENBERG;DAVID ISENBERG;DAVID JAYNE;DIMITRIOS T. BOUMPAS;ELENA ZAKHAROVA","1442;1441;1113;1104;1070;1065;1004;1004;976;970;957;957;957;957;957;957;957;957;957;957","SUSANNA ESPOSITO;MASSIMO COLOMBO;ELIO SCARPINI;NEREO BRESOLIN;PIETRO LAMPERTICO;GABRIELA MORONI;GIACOMO P. COMI;DANIELA GALIMBERTI;FLORA PEYVANDI;NICOLA PRINCIPI;KHALED M. MUSALLAM;ALESSANDRA IURLO;DARIO CONSONNI;STEFANO GATTI;EDGARDO SOMIGLIANA;PIER MANNUCCIO MANNUCCI;FABIO MOSCA;LETIZIA TARANTINI;MARCO MOIA;STEFANIA CORTI","1411;1395;1104;1065;976;957;953;936;916;907;837;827;797;680;676;661;656;647;636;629","SUSANNA ESPOSITO;DANIELA GALIMBERTI;ELIO SCARPINI;DARIO CONSONNI;AGOSTINO CORTELEZZI;GIACOMO P. COMI;NEREO BRESOLIN;FABIO MOSCA;MARIA DOMENICA CAPPELLINI;NICOLA PRINCIPI;MASSIMO COLOMBO;FLORA PEYVANDI;EDGARDO SOMIGLIANA;LUIGI FEDELE;ANTONINO NERI;ALESSIO AGHEMO;BERNARDO DELL’OSSO;FRANCESCO BLASI;PAOLO BECK‐PECCOZ;PIER MANNUCCIO MANNUCCI","27;23;22;20;19;18;18;18;18;18;16;15;14;14;13;12;12;12;12;12","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;PSYCHOLOGY;COMPUTER SCIENCE;MATHEMATICS;ENGINEERING;POLITICAL SCIENCE;ECONOMICS;SOCIOLOGY;PHILOSOPHY;MATERIALS SCIENCE;BUSINESS;GEOGRAPHY;HISTORY;ENVIRONMENTAL SCIENCE;ART","679;303;67;59;51;42;26;25;22;20;19;14;11;7;7;3;2;1","INTERNAL MEDICINE;GENETICS;SURGERY;IMMUNOLOGY;PATHOLOGY;GASTROENTEROLOGY;PEDIATRICS;ENDOCRINOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;PSYCHIATRY;INTENSIVE CARE MEDICINE;ONCOLOGY;CARDIOLOGY;OPTICS;ANESTHESIA;CANCER RESEARCH;CELL BIOLOGY;RADIOLOGY;VIROLOGY","485;203;174;147;118;95;87;76;69;65;63;57;45;38;36;35;35;35;35;34","GENE;DISEASE;POPULATION;PREGNANCY;TRANSPLANTATION;ANTIBODY;CANCER;VIRUS;ADVERSE EFFECT;CONFIDENCE INTERVAL;COHORT;INCIDENCE (GEOMETRY);ODDS RATIO;RECEPTOR;RETROSPECTIVE COHORT STUDY;IMMUNE SYSTEM;LUNG;PLATELET;RANDOMIZED CONTROLLED TRIAL;ANEMIA","158;92;62;46;38;36;35;32;31;31;30;30;28;28;27;24;24;23;23;22","GENOTYPE;GENE EXPRESSION;ALLELE;MUTATION;PHENOTYPE;METHYLATION;DEMENTIA;TOLERABILITY;EPIGENETICS;CHRONIC LYMPHOCYTIC LEUKEMIA;EXON;FETUS;HEPATITIS C VIRUS;LIVER TRANSPLANTATION;CHROMOSOME;CHRONIC HEPATITIS;COMMUNITY-ACQUIRED PNEUMONIA;GESTATIONAL AGE;PROTEINURIA;AGONIST;FATTY LIVER;HAZARD RATIO;HEPATITIS B VIRUS;HUMAN LEUKOCYTE ANTIGEN;LOCUS (GENETICS);PARKINSON'S DISEASE;PLACEBO;RITUXIMAB;VON WILLEBRAND FACTOR","43;35;32;25;21;17;14;13;12;11;11;11;11;11;10;10;10;10;10;9;9;9;9;9;9;9;9;9;9","DNA METHYLATION;SINGLE-NUCLEOTIDE POLYMORPHISM;FRONTOTEMPORAL DEMENTIA;MISSENSE MUTATION;HBSAG;RIBAVIRIN;VON WILLEBRAND DISEASE;HAPLOTYPE;ALLELE FREQUENCY;GENE EXPRESSION PROFILING;GENOTYPING;PNEUMOCOCCAL CONJUGATE VACCINE;PRENATAL DIAGNOSIS;PROMOTER;STEATOHEPATITIS;CABERGOLINE;COMPARATIVE GENOMIC HYBRIDIZATION;CORONAVIRUS DISEASE 2019 (COVID-19);CYTOGENETICS;IGHV@;LOSS OF HETEROZYGOSITY;MYELOPROLIFERATIVE NEOPLASM;PENETRANCE;PLACENTA;PODOCYTE;X-INACTIVATION","23;23;9;9;8;8;8;7;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4","HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;;AGED;ITALY;ADOLESCENT;YOUNG ADULT;CHILD;TREATMENT OUTCOME;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;RISK FACTORS;CHILD, PRESCHOOL;BIOMARKERS;INFANT;HEPATITIS C, CHRONIC;MUTATION","529;366;361;250;223;203;170;127;103;97;84;75;72;62;62;61;53;48;47;45","MANAGEMENT AND TREATMENT OF HEMOPHILIA;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;HEPATITIS C INFECTION AND TREATMENT;PLATELET DISORDERS AND THROMBOSIS MECHANISMS;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;HEPATITIS B INFECTION AND TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;MANAGEMENT AND EPIDEMIOLOGY OF PNEUMONIA;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;EPIGENETIC MODIFICATIONS AND THEIR FUNCTIONAL IMPLICATIONS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EFFECTS OF BRAIN STIMULATION ON MOTOR CORTEX;EPIDEMIOLOGY AND MANAGEMENT OF BIPOLAR DISORDER;HEALTH EFFECTS OF AIR POLLUTION;MOLECULAR MECHANISMS OF MUSCLE REGENERATION AND ATROPHY;MULTIPOTENT MESENCHYMAL STEM CELLS;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY","22;18;13;12;12;11;10;10;9;9;7;7;7;6;6;6;6;6;6;6","TREATMENT;TOLERABILITY;DNA METHYLATION;ETIOLOGY;HEPATITIS C;REGIMEN;PATHOGENESIS;VON WILLEBRAND DISEASE;LIVING DONOR LIVER TRANSPLANTATION;BETA THALASSEMIA;CLINICAL ENDPOINT;FRONTOTEMPORAL LOBAR DEGENERATION;INTERQUARTILE RANGE;NEURODEGENERATION;POSITIVE END-EXPIRATORY PRESSURE;PRETERM INFANTS;SNP;STROKE (ENGINE);DIAGNOSIS;EXPOSURE ASSESSMENT","32;13;12;11;11;11;10;10;9;8;8;8;8;8;8;8;8;8;7;7","DNA METHYLATION;CHRONIC LYMPHOCYTIC;LUNG CANCER;STEM CELLS;LYMPHOCYTIC LEUKEMIA;MULTIPLE SCLEROSIS;ALZHEIMERS DISEASE;CHRONIC HEPATITIS;RISK FACTORS;VON WILLEBRAND;COHORT STUDY;COMMUNITY-ACQUIRED PNEUMONIA;ADULT PATIENTS;BIPOLAR DISORDER;CYSTIC FIBROSIS;PRETERM INFANTS;STEM CELL;CASE-CONTROL STUDY;CONTROLLED TRIAL;CURRENT STIMULATION;DIRECT CURRENT;DISEASE RESULTS;KIDNEY DISEASE;LONG-TERM OUTCOME;LUNG FUNCTION;LUPUS ERYTHEMATOSUS;MESENCHYMAL STEM;MULTIPLE MYELOMA;OTITIS MEDIA;RANDOMIZED CONTROLLED","13;10;10;10;9;9;8;8;8;8;7;7;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;5","PUBMED SCOPUS;CROSSREF PUBMED;DNA METHYLATION;LUNG CANCER;CELL LINES;VON WILLEBRAND;IRIEPC MV;COAGULANT ACTIVITY;STATISTICALLY SIGNIFICANT;CONFIDENCE INTERVAL;STEM CELLS;ENDOTHELIAL PROGENITOR;PROGENITOR CELLS;CLINICAL BLEEDING;GENE EXPRESSION;LOGISTIC REGRESSION;ODDS RATIO;PERIPHERAL BLOOD;PLATELET COUNT;RISK FACTORS;STEM CELL;DE NOVO;RARE BLEEDING;ADVERSE EVENTS;FACTOR ACTIVITY;LABORATORY PHENOTYPE;PATIENTS TREATED;BLEEDING SEVERITY;CELL LINE;INTERVAL CI","104;86;55;39;30;26;25;24;24;23;23;22;19;18;17;17;17;17;17;17;17;16;16;15;15;15;15;14;14;14",247,0.33,3,33.23,6,442.226,24.85,1,248,4.46,1,21,1.59,1,5,3.6,1,13,4.65,1,53,4,1,18,0,0,0,1.5,1,4,29.42,1,298,1,1,1,1,1,1,22.55,1,218,3.5,2,5,1.77,1,6,1.89,1,5,6.96,1,44,16.79,1,144,4.17,1,25,0.16,0,2,0,0,0,144.89,22,751,139.69,22,752,7,0,4,7,0,5,0,0,0,0,0,0,6,5,5,1,3.26666666666667,1.5,5,2,11,0,0,2,1,0,3,0,3,1,1,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,3,0,2,0,3,1,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"SCORZA RAFFAELLA;BONINO FERRUCCIO;CRESPIATICO LORETTA;DRAGO FRANCESCA;ESPADAS DE ARIAS ALEJANDRO;POLI FRANCESCA;VILLA MARIA ANTONIETTA;CATANIA ANNA;GRIECO PAOLO;LI MIN","4;3;3;3;3;3;3;2;2;2","FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO;FOND IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO;ANDRIOLO GABRIELLA;BONINO FERRUCCIO;FRASCA STEFANIA;GIOVENTU SILVIA;INDIVIDUAL;LAZZARI LORENZA;MONTELATICI ELISA GIOVANNA ANGELA;REBULLA PAOLO","9;6;1;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3203 DENTISTRY;34 CHEMICAL SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;40 ENGINEERING;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS;3202 CLINICAL SCIENCES;33 BUILT ENVIRONMENT AND DESIGN","16;4;4;3;3;3;2;2;2;2","BIOTECHNOLOGY;CLINICAL RESEARCH;GENETICS;VACCINE RELATED;ASSISTIVE TECHNOLOGY;BIOENGINEERING;BRAIN DISORDERS;DENTAL/ORAL AND CRANIOFACIAL DISEASE;KIDNEY DISEASE;NEUROSCIENCES","2;2;2;2;1;1;1;1;1;1","5.1 PHARMACEUTICALS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","2;1;1","A61K31/245;A61P31/04;A61P31/10;A61P9/10;C07K7/06;C12Q1/68;A61K31/4164;A61K31/4196;A61K31/506;A61K31/7048","3;3;3;3;3;3;2;2;2;2","A61K31/245;A61P21/00;A61P29/00;A61P3/10;A61P7/02;A61P9/00;A61P9/10;A61P9/12;C07K14/68;C12Q1/6881","4;4;4;4;4;4;4;4;4;4",2,201000,16108.97,1.5,12.5,1,1,15.5,"CATHOLIC UNIVERSITY OF THE SACRED HEART;FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO;FONDAZIONE ISTITUTO NEUROLOGICO NAZIONALE CASIMIRO MONDINO;UNIVERSITY OF MESSINA;UNIVERSITY OF PADUA;UNIVERSITY OF TURIN;BAMBINO GESÙ CHILDREN'S HOSPITAL;CENTRO CLINICO NEMO;FONDAZIONE SANTA LUCIA;FONDAZIONE STELLA MARIS;ISTITUTO DELLE SCIENZE NEUROLOGICHE DI BOLOGNA;ISTITUTO GIANNINA GASLINI;SAPIENZA UNIVERSITY OF ROME;UNIVERSITY OF BRESCIA;UNIVERSITY OF CAMPANIA ""LUIGI VANVITELLI"";UNIVERSITY OF MODENA AND REGGIO EMILIA;UNIVERSITY OF NAPLES FEDERICO II;UNIVERSITY OF PISA;UNIVERSITY OF VERONA","2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","TELETHON FOUNDATION","2",NA,NA,"TELETHON - UILDM CLINICAL GRANT PROJECTS - 2011 (PROGRAM)","2","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;3202 CLINICAL SCIENCES","2;1;1;1","BRAIN DISORDERS;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);MUSCULAR DYSTROPHY;RARE DISEASES;CLINICAL RESEARCH;FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY;GENETICS;NEUROSCIENCES;PATIENT SAFETY;PEDIATRIC","2;2;2;2;1;1;1;1;1;1","MUSCULOSKELETAL","2",NA,NA,NA,NA,NA,NA,"A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1;1",NA,NA,42,"PUBLIC LIBRARY OF SCIENCE","42","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;3202 CLINICAL SCIENCES;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;4203 HEALTH SERVICES AND SYSTEMS;49 MATHEMATICAL SCIENCES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4202 EPIDEMIOLOGY;3213 PAEDIATRICS;44 HUMAN SOCIETY;4905 STATISTICS;3204 IMMUNOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;36 CREATIVE ARTS AND WRITING;4403 DEMOGRAPHY;4904 PURE MATHEMATICS;52 PSYCHOLOGY","30;26;18;11;9;8;5;5;4;4;4;3;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;GENETICS;CANCER;PEDIATRIC;TOBACCO;TOBACCO SMOKE AND HEALTH;BEHAVIORAL AND SOCIAL SCIENCE;LUNG;PREVENTION;BRAIN DISORDERS;CHRONIC PAIN;PAIN RESEARCH;LUNG CANCER;MENTAL HEALTH;AGING;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DEPRESSION;HEMATOLOGY;HUMAN FETAL TISSUE","16;9;5;5;5;5;4;4;4;3;3;3;2;2;1;1;1;1;1;1","CANCER;MUSCULOSKELETAL;MENTAL HEALTH;RESPIRATORY;GENERIC HEALTH RELEVANCE","5;3;2;2;1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;8.1 ORGANISATION AND DELIVERY OF SERVICES","1;1;1;1","POPULATION & SOCIETY;CLINICAL;BIOMEDICAL;HEALTH SERVICES & SYSTEMS","6;3;2;1","PUBLIC HEALTH;CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","11;6;2","LUNG CANCER;MELANOMA;LEUKEMIA / LEUKAEMIA;NOT SITE-SPECIFIC CANCER","5;3;1;1","3 GOOD HEALTH AND WELL BEING","1",39,4.14,561.85,11,30.85,1,2,7,0,6,0,6,17,0,27,8,0,0,0,0,0,0,35,3,1,34,4,0,1,0,0,0,0,0,0,"United States;Italy;United Kingdom;France;Spain","6;4;4;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;3213 PAEDIATRICS;51 PHYSICAL SCIENCES;31 BIOLOGICAL SCIENCES;3103 ECOLOGY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;37 EARTH SCIENCES;3701 ATMOSPHERIC SCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;5105 MEDICAL AND BIOLOGICAL PHYSICS","38;21;9;5;3;3;2;2;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;CANCER;LUNG;HEMATOLOGY;PEDIATRIC;DIGESTIVE DISEASES;INFECTIOUS DISEASES;PREVENTION;CHRONIC LIVER DISEASE AND CIRRHOSIS;LIVER DISEASE;PATIENT SAFETY;HEPATITIS;NEUROSCIENCES;STEM CELL RESEARCH;TRANSPLANTATION;AUTOIMMUNE DISEASE;BIOENGINEERING;BRAIN DISORDERS","32;16;15;11;10;8;8;6;6;6;5;5;5;4;4;4;4;3;3;3","RESPIRATORY;INFECTION;CANCER;ORAL AND GASTROINTESTINAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM;MUSCULOSKELETAL;NEUROLOGICAL;RENAL AND UROGENITAL","6;5;4;2;2;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;3.3 NUTRITION AND CHEMOPREVENTION;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.4 POPULATION SCREENING;6.4 SURGERY;6.7 PHYSICAL","17;6;5;3;2;1;1;1;1;1","LEUKEMIA / LEUKAEMIA;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;LIVER CANCER;BLOOD CANCER;BREAST CANCER;COLON AND RECTAL CANCER;ENDOMETRIAL CANCER;HODGKIN'S DISEASE;MYELOMA;NEUROBLASTOMA;NOT SITE-SPECIFIC CANCER;THYROID CANCER","4;4;4;3;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;3.3 CHEMOPREVENTION;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS","11;3;2;2;2;2;1;1"
"IRCCS_CAGRANDA",2013,946,10.5253699788584,3.40063424947145,0.294062791420578,0.453488372093023,0.41014799154334,0.241014799154334,0.427061310782241,25,463,207,102,126,0.49,0.22,0.11,0.13,34.16,0.978933637822933,0.356236786469345,0.931289640591966,5.63270868824531,0.505581736429419,0.491197744920753,0.494009873489366,0.492469495415923,"SUSANNA ESPOSITO;PIER ALBERTO BERTAZZI;DARIO CONSONNI;FLORA PEYVANDI;AGOSTINO CORTELEZZI;FABIO MOSCA;NICOLA PRINCIPI;LUCIANO GATTINONI;ALBERTO PRIORI;MARIA DOMENICA CAPPELLINI;GIACOMO P. COMI;ANTONINO NERI;EDGARDO SOMIGLIANA;DANIELA GALIMBERTI;LUCA VALENTI;FRANCESCO BLASI;ELIO SCARPINI;LUCA BALDINI;LUIGI FEDELE;PAOLO BECK‐PECCOZ","31;30;27;26;23;23;21;21;20;19;18;18;18;18;17;16;16;16;15;15","SUSANNA ESPOSITO;PIER ALBERTO BERTAZZI;DARIO CONSONNI;ALBERTO PRIORI;LUCIANO GATTINONI;ARMANDO TRIPODI;FLORA PEYVANDI;STEFANO VERALDI;NICOLA PRINCIPI;EDGARDO SOMIGLIANA;PIETRO LAMPERTICO;DOMENICO PANUCCIO;FABIO MOSCA;SILVIA FUSTINONI;MARIA DOMENICA CAPPELLINI;LUCA VALENTI;G. COSTA;LUIGI FEDELE;FRANCESCO BLASI;FLAVIO CAPRIOLI","5.04;4.33;4.19;3.86;3.24;3.2;3.11;2.83;2.78;2.6;2.5;2.5;2.47;2.44;2.43;2.38;2.33;2.17;2.11;2.08","SUSANNA ESPOSITO;PIER ALBERTO BERTAZZI;DARIO CONSONNI;FLORA PEYVANDI;AGOSTINO CORTELEZZI;FABIO MOSCA;NICOLA PRINCIPI;LUCIANO GATTINONI;ALBERTO PRIORI;MARIA DOMENICA CAPPELLINI;GIACOMO P. COMI;ANTONINO NERI;EDGARDO SOMIGLIANA;DANIELA GALIMBERTI;LUCA VALENTI;FRANCESCO BLASI;ELIO SCARPINI;LUCA BALDINI;LUIGI FEDELE;PAOLO BECK‐PECCOZ","31;30;27;26;23;23;21;21;20;19;18;18;18;18;17;16;16;16;15;15","SUSANNA ESPOSITO;PIER ALBERTO BERTAZZI;DARIO CONSONNI;ALBERTO PRIORI;LUCIANO GATTINONI;ARMANDO TRIPODI;FLORA PEYVANDI;STEFANO VERALDI;NICOLA PRINCIPI;EDGARDO SOMIGLIANA;PIETRO LAMPERTICO;DOMENICO PANUCCIO;FABIO MOSCA;SILVIA FUSTINONI;MARIA DOMENICA CAPPELLINI;LUCA VALENTI;G. COSTA;LUIGI FEDELE;FRANCESCO BLASI;FLAVIO CAPRIOLI","5.04;4.33;4.19;3.86;3.24;3.2;3.11;2.83;2.78;2.6;2.5;2.5;2.47;2.44;2.43;2.38;2.33;2.17;2.11;2.08","LUCIANO GATTINONI;SUSANNA ESPOSITO;MASSIMO COLOMBO;DANIELA GALIMBERTI;PIER ALBERTO BERTAZZI;MARIA PIA RASTALDI;LUCA VALENTI;JOHANNA G. VAN DER BOM;GIACOMO P. COMI;ANDREA BACCARELLI;ELENA SANTAGOSTINO;MASSIMO CRESSONI;ROLF LJUNG;DARIO CONSONNI;ELIO SCARPINI;H. MARIJKE VAN DEN BERG;SAMANTHA C. GOUW;LUIGI FEDELE;ANNE MÄKIPERNAA;MAURIZIO MOGGIO","1115;1068;1030;1025;971;957;933;902;895;883;856;840;836;835;775;770;704;680;669;667","SUSANNA ESPOSITO;DANIELA GALIMBERTI;LUCIANO GATTINONI;PIER ALBERTO BERTAZZI;LUCA VALENTI;GIACOMO P. COMI;MASSIMO COLOMBO;ELENA SANTAGOSTINO;ELIO SCARPINI;DARIO CONSONNI;MAURIZIO MOGGIO;LUIGI FEDELE;DAVIDE CHIUMELLO;CHIARA FENOGLIO;ROBERTA FERRUCCI;ALBERTO PRIORI;MARIA PIA RASTALDI;AGOSTINO CORTELEZZI;MASSIMO IAVARONE;STEFANO GATTI","1059;1025;978;970;933;885;861;856;775;749;657;651;646;644;626;624;623;609;584;580","SUSANNA ESPOSITO;PIER ALBERTO BERTAZZI;DARIO CONSONNI;FLORA PEYVANDI;AGOSTINO CORTELEZZI;FABIO MOSCA;ALBERTO PRIORI;MARIA DOMENICA CAPPELLINI;NICOLA PRINCIPI;ANTONINO NERI;DANIELA GALIMBERTI;EDGARDO SOMIGLIANA;GIACOMO P. COMI;LUCA VALENTI;LUCIANO GATTINONI;LUCA BALDINI;ELIO SCARPINI;MASSIMO COLOMBO;LUIGI FEDELE;SILVIA FUSTINONI","30;27;26;24;23;22;20;19;19;18;18;17;17;17;17;16;16;16;14;14","MEDICINE;BIOLOGY;CHEMISTRY;PSYCHOLOGY;PHYSICS;ENGINEERING;COMPUTER SCIENCE;MATHEMATICS;SOCIOLOGY;ECONOMICS;POLITICAL SCIENCE;MATERIALS SCIENCE;PHILOSOPHY;BUSINESS;ENVIRONMENTAL SCIENCE;GEOGRAPHY;GEOLOGY;ART;HISTORY","869;370;95;86;57;51;47;39;35;28;27;17;16;8;8;8;4;3;3","INTERNAL MEDICINE;GENETICS;SURGERY;PATHOLOGY;IMMUNOLOGY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;PEDIATRICS;BIOCHEMISTRY;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;CARDIOLOGY;PSYCHIATRY;ONCOLOGY;RADIOLOGY;ANESTHESIA;NEUROSCIENCE;CELL BIOLOGY;VIROLOGY;CANCER RESEARCH","623;221;196;179;155;128;114;104;96;92;71;69;69;66;61;51;41;39;38;36","GENE;DISEASE;POPULATION;PREGNANCY;CONFIDENCE INTERVAL;ANTIBODY;CANCER;VIRUS;TRANSPLANTATION;COHORT;DIABETES MELLITUS;ALTERNATIVE MEDICINE;LUNG;ADVERSE EFFECT;PLATELET;BONE MARROW;IMMUNE SYSTEM;PNEUMONIA;CIRRHOSIS;INFLAMMATION;KIDNEY;LEUKEMIA;PROSPECTIVE COHORT STUDY;RECEPTOR;STEM CELL;STIMULATION","167;117;90;53;47;46;43;42;37;35;34;31;30;27;27;25;25;25;24;24;24;24;24;24;24;24","MUTATION;GENE EXPRESSION;GENOTYPE;PHENOTYPE;ALLELE;GESTATIONAL AGE;CHRONIC LYMPHOCYTIC LEUKEMIA;COMMUNITY-ACQUIRED PNEUMONIA;HAZARD RATIO;TRANSCRANIAL DIRECT-CURRENT STIMULATION;EPIGENETICS;CHRONIC HEPATITIS;FETUS;HEPATITIS C VIRUS;LIVER TRANSPLANTATION;METHYLATION;MICRORNA;PLACEBO;RITUXIMAB;TYPE 2 DIABETES","40;33;26;24;22;21;16;16;15;15;13;12;12;12;12;12;12;12;12;12","DNA METHYLATION;RIBAVIRIN;MISSENSE MUTATION;SINGLE-NUCLEOTIDE POLYMORPHISM;FRONTOTEMPORAL DEMENTIA;IGHV@;ADAMTS13;GENE EXPRESSION PROFILING;GENE MUTATION;PRENATAL DIAGNOSIS;ATYPICAL HEMOLYTIC UREMIC SYNDROME;BRONCHOPULMONARY DYSPLASIA;DABIGATRAN;ECULIZUMAB;EXOME SEQUENCING;IMATINIB MESYLATE;INEFFECTIVE ERYTHROPOIESIS;INTERNATIONAL PROGNOSTIC INDEX;NONALCOHOLIC FATTY LIVER DISEASE;PNEUMOCOCCAL CONJUGATE VACCINE;VON WILLEBRAND DISEASE","20;13;12;10;9;8;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5","HUMANS;MALE;FEMALE;;ADULT;MIDDLE AGED;AGED;ITALY;ADOLESCENT;YOUNG ADULT;CHILD;TREATMENT OUTCOME;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;CHILD, PRESCHOOL;RISK FACTORS;BIOMARKERS;FOLLOW-UP STUDIES;PROSPECTIVE STUDIES;PROGNOSIS","649;458;457;280;278;272;212;134;126;118;99;90;84;81;77;77;69;62;59;56","EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HEPATITIS C INFECTION AND TREATMENT;MANAGEMENT AND TREATMENT OF HEMOPHILIA;MANAGEMENT AND EPIDEMIOLOGY OF PNEUMONIA;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;EFFECTS OF BRAIN STIMULATION ON MOTOR CORTEX;ROLE OF COMPLEMENT SYSTEM IN IMMUNE RESPONSE;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;HEALTH EFFECTS OF AIR POLLUTION;HEPATITIS B INFECTION AND TREATMENT;ACUTE MYELOID LEUKEMIA;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;LYMPHOID NEOPLASMS;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;EFFICACY AND RESISTANCE IN CML TREATMENT;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;ATRIAL FIBRILLATION;DENTAL IMPLANTOLOGY AND PERI-IMPLANT DISEASES;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS","20;20;18;18;17;16;13;13;12;10;10;9;9;9;8;8;8;7;7;7","TREATMENT;TRANSCRANIAL DIRECT CURRENT STIMULATION;TRANSCRANIAL MAGNETIC STIMULATION;STROKE (ENGINE);PATHOGENESIS;LIVER BIOPSY;PRETERM INFANTS;POSITIVE END-EXPIRATORY PRESSURE;EXPOSURE ASSESSMENT;HEPATITIS C;CORTICAL EXCITABILITY;INTERQUARTILE RANGE;COMMUNITY-ACQUIRED PNEUMONIA;DEPRESSION (ECONOMICS);DNA METHYLATION;IRON OVERLOAD;NEUROPHYSIOLOGICAL EFFECTS;RECOMBINANT FACTOR VIIA;CHILDHOOD PNEUMONIA;DIAGNOSIS","38;17;17;16;15;14;14;13;11;11;10;10;9;9;9;9;9;9;8;8","CHRONIC HEPATITIS;CHRONIC LYMPHOCYTIC;COMMUNITY-ACQUIRED PNEUMONIA;CYSTIC FIBROSIS;LYMPHOCYTIC LEUKEMIA;CURRENT STIMULATION;DIRECT CURRENT;RISK FACTORS;ELDERLY PATIENTS;TYPE DIABETES;LIVER DISEASE;LUNG CANCER;STEM CELL;TRANSCRANIAL DIRECT;ACUTE RESPIRATORY;MULTIPLE SCLEROSIS;STEM CELLS;CELL CARCINOMA;CLINICAL TRIAL;FATTY LIVER;LIVER TRANSPLANTATION;PHASE II;PROSPECTIVE STUDY;CELL TRANSPLANTATION;CONTROLLED TRIAL;DISTRESS SYNDROME;DNA METHYLATION;HEMOLYTIC UREMIC;HEPATOCELLULAR CARCINOMA;INFLAMMATORY BOWEL","15;14;13;13;13;11;11;11;10;10;9;9;9;9;8;8;8;7;7;7;7;7;7;6;6;6;6;6;6;6","PUBMED SCOPUS;CROSSREF PUBMED;RISK FACTORS;LUNG CANCER;CONFIDENCE INTERVAL;INSULIN RESISTANCE;NEPHROTIC SYNDROME;ADIPOSE TISSUE;CYSTIC FIBROSIS;FOCAL SEGMENTAL;NEPHROL -CROSSREF;MRNA LEVELS;BLOOD PRESSURE;IED MICE;LIVER DISEASE;LOGISTIC REGRESSION;LOW OXYGEN;SAMAMA MM;DNA METHYLATION;GENE EXPRESSION;INTERNAL MEDICINE;IRON OVERLOAD;KIDNEY DISEASE;PRENATAL DIAGNOSIS;SOC NEPHROL;STEROID-RESISTANT NEPHROTIC;VISCERAL ADIPOSE;HUMAN DNA;ODDS RATIO;PATIENTS TREATED","127;82;46;41;30;27;27;26;23;22;22;21;20;19;19;18;18;18;17;17;17;17;17;17;17;17;17;16;16;16",324,0.34,2.725,25.5,5.35,209.199999999999,15.62,1,281,3.32,1,19,1.54,1,4,1,1,1,4.03,1,22,3.14,1,13,0,0,0,1.35,1,3,17.88,1,350,0,0,0,1,1,1,14.15,1,275,1,1,1,1.57,1,4,1.58,1,4,3,1,10,12.2,1,258,2.96,1,11,0.26,0,7,0,0,0,105.21,7,348,105.47,7,351,8,1,2,5,0,5,0,1,0,0,0,0,5,6,3,4,4,1.07142857142857,1,1,8,0,1,2,0,0,4,0,2,1,0,0,2,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,1,2,0,4,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BONINO FERRUCCIO;CATANIA ANNA;GRIECO PAOLO;LAZZARI LORENZA;NOVELLINO ETTORE;REBULLA PAOLO;ANDRIOLO GABRIELLA;FRASCA STEFANIA;MONTELATICI ELISA GIOVANNA ANGELA;COGIAMANIAN FILIPPO MARIA","7;4;4;4;4;4;3;3;3;2","FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO;FOND IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO;TECNOLINE S R L","9;5;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3203 DENTISTRY;34 CHEMICAL SCIENCES;3202 CLINICAL SCIENCES;40 ENGINEERING;42 HEALTH SCIENCES;33 BUILT ENVIRONMENT AND DESIGN;3401 ANALYTICAL CHEMISTRY;3403 MACROMOLECULAR AND MATERIALS CHEMISTRY;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY","11;3;3;2;2;2;1;1;1;1","DENTAL/ORAL AND CRANIOFACIAL DISEASE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;BEHAVIORAL AND SOCIAL SCIENCE;BIOMEDICAL IMAGING;CLINICAL RESEARCH;KIDNEY DISEASE;NEUROSCIENCES","2;2;2;1;1;1;1;1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS","2;1;1","A61K35/32;A61K38/34;C07K14/68;A01N1/02;A61N1/20;C12N5/071;A01N63/00;A61B10/00;A61K31/245;A61K35/19","3;3;3;2;2;2;1;1;1;1","A61P31/04;A61P31/10;C07K14/68;A01N1/02;A01N1/0284;A61K35/32;C12N5/0653;C12N5/0654;C12N5/0655;C12N5/0664","4;4;4;3;3;3;3;3;3;3",5,28550615.8,879902.04,5.4,20.4,8.2,1,171,"FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO;UNIVERSITY OF GREIFSWALD;DÉLÉGATION PARIS 11;ERASMUS MC;UNIVERSITY MEDICAL CENTER FREIBURG;UNIVERSITY OF HELSINKI;AMGEN (SWITZERLAND);ANDALUSIAN HEALTH SERVICE;ANTWERP UNIVERSITY HOSPITAL;AO FOUNDATION;ARTTIC (FRANCE);ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS;ASTRAZENECA (SWEDEN);AUCKLAND UNIVERSITY OF TECHNOLOGY;AUGUST PI I SUNYER BIOMEDICAL RESEARCH INSTITUTE;AUTONOMOUS UNIVERSITY OF MADRID;AZIENDA OSPEDALIERA CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO;AZIENDA OSPEDALIERA SAN GERARDO;BARCELONA INSTITUTE FOR GLOBAL HEALTH;BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS","5;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;TELETHON FOUNDATION","3;2","COALITION S;EC & ERC - EUROPEAN UNION","3;3","FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2013-INNOVATION-1 (CALL FOR PROPOSAL);CP-IP - LARGE-SCALE INTEGRATING PROJECT (FUNDING SCHEME);CSA-SA - SUPPORT ACTIONS (FUNDING SCHEME);FP7-JTI - SPECIFIC PROGRAMME ""COOPERATION"": JOINT TECHNOLOGY INITIATIVES (PROGRAMME);IMI-JU-06-2012 (CALL FOR PROPOSAL);JTI-CP-IMI - JOINT TECHNOLOGY INITIATIVES - COLLABORATIVE PROJECT (IMI) (FUNDING SCHEME);TELETHON GRANT PROJECTS - 2013 (PROGRAM);TELETHON NETWORK OF GENETIC BIOBANKS - RENEWAL 2012 (PROGRAM)","2;2;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;3202 CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3507 STRATEGY, MANAGEMENT AND ORGANISATIONAL BEHAVIOUR;48 LAW AND LEGAL STUDIES;4807 PUBLIC LAW","3;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;NEUROSCIENCES;ANTIMICROBIAL RESISTANCE;BIODEFENSE;BIOTECHNOLOGY;BRAIN DISORDERS;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;COMPARATIVE EFFECTIVENESS RESEARCH;EMERGING INFECTIOUS DISEASES;GENETIC TESTING;GENETICS;HEALTH SERVICES;INFECTIOUS DISEASES;KIDNEY DISEASE;PHYSICAL INJURY - ACCIDENTS AND ADVERSE EFFECTS;PREVENTION;TRAUMATIC BRAIN INJURY (TBI);TRAUMATIC HEAD AND SPINE INJURY;VACCINE RELATED","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GENERIC HEALTH RELEVANCE;INFECTION;INJURIES AND ACCIDENTS;RENAL AND UROGENITAL","1;1;1;1","1.5 RESOURCES AND INFRASTRUCTURE (UNDERPINNING);2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS","1;1;1;1;1","NOT SITE-SPECIFIC CANCER","1","1.5 RESOURCES AND INFRASTRUCTURE;2.4 RESOURCES AND INFRASTRUCTURE RELATED TO ETIOLOGY;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","1;1;1;1","A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","3;1","3 GOOD HEALTH AND WELL BEING","2",61,"PUBLIC LIBRARY OF SCIENCE","61","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;49 MATHEMATICAL SCIENCES;4905 STATISTICS;42 HEALTH SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;39 EDUCATION;3101 BIOCHEMISTRY AND CELL BIOLOGY;3105 GENETICS;3107 MICROBIOLOGY;3904 SPECIALIST STUDIES IN EDUCATION;40 ENGINEERING;51 PHYSICAL SCIENCES;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3215 REPRODUCTIVE MEDICINE;34 CHEMICAL SCIENCES;4013 GEOMATIC ENGINEERING;44 HUMAN SOCIETY;3009 VETERINARY SCIENCES","70;23;21;13;7;6;5;5;3;3;3;3;3;3;2;2;2;2;2;1","CLINICAL RESEARCH;GENETICS;RARE DISEASES;HEMATOLOGY;KIDNEY DISEASE;TRANSPLANTATION;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;LIVER DISEASE;AGING;BRAIN DISORDERS;CARDIOVASCULAR;EMERGING INFECTIOUS DISEASES;HUMAN GENOME;INFECTIOUS DISEASES;NEUROSCIENCES;ORGAN TRANSPLANTATION;ORPHAN DRUG;PREVENTION","7;5;5;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2","GENERIC HEALTH RELEVANCE;ORAL AND GASTROINTESTINAL;RENAL AND UROGENITAL;CANCER;CARDIOVASCULAR;INFECTION;NEUROLOGICAL","4;4;4;2;1;1;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;8.1 ORGANISATION AND DELIVERY OF SERVICES","3;1;1;1;1","CLINICAL;BIOMEDICAL","5;3","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","25;3","LIVER CANCER;KIDNEY CANCER;BRAIN TUMOR;COLON AND RECTAL CANCER;KAPOSI'S SARCOMA;NOT SITE-SPECIFIC CANCER;SARCOMA","5;2;1;1;1;1;1","3 GOOD HEALTH AND WELL BEING","1",50,5.72,690.52,13,44.22,0,2,7,0,12,0,4,25,0,30,15,1,0,0,0,0,0,45,2,3,45,4,0,1,0,0,0,0,0,0,"Italy;United States;Germany;Japan;United Kingdom","6;6;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;3204 IMMUNOLOGY;3213 PAEDIATRICS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;31 BIOLOGICAL SCIENCES;3103 ECOLOGY;3203 DENTISTRY;3207 MEDICAL MICROBIOLOGY;3208 MEDICAL PHYSIOLOGY;3210 NUTRITION AND DIETETICS;3215 REPRODUCTIVE MEDICINE;33 BUILT ENVIRONMENT AND DESIGN;3304 URBAN AND REGIONAL PLANNING;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;40 ENGINEERING","47;23;9;7;4;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;RARE DISEASES;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;LUNG;CANCER;BIOENGINEERING;DIGESTIVE DISEASES;HEMATOLOGY;PATIENT SAFETY;ASSISTIVE TECHNOLOGY;NEUROSCIENCES;AUTOIMMUNE DISEASE;BRAIN DISORDERS;PEDIATRIC;TRANSPLANTATION;CARDIOVASCULAR;HEART DISEASE;NUTRITION;ORPHAN DRUG;PREVENTION","41;23;19;11;10;9;8;8;8;7;7;6;5;5;5;4;4;4;4;4","CANCER;RESPIRATORY;NEUROLOGICAL;CARDIOVASCULAR;CONGENITAL;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;METABOLIC AND ENDOCRINE;MUSCULOSKELETAL;ORAL AND GASTROINTESTINAL;RENAL AND UROGENITAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;STROKE","7;6;4;2;2;2;2;2;2;2;2;2;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.2 CELLULAR AND GENE THERAPIES;3.3 NUTRITION AND CHEMOPREVENTION;7.1 INDIVIDUAL CARE NEEDS","18;3;3;2;2;2;2;2;1;1","LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;LUNG CANCER;BRAIN TUMOR;COLON AND RECTAL CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;HODGKIN'S DISEASE;THYROID CANCER","7;3;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","10;2;1;1"
"IRCCS_CAGRANDA",2014,946,11.1331923890063,3.33192389006343,0.3001269035533,0.466173361522199,0.446088794926004,0.214587737843552,0.464059196617336,9,503,214,77,82,0.53,0.23,0.08,0.09,34.31,0.907919949322774,0.352008456659619,0.940803382663848,5.62954414310444,0.508685486270001,0.455168491812362,0.468550993741833,0.465558875291614,"SUSANNA ESPOSITO;FABIO MOSCA;DANIELA GALIMBERTI;GIACOMO P. COMI;DARIO CONSONNI;LUCIANO GATTINONI;MARIA DOMENICA CAPPELLINI;AGOSTINO CORTELEZZI;FLORA PEYVANDI;NICOLA PRINCIPI;ELIO SCARPINI;PIER MANNUCCIO MANNUCCI;PAOLO BECK‐PECCOZ;FRANCESCO BLASI;ALESSANDRA IURLO;GIAMPIETRO FARRONATO;NEREO BRESOLIN;PIER ALBERTO BERTAZZI;ALESSIO AGHEMO;PIERGIORGIO MESSA","34;30;24;23;23;23;22;21;20;20;19;17;17;16;16;16;16;15;15;15","SUSANNA ESPOSITO;FABIO MOSCA;GIANLUCA NAZZARO;NICOLA PRINCIPI;GIAMPIETRO FARRONATO;FLORA PEYVANDI;STEFANO VERALDI;PIER MANNUCCIO MANNUCCI;MARIA DOMENICA CAPPELLINI;CARLO AGOSTONI;DARIO CONSONNI;FRANCESCO BLASI;LUCIANO GATTINONI;ALESSIO AGHEMO;A. CARLO ALTAMURA;B CANTONI;ALBERTO PRIORI;G. GALBIATI;CINZIA MASPERO;GIACOMO P. COMI","6.21;4.73;4.4;3.28;3.19;2.95;2.87;2.78;2.69;2.63;2.5;2.23;2.2;2.19;2.19;2;1.96;1.91;1.91;1.9","SUSANNA ESPOSITO;FABIO MOSCA;DANIELA GALIMBERTI;GIACOMO P. COMI;DARIO CONSONNI;LUCIANO GATTINONI;MARIA DOMENICA CAPPELLINI;AGOSTINO CORTELEZZI;FLORA PEYVANDI;NICOLA PRINCIPI;ELIO SCARPINI;PIER MANNUCCIO MANNUCCI;PAOLO BECK‐PECCOZ;FRANCESCO BLASI;ALESSANDRA IURLO;GIAMPIETRO FARRONATO;NEREO BRESOLIN;PIER ALBERTO BERTAZZI;ALESSIO AGHEMO;PIERGIORGIO MESSA","34;30;24;23;23;23;22;21;20;20;19;17;17;16;16;16;16;15;15;15","SUSANNA ESPOSITO;FABIO MOSCA;GIANLUCA NAZZARO;NICOLA PRINCIPI;GIAMPIETRO FARRONATO;FLORA PEYVANDI;STEFANO VERALDI;PIER MANNUCCIO MANNUCCI;MARIA DOMENICA CAPPELLINI;CARLO AGOSTONI;DARIO CONSONNI;FRANCESCO BLASI;LUCIANO GATTINONI;ALESSIO AGHEMO;A. CARLO ALTAMURA;B CANTONI;ALBERTO PRIORI;G. GALBIATI;CINZIA MASPERO;GIACOMO P. COMI","6.21;4.73;4.4;3.28;3.19;2.95;2.87;2.78;2.69;2.63;2.5;2.23;2.2;2.19;2.19;2;1.96;1.91;1.91;1.9","DANIELA GALIMBERTI;SANDRO SORBI;LUCIANO GATTINONI;EKATERINA ROGAEVA;PETER ST GEORGE‐HYSLOP;AGUSTÍN RUIZ;ALBERTO LLEÓ;CARLOS CRUCHAGA;ISABEL HERNÁNDEZ;JOHN COLLINGE;JORDI CLARIMÓN;JOHN HARDY;PIETRO CAIRONI;MATTHEW J. HUENTELMAN;GIANNI TOGNONI;ROBERTO LATINI;SERGE MASSON;CATERINA FANIZZA;MARILENA ROMERO;ADAM C. NAJ","2541;1898;1869;1831;1831;1753;1753;1753;1753;1753;1753;1618;1514;1492;1446;1446;1446;1422;1422;1402","DANIELA GALIMBERTI;LUCIANO GATTINONI;PIETRO CAIRONI;ELIO SCARPINI;PIER MANNUCCIO MANNUCCI;G. IAPICHINO;LUISA CASPANI;DARIO CONSONNI;SUSANNA ESPOSITO;FABIO MOSCA;GIACOMO P. COMI;CHIARA FENOGLIO;LUCA VALENTI;PIER ALBERTO BERTAZZI;MASSIMO CUGNO;NINO STOCCHETTI;MARCO MAGGIONI;MARÍA SERPENTE;SILVIA FARGION;ANNA LUDOVICA FRACANZANI","2510;1869;1514;1223;1088;1072;1072;1070;965;887;830;776;733;730;719;697;676;653;637;625","SUSANNA ESPOSITO;FABIO MOSCA;LUCIANO GATTINONI;DARIO CONSONNI;DANIELA GALIMBERTI;MARIA DOMENICA CAPPELLINI;MASSIMO COLOMBO;NICOLA PRINCIPI;ELIO SCARPINI;GIACOMO P. COMI;AGOSTINO CORTELEZZI;FRANCESCO BLASI;FLORA PEYVANDI;ALESSANDRA IURLO;ALESSIO AGHEMO;NEREO BRESOLIN;PIER ALBERTO BERTAZZI;PIERGIORGIO MESSA;PIER MANNUCCIO MANNUCCI;PAOLO BECK‐PECCOZ","34;28;23;23;21;21;20;20;18;17;17;16;16;16;15;15;15;15;15;14","MEDICINE;BIOLOGY;CHEMISTRY;PSYCHOLOGY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;ENGINEERING;SOCIOLOGY;POLITICAL SCIENCE;PHILOSOPHY;ECONOMICS;MATERIALS SCIENCE;BUSINESS;ENVIRONMENTAL SCIENCE;GEOGRAPHY;ART;HISTORY;GEOLOGY","882;366;78;74;64;37;37;29;28;25;24;23;11;9;5;5;4;3;1","INTERNAL MEDICINE;GENETICS;SURGERY;IMMUNOLOGY;PATHOLOGY;GASTROENTEROLOGY;PEDIATRICS;BIOCHEMISTRY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;PSYCHIATRY;INTENSIVE CARE MEDICINE;ONCOLOGY;CARDIOLOGY;CANCER RESEARCH;RADIOLOGY;ANESTHESIA;CELL BIOLOGY;DERMATOLOGY;VIROLOGY","612;234;183;157;157;135;130;93;92;86;80;77;69;64;60;60;57;47;46;42","GENE;DISEASE;POPULATION;PREGNANCY;CANCER;COHORT;VIRUS;LUNG;ANTIBODY;RANDOMIZED CONTROLLED TRIAL;TRANSPLANTATION;CHEMOTHERAPY;CONFIDENCE INTERVAL;PLATELET;ALTERNATIVE MEDICINE;BONE MARROW;ODDS RATIO;DIABETES MELLITUS;INCIDENCE (GEOMETRY);PROSPECTIVE COHORT STUDY","168;122;80;60;54;46;46;40;36;32;31;30;30;29;28;28;27;26;26;25","GENE EXPRESSION;MUTATION;GENOTYPE;PHENOTYPE;ALLELE;DEMENTIA;GESTATIONAL AGE;HEPATITIS C VIRUS;FETUS;GENOME;METHYLATION;CYCLOPHOSPHAMIDE;CHRONIC HEPATITIS;EPIGENETICS;RITUXIMAB;CLINICAL ENDPOINT;FATTY LIVER;HAEMOPHILIA A;MICRORNA;PROTEINURIA","31;29;26;24;22;22;20;20;18;14;14;13;12;12;12;11;11;11;11;11","DNA METHYLATION;FRONTOTEMPORAL DEMENTIA;RIBAVIRIN;SINGLE-NUCLEOTIDE POLYMORPHISM;MISSENSE MUTATION;NONALCOHOLIC FATTY LIVER DISEASE;SMALL FOR GESTATIONAL AGE;EXOME SEQUENCING;FLUDARABINE;GENE EXPRESSION PROFILING;PODOCYTE;BRONCHOPULMONARY DYSPLASIA;HAPLOTYPE;HERPESVIRIDAE;IGHV@;LAMIVUDINE;PROBAND;ECULIZUMAB;FRAMESHIFT MUTATION;HBSAG;IMATINIB MESYLATE;PLACENTAL GROWTH FACTOR;POINT MUTATION;STEATOHEPATITIS","20;16;14;13;10;8;8;7;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5","HUMANS;FEMALE;MALE;;ADULT;MIDDLE AGED;AGED;ITALY;ADOLESCENT;YOUNG ADULT;CHILD;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;AGED, 80 AND OVER;CHILD, PRESCHOOL;PROSPECTIVE STUDIES;RISK FACTORS;FOLLOW-UP STUDIES;BIOMARKERS;CASE-CONTROL STUDIES","636;458;446;296;279;269;200;149;114;114;107;93;92;90;69;66;61;59;52;52","HEPATITIS C INFECTION AND TREATMENT;MANAGEMENT AND TREATMENT OF HEMOPHILIA;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;MANAGEMENT AND EPIDEMIOLOGY OF PNEUMONIA;ROLE OF COMPLEMENT SYSTEM IN IMMUNE RESPONSE;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;ACUTE MYELOID LEUKEMIA;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;EFFICACY AND RESISTANCE IN CML TREATMENT;HEALTH EFFECTS OF AIR POLLUTION;HEPATITIS B INFECTION AND TREATMENT;ORGAN TRANSPLANTATION AND REJECTION;PATHOPHYSIOLOGY AND MANAGEMENT OF PREECLAMPSIA;PATHOPHYSIOLOGY OF GLOMERULAR DISEASES AND NEPHROTIC SYNDROMES;DENTAL IMPLANTOLOGY AND PERI-IMPLANT DISEASES","23;20;17;17;16;14;13;12;12;11;8;8;8;8;8;8;8;8;8;7","TREATMENT;HEPATITIS C;POSITIVE END-EXPIRATORY PRESSURE;PRETERM INFANTS;CLINICAL ENDPOINT;CONCORDANCE;REGIMEN;DIAGNOSIS;FRONTOTEMPORAL LOBAR DEGENERATION;INTERQUARTILE RANGE;TOLERABILITY;TRANSFUSION THERAPY;DNA METHYLATION;ETIOLOGY;PATHOGENESIS;STEATOSIS;DEPRESSION (ECONOMICS);HEMOPHILIA;HEPATITIS B;LUNG TRANSPLANT","37;19;14;14;12;12;12;11;11;10;10;10;9;9;9;9;8;8;8;8","MYELOID LEUKEMIA;PRETERM INFANTS;MULTIPLE MYELOMA;STEM CELL;STEM CELLS;ALZHEIMERS DISEASE;CHRONIC LYMPHOCYTIC;COMMUNITY-ACQUIRED PNEUMONIA;CHRONIC HEPATITIS;CHRONIC MYELOID;HEPATOCELLULAR CARCINOMA;ITALIAN SOCIETY;LYMPHOCYTIC LEUKEMIA;ATRIAL FIBRILLATION;CELL TRANSPLANTATION;CYSTIC FIBROSIS;DNA METHYLATION;ELDERLY PATIENTS;LUNG CANCER;MULTICENTER STUDY;VON WILLEBRAND;ANGIOGENIC FACTORS;CELL CARCINOMA;COHORT STUDY;CURRENT STIMULATION;DIRECT CURRENT;FRONTOTEMPORAL LOBAR;LOBAR DEGENERATION;SYSTEMIC SCLEROSIS;ACUTE MYELOID","13;11;10;10;10;9;9;9;8;8;8;8;8;7;7;7;7;7;7;7;7;6;6;6;6;6;6;6;6;5","THYROID HORMONE;MONTPELLIER F-;JAMA DERMATOLOGY;LUNG CANCER;ODDS RATIO;RISK FACTORS;PRETERM INFANTS;CHU MONTPELLIER;INCREASED RISK;CONFIDENCE INTERVAL;PUBMED SCOPUS;F- FRANCESEARCH;DNA METHYLATION;CELL LINES;DE GÉNÉTIQUE;REGGIO EMILIA;AIR POLLUTION;GESTATIONAL AGE;CROSSREF PUBMED;GÉNÉTIQUE MOLÉCULAIRE;INTENSIVE CARE;INTRACRANIAL PRESSURE;LABORATOIRE DE;LATE PRETERM;BONE MARROW;CLINICAL DATA;LUNG FUNCTION;MAGNETIC RESONANCE;PATIENTS TREATED;RESPIRATORY DISTRESS","58;28;24;24;24;24;23;22;22;21;21;20;19;18;18;18;17;17;16;16;16;16;16;16;15;15;15;15;15;15",381,0.4,1.5,26.46,4.25,314,16.57,1,280,5.74,1,53,1.92,1,7,1.6,1,6,4.2,1,43,3.32,1,14,0,0,0,1.67,1,3,18.59,1,341,0,0,0,1,1,1,12.28,1,242,1.67,1,3,3.3,1,16,1.92,1,8,3.47,1,42,9.29,1,167,3.14,1,25,0.15,0,2,0,0,0,121.7,5,1476,121.79,5,1477,7,1,4,4,0,3,0,2,0,0,0,0,9,5,0,2,3.07142857142857,1,4,0,6,0,3,3,0,0,2,0,1,0,0,0,4,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5,0,2,1,0,1,2,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BARDELLA MARIA TERESA;BESANA VALERIA;BRANCALEONI VALENTINA;CAPPELLINI MARIA DOMENICA;DI PIERRO ELENA;ELLI LUCA;LATTUADA DEBORA;RONCORONI LEDA;TOMBA CAROLINA;CADRINGHER PAOLO","3;3;3;3;3;3;3;3;3;2","FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO;FOND IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO;FONDAZIONE D AMICO PER LA RICERCA SULLE MALATTIE RENALI","9;4;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3202 CLINICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3105 GENETICS;49 MATHEMATICAL SCIENCES","16;9;3;3;3;3;3;1;1;1","GENETICS;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CONDITIONS AFFECTING THE EMBRYONIC AND FETAL PERIODS;DENTAL/ORAL AND CRANIOFACIAL DISEASE;NUTRITION;PEDIATRIC;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;BIOMEDICAL IMAGING;BIOTECHNOLOGY","5;3;3;3;3;3;3;3;2;1",NA,NA,"C12Q1/68;A61K49/00;G01N33/80;A61B6/00;A61B6/03;A61K31/165;A61K31/4164;A61K31/4196;A61K31/506;A61K31/7048","4;3;3;2;2;1;1;1;1;1","C12Q2600/156;A61K49/00;A61K49/0004;C12Q1/6879;C12Q1/6883;C12Q2600/16;G01N2400/40;G01N2800/385;G01N33/80;A61B6/032","4;3;3;3;3;3;3;3;3;2",6,2226849.5,177573.41,3.33333333333333,11.3333333333333,3.16666666666667,0.833333333333333,17.1666666666667,"FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO;CATHOLIC UNIVERSITY OF THE SACRED HEART;UNIVERSITY OF MESSINA;UNIVERSITY OF TURIN;FONDAZIONE ISTITUTO NEUROLOGICO NAZIONALE CASIMIRO MONDINO;ISTITUTO GIANNINA GASLINI;OSPEDALE SAN CAMILLO;UNIVERSITY OF BRESCIA;UNIVERSITY OF PISA;UNIVERSITY OF VERONA;ANDALUSIAN HEALTH SERVICE;ANDALUSIAN SCHOOL OF PUBLIC HEALTH;AUGUST PI I SUNYER BIOMEDICAL RESEARCH INSTITUTE;BAMBINO GESÙ CHILDREN'S HOSPITAL;BAYER (GERMANY);CAPITAL REGION OF DENMARK;CHARITÉ - UNIVERSITY MEDICINE BERLIN;ELI LILLY (UNITED KINGDOM);FONDAZIONE POLITECNICO DI MILANO;FONDAZIONE SANTA LUCIA","6;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","TELETHON FOUNDATION;EUROPEAN COMMISSION","4;2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","TELETHON - UILDM CLINICAL GRANT PROJECTS - 2013 (PROGRAM);CIP - COMPETITIVENESS AND INNOVATION FRAMEWORK PROGRAMME (CIP)(2007-2013) (PROGRAMME);CIP-ICT-PSP-2013-7 (CALL FOR PROPOSAL);FP7-JTI - SPECIFIC PROGRAMME ""COOPERATION"": JOINT TECHNOLOGY INITIATIVES (PROGRAMME);IMI-JU-08-2012 (CALL FOR PROPOSAL);JTI-CP-IMI - JOINT TECHNOLOGY INITIATIVES - COLLABORATIVE PROJECT (IMI) (FUNDING SCHEME);PB - PILOT TYPE B (FUNDING SCHEME);TELETHON GRANT PROJECTS - 2014 (PROGRAM)","3;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;3202 CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY;3213 PAEDIATRICS;42 HEALTH SCIENCES","6;3;2;2;1;1;1","RARE DISEASES;BRAIN DISORDERS;GENETICS;NEUROSCIENCES;PEDIATRIC;CLINICAL RESEARCH;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);MUSCULAR DYSTROPHY;ARTHRITIS;AUTOIMMUNE DISEASE;BIOENGINEERING;CONGENITAL STRUCTURAL ANOMALIES;FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY;HUMAN GENOME;INFANT MORTALITY;LUPUS;NEURODEGENERATIVE;ORPHAN DRUG;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;PRETERM, LOW BIRTH WEIGHT AND HEALTH OF THE NEWBORN","5;4;3;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","MUSCULOSKELETAL;INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL","3;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES","3;3;1;1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE;A04 PSYCHOLOGY, PSYCHIATRY AND NEUROSCIENCE;A05 BIOLOGICAL SCIENCES;B12 ENGINEERING","3;1;1;1",NA,NA,29,"PUBLIC LIBRARY OF SCIENCE","29","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3105 GENETICS;34 CHEMICAL SCIENCES;42 HEALTH SCIENCES;49 MATHEMATICAL SCIENCES;4905 STATISTICS;3211 ONCOLOGY AND CARCINOGENESIS;3401 ANALYTICAL CHEMISTRY;44 HUMAN SOCIETY;47 LANGUAGE, COMMUNICATION AND CULTURE;52 PSYCHOLOGY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3213 PAEDIATRICS;3215 REPRODUCTIVE MEDICINE;37 EARTH SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4202 EPIDEMIOLOGY;4403 DEMOGRAPHY","27;10;8;4;4;4;4;3;2;2;2;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;GENETICS;KIDNEY DISEASE;AUTOIMMUNE DISEASE;CANCER;CARDIOVASCULAR;RARE DISEASES;ACQUIRED COGNITIVE IMPAIRMENT;AGING;ALZHEIMER'S DISEASE;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD);BEHAVIORAL AND SOCIAL SCIENCE;BRAIN DISORDERS;DEMENTIA;DIGESTIVE DISEASES;HEART DISEASE;LIVER CANCER;LIVER DISEASE;NEURODEGENERATIVE;NEUROSCIENCES","4;4;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;GENERIC HEALTH RELEVANCE;RENAL AND UROGENITAL","4;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","4;4;1;1;1","BIOMEDICAL;CLINICAL","5;5","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;HEALTH SERVICES RESEARCH","13;3;1","KIDNEY CANCER;LIVER CANCER;NOT SITE-SPECIFIC CANCER","3;1;1","3 GOOD HEALTH AND WELL BEING","1",46,4.77,533.76,14,42.67,5,4,9,2,8,0,1,17,0,31,14,0,0,0,0,0,0,43,1,2,44,1,0,1,0,0,0,0,0,0,"United States;Germany;Belgium;France;Spain;Austria;Sweden;Switzerland;Italy;United Kingdom","17;9;5;4;4;2;2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;3207 MEDICAL MICROBIOLOGY;3213 PAEDIATRICS;3203 DENTISTRY;3205 MEDICAL BIOCHEMISTRY AND METABOLOMICS;3212 OPHTHALMOLOGY AND OPTOMETRY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3204 IMMUNOLOGY;3215 REPRODUCTIVE MEDICINE;4207 SPORTS SCIENCE AND EXERCISE;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","45;21;8;5;5;3;3;2;2;2;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;CANCER;HEMATOLOGY;PREVENTION;PEDIATRIC;DIGESTIVE DISEASES;INFECTIOUS DISEASES;EMERGING INFECTIOUS DISEASES;TRANSPLANTATION;AGING;AUTOIMMUNE DISEASE;LIVER DISEASE;PATIENT SAFETY;CHRONIC LIVER DISEASE AND CIRRHOSIS;GENETICS;HEPATITIS;LUNG;ORPHAN DRUG","43;26;15;12;11;10;9;8;8;6;6;5;5;5;5;4;4;4;4;4","INFECTION;CANCER;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM;EYE;GENERIC HEALTH RELEVANCE;ORAL AND GASTROINTESTINAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY;BLOOD;MENTAL HEALTH;METABOLIC AND ENDOCRINE;NEUROLOGICAL","7;5;3;3;2;2;2;2;2;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.4 SURVEILLANCE AND DISTRIBUTION;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS;3.3 NUTRITION AND CHEMOPREVENTION","20;7;6;3;2;2;2;2;1","LEUKEMIA / LEUKAEMIA;LIVER CANCER;NON-HODGKIN'S LYMPHOMA;LUNG CANCER;NOT SITE-SPECIFIC CANCER;BLOOD CANCER;COLON AND RECTAL CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;MYELOMA","5;5;5;2;2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;3.3 CHEMOPREVENTION;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","15;3;3;2;1;1;1"
"IRCCS_CAGRANDA",2015,1004,11.5029880478088,3.39541832669323,0.29451452038721,0.431274900398406,0.421314741035857,0.349601593625498,0.495019920318725,13,517,233,87,84,0.51,0.23,0.09,0.08,33.14,0.889348433972152,0.370517928286853,0.946215139442231,5.61651469098278,0.499219802166426,0.483607813579549,0.492718741326672,0.48898037536955,"SUSANNA ESPOSITO;DARIO CONSONNI;AGOSTINO CORTELEZZI;NICOLA PRINCIPI;FABIO MOSCA;FRANCESCO BLASI;NICOLA MONTANO;ANTONINO NERI;FLORA PEYVANDI;DANIELA GALIMBERTI;MARIA DOMENICA CAPPELLINI;LUCIANO GATTINONI;GIACOMO P. COMI;LUCA VALENTI;PIER MANNUCCIO MANNUCCI;SILVIA FARGION;ELIO SCARPINI;ALBERTO PRIORI;CARLA COLOMBO;ERMINIO TORRESANI","40;28;28;26;24;23;21;21;20;20;19;19;17;17;17;17;16;16;16;15","SUSANNA ESPOSITO;NICOLA PRINCIPI;NICOLA MONTANO;FLORA PEYVANDI;FRANCESCO BLASI;PIER MANNUCCIO MANNUCCI;MARIA DOMENICA CAPPELLINI;DARIO CONSONNI;FABIO MOSCA;PAOLO VERCELLINI;ALBERTO PRIORI;MASSIMO COLOMBO;GIOVANNI CASAZZA;AGOSTINO CORTELEZZI;LUCIANO GATTINONI;GIANLUCA NAZZARO;DARIO CONTE;GIORGIO COSTANTINO;GIAMPIETRO FARRONATO;CARLO AGOSTONI","7.71;4.95;4.55;3.55;3.47;3.31;3.31;3.17;2.75;2.72;2.26;2.12;2.07;2;1.97;1.92;1.92;1.89;1.89;1.88","SUSANNA ESPOSITO;DARIO CONSONNI;AGOSTINO CORTELEZZI;NICOLA PRINCIPI;FABIO MOSCA;FRANCESCO BLASI;NICOLA MONTANO;ANTONINO NERI;FLORA PEYVANDI;DANIELA GALIMBERTI;MARIA DOMENICA CAPPELLINI;LUCIANO GATTINONI;GIACOMO P. COMI;LUCA VALENTI;PIER MANNUCCIO MANNUCCI;SILVIA FARGION;ELIO SCARPINI;ALBERTO PRIORI;CARLA COLOMBO;ERMINIO TORRESANI","40;28;28;26;24;23;21;21;20;20;19;19;17;17;17;17;16;16;16;15","SUSANNA ESPOSITO;NICOLA PRINCIPI;NICOLA MONTANO;FLORA PEYVANDI;FRANCESCO BLASI;PIER MANNUCCIO MANNUCCI;MARIA DOMENICA CAPPELLINI;DARIO CONSONNI;FABIO MOSCA;PAOLO VERCELLINI;ALBERTO PRIORI;MASSIMO COLOMBO;AGOSTINO CORTELEZZI;LUCIANO GATTINONI;GIANLUCA NAZZARO;DARIO CONTE;GIORGIO COSTANTINO;GIAMPIETRO FARRONATO;CARLO AGOSTONI;CARLA COLOMBO","7.71;4.95;4.55;3.55;3.47;3.31;3.31;3.17;2.75;2.72;2.26;2.12;2;1.97;1.92;1.92;1.89;1.89;1.88;1.86","CARLA COLOMBO;J.S. ELBORN;BONNIE W. RAMSEY;CLAIRE WAINWRIGHT;DAVID WALTZ;EDWARD F. MCKONE;FÉLIX RATJEN;GAUTHAM MARIGOWDA;JANE C. DAVIES;K. DE BOECK;KAREN MCCOY;MARCO CIPOLLI;MICHAEL BOYLE;MICHAEL W. KONSTAN;PATRICK A. FLUME;STEVEN M. ROWE;SUSANNA A. MCCOLLEY;XIAOHONG HUANG;À. MUNCK;DANIELA GALIMBERTI","2032;1869;1492;1492;1492;1492;1492;1492;1492;1492;1492;1492;1492;1492;1492;1492;1492;1492;1492;1323","CARLA COLOMBO;DANIELA GALIMBERTI;ELIO SCARPINI;MONICA FUMAGALLI;MANUELA CAROLI;LUCA VALENTI;SUSANNA ESPOSITO;SILVIA FARGION;FABIO MOSCA;FLAVIO CAPRIOLI;DARIO CONSONNI;FRANCESCO BLASI;PAOLA DONGIOVANNI;ANTONINO NERI;PIETRO LAMPERTICO;LUCA ELLI;NICOLA PRINCIPI;PAOLO VERCELLINI;M. COLOMBO;GIOVANNA MANTOVANI","1965;1316;1220;1125;1123;921;844;806;795;757;751;704;702;690;660;627;626;604;565;548","SUSANNA ESPOSITO;DARIO CONSONNI;NICOLA PRINCIPI;AGOSTINO CORTELEZZI;FABIO MOSCA;FRANCESCO BLASI;MASSIMO COLOMBO;CARLA COLOMBO;NICOLA MONTANO;ANTONINO NERI;DANIELA GALIMBERTI;FLORA PEYVANDI;MARIA DOMENICA CAPPELLINI;ELENA SANTAGOSTINO;PIER MANNUCCIO MANNUCCI;LUCIANO GATTINONI;ERMINIO TORRESANI;GIACOMO P. COMI;MONICA FUMAGALLI;ELIO SCARPINI","38;26;26;25;23;23;22;22;21;21;19;18;17;16;16;16;15;15;15;15","MEDICINE;BIOLOGY;CHEMISTRY;PSYCHOLOGY;COMPUTER SCIENCE;PHYSICS;ENGINEERING;MATHEMATICS;POLITICAL SCIENCE;ECONOMICS;SOCIOLOGY;MATERIALS SCIENCE;PHILOSOPHY;GEOGRAPHY;BUSINESS;ART;HISTORY;ENVIRONMENTAL SCIENCE;GEOLOGY","923;373;93;83;71;71;42;34;29;26;25;18;16;12;9;8;4;2;1","INTERNAL MEDICINE;GENETICS;SURGERY;PATHOLOGY;IMMUNOLOGY;GASTROENTEROLOGY;PEDIATRICS;ENVIRONMENTAL HEALTH;PSYCHIATRY;CARDIOLOGY;INTENSIVE CARE MEDICINE;BIOCHEMISTRY;ENDOCRINOLOGY;CANCER RESEARCH;ONCOLOGY;RADIOLOGY;ANESTHESIA;NEUROSCIENCE;VIROLOGY;MICROBIOLOGY","670;219;213;183;171;140;128;102;95;92;89;87;79;63;63;60;58;49;49;48","GENE;DISEASE;POPULATION;PREGNANCY;CANCER;TRANSPLANTATION;ANTIBODY;CONFIDENCE INTERVAL;VIRUS;COHORT;CHEMOTHERAPY;INCIDENCE (GEOMETRY);LUNG;CLINICAL TRIAL;ADVERSE EFFECT;ANTIBIOTICS;ODDS RATIO;PLATELET;MYOCARDIAL INFARCTION;RETROSPECTIVE COHORT STUDY","157;147;91;56;53;47;43;43;43;42;36;32;32;31;30;30;29;29;28;28","MUTATION;GENOTYPE;PHENOTYPE;GENE EXPRESSION;FETUS;PARKINSON'S DISEASE;DEMENTIA;GESTATIONAL AGE;LIVER TRANSPLANTATION;HEPATITIS C VIRUS;STREPTOCOCCUS PNEUMONIAE;ALLELE;HAZARD RATIO;RITUXIMAB;CYCLOPHOSPHAMIDE;HEART RATE;PLACEBO;FATTY LIVER;LUNG VOLUMES;HEPATITIS B VIRUS;IMATINIB;MICRORNA","36;35;27;26;21;19;16;16;16;15;15;14;14;13;12;12;12;11;11;10;10;10","DNA METHYLATION;SINGLE-NUCLEOTIDE POLYMORPHISM;DEEP BRAIN STIMULATION;RIBAVIRIN;PNEUMOCOCCAL CONJUGATE VACCINE;AUTONOMIC NERVOUS SYSTEM;FRONTOTEMPORAL DEMENTIA;HEART RATE VARIABILITY;PNEUMOCOCCAL INFECTIONS;DASATINIB;FLUDARABINE;PROSTATECTOMY;COMPOUND HETEROZYGOSITY;HBSAG;NONALCOHOLIC FATTY LIVER DISEASE;PROBAND;BRONCHOPULMONARY DYSPLASIA;HAPLOTYPE;LAMIVUDINE;NILOTINIB;OVARIAN RESERVE;PAPILLARY THYROID CANCER;PRENATAL DIAGNOSIS;SANGER SEQUENCING;TICAGRELOR","15;13;12;10;9;8;8;8;8;7;7;7;6;6;6;6;5;5;5;5;5;5;5;5;5","HUMANS;FEMALE;MALE;;MIDDLE AGED;ADULT;AGED;ITALY;ADOLESCENT;YOUNG ADULT;CHILD;TREATMENT OUTCOME;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;CHILD, PRESCHOOL;PROSPECTIVE STUDIES;INFANT;RISK FACTORS;BIOMARKERS;MUTATION","680;481;457;307;295;260;222;147;131;110;103;91;87;77;76;71;65;62;58;58","MANAGEMENT AND TREATMENT OF HEMOPHILIA;MANAGEMENT AND EPIDEMIOLOGY OF PNEUMONIA;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;HEPATITIS C INFECTION AND TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;DEEP BRAIN STIMULATION FOR NEUROLOGICAL DISORDERS;EFFICACY AND RESISTANCE IN CML TREATMENT;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;ROLE OF COMPLEMENT SYSTEM IN IMMUNE RESPONSE;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;EFFECTS OF BRAIN STIMULATION ON MOTOR CORTEX;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;HEPATITIS B INFECTION AND TREATMENT;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;DENTAL IMPLANTOLOGY AND PERI-IMPLANT DISEASES;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE","29;21;19;17;16;12;12;11;11;11;10;10;10;10;10;10;10;9;8;8","TREATMENT;HEPATITIS C;INTERQUARTILE RANGE;CARRIAGE;LIVER DISEASE;REGIMEN;ETIOLOGY;CYSTIC FIBROSIS;DEEP BRAIN STIMULATION;NONINVASIVE VENTILATION;POSITIVE END-EXPIRATORY PRESSURE;CHILDHOOD PNEUMONIA;DISCONTINUATION;PRETERM INFANTS;TRANSCRANIAL DIRECT CURRENT STIMULATION;TRANSCRANIAL MAGNETIC STIMULATION;PATHOGENESIS;RECOMBINANT FACTOR VIIA;STEATOSIS;CLINICAL ENDPOINT","35;17;15;14;14;14;13;12;12;12;12;11;11;11;11;11;10;10;10;9","CYSTIC FIBROSIS;HEPATOCELLULAR CARCINOMA;MULTIPLE SCLEROSIS;PARKINSONS DISEASE;MYELOID LEUKEMIA;BRAIN STIMULATION;CHRONIC HEPATITIS;CHRONIC LYMPHOCYTIC;COHORT STUDY;DEEP BRAIN;LYMPHOCYTIC LEUKEMIA;PATIENTS TREATED;PILOT STUDY;RETROSPECTIVE STUDY;CLINICAL TRIAL;ELDERLY PATIENTS;FRONTOTEMPORAL DEMENTIA;PATIENTS UNDERGOING;PRETERM INFANTS;CHRONIC MYELOID;CLINICAL PRACTICE;CLINICAL STUDY;LIVER DISEASE;MYOCARDIAL INFARCTION;PRELIMINARY RESULTS;RADICAL PROSTATECTOMY;STEM CELLS;ACUTE RESPIRATORY;ATRIAL FIBRILLATION;BIRTH WEIGHT","16;13;11;11;10;9;9;9;9;9;9;9;9;9;8;8;8;8;8;7;7;7;7;7;7;7;7;6;6;6","MILAN ITALY;SAN RAFFAELE;INSTITUTE MILAN;RAFFAELE SCIENTIFIC;SCIENTIFIC INSTITUTE;IRCCS SAN;ITALY SEARCH;RISK FACTORS;CONFIDENCE INTERVAL;ODDS RATIO;MAGGIORE POLICLINICO;AIR POLLUTION;FONDAZIONE IRCCS;CYSTIC FIBROSIS;OSPEDALE MAGGIORE;PRETERM INFANTS;TR-LIKE CELLS;ADVISORY COMMITTEES;ENTITYS BOARD;GRANDA OSPEDALE;LUNG CANCER;ADVERSE EVENTS;INCREASED RISK;PUBMED SCOPUS;UNIT IRCCS;GENE EXPRESSION;STEM CELL;BLOOD PRESSURE;CROSSREF PUBMED;HEALTHY CONTROLS","117;69;66;66;66;64;56;47;37;34;31;30;29;26;26;26;26;25;25;25;25;24;24;24;24;23;23;22;22;21",459,0.46,2,32.59,7.33,418.088,20.33,2,243,2.75,1,16,1.68,1,6,1.6,1,4,4.02,1,35,2.58,1,10,0,0,0,1.22,1,3,24.04,2,283,1,1,1,1,1,1,16.05,1,175,1.67,1,5,2.67,1,15,1.6,1,3,4.22,1,30,11.13,1,120,3.85,1,39,0.1,0,2,0,0,0,127.5,5,856,127.6,5,856,7,3,1,1,0,2,0,3,1,0,0,0,5,5,1,2,4,1.09090909090909,1,1,6,1,1,3,0,0,4,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,1,1,1,0,1,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"LAZZARI LORENZA;REBULLA PAOLO;BARDELLA MARIA TERESA;ELLI LUCA;RONCORONI LEDA;TOMBA CAROLINA;GREPPI NOEMI;PARAZZI VALENTINA;ANDRIOLO GABRIELLA;BONINO FERRUCCIO","4;4;3;3;3;3;2;2;1;1","FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO;FOND IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO;TECNOLINE SRL","10;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3202 CLINICAL SCIENCES;40 ENGINEERING;31 BIOLOGICAL SCIENCES;3203 DENTISTRY;3206 MEDICAL BIOTECHNOLOGY;3215 REPRODUCTIVE MEDICINE;34 CHEMICAL SCIENCES","14;3;3;2;2;1;1;1;1;1","CLINICAL RESEARCH;DENTAL/ORAL AND CRANIOFACIAL DISEASE;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;NUTRITION;STEM CELL RESEARCH;CONTRACEPTION/REPRODUCTION;KIDNEY DISEASE;REGENERATIVE MEDICINE;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN","4;4;3;3;2;1;1;1;1;1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1;1","A61K49/00;C12N5/00;A61K35/16;A61K35/19;A61P17/02;A61P7/00;C12N5/02;A01N1/02;A61B10/00;A61K35/12","3;3;2;2;2;2;2;1;1;1","A61K49/00;A61K49/0004;C12N5/0018;A61K35/19;A61P17/00;A61P17/02;A61P7/00;C12N2500/84;C12N2502/115;C12N5/0037","3;3;3;2;2;2;2;2;2;2",4,1950650,180649.72,3.25,8,4,0.5,23,"FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO;ABBOTT (NETHERLANDS);ASTON UNIVERSITY;ASTRAZENECA (SWEDEN);BIOMEDICAL PRIMATE RESEARCH CENTRE;DEPARTMENT OF HEALTH;ERASMUS MC;ESCOLA SUPERIOR DE ENFERMAGEM DE COIMBRA;EUROPEAN MEDICINES AGENCY;EVERIS (SPAIN);GHENT UNIVERSITY;GLAXOSMITHKLINE (BELGIUM);GLAXOSMITHKLINE (ITALY);ISTITUTO SUPERIORE DI SANITÀ;JANSSEN (NETHERLANDS);LANCASTER UNIVERSITY;MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH;PAUL EHRLICH INSTITUT;ROESSINGH RESEARCH AND DEVELOPMENT;SANOFI (FRANCE)","4;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;TELETHON FOUNDATION","2;2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","3RD HEALTH PROGRAMME (PROGRAMME);FP7-JTI - SPECIFIC PROGRAMME ""COOPERATION"": JOINT TECHNOLOGY INITIATIVES (PROGRAMME);IMI-JU-10-2013 (CALL FOR PROPOSAL);JTI-CP-IMI - JOINT TECHNOLOGY INITIATIVES - COLLABORATIVE PROJECT (IMI) (FUNDING SCHEME);TELETHON EXPLORATORY PROJECTS 2014 (PROGRAM);TELETHON GRANT PROJECTS - 2015 (PROGRAM)","1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3202 CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY;3207 MEDICAL MICROBIOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;46 INFORMATION AND COMPUTING SCIENCES","3;1;1;1;1;1;1;1;1","BIODEFENSE;BIOTECHNOLOGY;BRAIN DISORDERS;CHRONIC LIVER DISEASE AND CIRRHOSIS;CLINICAL RESEARCH;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;EPILEPSY;GENE THERAPY;GENETICS;HEALTH SERVICES;IMMUNIZATION;INFECTIOUS DISEASES;INFLUENZA;LIVER DISEASE;NEURODEGENERATIVE;NEUROSCIENCES;NUTRITION;PEDIATRIC;PNEUMONIA & INFLUENZA","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","INFECTION;METABOLIC AND ENDOCRINE;NEUROLOGICAL;ORAL AND GASTROINTESTINAL","1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;3.4 VACCINES;5.2 CELLULAR AND GENE THERAPIES","1;1;1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;A04 PSYCHOLOGY, PSYCHIATRY AND NEUROSCIENCE","2;1;1","3 GOOD HEALTH AND WELL BEING","1",46,"PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE;TAYLOR & FRANCIS GROUP","39;5;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;49 MATHEMATICAL SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;46 INFORMATION AND COMPUTING SCIENCES;4905 STATISTICS;3101 BIOCHEMISTRY AND CELL BIOLOGY;3207 MEDICAL MICROBIOLOGY;4202 EPIDEMIOLOGY;3103 ECOLOGY;3105 GENETICS;3213 PAEDIATRICS;4605 DATA MANAGEMENT AND DATA SCIENCE;48 LAW AND LEGAL STUDIES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3215 REPRODUCTIVE MEDICINE;34 CHEMICAL SCIENCES","55;14;12;11;9;7;7;4;3;3;3;2;2;2;2;2;1;1;1;1","CLINICAL RESEARCH;HEMATOLOGY;GENETICS;INFECTIOUS DISEASES;PREVENTION;UROLOGIC DISEASES;CANCER;SEPSIS;BIOTECHNOLOGY;NUTRITION;RARE DISEASES;AGING;CHRONIC LIVER DISEASE AND CIRRHOSIS;DIGESTIVE DISEASES;LIVER DISEASE;LUNG;PEDIATRIC;ACQUIRED COGNITIVE IMPAIRMENT;ALZHEIMER'S DISEASE;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD)","14;6;5;5;5;5;4;4;3;3;3;2;2;2;2;2;2;1;1;1","CANCER;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;REPRODUCTIVE HEALTH AND CHILDBIRTH;METABOLIC AND ENDOCRINE","7;7;4;3;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING","5;2;2;2;1","CLINICAL;BIOMEDICAL;POPULATION & SOCIETY","7;4;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","21;5;2","LEUKEMIA / LEUKAEMIA;PROSTATE CANCER;CERVICAL CANCER;KIDNEY CANCER;LIVER CANCER;LUNG CANCER","3;3;1;1;1;1","3 GOOD HEALTH AND WELL BEING","2",44,4.03,856.29,14,62.16,1,1,8,0,10,0,7,17,0,27,12,0,0,0,0,0,0,39,2,3,38,5,0,0,0,0,0,1,0,0,"Italy;Germany;United States;Belgium;Switzerland;France;Japan;Spain;Australia;Austria;Netherlands;Sweden;United Kingdom","9;6;6;3;3;2;2;2;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3213 PAEDIATRICS;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;31 BIOLOGICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3002 AGRICULTURE, LAND AND FARM MANAGEMENT;3210 NUTRITION AND DIETETICS;41 ENVIRONMENTAL SCIENCES;4102 ECOLOGICAL APPLICATIONS;48 LAW AND LEGAL STUDIES","42;21;5;4;3;3;3;3;3;2;2;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;PATIENT SAFETY;DIGESTIVE DISEASES;HEMATOLOGY;PEDIATRIC;NUTRITION;PREVENTION;CANCER;LIVER DISEASE;INFANT MORTALITY;LUNG;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;PRETERM, LOW BIRTH WEIGHT AND HEALTH OF THE NEWBORN;AUTOIMMUNE DISEASE;BIOENGINEERING;CHRONIC LIVER DISEASE AND CIRRHOSIS;HEPATITIS;NEUROSCIENCES","35;22;16;10;9;8;8;6;6;5;5;4;4;4;4;3;3;3;3;3","ORAL AND GASTROINTESTINAL;BLOOD;CANCER;INFECTION;RENAL AND UROGENITAL;RESPIRATORY;CONGENITAL;INFLAMMATORY AND IMMUNE SYSTEM;METABOLIC AND ENDOCRINE;MUSCULOSKELETAL;NEUROLOGICAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;SKIN","8;3;2;2;2;2;1;1;1;1;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","24;3;2;2;1;1;1","LEUKEMIA / LEUKAEMIA;LIVER CANCER;BREAST CANCER;COLON AND RECTAL CANCER;KIDNEY CANCER;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER","4;2;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;3.3 CHEMOPREVENTION;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER","4;3;2;1"
"IRCCS_CAGRANDA",2016,1042,12.0652591170825,3.52303262955854,0.283846363388722,0.439539347408829,0.40978886756238,0.436660268714012,0.519193857965451,7,504,274,77,97,0.48,0.26,0.07,0.09,36.76,1.13167088375296,0.394433781190019,0.959692898272553,5.36869909751265,0.519589955350267,0.480428922716051,0.478127224234081,0.476059882414968,"SUSANNA ESPOSITO;DARIO CONSONNI;FABIO MOSCA;FLORA PEYVANDI;DANIELA GALIMBERTI;AGOSTINO CORTELEZZI;FRANCESCO BLASI;ALESSANDRA IURLO;PIER ALBERTO BERTAZZI;ELIO SCARPINI;ANGELA CECILIA PESATORI;NICOLA PRINCIPI;LUCA VALENTI;ALESSIO AGHEMO;MARIA DOMENICA CAPPELLINI;PIER MANNUCCIO MANNUCCI;SILVIA FARGION;IDA MARTINELLI;BERNARDO DELL’OSSO;MONICA FUMAGALLI","50;41;32;31;26;23;22;21;19;19;18;17;16;16;16;16;16;15;15;15","SUSANNA ESPOSITO;DARIO CONSONNI;FLORA PEYVANDI;FABIO MOSCA;FRANCESCO BLASI;STEFANO VERALDI;NICOLA PRINCIPI;ALESSIO AGHEMO;PIER ALBERTO BERTAZZI;LORENZO PIGNATARO;ARMANDO TRIPODI;MASSIMO CARLO MAURI;GIAMPIETRO FARRONATO;CARLO MAIORANA;DANIELA GALIMBERTI;BERNARDO DELL’OSSO;AGOSTINO CORTELEZZI;PIER MANNUCCIO MANNUCCI;MASSIMO CASTELLANI;ANGELA CECILIA PESATORI","7.86;5.03;4.56;3.35;2.98;2.84;2.77;2.58;2.42;2.4;2.1;2.1;2.08;1.98;1.97;1.92;1.91;1.9;1.82;1.8","SUSANNA ESPOSITO;DARIO CONSONNI;FABIO MOSCA;FLORA PEYVANDI;DANIELA GALIMBERTI;AGOSTINO CORTELEZZI;FRANCESCO BLASI;ALESSANDRA IURLO;PIER ALBERTO BERTAZZI;ELIO SCARPINI;ANGELA CECILIA PESATORI;NICOLA PRINCIPI;LUCA VALENTI;ALESSIO AGHEMO;MARIA DOMENICA CAPPELLINI;PIER MANNUCCIO MANNUCCI;SILVIA FARGION;IDA MARTINELLI;BERNARDO DELL’OSSO;MONICA FUMAGALLI","50;41;32;31;26;23;22;21;19;19;18;17;16;16;16;16;16;15;15;15","SUSANNA ESPOSITO;DARIO CONSONNI;FLORA PEYVANDI;FABIO MOSCA;FRANCESCO BLASI;STEFANO VERALDI;NICOLA PRINCIPI;ALESSIO AGHEMO;PIER ALBERTO BERTAZZI;LORENZO PIGNATARO;ARMANDO TRIPODI;MASSIMO CARLO MAURI;GIAMPIETRO FARRONATO;CARLO MAIORANA;DANIELA GALIMBERTI;BERNARDO DELL’OSSO;AGOSTINO CORTELEZZI;PIER MANNUCCIO MANNUCCI;MASSIMO CASTELLANI;ANGELA CECILIA PESATORI","7.86;5.03;4.56;3.35;2.98;2.84;2.77;2.58;2.42;2.4;2.1;2.1;2.08;1.98;1.97;1.92;1.91;1.9;1.82;1.8","LUCIANO GATTINONI;ANTONIO PESENTI;SUSANNA ESPOSITO;LAURENT BROCHARD;ARTHUR S. SLUTSKY;FLORA PEYVANDI;DARIO CONSONNI;VALENTINA VAIRA;DANIELA GALIMBERTI;PIER ALBERTO BERTAZZI;CARLA COLOMBO;SILVANO BÒSARI;VALENTINA BOLLATI;LUCA VALENTI;MASSIMO CRESSONI;PAOLO CADRINGHER;STEFANO ALIBERTI;FABIO MOSCA;PIER MANNUCCIO MANNUCCI;CHIARA CHIURAZZI","2021;1988;1696;1650;1544;1406;1346;1232;1213;1200;1195;1162;1123;1120;1109;1078;1070;1065;1058;1049","ANTONIO PESENTI;SUSANNA ESPOSITO;FLORA PEYVANDI;DARIO CONSONNI;DANIELA GALIMBERTI;CARLA COLOMBO;PIER ALBERTO BERTAZZI;SILVANO BÒSARI;LUCA VALENTI;VALENTINA VAIRA;PAOLO CADRINGHER;VALENTINA BOLLATI;FABIO MOSCA;PAOLA DONGIOVANNI;A. PALLESCHI;PIER MANNUCCIO MANNUCCI;SILVIA FARGION;EDGARDO SOMIGLIANA;ELENA SANTAGOSTINO;STEFANO ALIBERTI","1776;1688;1406;1346;1213;1195;1181;1162;1120;1116;1078;1073;1054;981;979;979;959;931;908;892","SUSANNA ESPOSITO;DARIO CONSONNI;FLORA PEYVANDI;FABIO MOSCA;DANIELA GALIMBERTI;AGOSTINO CORTELEZZI;ALESSANDRA IURLO;FRANCESCO BLASI;MASSIMO COLOMBO;ELIO SCARPINI;CARLA COLOMBO;PIER ALBERTO BERTAZZI;NICOLA PRINCIPI;ALESSIO AGHEMO;LUCA VALENTI;SILVIA FARGION;MARIA DOMENICA CAPPELLINI;BERNARDO DELL’OSSO;IDA MARTINELLI;PIER MANNUCCIO MANNUCCI","49;43;31;31;26;23;22;22;19;19;19;17;17;16;16;16;15;15;15;15","MEDICINE;BIOLOGY;PSYCHOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;POLITICAL SCIENCE;ECONOMICS;SOCIOLOGY;MATERIALS SCIENCE;PHILOSOPHY;BUSINESS;ART;GEOGRAPHY;GEOLOGY;ENVIRONMENTAL SCIENCE;HISTORY","950;401;98;93;85;70;34;29;29;28;28;27;19;13;10;9;7;6;5","INTERNAL MEDICINE;GENETICS;SURGERY;PATHOLOGY;IMMUNOLOGY;GASTROENTEROLOGY;PEDIATRICS;BIOCHEMISTRY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;PSYCHIATRY;INTENSIVE CARE MEDICINE;CARDIOLOGY;ANESTHESIA;RADIOLOGY;CELL BIOLOGY;NEUROSCIENCE;ONCOLOGY;OPTICS;CANCER RESEARCH","669;250;221;177;167;140;128;92;87;87;82;80;71;68;64;59;54;52;49;47","GENE;DISEASE;PREGNANCY;POPULATION;LUNG;COHORT;CANCER;CONFIDENCE INTERVAL;TRANSPLANTATION;INCIDENCE (GEOMETRY);VIRUS;CIRRHOSIS;PLATELET;PROSPECTIVE COHORT STUDY;ADVERSE EFFECT;ANTIBODY;RANDOMIZED CONTROLLED TRIAL;THROMBOSIS;CLINICAL TRIAL;RETROSPECTIVE COHORT STUDY","171;143;79;72;61;60;45;45;43;39;37;34;34;34;33;33;33;31;29;29","FETUS;GENE EXPRESSION;MUTATION;GESTATIONAL AGE;GENOTYPE;PHENOTYPE;DEMENTIA;HAZARD RATIO;ALLELE;GESTATION;HEPATITIS C VIRUS;CLINICAL ENDPOINT;TOLERABILITY;BIRTH WEIGHT;CHRONIC LYMPHOCYTIC LEUKEMIA;MICRORNA;FATTY LIVER;HAEMATOPOIESIS;HAEMOPHILIA A;METHYLATION;PARKINSON'S DISEASE;PLACEBO;VON WILLEBRAND FACTOR","38;36;35;31;30;24;20;20;17;15;15;13;13;12;12;12;11;11;11;11;11;11;11","DNA METHYLATION;FRONTOTEMPORAL DEMENTIA;PRENATAL DIAGNOSIS;SINGLE-NUCLEOTIDE POLYMORPHISM;MISSENSE MUTATION;RIBAVIRIN;HAEMOPHILIA B;DASATINIB;EXOME SEQUENCING;NILOTINIB;CROSSOVER STUDY;DEEP BRAIN STIMULATION;NONALCOHOLIC FATTY LIVER DISEASE;ADAMTS13;AMNIOTIC FLUID;COMPOUND HETEROZYGOSITY;DIFFUSING CAPACITY;GENE EXPRESSION PROFILING;IMATINIB MESYLATE;PROSTATECTOMY;SANGER SEQUENCING;TRANSIENT ELASTOGRAPHY;VON WILLEBRAND DISEASE","19;11;11;11;10;10;8;7;7;7;6;6;6;5;5;5;5;5;5;5;5;5;5","HUMANS;FEMALE;MALE;MIDDLE AGED;;ADULT;AGED;ITALY;ADOLESCENT;CHILD;YOUNG ADULT;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;CHILD, PRESCHOOL;BIOMARKERS;RISK FACTORS;PROSPECTIVE STUDIES;INFANT;ANIMALS","732;508;484;306;288;288;239;193;124;120;120;90;84;83;82;81;77;69;61;55","MANAGEMENT AND TREATMENT OF HEMOPHILIA;HEPATITIS C INFECTION AND TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;EFFICACY AND RESISTANCE IN CML TREATMENT;HEALTH EFFECTS OF AIR POLLUTION;MANAGEMENT AND EPIDEMIOLOGY OF PNEUMONIA;ROLE OF COMPLEMENT SYSTEM IN IMMUNE RESPONSE;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;PATHOPHYSIOLOGY AND MANAGEMENT OF PREECLAMPSIA;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;MOLECULAR MECHANISMS OF MUSCLE REGENERATION AND ATROPHY;ORGAN TRANSPLANTATION AND REJECTION;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;ATRIAL FIBRILLATION","27;20;17;17;14;13;13;12;12;11;11;11;10;10;10;10;10;9;9;8","TREATMENT;HEPATITIS C;ETIOLOGY;POSITIVE END-EXPIRATORY PRESSURE;NEURODEGENERATION;CLINICAL ENDPOINT;TOLERABILITY;DEEP VEIN THROMBOSIS;EXPOSURE ASSESSMENT;VENOUS THROMBOEMBOLISM;LIVER DISEASE;CONCOMITANT;DIAGNOSIS;DISCONTINUATION;IMPLANT STABILITY;PATHOGENESIS;REGIMEN;FETAL DNA ANALYSIS;MESENCHYMAL STEM CELLS;COPD","34;17;16;15;14;13;13;12;12;12;11;10;10;10;10;10;10;9;9;8","COHORT STUDY;CYSTIC FIBROSIS;LIVER DISEASE;VEIN THROMBOSIS;ALZHEIMERS DISEASE;CHRONIC HEPATITIS;MUSCULAR DYSTROPHY;RISK FACTORS;STEM CELL;CHRONIC LYMPHOCYTIC;CONTROLLED TRIAL;DISTRESS SYNDROME;FATTY LIVER;ITALIAN PATIENTS;LYMPHOCYTIC LEUKEMIA;OBSERVATIONAL STUDY;RESPIRATORY DISTRESS;STEM CELLS;CELL TRANSPLANTATION;COMMUNITY-ACQUIRED PNEUMONIA;FRONTOTEMPORAL DEMENTIA;PARKINSONS DISEASE;PATIENTS UNDERGOING;PROSPECTIVE STUDY;ACUTE RESPIRATORY;CHRONIC MYELOID;ENDOTHELIAL CELLS;HEPATOCELLULAR CARCINOMA;IRON OVERLOAD;LUNG TRANSPLANTATION","15;14;12;11;10;10;10;10;10;9;9;9;9;9;9;9;9;9;8;8;8;8;8;8;7;7;7;7;7;7","PUBMED SCOPUS;CROSSREF PUBMED;FONDAZIONE IRCCS;BACTERIAL MENINGITIS;MAGGIORE POLICLINICO;OSPEDALE MAGGIORE;GRANDA OSPEDALE;RISK FACTORS;ALLERGY RESEARCH;CHRISTINE KÜHNE;CK-CARE DAVOS-AUGSBURG-BONN-ST;DAVOS SWITZERLAND;DAVOS-AUGSBURG-BONN-ST GALLEN-ZÜRICH;EDUCATION CK-CARE;GALLEN-ZÜRICH DAVOS;KÜHNE CENTER;MILAN ITALY;POLICLINICO MILAN;INCREASED RISK;CONFIDENCE INTERVAL;GESTATIONAL AGE;DERMATOLOGY UNIVERSITY;MILAN ITALYSEARCH;CÀ GRANDA;SIGNIFICANTLY LOWER;ADVERSE EVENTS;BONE MARROW;IRCCS CÀ;PRETERM INFANTS;CLINICAL TRIALS","96;67;47;46;45;45;43;41;40;40;40;40;40;40;40;40;39;34;32;31;31;28;28;26;26;25;25;25;24;23",511,0.49,2.35,48.74,9.5,637.474,27.58,1,740,2.94,1,23,1.77,1,13,1.8,1,9,5.52,1,79,2.97,1,21,0,0,0,1.32,1,3,37.13,1,876,0,0,0,1,1,1,21.93,1,695,1.5,1,3,2.62,1,5,1.96,1,12,4.65,1,57,15.49,1,418,6.96,1,212,0.14,0,6,0,0,0,147.28,13,1101,147.42,13,1101,10,1,3,8,2,5,0,1,0,0,0,0,11,6,3,3,2.5,1.25,9,4,7,0,3,3,0,0,4,0,0,0,0,0,5,2,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,7,3,2,2,0,1,3,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"REBULLA PAOLO;LATTUADA DEBORA;MAZZARO GIOVANNI;PARATI EUGENIO;RASPOLLINI ELISABETTA;VILLA STEFANIA;ラットゥアーダ、  デヴォラ;BESANA VALERIA;BRANCALEONI VALENTINA;CAIRONI PIETRO","7;4;3;3;3;3;2;1;1;1","FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO;FOND IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO;FOND IRCCS CA' GRANDA - OSPEDALE MAGGIORE POLICLINICO;EPISKEY SRL;MEDITALIA S R L;MEDITALIA SRL;UNIV DEGLI STUDI MILANO;UNIV MILANO BICOCCA","12;5;3;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;40 ENGINEERING;31 BIOLOGICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;4003 BIOMEDICAL ENGINEERING;3202 CLINICAL SCIENCES;3212 OPHTHALMOLOGY AND OPTOMETRY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;51 PHYSICAL SCIENCES","22;7;6;5;4;3;3;1;1","PEDIATRIC;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;GENETICS;CONDITIONS AFFECTING THE EMBRYONIC AND FETAL PERIODS","5;5;4;2","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1","A61K35/51;C12N5/078;C12Q1/68;G01N33/80;A61P27/02;G01N33/53;A61J1/10;A61K35/16;A61K35/19;A61M1/02","4;4;4;4;3;3;2;2;2;2","C12Q1/6879;G01N2400/40;G01N2800/385;G01N33/80;A61K35/19;A61P17/00;A61J1/10;A61J1/20;A61J1/2024;A61J1/2027","7;7;7;7;4;4;3;3;3;3",5,1866168.75,319303.52,3.75,6.8,3.4,1,13,"FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO;CENTRO CLINICO NEMO;BAMBINO GESÙ CHILDREN'S HOSPITAL;CATHOLIC UNIVERSITY OF THE SACRED HEART;DÉLÉGATION PARIS 11;FONDAZIONE ISTITUTO NEUROLOGICO NAZIONALE CASIMIRO MONDINO;FONDAZIONE STELLA MARIS;FUNDACIÓN PARA EL FOMENTO DE LA INVESTIGACIÓN SANITARIA Y BIOMÉDICA DE LA COMUNITAT VALENCIANA;GOETHE UNIVERSITY FRANKFURT;INSPHERO (SWITZERLAND);ISTITUTO GIANNINA GASLINI;NATIONAL RESEARCH COUNCIL;OSPEDALE BELLARIA;OSPEDALE REGINA MARGHERITA;PAUL EHRLICH INSTITUT;PERSPECTUM (UNITED KINGDOM);POLICLINICO TOR VERGATA;QUEEN MARY UNIVERSITY OF LONDON;RANDOX (UNITED KINGDOM);SANOFI (GERMANY)","5;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;TELETHON FOUNDATION;DEUTSCHE FORSCHUNGSGEMEINSCHAFT","2;2;1","COALITION S;EC & ERC - EUROPEAN UNION","2;2","TELETHON - UILDM CLINICAL GRANT PROJECTS - 2015 (PROGRAM);H2020-EU.1.3. - EXCELLENT SCIENCE - MARIE SKŁODOWSKA-CURIE ACTIONS (PROGRAMME);H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);H2020-MSCA-RISE-2015 (CALL FOR PROPOSAL);H2020-PHC-2015-TWO-STAGE (CALL FOR PROPOSAL);MSCA-RISE - MARIE SKŁODOWSKA-CURIE RESEARCH AND INNOVATION STAFF EXCHANGE (RISE) (FUNDING SCHEME);RESEARCH GRANTS (DFG PROGRAMME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","2;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3206 MEDICAL BIOTECHNOLOGY","5;3;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;BRAIN DISORDERS;DIABETES;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);MUSCULAR DYSTROPHY;RARE DISEASES;BEHAVIORAL AND SOCIAL SCIENCE;BIOTECHNOLOGY;CANCER;CHRONIC LIVER DISEASE AND CIRRHOSIS;COMPLEMENTARY AND INTEGRATIVE HEALTH;DIGESTIVE DISEASES;DUCHENNE/ BECKER MUSCULAR DYSTROPHY;GENETICS;HEPATITIS;HEPATITIS - B;INFECTIOUS DISEASES;LIVER DISEASE;NEUROSCIENCES","4;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","INFECTION;METABOLIC AND ENDOCRINE;MUSCULOSKELETAL;ORAL AND GASTROINTESTINAL","1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.2 CELLULAR AND GENE THERAPIES;6.1 PHARMACEUTICALS","2;1;1;1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;A05 BIOLOGICAL SCIENCES","3;1;1",NA,NA,75,"PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE;AMERICAN ASSOCIATION FOR CANCER RESEARCH;TAYLOR & FRANCIS GROUP","64;6;3;2","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3105 GENETICS;42 HEALTH SCIENCES;3107 MICROBIOLOGY;3207 MEDICAL MICROBIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;34 CHEMICAL SCIENCES;38 ECONOMICS;40 ENGINEERING;49 MATHEMATICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4008 ELECTRICAL ENGINEERING;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;52 PSYCHOLOGY;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES","86;32;25;9;7;4;4;4;3;3;3;3;2;2;2;2;2;2;2;1","GENETICS;CLINICAL RESEARCH;HUMAN GENOME;PREVENTION;BIOTECHNOLOGY;CANCER;CHRONIC LIVER DISEASE AND CIRRHOSIS;DIGESTIVE DISEASES;HEMATOLOGY;HEPATITIS;LIVER DISEASE;LUNG;AGING;BIOENGINEERING;BRAIN DISORDERS;CARDIOVASCULAR;CHRONIC PAIN;DENTAL/ORAL AND CRANIOFACIAL DISEASE;INFECTIOUS DISEASES;LUNG CANCER","7;4;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","ORAL AND GASTROINTESTINAL;CANCER;CARDIOVASCULAR;RENAL AND UROGENITAL;GENERIC HEALTH RELEVANCE;INFECTION;MENTAL HEALTH;METABOLIC AND ENDOCRINE;RESPIRATORY","7;4;4;3;1;1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.3 PSYCHOLOGICAL, SOCIAL AND ECONOMIC FACTORS;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","13;3;2;2;2;2;1;1","BIOMEDICAL;CLINICAL;POPULATION & SOCIETY","9;6;3","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","28;10;4","LIVER CANCER;NOT SITE-SPECIFIC CANCER;BLADDER CANCER;LUNG CANCER","7;6;3;2","3 GOOD HEALTH AND WELL BEING;4 QUALITY EDUCATION","2;1",43,3.67,590.48,18,56.3,1,0,10,1,7,0,7,17,0,33,8,0,0,0,0,0,0,39,2,2,41,2,0,0,0,0,0,0,0,0,"United States;Germany;Italy;Japan;Netherlands;United Kingdom","6;3;3;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3213 PAEDIATRICS;3207 MEDICAL MICROBIOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3203 DENTISTRY;3208 MEDICAL PHYSIOLOGY;3210 NUTRITION AND DIETETICS;40 ENGINEERING;42 HEALTH SCIENCES;46 INFORMATION AND COMPUTING SCIENCES;4605 DATA MANAGEMENT AND DATA SCIENCE","41;27;5;5;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;PEDIATRIC;PATIENT SAFETY;HEMATOLOGY;CANCER;DIGESTIVE DISEASES;LUNG;NEUROSCIENCES;INFANT MORTALITY;PREVENTION;AUTOIMMUNE DISEASE;BIOENGINEERING;CARDIOVASCULAR;NEURODEGENERATIVE;NUTRITION;ORPHAN DRUG;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;PRETERM, LOW BIRTH WEIGHT AND HEALTH OF THE NEWBORN","39;28;16;13;10;7;6;6;6;6;5;5;4;4;4;4;4;4;4;4","ORAL AND GASTROINTESTINAL;CANCER;NEUROLOGICAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;CONGENITAL;INFECTION;METABOLIC AND ENDOCRINE;MUSCULOSKELETAL;RESPIRATORY;RENAL AND UROGENITAL","4;3;3;3;2;2;2;2;2;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.4 SURGERY;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.7 PHYSICAL","27;3;2;2;2;1;1","LEUKEMIA / LEUKAEMIA;COLON AND RECTAL CANCER;LIVER CANCER;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER","5;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;3.2 NUTRITIONAL SCIENCE IN CANCER PREVENTION;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","6;1;1"
"IRCCS_CAGRANDA",2017,1081,13.6827012025902,3.34505087881591,0.298949115044248,0.401480111008326,0.376503237742831,0.371877890841813,0.5263644773358,8,545,259,103,87,0.5,0.24,0.1,0.08,28.93,0.98162403404436,0.429232192414431,0.963922294172063,5.38832880961616,0.532717313600994,0.50149826698151,0.480442063808638,0.50354506284001,"FRANCESCO BLASI;FABIO MOSCA;AGOSTINO CORTELEZZI;DANIELA GALIMBERTI;A. CARLO ALTAMURA;FLORA PEYVANDI;DARIO CONSONNI;PAOLO BRAMBILLA;SUSANNA ESPOSITO;MARIA DOMENICA CAPPELLINI;MARIO NOSOTTI;ALESSANDRA IURLO;A. PALLESCHI;LUCA VALENTI;BERNARDO DELL’OSSO;STEFANO ALIBERTI;ALDO BRUNO GIANNÌ;DAVIDE TOSI;FRANCESCO VIOLA;EDGARDO SOMIGLIANA","29;29;25;25;25;24;23;23;22;22;21;20;19;19;19;19;18;18;17;17","FRANCESCO BLASI;DARIO CONSONNI;STEFANO VERALDI;FABIO MOSCA;SUSANNA ESPOSITO;FLORA PEYVANDI;ALDO BRUNO GIANNÌ;MARIA DOMENICA CAPPELLINI;E. MONTANARI;A. CARLO ALTAMURA;NICOLA PRINCIPI;PAOLO BRAMBILLA;EDGARDO SOMIGLIANA;PAOLO VERCELLINI;GIANLUCA NAZZARO;LUCA VALENTI;MARIO NOSOTTI;DAVIDE TOSI;A. PALLESCHI;GREGORIO P. MILANI","3.84;3.59;3.55;3;2.97;2.73;2.69;2.62;2.48;2.45;2.44;2.42;2.37;2.36;2.17;2.16;2.08;1.97;1.94;1.89","FRANCESCO BLASI;FABIO MOSCA;AGOSTINO CORTELEZZI;DANIELA GALIMBERTI;A. CARLO ALTAMURA;FLORA PEYVANDI;DARIO CONSONNI;PAOLO BRAMBILLA;SUSANNA ESPOSITO;MARIA DOMENICA CAPPELLINI;MARIO NOSOTTI;ALESSANDRA IURLO;A. PALLESCHI;LUCA VALENTI;BERNARDO DELL’OSSO;STEFANO ALIBERTI;ALDO BRUNO GIANNÌ;DAVIDE TOSI;FRANCESCO VIOLA;EDGARDO SOMIGLIANA","29;29;25;25;25;24;23;23;22;22;21;20;19;19;19;19;18;18;17;17","FRANCESCO BLASI;DARIO CONSONNI;STEFANO VERALDI;FABIO MOSCA;SUSANNA ESPOSITO;FLORA PEYVANDI;ALDO BRUNO GIANNÌ;MARIA DOMENICA CAPPELLINI;E. MONTANARI;A. CARLO ALTAMURA;NICOLA PRINCIPI;PAOLO BRAMBILLA;EDGARDO SOMIGLIANA;PAOLO VERCELLINI;GIANLUCA NAZZARO;LUCA VALENTI;MARIO NOSOTTI;DAVIDE TOSI;A. PALLESCHI;GREGORIO P. MILANI","3.84;3.59;3.55;3;2.97;2.73;2.69;2.62;2.48;2.45;2.44;2.42;2.37;2.36;2.17;2.16;2.08;1.97;1.94;1.89","STEFANO ALIBERTI;JAMES D. CHALMERS;FRANCESCO BLASI;ADAM T. HILL;PIETER GOEMINNE;ANTHONY DE SOYZA;EVA POLVERINO;CHARLES HAWORTH;MICHAEL R. LOEBINGER;TOBIAS WELTE;FELIX C. RINGSHAUSEN;J.S. ELBORN;MONTSERRAT VENDRELL;KATERINA DIMAKOU;MARLÈNE MURRIS;SILVIA FARGION;LUCA VALENTI;ANTONIO PESENTI;ELENA SANTAGOSTINO;ANTONI TORRES","1697;1563;1495;1419;1419;1364;1347;1332;1332;1322;1292;1292;1292;1277;1277;1230;1186;1127;1078;1077","STEFANO ALIBERTI;FRANCESCO BLASI;ANTONIO PESENTI;ELENA SANTAGOSTINO;SILVIA FARGION;LUCA VALENTI;DANIELA GALIMBERTI;IDA MARTINELLI;GIACOMO GRASSELLI;PAOLA DONGIOVANNI;ALBERTO MAINO;EDGARDO SOMIGLIANA;MARIO SALVI;FLORA PEYVANDI;ANNA LUDOVICA FRACANZANI;PIETRO LAMPERTICO;DARIO CONSONNI;PAOLO VERCELLINI;A. CARLO ALTAMURA;ANDREA LAUTERIO","1697;1477;1103;1078;1042;998;963;955;929;887;788;742;704;645;613;591;583;565;517;510","FRANCESCO BLASI;FABIO MOSCA;A. CARLO ALTAMURA;DANIELA GALIMBERTI;FLORA PEYVANDI;DARIO CONSONNI;PAOLO BRAMBILLA;AGOSTINO CORTELEZZI;MARIO NOSOTTI;ALESSANDRA IURLO;STEFANO FERRERO;A. PALLESCHI;BERNARDO DELL’OSSO;STEFANO ALIBERTI;LUCA VALENTI;DAVIDE TOSI;MARIA DOMENICA CAPPELLINI;EDGARDO SOMIGLIANA;FRANCESCO VIOLA;ALDO BRUNO GIANNÌ","28;27;25;25;24;23;22;21;21;21;20;19;19;19;18;18;18;17;17;16","MEDICINE;BIOLOGY;PSYCHOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;ECONOMICS;MATHEMATICS;SOCIOLOGY;POLITICAL SCIENCE;MATERIALS SCIENCE;PHILOSOPHY;ART;BUSINESS;GEOGRAPHY;HISTORY;GEOLOGY;ENVIRONMENTAL SCIENCE","1018;372;108;81;71;57;54;40;40;34;25;20;14;9;7;5;4;3;2","INTERNAL MEDICINE;SURGERY;GENETICS;PATHOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;PEDIATRICS;PSYCHIATRY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;RADIOLOGY;ENDOCRINOLOGY;BIOCHEMISTRY;ONCOLOGY;CARDIOLOGY;CANCER RESEARCH;NEUROSCIENCE;DERMATOLOGY;CELL BIOLOGY;ANESTHESIA","730;233;224;216;161;142;128;114;98;97;95;93;87;73;69;63;62;54;51;49","DISEASE;GENE;POPULATION;CANCER;COHORT;PREGNANCY;LUNG;MAGNETIC RESONANCE IMAGING;TRANSPLANTATION;RETROSPECTIVE COHORT STUDY;INCIDENCE (GEOMETRY);ANTIBODY;RANDOMIZED CONTROLLED TRIAL;VIRUS;BONE MARROW;IMMUNE SYSTEM;CONFIDENCE INTERVAL;LOGISTIC REGRESSION;RECEPTOR;ADVERSE EFFECT;ANTIBIOTICS","161;147;86;73;59;59;58;46;46;41;40;39;36;32;30;30;29;29;29;28;28","MUTATION;GENOTYPE;PHENOTYPE;GESTATIONAL AGE;BIPOLAR DISORDER;WHITE MATTER;DEMENTIA;FETUS;GENE EXPRESSION;ALLELE;BREAST CANCER;CLINICAL ENDPOINT;COLORECTAL CANCER;IMATINIB;LUNG TRANSPLANTATION;MICRORNA;HAZARD RATIO;FATTY LIVER;HEPATITIS C VIRUS;INSULIN RESISTANCE;LIVER TRANSPLANTATION;PLACEBO","38;32;32;23;20;19;18;18;18;17;16;16;14;14;14;13;12;11;11;11;11;11","DNA METHYLATION;MISSENSE MUTATION;FRONTOTEMPORAL DEMENTIA;NONALCOHOLIC FATTY LIVER DISEASE;EXOME SEQUENCING;COMPOUND HETEROZYGOSITY;DASATINIB;NILOTINIB;SINGLE-NUCLEOTIDE POLYMORPHISM;IMATINIB MESYLATE;GENOTYPING;HEART RATE VARIABILITY;MANIA;VOXEL-BASED MORPHOMETRY;ALTERNATIVE SPLICING;CORONAVIRUS DISEASE 2019 (COVID-19);DIFFUSING CAPACITY;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;LAMIVUDINE;RIBAVIRIN","13;13;11;10;9;8;8;8;8;7;6;6;6;6;5;5;5;5;5;5","HUMANS;FEMALE;MALE;;MIDDLE AGED;ADULT;AGED;ITALY;YOUNG ADULT;ADOLESCENT;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;CHILD;AGED, 80 AND OVER;CHILD, PRESCHOOL;RISK FACTORS;PROSPECTIVE STUDIES;LIVER CIRRHOSIS;INFANT;MAGNETIC RESONANCE IMAGING","724;520;496;341;321;314;244;180;131;123;120;106;100;89;82;80;75;74;63;59","MANAGEMENT AND TREATMENT OF HEMOPHILIA;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;EPIDEMIOLOGY AND MANAGEMENT OF BIPOLAR DISORDER;EFFICACY AND RESISTANCE IN CML TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;HEPATITIS C INFECTION AND TREATMENT;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;DIAGNOSIS AND TREATMENT OF LUNG CANCER;HEPATITIS B INFECTION AND TREATMENT;MANAGEMENT AND EPIDEMIOLOGY OF PNEUMONIA;DENTAL IMPLANTOLOGY AND PERI-IMPLANT DISEASES;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;ORGAN TRANSPLANTATION AND REJECTION;CEREBELLAR CONTRIBUTIONS TO NEUROLOGICAL DISORDERS AND FUNCTIONS;PREVALENCE AND MANAGEMENT OF KIDNEY STONES;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;ACUTE MYELOID LEUKEMIA;ATRIAL FIBRILLATION","20;20;19;18;18;15;13;12;12;11;11;11;10;10;10;9;9;9;8;8","TREATMENT;CLINICAL ENDPOINT;ETIOLOGY;NEUROIMAGING DATA ANALYSIS;STROKE (ENGINE);CYSTIC FIBROSIS;HEPATITIS C;LIVER DISEASE;POSITIVE END-EXPIRATORY PRESSURE;BIPOLAR SPECTRUM DISORDER;DEPRESSION (ECONOMICS);NEPHROLOGY;SINGLE CENTER;CONCOMITANT;HEMATOLOGY;INTERQUARTILE RANGE;NEURODEGENERATION;NONINVASIVE VENTILATION;PRETERM INFANTS;CROSS-SECTIONAL STUDY","39;16;15;14;14;12;12;12;12;11;11;11;11;10;10;10;10;10;10;9","COHORT STUDY;CYSTIC FIBROSIS;BIPOLAR DISORDER;HEPATOCELLULAR CARCINOMA;MYELOID LEUKEMIA;CHRONIC MYELOID;FRONTOTEMPORAL DEMENTIA;LIVER DISEASE;RISK FACTORS;STEM CELL;ATRIAL FIBRILLATION;LUNG CANCER;OBSERVATIONAL STUDY;BONE MARROW;CHRONIC LYMPHOCYTIC;CLINICAL PRACTICE;LYMPHOCYTIC LEUKEMIA;MULTICENTRE STUDY;STEM CELLS;SYSTEMIC SCLEROSIS;CELL TRANSPLANTATION;COMMUNITY-ACQUIRED PNEUMONIA;CROSS-SECTIONAL STUDY;FATTY LIVER;GENETIC FRONTOTEMPORAL;INTENSIVE CARE;LUNG TRANSPLANTATION;PRETERM INFANTS;PROSPECTIVE STUDY;WHITE MATTER","15;15;14;14;14;13;12;12;12;12;11;10;9;8;8;8;8;8;8;8;7;7;7;7;7;7;7;7;7;7","PUBMED SCOPUS;CROSSREF PUBMED;METABOLIC ACIDOSIS;SERUM BICARBONATE;CHRONIC KIDNEY;KIDNEY DISEASE;CONFIDENCE INTERVAL;CYSTIC FIBROSIS;LUNG CANCER;HYPERTENSIVE DISORDERS;RISK FACTORS;BONE MARROW;CLINICAL TRIALS;HEALTHY CONTROLS;LOGISTIC REGRESSION;MAGNETIC RESONANCE;CAROTID ARTERY;INCREASED RISK;MULTIVARIATE ANALYSIS;SIGNIFICANTLY LOWER;BLOOD PRESSURE;GASTRIC ACIDITY;HEPATOCELLULAR CARCINOMA;LIVER DISEASE;COHORT STUDY;HR CI;ADVERSE EVENTS;MAJOR BLEEDING;COMPUTED TOMOGRAPHY;HAZARD RATIO","120;72;58;52;42;42;40;38;37;36;33;31;29;29;28;28;27;27;26;23;22;22;22;22;21;21;20;20;19;19",546,0.51,2.25,46.39,6.75,815.094,31.28,1,292,4.02,1,39,1.61,1,7,1.77,1,5,7.94,1,98,2.88,1,7,0,0,0,1.21,1,2,37.31,1,369,1,1,1,1,1,1,27,1,276,1,1,1,1.57,1,4,2.13,1,15,4.76,1,31,18.02,1,163,5.58,1,92,0.07,0,2,0,0,0,120.77,0,960,122.17,0,960,9,2,0,3,1,5,0,0,2,0,0,0,7,5,1,1,2.83333333333333,1.53846153846154,3,3,7,0,0,3,1,0,3,0,3,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,3,0,1,0,3,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"REBULLA PAOLO;RASPOLLINI ELISABETTA;VILLA STEFANIA;ALFIERI CARLO;CHATZIANTONIOU CHRISTOS;DUSSAULE JEAN-CLAUDE;LATTUADA DEBORA;MESSA PIERGIORGIO;BESANA VALERIA;BRANCALEONI VALENTINA","4;3;3;2;2;2;2;2;1;1","FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO;ASSISTANCE PUBLIQUE HOPITAUX DE PARIS APHP;INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSERM;UNIVERSITE PIERRE ET MARIE CURIE PARIS 6;FOND IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO;FOND IRCCS CA' GRANDA - OSPEDALE MAGGIORE POLICLINICO;MEDITALIA S R L","11;2;2;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3212 OPHTHALMOLOGY AND OPTOMETRY;3202 CLINICAL SCIENCES;40 ENGINEERING;3101 BIOCHEMISTRY AND CELL BIOLOGY;3105 GENETICS;3215 REPRODUCTIVE MEDICINE;4003 BIOMEDICAL ENGINEERING","16;4;4;3;2;1;1;1;1","BIOTECHNOLOGY;KIDNEY DISEASE;ORGAN TRANSPLANTATION;RARE DISEASES;TRANSPLANTATION;BIOMEDICAL IMAGING;CONDITIONS AFFECTING THE EMBRYONIC AND FETAL PERIODS;GENETICS;HEMATOLOGY;PEDIATRIC","3;2;2;2;2;1;1;1;1;1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1;1","A61K35/51;A61P27/02;A61K38/18;A61K47/02;A61K47/12;A61K47/26;C12N5/00;G01N33/68;G01N33/80;A61B6/00","4;3;2;2;2;2;2;2;2;1","A61K35/51;A61K38/1808;A61K47/02;A61K47/12;A61K47/26;A61P17/00;A61P19/02;A61P25/00;A61P27/02;A61P29/00","3;3;3;3;3;3;3;3;3;3",4,3777606,295630.82,4.25,12,3.5,1,37.75,"FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO;POLITECNICO DI MILANO;UNIVERSITY OF BOLOGNA;UNIVERSITY OF MILAN;AB.ACUS (ITALY);AUGUST PI I SUNYER BIOMEDICAL RESEARCH INSTITUTE;AUTONOMOUS UNIVERSITY OF MADRID;AZIENDA OSPEDALIERA UNIVERSITARIA PISANA;CATHOLIC UNIVERSITY OF THE SACRED HEART;CENTRE HOSPITALIER UNIVERSITAIRE DE TOURS;CENTRO TECNOLÓXICO DE TELECOMUNICACIÓNS DE GALICIA;DÉLÉGATION PARIS 11;EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK - ERIC;FUNDACIÓ EURECAT;GOVERNMENT OF EXTREMADURA;HEINRICH HEINE UNIVERSITY DÜSSELDORF;HOSPITAL UNIVERSITARIO INFANTA CRISTINA;HOSPITAL UNIVERSITARIO LA PAZ;HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA;ISTITUTO ORTOPEDICO RIZZOLI","4;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;TELETHON FOUNDATION","3;1","COALITION S;EC & ERC - EUROPEAN UNION","3;3","RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME);H2020-EU.1.3. - EXCELLENT SCIENCE - MARIE SKŁODOWSKA-CURIE ACTIONS (PROGRAMME);H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - LEADERSHIP IN ENABLING AND INDUSTRIAL TECHNOLOGIES - INFORMATION AND COMMUNICATION TECHNOLOGIES (ICT) (PROGRAMME);H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);H2020-ICT-2016-1 (CALL FOR PROPOSAL);H2020-MSCA-ITN-2017 (CALL FOR PROPOSAL);MSCA-ITN - MARIE SKŁODOWSKA-CURIE INNOVATIVE TRAINING NETWORKS (ITN) (FUNDING SCHEME);TELETHON SPECIAL PROJECTS - 2016 (PROGRAM)","2;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;46 INFORMATION AND COMPUTING SCIENCES;4608 HUMAN-CENTRED COMPUTING","3;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;BEHAVIORAL AND SOCIAL SCIENCE;CARDIOVASCULAR;COMPARATIVE EFFECTIVENESS RESEARCH;HEART DISEASE;NEUROSCIENCES;PEDIATRIC RESEARCH INITIATIVE;RARE DISEASES;REGENERATIVE MEDICINE;TRANSPLANTATION","2;2;1;1;1;1;1;1;1;1;1","MUSCULOSKELETAL","2","5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES","1;1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;B11 COMPUTER SCIENCE AND INFORMATICS;C17 BUSINESS AND MANAGEMENT STUDIES","1;1;1;1",NA,NA,46,"PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE;KARGER PUBLISHERS","43;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;52 PSYCHOLOGY;42 HEALTH SCIENCES;3202 CLINICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3105 GENETICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;44 HUMAN SOCIETY;46 INFORMATION AND COMPUTING SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;34 CHEMICAL SCIENCES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;4206 PUBLIC HEALTH;43 HISTORY, HERITAGE AND ARCHAEOLOGY;4303 HISTORICAL STUDIES;4403 DEMOGRAPHY;49 MATHEMATICAL SCIENCES;5202 BIOLOGICAL PSYCHOLOGY","36;15;9;8;7;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2","CLINICAL RESEARCH;PREVENTION;BRAIN DISORDERS;GENETICS;NEUROSCIENCES;RARE DISEASES;BIOTECHNOLOGY;CANCER;DIGESTIVE DISEASES;HEMATOLOGY;LIVER DISEASE;LUNG;NEURODEGENERATIVE;ORGAN TRANSPLANTATION;TRANSPLANTATION;ACQUIRED COGNITIVE IMPAIRMENT;AGING;ALCOHOLISM, ALCOHOL USE AND HEALTH;ALZHEIMER'S DISEASE;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD)","8;6;5;4;4;4;3;3;2;2;2;2;2;2;2;1;1;1;1;1","CARDIOVASCULAR;CANCER;MENTAL HEALTH;ORAL AND GASTROINTESTINAL;METABOLIC AND ENDOCRINE;GENERIC HEALTH RELEVANCE;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL;STROKE","5;4;4;3;2;1;1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;5.2 CELLULAR AND GENE THERAPIES","5;3;3;3;1;1;1","CLINICAL;BIOMEDICAL;POPULATION & SOCIETY","9;3;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","16;3;1","LIVER CANCER;LUNG CANCER;NOT SITE-SPECIFIC CANCER","3;2;1","3 GOOD HEALTH AND WELL BEING","2",76,4.08,776.44,36,79.5,0,1,14,2,25,0,2,32,0,55,21,0,0,0,0,0,0,69,2,5,74,0,0,2,0,0,0,0,0,0,"United States;Italy;France;Japan;Switzerland;United Kingdom;Australia;Germany;Netherlands;Portugal;Spain","34;14;2;2;2;2;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;42 HEALTH SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;4203 HEALTH SERVICES AND SYSTEMS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3213 PAEDIATRICS;3215 REPRODUCTIVE MEDICINE;4205 NURSING;31 BIOLOGICAL SCIENCES;3204 IMMUNOLOGY;3206 MEDICAL BIOTECHNOLOGY;3207 MEDICAL MICROBIOLOGY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3507 STRATEGY, MANAGEMENT AND ORGANISATIONAL BEHAVIOUR;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","69;41;11;10;9;8;5;4;3;2;2;2;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;PATIENT SAFETY;HEMATOLOGY;PEDIATRIC;CANCER;LUNG;DIGESTIVE DISEASES;AGING;BRAIN DISORDERS;CARDIOVASCULAR;INFECTIOUS DISEASES;PREVENTION;NEUROSCIENCES;TRANSPLANTATION;BIOENGINEERING;CHRONIC LIVER DISEASE AND CIRRHOSIS;COMPARATIVE EFFECTIVENESS RESEARCH;EMERGING INFECTIOUS DISEASES","70;46;30;21;20;17;14;12;11;8;7;7;7;7;6;6;5;5;5;5","CANCER;NEUROLOGICAL;CARDIOVASCULAR;INFECTION;ORAL AND GASTROINTESTINAL;RESPIRATORY;BLOOD;CONGENITAL;RENAL AND UROGENITAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;EYE;INJURIES AND ACCIDENTS;MENTAL HEALTH;SKIN","6;6;5;5;4;3;2;2;2;2;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.4 SURGERY;6.2 CELLULAR AND GENE THERAPIES;7.1 INDIVIDUAL CARE NEEDS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT","45;7;4;4;4;2;2;1","LEUKEMIA / LEUKAEMIA;MYELOMA;NON-HODGKIN'S LYMPHOMA;COLON AND RECTAL CANCER;LUNG CANCER;BREAST CANCER;HODGKIN'S DISEASE","12;3;3;2;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","8;4;2;1;1"
"IRCCS_CAGRANDA",2018,1278,14.4765258215962,3.339593114241,0.299437675726336,0.382629107981221,0.343505477308294,0.394366197183099,0.556338028169014,10,626,333,99,97,0.49,0.26,0.08,0.08,32.18,1.05466724009752,0.424100156494523,0.970266040688576,5.33657786885248,0.547239408865618,0.508783229004241,0.477263262732718,0.497704830622311,"PIETRO LAMPERTICO;FRANCESCO BLASI;STEFANO ALIBERTI;ALESSANDRA IURLO;DARIO CONSONNI;E. MONTANARI;FABIO MOSCA;MATTEO CESARI;LUCA BOERI;FLORA PEYVANDI;DANIELA GALIMBERTI;FABIO TRIULZI;GIACOMO P. COMI;MASSIMILIANO BONIFACIO;ELISABETTA ABRUZZESE;ANGELA CECILIA PESATORI;SILVIA FARGION;VALENTINA BOLLATI;ELIO SCARPINI;A. PALLESCHI","45;42;42;35;35;33;30;25;24;23;23;23;22;22;21;20;20;19;19;19","DARIO CONSONNI;STEFANO ALIBERTI;STEFANO VERALDI;PIETRO LAMPERTICO;GIANLUCA NAZZARO;MATTEO CESARI;FRANCESCO BLASI;E. MONTANARI;FABIO MOSCA;SILVIA FUSTINONI;FERRUCCIO CERIOTTI;VALENTINA BOLLATI;PIERGIORGIO MESSA;EMILIO BERTI;ANGELA CECILIA PESATORI;FLORA PEYVANDI;PIER MANNUCCIO MANNUCCI;SIMONE GAMBAZZA;EDGARDO SOMIGLIANA;GIOVANNI GENOVESE","4.38;4.12;4.06;4.02;3.82;3.47;3.4;3.24;3.18;2.7;2.69;2.69;2.36;2.33;2.27;2.27;2.24;2.24;2.21;2.17","PIETRO LAMPERTICO;FRANCESCO BLASI;STEFANO ALIBERTI;ALESSANDRA IURLO;DARIO CONSONNI;E. MONTANARI;FABIO MOSCA;MATTEO CESARI;LUCA BOERI;FLORA PEYVANDI;DANIELA GALIMBERTI;FABIO TRIULZI;GIACOMO P. COMI;ANGELA CECILIA PESATORI;SILVIA FARGION;VALENTINA BOLLATI;ELIO SCARPINI;A. PALLESCHI;ANTONINO NERI;ALESSIO AGHEMO","45;42;42;35;35;33;30;25;24;23;23;23;22;20;20;19;19;19;19;19","DARIO CONSONNI;STEFANO ALIBERTI;STEFANO VERALDI;PIETRO LAMPERTICO;GIANLUCA NAZZARO;MATTEO CESARI;FRANCESCO BLASI;E. MONTANARI;FABIO MOSCA;SILVIA FUSTINONI;FERRUCCIO CERIOTTI;VALENTINA BOLLATI;PIERGIORGIO MESSA;EMILIO BERTI;ANGELA CECILIA PESATORI;FLORA PEYVANDI;PIER MANNUCCIO MANNUCCI;SIMONE GAMBAZZA;EDGARDO SOMIGLIANA;GIOVANNI GENOVESE","4.38;4.12;4.06;4.02;3.82;3.47;3.4;3.24;3.18;2.7;2.69;2.69;2.36;2.33;2.27;2.27;2.24;2.24;2.21;2.17","MATTEO CESARI;FRANCESCO LANDI;ALFONSO J. CRUZ‐JENTOFT;CORNEL SIEBER;JOS M. G. A. SCHOLS;FINBARR C. MARTIN;IVAN BAUTMANS;JÜRGEN M. BAUER;TOMMY CEDERHOLM;ANTONIO CHERUBINI;EVA TOPINKOVÁ;MARCELLO MAGGIO;MAURO ZAMBONI;YVES ROLLAND;AVAN AIHIE SAYER;CYRUS COOPER;DOLORES SÁNCHEZ‐RODRÍGUEZ;GÜLISTAN BAHAT;JEAN‐PIERRE BAEYENS;JEAN‐PIERRE MICHEL","10442;10026;9976;9976;9976;9912;9912;9912;9912;9284;9284;9284;9243;9237;9220;9220;9220;9220;9220;9220","MATTEO CESARI;ELIO SCARPINI;STEFANO ALIBERTI;PIETRO LAMPERTICO;FRANCESCO BLASI;IDA MARTINELLI;SILVANO BÒSARI;ANTONINO NERI;FABIO MOSCA;MARIA ELISA MANCUSO;DARIO CONSONNI;DANIELA GALIMBERTI;SARA MASSIRONI;ANGELO VALERIO MARZANO;FLAVIO CAPRIOLI;GIORGIO FUMAGALLI;ANTONIO PESENTI;LAURA GHEZZI;FERRUCCIO CERIOTTI;ANDREA ARIGHI","10414;1763;1071;1047;1033;855;784;773;735;705;659;653;652;632;620;541;534;497;479;470","PIETRO LAMPERTICO;FRANCESCO BLASI;STEFANO ALIBERTI;ALESSANDRA IURLO;DARIO CONSONNI;E. MONTANARI;FABIO MOSCA;MATTEO CESARI;LUCA BOERI;DANIELA GALIMBERTI;FABIO TRIULZI;SILVIA FARGION;FLORA PEYVANDI;GIACOMO P. COMI;ELIO SCARPINI;A. PALLESCHI;ANGELA CECILIA PESATORI;ANTONINO NERI;MARIO NOSOTTI;CARLA COLOMBO","45;43;39;35;34;32;30;23;22;21;21;20;19;19;18;18;18;18;17;16","MEDICINE;BIOLOGY;CHEMISTRY;PSYCHOLOGY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;ECONOMICS;POLITICAL SCIENCE;SOCIOLOGY;MATERIALS SCIENCE;PHILOSOPHY;BUSINESS;ART;GEOGRAPHY;ENVIRONMENTAL SCIENCE;GEOLOGY;HISTORY","1190;441;107;98;88;80;51;49;40;36;29;20;19;10;4;4;2;2;2","INTERNAL MEDICINE;SURGERY;GENETICS;PATHOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;PEDIATRICS;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;PSYCHIATRY;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;RADIOLOGY;ONCOLOGY;CANCER RESEARCH;CARDIOLOGY;NEUROSCIENCE;ANESTHESIA;DERMATOLOGY;MICROBIOLOGY","871;280;271;264;185;182;141;131;130;118;101;100;98;92;74;72;63;59;53;52","GENE;DISEASE;POPULATION;COHORT;CANCER;TRANSPLANTATION;PREGNANCY;LUNG;RANDOMIZED CONTROLLED TRIAL;CONFIDENCE INTERVAL;RETROSPECTIVE COHORT STUDY;ANTIBODY;PROSPECTIVE COHORT STUDY;VIRUS;ADVERSE EFFECT;COGNITION;CHEMOTHERAPY;INCIDENCE (GEOMETRY);ALTERNATIVE MEDICINE;BACTERIA;BONE MARROW;IMMUNE SYSTEM","189;188;116;99;87;70;67;60;56;55;55;52;50;45;43;43;37;34;33;32;32;32","MUTATION;PHENOTYPE;GENE EXPRESSION;DEMENTIA;GENOTYPE;HAZARD RATIO;HEPATITIS C VIRUS;IMATINIB;BRONCHIECTASIS;GESTATIONAL AGE;BREAST CANCER;FETUS;PARKINSON'S DISEASE;CLINICAL ENDPOINT;LUNG TRANSPLANTATION;MICRORNA;EPIGENETICS;HEMATOPOIETIC STEM CELL TRANSPLANTATION;LIVER TRANSPLANTATION;RITUXIMAB","47;33;29;25;24;23;21;20;19;19;18;18;18;17;16;16;15;15;15;15","DNA METHYLATION;FRONTOTEMPORAL DEMENTIA;MISSENSE MUTATION;EXOME SEQUENCING;IMATINIB MESYLATE;ANTIRETROVIRAL THERAPY;DASATINIB;NILOTINIB;DEEP BRAIN STIMULATION;FRAMESHIFT MUTATION;LAMIVUDINE;PRENATAL DIAGNOSIS;VON WILLEBRAND DISEASE;GENOTYPING;INDUCED PLURIPOTENT STEM CELL;RUXOLITINIB;SINGLE-NUCLEOTIDE POLYMORPHISM;ANTIVIRAL TREATMENT;FLUDARABINE;HBSAG;IBRUTINIB;INEFFECTIVE ERYTHROPOIESIS;KARYOTYPE;NONALCOHOLIC FATTY LIVER DISEASE;RIBAVIRIN;SANGER SEQUENCING","16;14;14;11;10;9;9;9;8;8;8;8;8;7;7;7;7;6;6;6;6;6;6;6;6;6","HUMANS;FEMALE;MALE;;MIDDLE AGED;ADULT;AGED;ITALY;YOUNG ADULT;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;ADOLESCENT;CHILD;PROSPECTIVE STUDIES;BIOMARKERS;RISK FACTORS;BRAIN;ANIMALS;INFANT","790;579;565;469;371;332;274;181;137;128;122;116;114;87;87;83;69;67;63;59","THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;MANAGEMENT AND TREATMENT OF HEMOPHILIA;HEPATITIS C INFECTION AND TREATMENT;EFFICACY AND RESISTANCE IN CML TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;ORGAN TRANSPLANTATION AND REJECTION;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;HEPATITIS B INFECTION AND TREATMENT;ATRIAL FIBRILLATION;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GENE THERAPY FOR SPINAL MUSCULAR ATROPHY","33;28;25;23;18;16;16;13;13;13;13;12;12;11;11;11;11;10;10;10","TREATMENT;HEPATITIS C;INTERQUARTILE RANGE;DISCONTINUATION;LIVER DISEASE;CLINICAL ENDPOINT;REGIMEN;CROSS-SECTIONAL STUDY;CYSTIC FIBROSIS;ETIOLOGY;NEURODEGENERATION;DIAGNOSIS;PATHOGENESIS;POSITIVE END-EXPIRATORY PRESSURE;AGING;HEMATOLOGY;HEPATITIS B;HEPATOCELLULAR CARCINOMA;PRETERM INFANTS;BRONCHIECTASIS","40;25;22;21;19;18;18;16;16;16;16;15;15;15;13;13;13;12;12;11","CYSTIC FIBROSIS;HEPATOCELLULAR CARCINOMA;STEM CELL;MYELOID LEUKEMIA;CELL TRANSPLANTATION;RANDOMIZED CONTROLLED;CHRONIC MYELOID;RISK FACTORS;ATRIAL FIBRILLATION;LIVER DISEASE;PATIENTS TREATED;PROSPECTIVE STUDY;VON WILLEBRAND;ELDERLY PATIENTS;RETROSPECTIVE STUDY;CONTROLLED TRIAL;LUNG TRANSPLANTATION;MESENCHYMAL STROMAL;PARKINSONS DISEASE;PRETERM INFANTS;COMMUNITY-ACQUIRED PNEUMONIA;LEUKEMIA PATIENTS;MULTICENTER STUDY;OBSERVATIONAL STUDY;CIRRHOTIC PATIENTS;CROSS-SECTIONAL STUDY;MULTIPLE MYELOMA;MUSCULAR ATROPHY;REAL LIFE;STEM CELLS","26;20;20;19;17;17;16;15;14;13;13;13;13;12;12;11;11;11;11;11;10;10;10;10;9;9;9;9;9;9","SPEAKERS BUREAU;ADVISORY COMMITTEES;ENTITYS BOARD;RESEARCH FUNDING;HONORARIA MEMBERSHIP;ADVISORY BOARD;PUBMED SCOPUS;CONSULTANCY HONORARIA;CONFIDENCE INTERVAL;RISK FACTORS;CROSSREF PUBMED;COMMITTEES RESEARCH;FUNDING SPEAKERS;NOVO NORDISK;PATIENTS TREATED;MEDIAN AGE;BOARD SPEAKERS;HAZARD RATIO;HONORARIA RESEARCH;MULTIVARIATE ANALYSIS;BONE MARROW;COMMITTEES SPEAKERS;CONSULTANCY RESEARCH;LUNG CANCER;ADULT PATIENTS;NOVARTIS CONSULTANCY;CSL BEHRING;CONSULTANCY NOVARTIS;PERIPHERAL BLOOD;SIGNIFICANT DIFFERENCES","311;306;306;239;141;96;90;73;65;64;59;57;57;55;54;49;48;45;43;43;39;39;38;37;35;35;33;32;32;32",607,0.47,2.75,58.93,9.5,979.720000000003,55.38,2,1319,2.69,1,26,1.82,1,9,1.38,1,3,6.08,1,75,1.88,1,4,1,1,1,1.53,1,4,66.13,2,1382,1.6,1,4,1,1,1,51.54,1,1248,2.5,1,7,1.39,1,2,2.55,1,16,9.71,1,156,35.75,1,1044,8.94,1,109,0.05,0,2,0,0,0,166.06,17,7120,166.11,17,7120,8,0,2,3,1,1,2,1,0,0,0,0,4,4,2,4,3.66666666666667,1.2,3,2,7,0,1,4,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,2,2,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"REBULLA PAOLO;BONINO FERRUCCIO;ANDRIOLO GABRIELLA;FRASCA STEFANIA;LAZZARI LORENZA;MAZZARO GIOVANNI;PANIGADA MAURO;PARATI EUGENIO;BARDELLA MARIA TERESA;CATANIA ANNA","4;3;2;2;2;2;2;2;1;1","FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO;FOND IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO;EPISKEY S R L;EPISKEY SRL","8;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;3202 CLINICAL SCIENCES;51 PHYSICAL SCIENCES;3203 DENTISTRY;3212 OPHTHALMOLOGY AND OPTOMETRY;33 BUILT ENVIRONMENT AND DESIGN;34 CHEMICAL SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY","7;5;3;2;2;1;1;1;1;1","DENTAL/ORAL AND CRANIOFACIAL DISEASE;EYE DISEASE AND DISORDERS OF VISION","1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS","1;1","A01N1/02;A61G7/07;A61G7/075;A61J1/20;A61K35/32;A61M1/02;A61M1/36;A61K35/51;A61K38/34;A61K49/00","2;2;2;2;2;2;2;1;1;1","A01N1/02;A01N1/0284;A61G7/07;A61G7/072;A61G7/075;A61G7/0755;A61K35/32;C12N5/0653;C12N5/0654;C12N5/0655","2;2;2;2;2;2;2;2;2;2",4,17243418.5,474306.79,5,16.25,7.75,0.75,16.3333333333333,"FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO;MINISTRY OF HEALTH;AGENCE DE LA BIOMÉDECINE;ANDALUSIAN HEALTH SERVICE;ARISTOTLE UNIVERSITY OF THESSALONIKI;AZIENDA SANITARIA UNIVERSITARIA FRIULI CENTRALE;BAMBINO GESÙ CHILDREN'S HOSPITAL;BANC DE SANG I TEIXITS;BAYER (GERMANY);BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS;CHARLES UNIVERSITY;CHILDREN'S MEMORIAL HEALTH INSTITUTE;COLUMBIA UNIVERSITY;CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE;DÉLÉGATION PARIS 11;ELI LILLY (UNITED KINGDOM);EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK - ERIC;EUROPEAN SOCIETY FOR PAEDIATRIC ONCOLOGY;GENERAL UNIVERSITY HOSPITAL IN PRAGUE;GHENT UNIVERSITY","4;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;TELETHON FOUNDATION","3;1","COALITION S;EC & ERC - EUROPEAN UNION","3;3","3RD HEALTH PROGRAMME (PROGRAMME);H2020-EU.1.3. - EXCELLENT SCIENCE - MARIE SKŁODOWSKA-CURIE ACTIONS (PROGRAMME);H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);H2020-JTI-IMI2-2016-10-TWO-STAGE (CALL FOR PROPOSAL);H2020-MSCA-RISE-2017 (CALL FOR PROPOSAL);MSCA-RISE - MARIE SKŁODOWSKA-CURIE RESEARCH AND INNOVATION STAFF EXCHANGE (RISE) (FUNDING SCHEME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3507 STRATEGY, MANAGEMENT AND ORGANISATIONAL BEHAVIOUR;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;48 LAW AND LEGAL STUDIES","2;1;1;1;1;1;1;1;1;1","BRAIN DISORDERS;CLINICAL RESEARCH;NEURODEGENERATIVE;NEUROSCIENCES;RARE DISEASES;BIOTECHNOLOGY;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HUNTINGTON'S DISEASE;ORPHAN DRUG","2;2;2;2;2;1;1;1;1","NEUROLOGICAL","2","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS","2;1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;B11 COMPUTER SCIENCE AND INFORMATICS","2;1;1",NA,NA,68,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;SPRINGER NATURE;KARGER PUBLISHERS;SCIELO JOURNALS;TAYLOR & FRANCIS GROUP;WILEY","50;9;4;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;49 MATHEMATICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3215 REPRODUCTIVE MEDICINE;4905 STATISTICS;52 PSYCHOLOGY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;41 ENVIRONMENTAL SCIENCES;4202 EPIDEMIOLOGY;3105 GENETICS;3209 NEUROSCIENCES;3213 PAEDIATRICS;4105 POLLUTION AND CONTAMINATION;34 CHEMICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;5202 BIOLOGICAL PSYCHOLOGY","69;16;15;12;11;6;5;5;5;4;4;4;4;3;3;3;3;2;2;2","CLINICAL RESEARCH;NEUROSCIENCES;CANCER;RARE DISEASES;BRAIN DISORDERS;NEURODEGENERATIVE;AGING;GENETICS;LUNG;PREVENTION;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;ACQUIRED COGNITIVE IMPAIRMENT;ALZHEIMER'S DISEASE;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD);DEMENTIA;HEMATOLOGY;LUNG CANCER;CARDIOVASCULAR;EYE DISEASE AND DISORDERS OF VISION;INFECTIOUS DISEASES","16;11;8;8;7;7;6;6;6;6;5;4;4;4;4;4;4;3;3;3","CANCER;NEUROLOGICAL;EYE;GENERIC HEALTH RELEVANCE;INFECTION;RESPIRATORY;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM;STROKE;CONGENITAL;MENTAL HEALTH;METABOLIC AND ENDOCRINE;MUSCULOSKELETAL","10;9;4;4;4;3;2;2;2;1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.4 SURVEILLANCE AND DISTRIBUTION;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;5.2 CELLULAR AND GENE THERAPIES;6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;7.3 MANAGEMENT AND DECISION MAKING;8.1 ORGANISATION AND DELIVERY OF SERVICES","11;5;5;2;1;1;1;1;1;1","CLINICAL;BIOMEDICAL;POPULATION & SOCIETY","14;4;4","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH;BASIC SCIENCE","20;12;6","LUNG CANCER;CERVICAL CANCER;ORAL CAVITY AND LIP CANCER;NOT SITE-SPECIFIC CANCER;BRAIN TUMOR;MELANOMA;PANCREATIC CANCER;PHARYNGEAL CANCER;RESPIRATORY SYSTEM","9;5;3;2;1;1;1;1;1","3 GOOD HEALTH AND WELL BEING;4 QUALITY EDUCATION;5 GENDER EQUALITY;8 DECENT WORK AND ECONOMIC GROWTH","4;1;1;1",80,4.04,448.64,34,71.44,0,1,13,1,29,0,3,33,0,50,26,0,0,0,0,0,0,74,3,3,76,4,0,0,0,0,0,0,0,0,"United States;Italy;United Kingdom;Brazil;Germany;Japan;Netherlands","24;5;3;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;3204 IMMUNOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;4203 HEALTH SERVICES AND SYSTEMS;3210 NUTRITION AND DIETETICS;3207 MEDICAL MICROBIOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3213 PAEDIATRICS;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4201 ALLIED HEALTH AND REHABILITATION SCIENCE","78;45;11;11;11;7;4;3;3;3;3;3;3;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;HEMATOLOGY;CANCER;PEDIATRIC;PATIENT SAFETY;AUTOIMMUNE DISEASE;DIGESTIVE DISEASES;LUNG;PREVENTION;BRAIN DISORDERS;EMERGING INFECTIOUS DISEASES;INFECTIOUS DISEASES;LIVER DISEASE;TRANSPLANTATION;NEUROSCIENCES;HEPATITIS;ORGAN TRANSPLANTATION;AGING","68;47;22;16;15;15;13;9;9;9;9;6;6;6;6;6;5;4;4;3","CANCER;INFLAMMATORY AND IMMUNE SYSTEM;BLOOD;INFECTION;METABOLIC AND ENDOCRINE;CONGENITAL;RENAL AND UROGENITAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY;CARDIOVASCULAR;EYE;GENERIC HEALTH RELEVANCE;NEUROLOGICAL;ORAL AND GASTROINTESTINAL","9;5;3;3;3;2;2;2;2;1;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;2.4 SURVEILLANCE AND DISTRIBUTION;3.3 NUTRITION AND CHEMOPREVENTION;6.4 SURGERY;6.7 PHYSICAL;7.1 INDIVIDUAL CARE NEEDS","48;5;4;3;3;2;2;1;1;1;1;1;1","LEUKEMIA / LEUKAEMIA;COLON AND RECTAL CANCER;LIVER CANCER;NON-HODGKIN'S LYMPHOMA;MYELOMA;NOT SITE-SPECIFIC CANCER","8;4;3;3;2;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.2 SURVEILLANCE","11;3;2;1;1;1;1;1"
"IRCCS_CAGRANDA",2019,1400,14.5914285714286,3.12214285714286,0.320292839167239,0.348571428571429,0.330714285714286,0.338571428571429,0.627142857142857,10,674,317,107,105,0.48,0.23,0.08,0.07,21.69,0.892002091255608,0.420714285714286,0.977142857142857,5.4200906344411,0.533669555816759,0.514105269385501,0.474230907643486,0.511207049710408,"ALESSANDRA IURLO;PIETRO LAMPERTICO;FLORA PEYVANDI;MATTEO CESARI;FABIO MOSCA;DANIELA GALIMBERTI;DARIO CONSONNI;MASSIMILIANO BONIFACIO;STEFANO ALIBERTI;FRANCESCO BLASI;FRANCESCO GROSSI;E. MONTANARI;PIERGIORGIO MESSA;DANIELE CATTANEO;MAURIZIO VECCHI;MARIA DOMENICA CAPPELLINI;PAOLA MARCHISIO;LUCA VALENTI;ELISABETTA ABRUZZESE;ANNA LUDOVICA FRACANZANI","43;40;39;37;35;34;33;30;30;29;29;26;26;24;23;23;23;22;22;20","FLORA PEYVANDI;MATTEO CESARI;STEFANO VERALDI;DARIO CONSONNI;PIERGIORGIO MESSA;GIANLUCA NAZZARO;FABIO MOSCA;MARIA DOMENICA CAPPELLINI;STEFANO ALIBERTI;FRANCESCO BLASI;PAOLA MARCHISIO;DANIELA GALIMBERTI;TOMMASO MAURI;CARLO AGOSTONI;DANIELE DONDOSSOLA;MAURIZIO VECCHI;PIETRO LAMPERTICO;ANTONIO PESENTI;GIACOMO GRASSELLI;E. MONTANARI","4.7;4.66;4.38;4.02;3.81;3.68;3.3;2.99;2.71;2.61;2.58;2.58;2.49;2.47;2.46;2.45;2.42;2.32;2.25;2.23","ALESSANDRA IURLO;PIETRO LAMPERTICO;FLORA PEYVANDI;MATTEO CESARI;FABIO MOSCA;DANIELA GALIMBERTI;DARIO CONSONNI;STEFANO ALIBERTI;FRANCESCO BLASI;FRANCESCO GROSSI;E. MONTANARI;PIERGIORGIO MESSA;DANIELE CATTANEO;MAURIZIO VECCHI;MARIA DOMENICA CAPPELLINI;PAOLA MARCHISIO;LUCA VALENTI;ANNA LUDOVICA FRACANZANI;CHIARA FENOGLIO;GIACOMO GRASSELLI","43;40;39;37;35;34;33;30;29;29;26;26;24;23;23;23;22;20;20;19","FLORA PEYVANDI;MATTEO CESARI;STEFANO VERALDI;DARIO CONSONNI;PIERGIORGIO MESSA;GIANLUCA NAZZARO;FABIO MOSCA;MARIA DOMENICA CAPPELLINI;STEFANO ALIBERTI;FRANCESCO BLASI;PAOLA MARCHISIO;DANIELA GALIMBERTI;TOMMASO MAURI;CARLO AGOSTONI;DANIELE DONDOSSOLA;MAURIZIO VECCHI;PIETRO LAMPERTICO;ANTONIO PESENTI;GIACOMO GRASSELLI;E. MONTANARI","4.7;4.66;4.38;4.02;3.81;3.68;3.3;2.99;2.71;2.61;2.58;2.58;2.49;2.47;2.46;2.45;2.42;2.32;2.25;2.23","ANǴELA TINCANI;RICARD CERVERA;GABRIELLA MORONI;MARTA MOSCA;MARCELLO GOVONI;DAVID JAYNE;ANDREA DORIA;ALESSIA ALUNNO;ANNE TROLDBORG;ANNEGRET KUHN;ANTONIS FANOURIAKIS;CAROLINE GORDON;ELISABET SVENUNGSSON;FRÉDÉRIC HOUSSIAU;GEORGE ΒERTSIAS;INGEBORG M. BAJEMA;J.L. LARSEN;JOERG WENZEL;JOHN BOLETIS;JOSEF S SMOLEN","1782;1691;1680;1676;1675;1647;1627;1624;1624;1624;1624;1624;1624;1624;1624;1624;1624;1624;1624;1624","GABRIELLA MORONI;MATTEO CESARI;LUCA VALENTI;ALESSANDRA IURLO;DANIELA GALIMBERTI;FRANCESCO GROSSI;PIETRO LAMPERTICO;MARIE SCULLY;FABIO MOSCA;PAOLA DONGIOVANNI;ELIO SCARPINI;NINO STOCCHETTI;DANIELE CATTANEO;ANNA LUDOVICA FRACANZANI;LUIGI BONI;MARIA DOMENICA CAPPELLINI;STEFANO ALIBERTI;E. MONTANARI;PAOLA MARCHISIO;MASSIMO PRIMIGNANI","1680;1189;1029;1025;1022;888;873;740;734;696;649;643;633;584;520;507;496;493;466;459","ALESSANDRA IURLO;PIETRO LAMPERTICO;FLORA PEYVANDI;DANIELA GALIMBERTI;DARIO CONSONNI;MATTEO CESARI;FABIO MOSCA;FRANCESCO GROSSI;STEFANO ALIBERTI;FRANCESCO BLASI;E. MONTANARI;DANIELE CATTANEO;MAURIZIO VECCHI;MARIA DOMENICA CAPPELLINI;PAOLA MARCHISIO;LUCA VALENTI;ANNA LUDOVICA FRACANZANI;PIERGIORGIO MESSA;GIOVANNA MANTOVANI;PAOLA DONGIOVANNI","43;39;37;32;32;31;31;29;29;29;26;24;23;22;22;21;21;18;18;18","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;PSYCHOLOGY;COMPUTER SCIENCE;MATHEMATICS;ENGINEERING;SOCIOLOGY;ECONOMICS;POLITICAL SCIENCE;MATERIALS SCIENCE;PHILOSOPHY;BUSINESS;ENVIRONMENTAL SCIENCE;HISTORY;GEOGRAPHY;ART;GEOLOGY","1328;474;112;102;100;91;62;54;40;38;32;28;25;11;9;9;8;7;3","INTERNAL MEDICINE;SURGERY;GENETICS;PATHOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;PEDIATRICS;ONCOLOGY;ENVIRONMENTAL HEALTH;PSYCHIATRY;BIOCHEMISTRY;INTENSIVE CARE MEDICINE;RADIOLOGY;CARDIOLOGY;ENDOCRINOLOGY;ANESTHESIA;CANCER RESEARCH;PALEONTOLOGY;NURSING;PHYSICAL THERAPY","995;327;274;257;202;187;173;139;137;130;123;113;105;97;90;78;65;55;52;52","DISEASE;GENE;POPULATION;CANCER;COHORT;PREGNANCY;TRANSPLANTATION;CONFIDENCE INTERVAL;PROSPECTIVE COHORT STUDY;RETROSPECTIVE COHORT STUDY;LUNG;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;ALTERNATIVE MEDICINE;ANTIBODY;CLINICAL TRIAL;OBSERVATIONAL STUDY;CHEMOTHERAPY;PLATELET;COGNITION;INCIDENCE (GEOMETRY);ODDS RATIO","231;181;117;111;108;91;72;68;64;64;62;58;52;50;50;47;47;46;40;39;39;39","FETUS;HAZARD RATIO;MUTATION;DEMENTIA;CLINICAL ENDPOINT;GESTATIONAL AGE;FATTY LIVER;GENOTYPE;PLACEBO;COLORECTAL CANCER;PHENOTYPE;GENE EXPRESSION;IMMUNOTHERAPY;IMATINIB;BRONCHIECTASIS;LIVER TRANSPLANTATION;HEMATOPOIETIC STEM CELL TRANSPLANTATION;BREAST CANCER;CHRONIC LYMPHOCYTIC LEUKEMIA;UNIVARIATE ANALYSIS","33;31;31;28;25;25;23;23;23;22;21;20;20;19;18;18;17;16;16;16","FRONTOTEMPORAL DEMENTIA;NONALCOHOLIC FATTY LIVER DISEASE;NIVOLUMAB;DASATINIB;SINGLE-NUCLEOTIDE POLYMORPHISM;DNA METHYLATION;NILOTINIB;ANTIRETROVIRAL THERAPY;COLONOSCOPY;IBRUTINIB;RIBAVIRIN;CYSTECTOMY;GREY MATTER;MISSENSE MUTATION;RUXOLITINIB;ACROMEGALY;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;PLACENTA;STEATOHEPATITIS;EXOME SEQUENCING;FLUDARABINE;GENE EXPRESSION PROFILING;IMATINIB MESYLATE;MICROVESICLES;MYELOPROLIFERATIVE NEOPLASM;PREDIABETES;PYRUVATE KINASE;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RIVAROXABAN;SEMEN ANALYSIS;TRANSCRIPTOME","17;14;13;12;10;9;9;8;8;8;8;7;7;7;7;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5","HUMANS;FEMALE;;MALE;MIDDLE AGED;ADULT;AGED;ITALY;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;YOUNG ADULT;ADOLESCENT;PROSPECTIVE STUDIES;TREATMENT OUTCOME;CHILD;CHILD, PRESCHOOL;RISK FACTORS;BIOMARKERS;LUNG NEOPLASMS;ANIMALS","795;587;583;552;367;352;319;232;132;131;127;124;108;108;107;74;72;70;61;60","EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;MANAGEMENT AND TREATMENT OF HEMOPHILIA;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;EFFICACY AND RESISTANCE IN CML TREATMENT;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HEPATITIS C INFECTION AND TREATMENT;ROLE OF COMPLEMENT SYSTEM IN IMMUNE RESPONSE;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME;CANCER IMMUNOTHERAPY;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;GENE THERAPY FOR SPINAL MUSCULAR ATROPHY;MECHANICAL CIRCULATORY SUPPORT SYSTEMS;ATRIAL FIBRILLATION;DENTAL IMPLANTOLOGY AND PERI-IMPLANT DISEASES;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;MECHANOSENSITIVE ION CHANNELS IN PHYSIOLOGY AND DISEASE;EPIDEMIOLOGY AND MANAGEMENT OF BIPOLAR DISORDER","33;29;24;23;23;20;20;16;15;14;14;13;13;13;12;11;11;11;11;10","TREATMENT;DISCONTINUATION;CLINICAL ENDPOINT;INTERQUARTILE RANGE;REGIMEN;ETIOLOGY;POSITIVE END-EXPIRATORY PRESSURE;UNIVARIATE ANALYSIS;EXTRACORPOREAL MEMBRANE OXYGENATION;FRAILTY;LIVER BIOPSY;STEATOSIS;IMPLANT STABILITY;MYELOFIBROSIS;SPINAL MUSCULAR ATROPHY;TREATMENT DISCONTINUATION;CONCOMITANT;DEPRESSION (ECONOMICS);DIAGNOSIS;HEMATOLOGY","49;27;25;21;19;17;17;16;15;14;14;14;13;13;13;13;12;12;12;12","LUNG CANCER;MYELOID LEUKEMIA;OBSERVATIONAL STUDY;PATIENTS TREATED;CYSTIC FIBROSIS;RISK FACTORS;CHRONIC MYELOID;COHORT STUDY;LIVER DISEASE;STEM CELL;HEPATOCELLULAR CARCINOMA;CELL LUNG;MULTICENTER STUDY;MULTIPLE MYELOMA;ALZHEIMERS DISEASE;LIVER TRANSPLANTATION;BIPOLAR DISORDER;CHRONIC HEPATITIS;CLINICAL TRIAL;ELDERLY PATIENTS;EXTRACORPOREAL MEMBRANE;FRONTOTEMPORAL DEMENTIA;ITALIAN SOCIETY;MEMBRANE OXYGENATION;CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;PILOT STUDY;ADULT PATIENTS;FATTY LIVER;INTENSIVE CARE","25;22;22;22;20;19;18;18;16;16;15;14;14;14;13;13;12;12;12;12;12;12;12;12;11;11;11;10;10;10","RESEARCH FUNDING;ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;CONSULTANCY HONORARIA;RISK FACTORS;CONSULTANCY RESEARCH;ADVERSE EVENTS;HONORARIA MEMBERSHIP;HONORARIA RESEARCH;LUNG CANCER;NOVARTIS HONORARIA;ADVISORY CONSULTANCY;MEDIAN AGE;MILAN ITALY;PATIENTS TREATED;COMMITTEES SPEAKERS;MULTIVARIATE ANALYSIS;HONORARIA INCYTE;HR CI;NOVARTIS CONSULTANCY;ADULT PATIENTS;HONORARIA NOVARTIS;STATISTICALLY SIGNIFICANT;CLINICAL TRIALS;FUNDING SPEAKERS;STEM CELL;CONFIDENCE INTERVAL;ODDS RATIO;HONORARIA PFIZER","311;294;294;251;132;89;75;73;71;61;58;57;56;56;55;55;52;52;49;49;48;46;46;46;45;45;45;44;44;43",657,0.47,3.5,36.26,10.35,807.5,31.43,2,372,2.12,1,16,1.23,1,3,0,0,0,4.17,1,95,3.86,1,11,1,1,1,1.19,1,3,38.47,2,464,1,1,1,1,1,1,28.53,1,370,1,1,1,1.4,1,2,1.86,1,10,6.13,1,77,18.89,1,247,5.65,1,36,0.02,0,1,0,0,0,100.78,6,2034,100.8,6,2034,8,1,1,8,0,1,0,0,0,0,0,0,7,2,2,3.4,2.45454545454545,1.18181818181818,2,2,5,0,0,2,1,0,1,0,0,2,0,0,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,9,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"MANTOVANI MARIO;PIGNATARO LORENZO;RINALDI VITTORIO;ARDISSINO GIANLUIGI;BARILANI MARIO;LAZZARI LORENZA;BONINO, FERRUCCIO;CADRINGHER PAOLO;CATANIA, ANNA;CRESSONI MASSIMO","3;3;3;2;2;2;1;1;1;1","FOND IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO;FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO;EPISKEY SRL;UNIV DEGLI STUDI MILANO","7;4;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3203 DENTISTRY;40 ENGINEERING;48 LAW AND LEGAL STUDIES;4806 PRIVATE LAW AND CIVIL OBLIGATIONS;3107 MICROBIOLOGY;3202 CLINICAL SCIENCES;33 BUILT ENVIRONMENT AND DESIGN","7;4;2;2;2;2;2;1;1;1","DENTAL/ORAL AND CRANIOFACIAL DISEASE;RARE DISEASES","2;1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","2","A61B1/24;A61B1/32;A61B13/00;A61K31/55;A61M1/36;A61P13/12;A61B6/00;A61B6/03;A61J1/10;A61J1/20","3;3;2;2;2;2;1;1;1;1","A61B1/24;A61B1/32;A61B13/00;A61K31/55;A61K35/545;A61K9/0019;A61K9/08;A61P13/12;A61P7/00;C12N2506/1369","3;3;3;2;2;2;2;2;2;2",2,20286596,414955.21,5.5,38.5,8,0.5,32,"FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO;ACADEMIC MEDICAL CENTER;ALACRIS (GERMANY);AMSTERDAM UMC LOCATION VUMC;ANDALUSIAN HEALTH SERVICE;ANDALUSIAN SCHOOL OF PUBLIC HEALTH;ASTRAZENECA (SWEDEN);AUGUST PI I SUNYER BIOMEDICAL RESEARCH INSTITUTE;AZIENDA OSPEDALIERA DI PADOVA;CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST;CAPITAL REGION OF DENMARK;CENTRE FOR GENOMIC REGULATION;CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE BREST;CENTRE HOSPITALIER UNIVERSITAIRE DE NANCY;CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED;CHARITÉ - UNIVERSITY MEDICINE BERLIN;CLINIQUES UNIVERSITAIRES SAINT-LUC;DÉLÉGATION PARIS 11;EUROPEAN RESEARCH AND PROJECT OFFICE;EUROPEAN RESPIRATORY SOCIETY","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;TELETHON FOUNDATION","1;1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);H2020-JTI-IMI2-2018-14-TWO-STAGE (CALL FOR PROPOSAL);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;3206 MEDICAL BIOTECHNOLOGY","2;1;1;1","GENETICS;BIOTECHNOLOGY;CLINICAL RESEARCH;GENE THERAPY;NEUROSCIENCES;RARE DISEASES;REGENERATIVE MEDICINE;STEM CELL RESEARCH","2;1;1;1;1;1;1;1","INFLAMMATORY AND IMMUNE SYSTEM","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.5 RESOURCES AND INFRASTRUCTURE (DETECTION);5.2 CELLULAR AND GENE THERAPIES","1;1;1;1;1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE","2",NA,NA,50,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;KARGER PUBLISHERS;TAYLOR & FRANCIS GROUP","41;7;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3107 MICROBIOLOGY;3213 PAEDIATRICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;42 HEALTH SCIENCES;3204 IMMUNOLOGY;3215 REPRODUCTIVE MEDICINE;3211 ONCOLOGY AND CARCINOGENESIS;34 CHEMICAL SCIENCES;44 HUMAN SOCIETY;49 MATHEMATICAL SCIENCES;52 PSYCHOLOGY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3205 MEDICAL BIOCHEMISTRY AND METABOLOMICS;3210 NUTRITION AND DIETETICS;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES","67;14;11;5;4;4;4;4;3;3;2;2;2;2;2;1;1;1;1;1","CLINICAL RESEARCH;RARE DISEASES;BRAIN DISORDERS;PREVENTION;AUTOIMMUNE DISEASE;GENETICS;PEDIATRIC;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;HEMATOLOGY;LUNG;NEUROSCIENCES;NUTRITION;ANTIMICROBIAL RESISTANCE;ATHEROSCLEROSIS;BEHAVIORAL AND SOCIAL SCIENCE;BIOMEDICAL IMAGING;BIOTECHNOLOGY;CARDIOVASCULAR","10;6;5;4;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1","REPRODUCTIVE HEALTH AND CHILDBIRTH;INFLAMMATORY AND IMMUNE SYSTEM;CANCER;NEUROLOGICAL;CARDIOVASCULAR;INFECTION;MUSCULOSKELETAL;ORAL AND GASTROINTESTINAL;STROKE","5;3;2;2;1;1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;4.4 POPULATION SCREENING;6.1 PHARMACEUTICALS;8.1 ORGANISATION AND DELIVERY OF SERVICES","6;2;2;1;1;1","CLINICAL;BIOMEDICAL;HEALTH SERVICES & SYSTEMS","9;4;2","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","22;2;2","LEUKEMIA / LEUKAEMIA;BLOOD CANCER;COLON AND RECTAL CANCER;HODGKIN'S DISEASE;LUNG CANCER;MYELOMA;NON-HODGKIN'S LYMPHOMA","5;2;1;1;1;1;1","3 GOOD HEALTH AND WELL BEING;16 PEACE, JUSTICE AND STRONG INSTITUTIONS","4;1",81,4.2,650.56,46,74.49,0,2,17,3,31,0,3,25,0,63,16,0,0,0,0,0,0,78,3,0,78,2,0,1,0,0,0,0,0,0,"United States;Italy;Germany;Japan;Spain;United Kingdom;Canada;Czechia;France;Switzerland","21;18;2;2;2;2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3213 PAEDIATRICS;31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3204 IMMUNOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3215 REPRODUCTIVE MEDICINE;3105 GENETICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3106 INDUSTRIAL BIOTECHNOLOGY;3207 MEDICAL MICROBIOLOGY;4202 EPIDEMIOLOGY;4204 MIDWIFERY","79;40;18;11;5;4;4;4;4;3;3;3;2;2;2;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;CANCER;HEMATOLOGY;PATIENT SAFETY;DIGESTIVE DISEASES;LUNG;PREVENTION;PEDIATRIC;LIVER DISEASE;CARDIOVASCULAR;AUTOIMMUNE DISEASE;INFECTIOUS DISEASES;CHRONIC LIVER DISEASE AND CIRRHOSIS;LYMPHOMA;ORPHAN DRUG;EMERGING INFECTIOUS DISEASES;NEURODEGENERATIVE;NEUROSCIENCES","74;54;31;21;21;19;16;16;14;13;12;10;8;8;7;7;7;6;6;6","CANCER;RESPIRATORY;INFLAMMATORY AND IMMUNE SYSTEM;INFECTION;CARDIOVASCULAR;REPRODUCTIVE HEALTH AND CHILDBIRTH;NEUROLOGICAL;ORAL AND GASTROINTESTINAL;CONGENITAL;RENAL AND UROGENITAL;SKIN;BLOOD;EYE;STROKE","17;8;7;6;5;5;3;3;2;2;2;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.7 PHYSICAL;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;3.3 NUTRITION AND CHEMOPREVENTION;3.4 VACCINES;5.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY","57;7;5;4;3;2;2;1;1;1;1;1","NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;LIVER CANCER;COLON AND RECTAL CANCER;HODGKIN'S DISEASE;LUNG CANCER;MYELOMA;BLADDER CANCER;BLOOD CANCER;KIDNEY CANCER","9;7;7;2;2;2;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;3.3 CHEMOPREVENTION;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","21;4;2;1;1;1"
"IRCCS_CAGRANDA",2020,1831,16.0720917531404,3.11086837793555,0.321453651685393,0.33205898416166,0.329874385581649,0.274713271436374,0.684871654833424,10,936,418,138,108,0.51,0.23,0.08,0.06,31.15,1.23634073185209,0.424358274167122,0.973784817039869,6.85284069340766,0.556063632623305,0.503369973535796,0.465719725818736,0.510305294272718,"FRANCESCO BLASI;MATTEO CESARI;STEFANO ALIBERTI;FABIO MOSCA;GIACOMO GRASSELLI;FLORA PEYVANDI;E. MONTANARI;PIETRO LAMPERTICO;PIERGIORGIO MESSA;DARIO CONSONNI;DANIELA GALIMBERTI;LUCA VALENTI;GIANPAOLO CARRAFIELLO;MARIO NOSOTTI;PAOLO BRAMBILLA;ANNA MARIA IERARDI;FRANCESCO GROSSI;ANDREA GORI;LORENZO ROSSO;ANGELO VALERIO MARZANO","56;46;46;46;42;41;36;36;34;33;32;30;30;29;29;26;25;24;24;23","MATTEO CESARI;FABIO MOSCA;PIERGIORGIO MESSA;FRANCESCO BLASI;FLORA PEYVANDI;STEFANO ALIBERTI;STEFANO VERALDI;E. MONTANARI;GIACOMO GRASSELLI;PIER MANNUCCIO MANNUCCI;DARIO CONSONNI;LORENZO PIGNATARO;EDGARDO SOMIGLIANA;GIANPAOLO CARRAFIELLO;ANNA MARIA IERARDI;ANGELO VALERIO MARZANO;A. PALLESCHI;PIER PAOLO POLI;CARLO MAIORANA;MASSIMILIANO BUOLI","7.5;5.6;5.41;4.99;4.63;4.27;4.27;3.94;3.63;3.55;3.34;3.2;3.07;2.95;2.91;2.89;2.8;2.74;2.71;2.62","FRANCESCO BLASI;MATTEO CESARI;STEFANO ALIBERTI;FABIO MOSCA;GIACOMO GRASSELLI;FLORA PEYVANDI;E. MONTANARI;PIETRO LAMPERTICO;PIERGIORGIO MESSA;DARIO CONSONNI;DANIELA GALIMBERTI;LUCA VALENTI;GIANPAOLO CARRAFIELLO;MARIO NOSOTTI;PAOLO BRAMBILLA;ANNA MARIA IERARDI;FRANCESCO GROSSI;ANDREA GORI;LORENZO ROSSO;ANGELO VALERIO MARZANO","56;46;46;46;42;41;36;36;34;33;32;30;30;29;29;26;25;24;24;23","MATTEO CESARI;FABIO MOSCA;PIERGIORGIO MESSA;FRANCESCO BLASI;FLORA PEYVANDI;STEFANO ALIBERTI;STEFANO VERALDI;E. MONTANARI;GIACOMO GRASSELLI;PIER MANNUCCIO MANNUCCI;DARIO CONSONNI;LORENZO PIGNATARO;EDGARDO SOMIGLIANA;GIANPAOLO CARRAFIELLO;ANNA MARIA IERARDI;ANGELO VALERIO MARZANO;A. PALLESCHI;PIER PAOLO POLI;CARLO MAIORANA;MASSIMILIANO BUOLI","7.5;5.6;5.41;4.99;4.63;4.27;4.27;3.94;3.63;3.55;3.34;3.2;3.07;2.95;2.91;2.89;2.8;2.74;2.71;2.62","GIACOMO GRASSELLI;ANTONIO ARTIGAS;MAURIZIO CECCONI;MASSIMILIANO GRECO;ROBERTO FUMAGALLI;THOMAS LÄNGER;GIUSEPPE FOTI;LUCA CABRINI;ANTONIO COLUCCELLO;FERDINANDO LUCA LORINI;GIANPAOLO CASTELLI;GIORGIO ANTONIO IOTTI;GIOVANNI ALBANO;SERGIO COLOMBO;NICOLA LATRONICO;ANDREA FORASTIERI MOLINARI;SERGIO CATTANEO;ALBERTO ZANELLA;MASSIMO ANTONELLI;FRANCESCO MOJOLI","13988;11254;10913;9728;8966;8963;8493;8265;8255;8255;8255;8255;8255;8255;8241;8220;8220;7857;7681;7194","ANTONIO ARTIGAS;GIACOMO GRASSELLI;ALBERTO ZANELLA;FLORA PEYVANDI;FRANCESCO GROSSI;MAURO PANIGADA;LUCA VALENTI;CRISTINA NOVEMBRINO;ARMANDO TRIPODI;STEFANO ALIBERTI;LUIGIA SCUDELLER;PAOLA TAGLIABUE;ELENA SANTAGOSTINO;NICOLA BOTTINO;PIETRO LAMPERTICO;FRANCESCO BLASI;E. FERRAZZI;VEENA CHANTARANGKUL;FABIO MOSCA;ANDREA GORI","11252;11233;7843;2644;1972;1903;1786;1745;1728;1721;1718;1545;1543;1433;1389;1341;1298;1297;1072;1017","FRANCESCO BLASI;STEFANO ALIBERTI;FABIO MOSCA;GIACOMO GRASSELLI;MATTEO CESARI;PIETRO LAMPERTICO;FLORA PEYVANDI;E. MONTANARI;PIERGIORGIO MESSA;DARIO CONSONNI;DANIELA GALIMBERTI;GIANPAOLO CARRAFIELLO;PAOLO BRAMBILLA;MARIO NOSOTTI;LUCA VALENTI;FRANCESCO GROSSI;ANNA LUDOVICA FRACANZANI;ANNA MARIA IERARDI;ELENA SANTAGOSTINO;ANDREA GORI","48;42;42;38;38;36;36;34;33;32;31;31;29;28;27;25;25;24;23;23","MEDICINE;BIOLOGY;PSYCHOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ECONOMICS;ENGINEERING;POLITICAL SCIENCE;MATHEMATICS;SOCIOLOGY;MATERIALS SCIENCE;PHILOSOPHY;BUSINESS;GEOGRAPHY;HISTORY;ART;GEOLOGY;ENVIRONMENTAL SCIENCE","1742;562;164;139;132;106;86;82;81;77;75;43;33;23;23;15;10;8;2","INTERNAL MEDICINE;SURGERY;PATHOLOGY;GENETICS;GASTROENTEROLOGY;IMMUNOLOGY;PEDIATRICS;INTENSIVE CARE MEDICINE;ENVIRONMENTAL HEALTH;VIROLOGY;PSYCHIATRY;RADIOLOGY;ONCOLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;CARDIOLOGY;ANESTHESIA;NURSING;OPTICS;FAMILY MEDICINE","1285;382;370;330;215;215;212;194;184;167;161;145;142;140;124;108;106;85;85;83","DISEASE;GENE;POPULATION;COHORT;OUTBREAK;CANCER;PREGNANCY;CONFIDENCE INTERVAL;LUNG;RETROSPECTIVE COHORT STUDY;TRANSPLANTATION;INCIDENCE (GEOMETRY);ADVERSE EFFECT;PROSPECTIVE COHORT STUDY;ANTIBODY;HEALTH CARE;CLINICAL TRIAL;RANDOMIZED CONTROLLED TRIAL;COHORT STUDY;LOGISTIC REGRESSION","482;205;154;138;134;131;116;100;97;88;77;74;62;59;58;56;55;51;48;48","INFECTIOUS DISEASE (MEDICAL SPECIALTY);2019-20 CORONAVIRUS OUTBREAK;MUTATION;HAZARD RATIO;PHENOTYPE;GENOTYPE;DEMENTIA;FETUS;GESTATIONAL AGE;GENE EXPRESSION;BREAST CANCER;CLINICAL ENDPOINT;COLORECTAL CANCER;FATTY LIVER;ALLELE;LUNG TRANSPLANTATION;GESTATION;INFERTILITY;BRONCHIECTASIS;IMMUNOTHERAPY","235;113;46;45;40;34;33;30;29;27;25;25;25;25;23;23;22;22;21;20","CORONAVIRUS DISEASE 2019 (COVID-19);FRONTOTEMPORAL DEMENTIA;ANTIRETROVIRAL THERAPY;DNA METHYLATION;SINGLE-NUCLEOTIDE POLYMORPHISM;NONALCOHOLIC FATTY LIVER DISEASE;PRENATAL DIAGNOSIS;DIFFUSING CAPACITY;EXOME SEQUENCING;MISSENSE MUTATION;COLONOSCOPY;STEATOHEPATITIS;TRANSCRIPTOME;ADAMTS13;DASATINIB;IBRUTINIB;MALE INFERTILITY;NILOTINIB;NIVOLUMAB;PEMBROLIZUMAB;VENETOCLAX","234;19;16;15;14;11;11;10;10;10;9;9;9;7;7;7;7;7;7;7;7",";HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;ITALY;AGED;COVID-19;CORONAVIRUS INFECTIONS;PNEUMONIA, VIRAL;RETROSPECTIVE STUDIES;SARS-COV-2;PANDEMICS;AGED, 80 AND OVER;ADOLESCENT;PROSPECTIVE STUDIES;CHILD;YOUNG ADULT;TREATMENT OUTCOME","942;875;515;481;345;319;300;277;230;214;205;175;118;109;105;104;101;100;100;98","CORONAVIRUS DISEASE 2019;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;MANAGEMENT AND TREATMENT OF HEMOPHILIA;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;ORGAN TRANSPLANTATION AND REJECTION;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME;DENTAL IMPLANTOLOGY AND PERI-IMPLANT DISEASES;IMPACT OF COVID-19 INFECTION ON PREGNANCY OUTCOMES;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;CANCER IMMUNOTHERAPY;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HEPATITIS C INFECTION AND TREATMENT;ACUTE MYELOID LEUKEMIA;EFFICACY AND RESISTANCE IN CML TREATMENT;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS","50;46;38;36;33;32;24;20;20;19;19;18;16;15;15;15;14;14;14;13","PANDEMIC;2019-20 CORONAVIRUS OUTBREAK;TREATMENT;INTERQUARTILE RANGE;CORONAVIRUS;REGIMEN;PREGNANCY;CROSS-SECTIONAL STUDY;CLINICAL ENDPOINT;NEURODEGENERATION;BETACORONAVIRUS;DEPRESSION (ECONOMICS);POSITIVE END-EXPIRATORY PRESSURE;CORONA VIRUS;IMPLANT STABILITY;NEPHROLOGY;UNIVARIATE ANALYSIS;CONCOMITANT;LUNG TRANSPLANT;STEATOSIS","114;111;54;36;29;29;26;25;24;24;22;21;19;18;18;18;18;17;17;17","COVID- PANDEMIC;COHORT STUDY;CYSTIC FIBROSIS;OBSERVATIONAL STUDY;RISK FACTORS;HEPATOCELLULAR CARCINOMA;PATIENTS TREATED;LUNG CANCER;BRAIN INJURY;CLINICAL PRACTICE;CORONAVIRUS DISEASE;LUNG TRANSPLANTATION;MYELOID LEUKEMIA;TRAUMATIC BRAIN;CANCER PATIENTS;ACUTE RESPIRATORY;FRONTOTEMPORAL DEMENTIA;LIVER DISEASE;CHRONIC HEPATITIS;KIDNEY DISEASE;LUPUS ERYTHEMATOSUS;MULTICENTRE STUDY;PILOT STUDY;SARS-COV- INFECTION;CHRONIC KIDNEY;CROSS-SECTIONAL STUDY;MULTICENTER STUDY;NORTHERN ITALY;PROSPECTIVE STUDY;SYSTEMIC LUPUS","36;26;25;24;22;20;19;18;17;17;17;17;17;17;15;14;14;14;13;13;13;13;13;13;12;12;12;12;12;12","RESEARCH FUNDING;ENTITYS BOARD;ADVISORY COMMITTEES;PUBMED SCOPUS;PERSONAL FEES;SPEAKERS BUREAU;CONSULTANCY HONORARIA;MILAN ITALY;CROSSREF PUBMED;OSPEDALE MAGGIORE;HR CI;MAGGIORE POLICLINICO;ACUTE RESPIRATORY;HONORARIA MEMBERSHIP;CORONAVIRUS DISEASE;COVID- PANDEMIC;HONORARIA RESEARCH;RISK FACTORS;COVID- PATIENTS;IRCCS CA;FONDAZIONE IRCCS;INTENSIVE CARE;CA GRANDA;MEDIAN AGE;GRANDA OSPEDALE;SARS-COV- INFECTION;CLINICAL PRACTICE;HEALTH CARE;ADVERSE EVENTS;MILANO MILAN","439;400;382;271;234;189;187;184;162;133;127;118;113;110;109;103;98;92;90;90;87;87;86;84;81;78;75;75;73;72",997,0.54,3,76.44,10.5,2840.14199999998,74.64,2,2955,1.83,1,8,2,1,17,0,0,0,7.01,1,121,1.38,1,3,1,1,1,1.41,1,4,88.16,2,3336,2.31,1,12,1,1,1,69.72,1,2803,1,1,1,1.29,1,2,3.24,1,76,11.04,1,360,51.2,1,2047,9.66,1,320,0,0,0,0,0,0,153.24,4,4096,152.26,4,4096,9,1,3,11,4,3,0,0,0,0,0,0,12,3,7,2,2.47619047619048,1.36363636363636,5,6,12,1,1,3,2,0,3,1,1,4,0,2,2,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,14,3,2,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ARDISSINO GIANLUIGI;BARABINO SILVIA MARIA LUISA;CORTI STEFANIA;GROPPELLI ANTONIO;LOFFREDA ALESSIA;MANTOVANI MARIO;NIZZARDO MONICA;PIGNATARO LORENZO;RINALDI VITTORIO;ARDISSINO GIANLUCA","3;3;3;3;3;3;3;3;3;2","FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO;FOND IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO;UNIV DEGLI STUDI MILANO;UNIV DEGLI STUDI DI MILANO BICOCCA;FOND IRCCS ""CA' GRANDA - OSPEDALE MAGGIORE POLICLINICO"";UNIVERSITA DEGLI STUDI DI MILANO BICOCCA;UNIVERSITA' DEGLI STUDI DI MILANO","13;8;4;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3107 MICROBIOLOGY;3203 DENTISTRY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;40 ENGINEERING;3101 BIOCHEMISTRY AND CELL BIOLOGY;34 CHEMICAL SCIENCES;48 LAW AND LEGAL STUDIES","19;12;5;4;4;3;3;2;2;2","RARE DISEASES;DENTAL/ORAL AND CRANIOFACIAL DISEASE;ACQUIRED COGNITIVE IMPAIRMENT;AGING;ALZHEIMER'S DISEASE;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD);BRAIN DISORDERS;DEMENTIA;NEURODEGENERATIVE;NEUROSCIENCES","6;4;2;2;2;2;2;2;2;2","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","2","A61B1/24;A61B1/32;A61B13/00;A61K31/55;A61P13/12;A61P7/00;C12N15/113;A61K31/712;A61K35/28;A61P29/00","5;5;4;4;4;4;4;2;2;2","C12N15/113;C12Q2600/178;A61B1/24;A61B1/32;A61B13/00;A61K31/55;A61K9/0019;A61K9/08;A61P13/12;A61P7/00","5;5;4;4;4;4;4;4;4;4",1,9983029,665535.27,4,15,8,1,15,"CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX;DÉLÉGATION PARIS 11;FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO;GILEAD SCIENCES (UNITED STATES);HOSPICES CIVILS DE LYON;INSERM TRANSFERT;INSTITUT NÉEL;INSTITUT PASTEUR;KAROLINSKA INSTITUTET;NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS;OSPEDALE DI PARMA;UNIVERSITY HOSPITAL OF LAUSANNE;UNIVERSITY MEDICAL CENTER FREIBURG;UNIVERSITY OF PARMA;VALL D'HEBRON HOSPITAL UNIVERSITARI","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY","1;1","BIODEFENSE;BIOTECHNOLOGY;CLINICAL RESEARCH;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;HEPATITIS;HEPATITIS - B;IMMUNIZATION;INFECTIOUS DISEASES;LIVER DISEASE;PREVENTION;VACCINE RELATED","1;1;1;1;1;1;1;1;1;1;1;1","INFECTION","1","5.1 PHARMACEUTICALS","1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1","3 GOOD HEALTH AND WELL BEING","1",76,"FRONTIERS;PUBLIC LIBRARY OF SCIENCE;ZENODO;SPRINGER NATURE;KARGER PUBLISHERS;UNIVERSITY COLLEGE LONDON;AMERICAN ASSOCIATION FOR CANCER RESEARCH","31;16;14;7;5;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;42 HEALTH SCIENCES;3107 MICROBIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3105 GENETICS;52 PSYCHOLOGY;3204 IMMUNOLOGY;3205 MEDICAL BIOCHEMISTRY AND METABOLOMICS;4202 EPIDEMIOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3206 MEDICAL BIOTECHNOLOGY;3210 NUTRITION AND DIETETICS;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;44 HUMAN SOCIETY;49 MATHEMATICAL SCIENCES;5202 BIOLOGICAL PSYCHOLOGY","109;55;18;16;11;10;9;7;5;3;3;3;2;2;2;2;2;2;2;2","GENETICS;CLINICAL RESEARCH;UROLOGIC DISEASES;PEDIATRIC;CANCER;RARE DISEASES;BRAIN DISORDERS;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);DIGESTIVE DISEASES;DUCHENNE/ BECKER MUSCULAR DYSTROPHY;MUSCULAR DYSTROPHY;NEUROSCIENCES;BIOMEDICAL IMAGING;KIDNEY DISEASE;STEM CELL RESEARCH;GENETIC TESTING;PREVENTION;AGING;BIOTECHNOLOGY","35;22;17;11;10;10;8;7;7;5;5;5;5;4;4;4;3;3;2;2","RENAL AND UROGENITAL;CANCER;ORAL AND GASTROINTESTINAL;MUSCULOSKELETAL;CARDIOVASCULAR;CONGENITAL;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL","18;11;5;3;2;1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS","29;7;5;4;2;1;1","BIOMEDICAL;CLINICAL","27;17","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","35;23","LIVER CANCER;NOT SITE-SPECIFIC CANCER;PROSTATE CANCER;THYROID CANCER;COLON AND RECTAL CANCER;LUNG CANCER","2;2;2;2;1;1","2 ZERO HUNGER;3 GOOD HEALTH AND WELL BEING;5 GENDER EQUALITY","1;1;1",99,3.23,1012.8,60,73.63,1,2,13,6,32,0,0,45,0,65,34,0,0,0,0,0,0,95,1,3,96,0,0,3,0,0,0,0,0,0,"United States;Italy;Germany;Netherlands;Switzerland;Japan;France;United Kingdom;Belgium;Austria;Czechia;Denmark;Poland;Portugal;Spain;Sweden","29;18;5;5;5;4;3;3;2;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3213 PAEDIATRICS;3207 MEDICAL MICROBIOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3204 IMMUNOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3206 MEDICAL BIOTECHNOLOGY;3210 NUTRITION AND DIETETICS;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3208 MEDICAL PHYSIOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE","96;61;15;12;8;5;5;4;4;4;3;3;2;2;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;PREVENTION;LUNG;CANCER;PATIENT SAFETY;HEMATOLOGY;INFECTIOUS DISEASES;DIGESTIVE DISEASES;PEDIATRIC;GENETICS;BIOENGINEERING;BRAIN DISORDERS;EMERGING INFECTIOUS DISEASES;LIVER DISEASE;ORPHAN DRUG;PNEUMONIA;HEALTH SERVICES;NEURODEGENERATIVE","92;60;34;25;24;19;19;18;18;16;10;9;8;8;7;7;7;7;6;6","CANCER;INFECTION;RESPIRATORY;CARDIOVASCULAR;MENTAL HEALTH;ORAL AND GASTROINTESTINAL;METABOLIC AND ENDOCRINE;CONGENITAL;INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL;BLOOD;EYE;MUSCULOSKELETAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;SKIN","13;9;6;4;4;4;3;2;2;2;1;1;1;1;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.2 CELLULAR AND GENE THERAPIES;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS;8.1 ORGANISATION AND DELIVERY OF SERVICES;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;3.3 NUTRITION AND CHEMOPREVENTION;3.4 VACCINES;6.6 PSYCHOLOGICAL AND BEHAVIOURAL;6.7 PHYSICAL","56;7;5;4;4;4;3;2;2;2;1;1;1;1;1","LEUKEMIA / LEUKAEMIA;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;LIVER CANCER;BLOOD CANCER;COLON AND RECTAL CANCER;BLADDER CANCER;HODGKIN'S DISEASE;MYELOMA;NOT SITE-SPECIFIC CANCER","7;5;5;3;2;2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;6.2 SURVEILLANCE","14;1;1;1;1;1"
"IRCCS_CAGRANDA",2021,1834,17.1564885496183,3.30370774263904,0.30269021290642,0.333151581243184,0.341875681570338,0.291712104689204,0.70937840785169,12,839,416,143,111,0.46,0.23,0.08,0.06,17.37,1.12656345817879,0.391494002181025,0.981461286804798,7.2846683422577,0.56233013346377,0.506917035205351,0.512048018429445,0.508627699985518,"FLORA PEYVANDI;FRANCESCO BLASI;LUCA VALENTI;DARIO CONSONNI;GIACOMO GRASSELLI;FABIO MOSCA;PIETRO LAMPERTICO;ANDREA GORI;ALESSANDRA BANDERA;PAOLO BRAMBILLA;STEFANO CARUGO;DANIELA GALIMBERTI;ANNA LUDOVICA FRACANZANI;WILMA BARCELLINI;MAURIZIO VECCHI;GIACOMO P. COMI;ALESSANDRA IURLO;FRANCESCO GROSSI;DANIELE PRATI;FERRUCCIO CERIOTTI","53;47;45;45;42;37;37;35;34;31;31;31;30;29;28;28;27;27;27;26","FLORA PEYVANDI;DARIO CONSONNI;EDGARDO SOMIGLIANA;FRANCESCO BLASI;STEFANO CARUGO;LUCA VALENTI;WILMA BARCELLINI;FABIO MOSCA;MASSIMILIANO BUOLI;LORENZO PIGNATARO;PIETRO LAMPERTICO;ANNA MARIA IERARDI;EMILIO BERTI;GIACOMO GRASSELLI;STEFANO VERALDI;GIANPAOLO CARRAFIELLO;GIOVANNI MONTINI;ANGELA CECILIA PESATORI;GIOVANNI B. FOGAZZI;MAURIZIO VECCHI","5.64;4.96;4.3;4.1;3.97;3.87;3.41;3.33;3.33;3.17;2.96;2.92;2.81;2.8;2.72;2.67;2.65;2.65;2.64;2.62","FLORA PEYVANDI;FRANCESCO BLASI;LUCA VALENTI;DARIO CONSONNI;GIACOMO GRASSELLI;FABIO MOSCA;PIETRO LAMPERTICO;ANDREA GORI;ALESSANDRA BANDERA;PAOLO BRAMBILLA;STEFANO CARUGO;DANIELA GALIMBERTI;ANNA LUDOVICA FRACANZANI;WILMA BARCELLINI;MAURIZIO VECCHI;GIACOMO P. COMI;ALESSANDRA IURLO;FRANCESCO GROSSI;DANIELE PRATI;FERRUCCIO CERIOTTI","53;47;45;45;42;37;37;35;34;31;31;31;30;29;28;28;27;27;27;26","FLORA PEYVANDI;DARIO CONSONNI;EDGARDO SOMIGLIANA;FRANCESCO BLASI;STEFANO CARUGO;LUCA VALENTI;WILMA BARCELLINI;FABIO MOSCA;MASSIMILIANO BUOLI;LORENZO PIGNATARO;PIETRO LAMPERTICO;ANNA MARIA IERARDI;EMILIO BERTI;GIACOMO GRASSELLI;STEFANO VERALDI;GIANPAOLO CARRAFIELLO;GIOVANNI MONTINI;ANGELA CECILIA PESATORI;GIOVANNI B. FOGAZZI;MAURIZIO VECCHI","5.64;4.96;4.3;4.1;3.97;3.87;3.41;3.33;3.33;3.17;2.96;2.92;2.81;2.8;2.72;2.67;2.65;2.65;2.64;2.62","ANDREA GORI;E. FERRAZZI;IRENE CETIN;GIACOMO GRASSELLI;FEDERICO PREFUMO;VALERIA SAVASI;PAOLO IVO CAVORETTO;ARIS T. PAPAGEORGHIOU;BABAGANA BAKO;BECKY LIU;CONSTANZA P. SOTO CONTI;D. ORÓS;EDUARDO ALFREDO DURO;ERNAWATI ERNAWATI;JOANNA SICHITIU;JORGE ARTURO CARDONA‐PÉREZ;JOSÉ VILLAR;KHOLIN A.M. KHOLIN;LOÏC SENTILHES;MOHAK MHATRE","2155;1585;1517;1515;1495;1491;1462;1461;1461;1461;1461;1461;1461;1461;1461;1461;1461;1461;1461;1461","ANDREA GORI;E. FERRAZZI;PAOLA ROGGERO;GIACOMO GRASSELLI;LUCA VALENTI;FRANCESCO GROSSI;FRANCESCO BLASI;GIUSEPPE RISTAGNO;STEFANO ALIBERTI;DANIELE PRATI;ANTONIO MUSCATELLO;FLORA PEYVANDI;DANIELA GALIMBERTI;ANNA LUDOVICA FRACANZANI;DARIO CONSONNI;ANTONIO PESENTI;ALESSANDRA BANDERA;ANGELO VALERIO MARZANO;GIANPAOLO CARRAFIELLO;LUCA BALDINI","1992;1563;1236;1162;1149;1115;901;896;783;779;764;752;747;724;697;695;690;657;604;498","FLORA PEYVANDI;FRANCESCO BLASI;DARIO CONSONNI;LUCA VALENTI;GIACOMO GRASSELLI;PIETRO LAMPERTICO;GIANPAOLO CARRAFIELLO;FABIO MOSCA;ANDREA GORI;STEFANO CARUGO;ALESSANDRA BANDERA;ANNA LUDOVICA FRACANZANI;PAOLO BRAMBILLA;WILMA BARCELLINI;MAURIZIO VECCHI;DANIELA GALIMBERTI;LUCA BOERI;ALESSANDRA IURLO;GIACOMO P. COMI;FERRUCCIO CERIOTTI","50;44;44;41;37;35;32;31;31;30;30;30;30;29;28;27;27;27;27;26","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;COMPUTER SCIENCE;CHEMISTRY;MATHEMATICS;ECONOMICS;ENGINEERING;SOCIOLOGY;POLITICAL SCIENCE;PHILOSOPHY;MATERIALS SCIENCE;BUSINESS;GEOGRAPHY;ART;HISTORY;GEOLOGY;ENVIRONMENTAL SCIENCE","1747;535;174;165;120;112;96;81;71;71;69;37;25;21;18;9;9;6;3","INTERNAL MEDICINE;SURGERY;PATHOLOGY;GENETICS;IMMUNOLOGY;GASTROENTEROLOGY;PEDIATRICS;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;PSYCHIATRY;ONCOLOGY;VIROLOGY;BIOCHEMISTRY;RADIOLOGY;CARDIOLOGY;ENDOCRINOLOGY;ANESTHESIA;FAMILY MEDICINE;OPTICS;NURSING","1305;371;361;313;274;233;230;224;184;172;158;148;146;138;118;109;89;87;84;83","DISEASE;GENE;POPULATION;COHORT;CANCER;OUTBREAK;RETROSPECTIVE COHORT STUDY;PREGNANCY;ANTIBODY;LUNG;CONFIDENCE INTERVAL;TRANSPLANTATION;INCIDENCE (GEOMETRY);ADVERSE EFFECT;COHORT STUDY;CHEMOTHERAPY;OBSERVATIONAL STUDY;PROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;HEALTH CARE;LOGISTIC REGRESSION","521;214;199;186;149;117;111;104;93;90;89;86;76;73;73;59;59;59;52;50;50","INFECTIOUS DISEASE (MEDICAL SPECIALTY);2019-20 CORONAVIRUS OUTBREAK;FATTY LIVER;MUTATION;GENE EXPRESSION;HAZARD RATIO;DEMENTIA;LIVER TRANSPLANTATION;PHENOTYPE;GENOTYPE;FETUS;COLORECTAL CANCER;GESTATIONAL AGE;CHRONIC LYMPHOCYTIC LEUKEMIA;IMMUNOTHERAPY;LUNG TRANSPLANTATION;RITUXIMAB;BREAST CANCER;UNIVARIATE ANALYSIS;CLINICAL ENDPOINT;INFERTILITY;SEROLOGY","259;95;42;40;39;37;35;35;35;31;29;28;27;26;24;21;21;20;20;19;19;19","CORONAVIRUS DISEASE 2019 (COVID-19);FRONTOTEMPORAL DEMENTIA;DNA METHYLATION;NONALCOHOLIC FATTY LIVER DISEASE;SINGLE-NUCLEOTIDE POLYMORPHISM;EXOME SEQUENCING;MISSENSE MUTATION;STEATOHEPATITIS;IBRUTINIB;PEMBROLIZUMAB;TRANSCRIPTOME;VENETOCLAX;DEEP BRAIN STIMULATION;PRENATAL DIAGNOSIS;NILOTINIB;ANTIRETROVIRAL THERAPY;MACHINE PERFUSION;SEROPREVALENCE;ATYPICAL HEMOLYTIC UREMIC SYNDROME;DASATINIB;ECULIZUMAB;IGHV@;MYELOPROLIFERATIVE NEOPLASM;PYRUVATE KINASE","258;23;21;17;16;12;12;12;11;11;11;11;10;10;9;8;8;8;7;7;7;7;7;7","HUMANS;;FEMALE;MALE;COVID-19;MIDDLE AGED;ADULT;ITALY;AGED;RETROSPECTIVE STUDIES;SARS-COV-2;PROSPECTIVE STUDIES;CHILD;TREATMENT OUTCOME;AGED, 80 AND OVER;YOUNG ADULT;ADOLESCENT;COHORT STUDIES;RISK FACTORS;CROSS-SECTIONAL STUDIES","919;897;403;357;347;256;245;239;211;191;154;91;90;87;81;78;73;72;68;62","EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;CORONAVIRUS DISEASE 2019;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;CORONAVIRUS DISEASE 2019 RESEARCH;MANAGEMENT AND TREATMENT OF HEMOPHILIA;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;ACUTE MYELOID LEUKEMIA;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;NEUROLOGICAL MANIFESTATIONS OF COVID-19 INFECTION;EFFICACY AND RESISTANCE IN CML TREATMENT;HEPATITIS C INFECTION AND TREATMENT;IMPACT OF COVID-19 INFECTION ON PREGNANCY OUTCOMES;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ORGAN TRANSPLANTATION AND REJECTION;ROLE OF COMPLEMENT SYSTEM IN IMMUNE RESPONSE;CANCER IMMUNOTHERAPY","50;38;35;32;26;25;22;20;19;19;19;19;17;15;15;15;15;15;15;14","PANDEMIC;2019-20 CORONAVIRUS OUTBREAK;TREATMENT;DISCONTINUATION;CROSS-SECTIONAL STUDY;LIVER DISEASE;NAFLD;INTERQUARTILE RANGE;DEPRESSION (ECONOMICS);ETIOLOGY;NEPHROLOGY;NEURODEGENERATION;CLINICAL ENDPOINT;DIAGNOSIS;STEATOSIS;UNIVARIATE ANALYSIS;CYSTIC FIBROSIS;PREGNANCY;CLINICAL CHARACTERISTICS;REFRACTORY (PLANETARY SCIENCE)","120;79;56;33;27;27;26;25;23;23;23;22;21;21;21;21;20;20;17;17","COHORT STUDY;COVID- PANDEMIC;OBSERVATIONAL STUDY;CYSTIC FIBROSIS;LIVER DISEASE;FATTY LIVER;INTENSIVE CARE;MULTIPLE MYELOMA;NORTHERN ITALY;SARS-COV- INFECTION;CROSS-SECTIONAL STUDY;MYELOID LEUKEMIA;RISK FACTORS;HEPATOCELLULAR CARCINOMA;LIVER TRANSPLANTATION;LUNG CANCER;RETROSPECTIVE STUDY;ITALIAN SOCIETY;MULTICENTER STUDY;PROSPECTIVE STUDY;CHRONIC MYELOID;COLORECTAL CANCER;COVID- PATIENTS;PATIENTS TREATED;CHRONIC LYMPHOCYTIC;FRONTOTEMPORAL DEMENTIA;MULTIPLE SCLEROSIS;COVID- OUTBREAK;LUNG TRANSPLANTATION;LYMPHOCYTIC LEUKEMIA","46;45;36;33;31;22;22;22;21;21;19;19;19;18;17;17;17;16;15;15;14;14;14;14;13;13;13;12;12;12","ADVISORY COMMITTEES;ENTITYS BOARD;RESEARCH FUNDING;CONSULTANCY HONORARIA;SPEAKERS BUREAU;LIVER DISEASE;HONORARIA MEMBERSHIP;COVID- PANDEMIC;RISK FACTORS;SARS-COV- INFECTION;CONFIDENCE INTERVAL;HONORARIA RESEARCH;HR CI;INTENSIVE CARE;MEDIAN AGE;CORONAVIRUS DISEASE;CURRENT EMPLOYMENT;PATIENTS TREATED;COVID- PATIENTS;ADVERSE EVENTS;COHORT STUDY;LOGISTIC REGRESSION;DISEASE COVID-;COMMITTEES SPEAKERS;INCREASED RISK;MILAN ITALY;ACUTE RESPIRATORY;CONSULTANCY RESEARCH;JANSSEN CONSULTANCY;ABBVIE CONSULTANCY","403;403;355;310;272;125;124;118;114;114;113;111;105;87;86;82;81;80;76;75;70;70;68;64;64;63;62;61;57;54",1015,0.55,2.85,88.81,10,4526.55199999995,96.07,2,3637,1.93,1,23,2.09,1,19,0,0,0,8.19,1,297,1.75,1,4,1,1,1,1.58,1,4,116.33,2,4379,2.7,1,12,1,1,1,92.37,1,3285,1.1,1,2,2.08,1,10,3.11,1,45,8.21,1,177,76.6,1,2868,9.81,1,191,0,0,0,0,0,0,72.84,2,1400,72.53,2,1400,10,1,3,8,2,1,0,0,0,0,0,0,9,1,5,1.5,2.69230769230769,2,2,9,8,0,1,3,0,0,2,0,0,2,0,1,3,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,10,1,0,2,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"MAZZARO GIOVANNI;PESENTI ANTONIO MARIA;REBULLA PAOLO;ZANELLA ALBERTO;BIANCHI MARIA;MONGUZZI ANGELO MARIA;RANGO MARIO;SQUARCINA LETIZIA;TEOFILI LUCIANA;TORRENTE YVAN","3;3;3;3;2;2;2;2;2;2","FOND IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO;FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO;UNIVERSITA DEGLI STUDI DI MILANO;UNIV DEGLI STUDI MILANO;EPISKEY S R L;EPISKEY SRL;FONDAZIONE IRCCS CA' GRANDA - OSPEDALE MAGGIORE POLICLINICO;FONDAZIONE POLICLINICO UNIV AGOSTINO GEMELLI IRCCS;FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS;MEDITALIA IND S R L","7;7;3;2;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;40 ENGINEERING;46 INFORMATION AND COMPUTING SCIENCES;4601 APPLIED COMPUTING;3215 REPRODUCTIVE MEDICINE;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;34 CHEMICAL SCIENCES;37 EARTH SCIENCES","8;3;3;3;3;2;1;1;1;1","BIOENGINEERING;CLINICAL RESEARCH;DENTAL/ORAL AND CRANIOFACIAL DISEASE;EYE DISEASE AND DISORDERS OF VISION","2;2;1;1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","1","A61M1/36;A61M1/02;A61M1/16;A61M1/34;B01D15/36;A61B13/00;A61J1/20;A61K31/28;A61K33/242;A61K35/28","6;3;3;3;2;1;1;1;1;1","A61M1/0209;A61M1/0272;A61M1/3693;A61M2202/0427;A61M1/1698;A61M1/3486;A61B5/0042;A61B5/0263;A61B5/055;A61J1/10","4;4;4;4;3;3;2;2;2;2",9,963355.56,256302.06,2.55555555555556,6.66666666666667,1.33333333333333,0.555555555555556,9.25,"FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO;BAMBINO GESÙ CHILDREN'S HOSPITAL;CENTRO CLINICO NEMO;UNIVERSITY OF MESSINA;AGOSTINO GEMELLI UNIVERSITY POLYCLINIC;FONDAZIONE STELLA MARIS;IRCCS OSPEDALE SAN RAFFAELE;ISTITUTO GIANNINA GASLINI;UNIVERSITY OF PADUA;FONDAZIONE ISTITUTO NEUROLOGICO NAZIONALE CASIMIRO MONDINO;ISTITUTO DELLE SCIENZE NEUROLOGICHE DI BOLOGNA;OSPEDALE BELLARIA;OSPEDALE REGINA MARGHERITA;UNIVERSITY OF CAMPANIA ""LUIGI VANVITELLI"";UNIVERSITY OF FERRARA;UNIVERSITY OF TURIN;ATOMIC ENERGY AND ALTERNATIVE ENERGIES COMMISSION;CATHOLIC UNIVERSITY OF THE SACRED HEART;DÉLÉGATION PARIS 11;FRENCH NATIONAL CENTRE FOR SCIENTIFIC RESEARCH","9;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;1;1;1;1","TELETHON FOUNDATION;EUROPEAN COMMISSION","8;1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","TELETHON-UILDM CLINICAL PROJECTS 2021 (PROGRAM);H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - LEADERSHIP IN ENABLING AND INDUSTRIAL TECHNOLOGIES - INFORMATION AND COMMUNICATION TECHNOLOGIES (ICT) (PROGRAMME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME);TELETHON SPECIAL PROJECTS - 2020 (PROGRAM)","3;1;1;1","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3105 GENETICS;3202 CLINICAL SCIENCES;50 PHILOSOPHY AND RELIGIOUS STUDIES;5002 HISTORY AND PHILOSOPHY OF SPECIFIC FIELDS","3;3;2;1;1;1","BRAIN DISORDERS;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;DUCHENNE/ BECKER MUSCULAR DYSTROPHY;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);LIVER DISEASE;MUSCULAR DYSTROPHY;PEDIATRIC;RARE DISEASES","1;1;1;1;1;1;1;1;1;1","MUSCULOSKELETAL","1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1;1","LIVER CANCER","1",NA,NA,"A01 CLINICAL MEDICINE;A05 BIOLOGICAL SCIENCES","1;1",NA,NA,137,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;ZENODO;SPRINGER NATURE;KARGER PUBLISHERS;TAYLOR & FRANCIS GROUP;SAGE JOURNALS","54;35;26;12;6;3;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;3105 GENETICS;52 PSYCHOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;49 MATHEMATICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;5203 CLINICAL AND HEALTH PSYCHOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3208 MEDICAL PHYSIOLOGY;3210 NUTRITION AND DIETETICS;46 INFORMATION AND COMPUTING SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3204 IMMUNOLOGY;3215 REPRODUCTIVE MEDICINE;34 CHEMICAL SCIENCES;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES","131;53;33;25;16;12;8;7;6;6;5;5;4;4;4;3;3;3;3;3","CLINICAL RESEARCH;RARE DISEASES;CANCER;PREVENTION;NEUROSCIENCES;GENETICS;PEDIATRIC;BRAIN DISORDERS;DIGESTIVE DISEASES;HEMATOLOGY;LUNG;AUTOIMMUNE DISEASE;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;KIDNEY DISEASE;HUMAN GENOME;NEURODEGENERATIVE;BREAST CANCER;INFECTIOUS DISEASES;NUTRITION;ORPHAN DRUG","38;30;18;16;15;13;13;10;9;9;9;7;7;7;6;6;5;5;5;5","CANCER;NEUROLOGICAL;RENAL AND UROGENITAL;INFECTION;REPRODUCTIVE HEALTH AND CHILDBIRTH;CARDIOVASCULAR;MUSCULOSKELETAL;CONGENITAL;INJURIES AND ACCIDENTS;ORAL AND GASTROINTESTINAL;RESPIRATORY;GENERIC HEALTH RELEVANCE;INFLAMMATORY AND IMMUNE SYSTEM;MENTAL HEALTH;METABOLIC AND ENDOCRINE","8;7;7;4;4;3;3;2;2;2;2;1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.4 SURVEILLANCE AND DISTRIBUTION;5.1 PHARMACEUTICALS","17;9;4;4;1;1","CLINICAL;BIOMEDICAL;HEALTH SERVICES & SYSTEMS;POPULATION & SOCIETY","23;12;6;2","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH;BASIC SCIENCE","63;14;9","LEUKEMIA / LEUKAEMIA;BREAST CANCER;NOT SITE-SPECIFIC CANCER;LIVER CANCER;LUNG CANCER;PANCREATIC CANCER;BRAIN TUMOR;COLON AND RECTAL CANCER;HODGKIN'S DISEASE;NERVOUS SYSTEM;NON-HODGKIN'S LYMPHOMA;SARCOMA","7;5;4;3;3;3;2;2;2;2;2;2","3 GOOD HEALTH AND WELL BEING","2",113,3.32,934.21,55,62.42,2,3,24,3,38,0,4,39,0,80,28,0,0,0,0,0,0,105,5,3,105,5,0,3,0,0,0,0,0,0,"United States;Italy;Germany;Switzerland;Belgium;Japan;United Kingdom;France;Netherlands;Portugal","16;9;4;3;2;2;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;52 PSYCHOLOGY;42 HEALTH SCIENCES;5202 BIOLOGICAL PSYCHOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;4203 HEALTH SERVICES AND SYSTEMS;3207 MEDICAL MICROBIOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3213 PAEDIATRICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;31 BIOLOGICAL SCIENCES;3204 IMMUNOLOGY;3105 GENETICS;3206 MEDICAL BIOTECHNOLOGY;3208 MEDICAL PHYSIOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","110;57;14;12;11;10;8;5;4;4;4;4;4;3;3;2;2;2;2;2","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;HEMATOLOGY;PATIENT SAFETY;PEDIATRIC;CANCER;LUNG;PREVENTION;INFECTIOUS DISEASES;DIGESTIVE DISEASES;BRAIN DISORDERS;CARDIOVASCULAR;LIVER DISEASE;NEUROSCIENCES;TRANSPLANTATION;LYMPHOMA;NEURODEGENERATIVE;BIOENGINEERING;HEART DISEASE","100;74;37;25;22;20;19;18;18;15;11;8;8;8;8;8;7;7;6;6","CANCER;INFECTION;CARDIOVASCULAR;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY;MENTAL HEALTH;ORAL AND GASTROINTESTINAL;EYE;INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL;CONGENITAL;RENAL AND UROGENITAL;BLOOD;METABOLIC AND ENDOCRINE;MUSCULOSKELETAL;SKIN","13;9;8;8;6;4;4;3;3;3;2;2;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.2 CELLULAR AND GENE THERAPIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;3.3 NUTRITION AND CHEMOPREVENTION;3.4 VACCINES;6.3 MEDICAL DEVICES;6.4 SURGERY;6.6 PSYCHOLOGICAL AND BEHAVIOURAL;6.7 PHYSICAL;7.1 INDIVIDUAL CARE NEEDS;7.3 MANAGEMENT AND DECISION MAKING","71;13;5;4;3;2;1;1;1;1;1;1;1;1;1;1","LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;LIVER CANCER;MYELOMA;HODGKIN'S DISEASE;KAPOSI'S SARCOMA;LUNG CANCER;NOT SITE-SPECIFIC CANCER;ANAL CANCER;SARCOMA","10;8;5;3;2;2;2;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","19;2;2;1;1;1"
"IRCCS_CAGRANDA",2022,1875,17.5445333333333,3.2816,0.30472940029254,0.325866666666667,0.3392,0.282133333333333,0.740266666666667,10,778,434,113,84,0.41,0.23,0.06,0.04,8.43,0.944212036450947,0.395733333333333,0.978133333333333,6.80445693635808,0.562277807656696,0.509758806728023,0.499895303854389,0.501631178680258,"FLORA PEYVANDI;WILMA BARCELLINI;ALESSANDRA IURLO;LUCA BOERI;ANDREA SALONIA;DARIO CONSONNI;FRANCESCO BLASI;ALESSANDRA BANDERA;FABIO MOSCA;PIETRO LAMPERTICO;PAOLO BRAMBILLA;STEFANO CARUGO;EDGARDO SOMIGLIANA;GIACOMO GRASSELLI;PAOLO CAPOGROSSO;ANGELO VALERIO MARZANO;EDOARDO POZZI;ANDREA GORI;GIUSEPPE FALLARA;FEDERICO BELLADELLI","50;48;47;44;35;35;34;34;33;33;32;32;32;31;31;30;30;30;30;29","WILMA BARCELLINI;STEFANO CARUGO;FLORA PEYVANDI;EDGARDO SOMIGLIANA;DARIO CONSONNI;BRUNO FATTIZZO;PIER MANNUCCIO MANNUCCI;PAOLA VIGANÒ;ANGELO VALERIO MARZANO;LUCA BOERI;GIANLUCA MARTINO TARTAGLIA;ALESSANDRA IURLO;FABIO MOSCA;CARLO ALFIERI;CARLO AGOSTONI;MARCO RESCHINI;GIUSEPPE CASTELLANO;MASSIMILIANO BUOLI;VALENTINA BOLLATI;GIANLUCA NAZZARO","5.59;5.23;5.05;4.1;4.07;3.86;3.8;3.55;3.41;3.39;3.24;3.23;2.83;2.73;2.68;2.66;2.65;2.59;2.54;2.54","FLORA PEYVANDI;WILMA BARCELLINI;ALESSANDRA IURLO;LUCA BOERI;DARIO CONSONNI;FRANCESCO BLASI;ALESSANDRA BANDERA;FABIO MOSCA;PIETRO LAMPERTICO;PAOLO BRAMBILLA;STEFANO CARUGO;EDGARDO SOMIGLIANA;GIACOMO GRASSELLI;ANGELO VALERIO MARZANO;ANDREA GORI;LUCA ELLI;BRUNO FATTIZZO;DANIELA GALIMBERTI;GIACOMO P. COMI;MAURIZIO VECCHI","50;48;47;44;35;34;34;33;33;32;32;32;31;30;30;29;29;29;28;27","WILMA BARCELLINI;STEFANO CARUGO;FLORA PEYVANDI;EDGARDO SOMIGLIANA;DARIO CONSONNI;BRUNO FATTIZZO;PIER MANNUCCIO MANNUCCI;PAOLA VIGANÒ;ANGELO VALERIO MARZANO;LUCA BOERI;GIANLUCA MARTINO TARTAGLIA;ALESSANDRA IURLO;FABIO MOSCA;CARLO ALFIERI;CARLO AGOSTONI;MARCO RESCHINI;GIUSEPPE CASTELLANO;MASSIMILIANO BUOLI;VALENTINA BOLLATI;GIANLUCA NAZZARO","5.59;5.23;5.05;4.1;4.07;3.86;3.8;3.55;3.41;3.39;3.24;3.23;2.83;2.73;2.68;2.66;2.65;2.59;2.54;2.54","BARBARA BORRONI;BEATRICE AROSIO;LUISA BENUSSI;ANNE BOLAND;ANTONIO DANIELE;BENJAMIN GRENIER‐BOLEY;CÉLINE BELLENGUEZ;FAHRI KÜÇÜKALI;IRIS E. JANSEN;ITZIAR DE ROJAS;MERÇÉ BOADA;PABLO GARCÍA‐GONZÁLEZ;SILVANA ARCHETTI;STÉPHANIE DEBETTE;TEEMU KUULASMAA;VICTORIA ÁLVAREZ;VILMANTAS GIEDRAITIS;CAROLINA DALMASSO;DELPHINE DAIAN;JÜRGEN DECKERT","1327;1260;1257;1236;1236;1236;1236;1236;1236;1236;1236;1236;1236;1236;1236;1236;1236;1235;1235;1235","MARINA ARCARO;SIMONA CICCONE;WILMA BARCELLINI;ALESSANDRA BANDERA;ANDREA GORI;ANGELO VALERIO MARZANO;FRANCESCO BLASI;GIACOMO GRASSELLI;FLORA PEYVANDI;FRANCESCO VIOLA;PAOLO BRAMBILLA;LUCA ELLI;LUCA VALENTI;MASSIMO IAVARONE;DARIO CONSONNI;ALESSANDRA IURLO;ANTONIO PESENTI;LUCA BOERI;GIANLUCA MARTINO TARTAGLIA;MARIA DOMENICA CAPPELLINI","1234;1190;530;515;488;459;426;391;388;374;282;278;268;263;255;251;238;230;226;221","FLORA PEYVANDI;ALESSANDRA IURLO;WILMA BARCELLINI;LUCA BOERI;DARIO CONSONNI;STEFANO CARUGO;PIETRO LAMPERTICO;ALESSANDRA BANDERA;ANGELO VALERIO MARZANO;FABIO MOSCA;GIUSEPPE CASTELLANO;ANDREA GORI;PAOLO BRAMBILLA;FRANCESCO BLASI;LUCA ELLI;EDGARDO SOMIGLIANA;DANIELA GALIMBERTI;MAURIZIO VECCHI;BRUNO FATTIZZO;CARLO ALFIERI","49;47;47;44;35;33;33;30;30;29;29;29;29;29;28;27;25;25;25;24","MEDICINE;BIOLOGY;PSYCHOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;ECONOMICS;ENGINEERING;SOCIOLOGY;MATHEMATICS;POLITICAL SCIENCE;MATERIALS SCIENCE;PHILOSOPHY;BUSINESS;HISTORY;GEOGRAPHY;ART;ENVIRONMENTAL SCIENCE;GEOLOGY","1776;574;172;152;127;112;80;78;75;70;57;29;29;18;14;13;10;5;3","INTERNAL MEDICINE;SURGERY;GENETICS;PATHOLOGY;IMMUNOLOGY;GASTROENTEROLOGY;PEDIATRICS;PSYCHIATRY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;RADIOLOGY;ONCOLOGY;BIOCHEMISTRY;CARDIOLOGY;ENDOCRINOLOGY;VIROLOGY;OPTICS;OBSTETRICS;ANESTHESIA;DERMATOLOGY","1334;400;373;352;301;258;246;203;198;150;137;133;127;122;122;108;93;83;81;78","DISEASE;GENE;COHORT;POPULATION;CANCER;PREGNANCY;RETROSPECTIVE COHORT STUDY;ANTIBODY;TRANSPLANTATION;CONFIDENCE INTERVAL;RANDOMIZED CONTROLLED TRIAL;INCIDENCE (GEOMETRY);ADVERSE EFFECT;CLINICAL TRIAL;LUNG;LOGISTIC REGRESSION;ALTERNATIVE MEDICINE;ANEMIA;VACCINATION;IMMUNE SYSTEM","443;231;205;176;136;134;121;104;87;85;82;80;78;76;76;75;64;64;62;61","INFECTIOUS DISEASE (MEDICAL SPECIALTY);CLINICAL ENDPOINT;2019-20 CORONAVIRUS OUTBREAK;PHENOTYPE;MUTATION;GENE EXPRESSION;BREAST CANCER;HAZARD RATIO;DEMENTIA;GENOTYPE;PLACEBO;INFERTILITY;GESTATIONAL AGE;FATTY LIVER;FETUS;MYELOFIBROSIS;KIDNEY TRANSPLANTATION;COLORECTAL CANCER;LIVER TRANSPLANTATION;CHRONIC LYMPHOCYTIC LEUKEMIA;MICRORNA","179;53;45;42;39;37;36;36;35;35;35;32;29;28;28;26;24;23;23;22;22","CORONAVIRUS DISEASE 2019 (COVID-19);FRONTOTEMPORAL DEMENTIA;RUXOLITINIB;MISSENSE MUTATION;PYRUVATE KINASE;EXOME SEQUENCING;DNA METHYLATION;SINGLE-NUCLEOTIDE POLYMORPHISM;TRANSCRIPTOME;COLONOSCOPY;ECULIZUMAB;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;INEFFECTIVE ERYTHROPOIESIS;NILOTINIB;ATYPICAL HEMOLYTIC UREMIC SYNDROME;IBRUTINIB;MALE INFERTILITY;VENETOCLAX;COLD AGGLUTININ DISEASE;MACHINE PERFUSION;MICROVESICLES","179;19;18;17;17;16;15;13;13;12;11;11;10;10;9;9;9;9;8;8;8","HUMANS;;FEMALE;COVID-19;RETROSPECTIVE STUDIES;MALE;ADULT;CHILD;ITALY;SARS-COV-2;AGED;TREATMENT OUTCOME;MIDDLE AGED;PREGNANCY;PROSPECTIVE STUDIES;MUTATION;ADOLESCENT;INFANT, NEWBORN;INFANT;PANDEMICS","955;890;265;259;199;186;140;114;102;100;86;85;72;71;71;54;51;49;48;47","EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;CORONAVIRUS DISEASE 2019 RESEARCH;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;ACUTE MYELOID LEUKEMIA;CORONAVIRUS DISEASE 2019;DISEASES RELATED TO BLOOD GROUP VARIANTS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;MECHANOSENSITIVE ION CHANNELS IN PHYSIOLOGY AND DISEASE;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;EPIDEMIOLOGY AND MANAGEMENT OF SEXUAL DYSFUNCTION;MANAGEMENT AND TREATMENT OF HEMOPHILIA;HEPATITIS C INFECTION AND TREATMENT;ROLE OF COMPLEMENT SYSTEM IN IMMUNE RESPONSE;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA","40;38;28;27;26;25;24;24;22;22;20;20;18;18;17;17;16;16;13;13","PANDEMIC;CLINICAL ENDPOINT;TREATMENT;2019-20 CORONAVIRUS OUTBREAK;DISCONTINUATION;CROSS-SECTIONAL STUDY;INTERQUARTILE RANGE;DEPRESSION (ECONOMICS);VACCINES;CONCOMITANT;NAFLD;NEPHROLOGY;TRANSFUSION THERAPY;NEUROIMAGING DATA ANALYSIS;REGIMEN;SINGLE CENTER;POSITIVE END-EXPIRATORY PRESSURE;UNIVARIATE ANALYSIS;CYSTIC FIBROSIS;RUXOLITINIB","74;53;39;37;35;30;27;25;24;23;23;23;22;21;21;21;20;20;19;18","COHORT STUDY;OBSERVATIONAL STUDY;CYSTIC FIBROSIS;RISK FACTORS;SARS-COV- INFECTION;COVID- PANDEMIC;CROSS-SECTIONAL STUDY;KINASE DEFICIENCY;MYELOID LEUKEMIA;NORTHERN ITALY;PATIENTS TREATED;PYRUVATE KINASE;BREAST CANCER;CLINICAL PRACTICE;LIVER TRANSPLANTATION;RETROSPECTIVE STUDY;CHRONIC LYMPHOCYTIC;LIVER DISEASE;LYMPHOCYTIC LEUKEMIA;CANCER PATIENTS;FRONTOTEMPORAL DEMENTIA;HEPATOCELLULAR CARCINOMA;INTENSIVE CARE;ITALIAN SOCIETY;KIDNEY DISEASE;MULTIPLE MYELOMA;CLINICAL OUTCOMES;COVID- PATIENTS;KIDNEY TRANSPLANT;MULTICENTER STUDY","33;33;31;22;21;20;20;17;17;17;17;17;16;16;16;16;15;15;15;14;14;14;14;14;14;14;13;13;13;13","RISK FACTORS;SARS-COV- INFECTION;ADVERSE EVENTS;MEDIAN AGE;PK DEFICIENCY;VIEW LARGEDOWNLOAD;PATIENTS TREATED;HR CI;COVID- PANDEMIC;LOGISTIC REGRESSION;INTENSIVE CARE;STATISTICALLY SIGNIFICANT;CLINICAL PRACTICE;SIGNIFICANT DIFFERENCES;LIVER DISEASE;INCREASED RISK;CLINICAL TRIALS;PRIMARY ENDPOINT;COHORT STUDY;CONFIDENCE INTERVAL;ACUTE RESPIRATORY;MEDIAN FOLLOW-UP;OBSERVATIONAL STUDY;RETROSPECTIVE STUDY;BONE MARROW;CLOSE MODAL;FIGURE VIEW;KIDNEY DISEASE;LARGEDOWNLOAD PPT;LARGEDOWNLOAD PPTFIGURE","133;117;106;102;102;92;90;89;84;78;67;65;64;64;63;60;59;59;58;54;52;52;52;49;46;46;46;46;46;46",890,0.47,2.05,58.53,8.5,2577.25,49.61,1,3082,1.33,1,6,1.51,1,11,0,0,0,7.12,1,277,1,1,1,1,1,1,1,1,1,58.42,1,3488,1.86,1,4,1,1,1,46.59,1,3008,1,1,1,1.43,1,4,2.24,1,38,6,1,71,35.47,1,2705,7.99,1,193,0,0,0,0,0,0,30.95,0,1014,30.95,0,1014,10,0,0,3,10,6,0,0,0,0,0,0,11,6,2,0,3.26315789473684,2.15789473684211,2,13,8,2,0,6,0,0,4,0,3,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,10,0,0,4,0,3,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"REBULLA PAOLO;NIZZARDO MONICA;MAZZARO GIOVANNI;BIANCHI MARIA;CORTI STEFANIA;FOUST KEVIN;LIKHITE SHIBI;PESENTI ANTONIO MARIA;TEOFILI LUCIANA;ZANELLA ALBERTO","6;5;4;3;3;3;3;3;3;3","FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO;UNIVERSITA DEGLI STUDI DI MILANO;UNIVERSITA CATTOLICA DEL SACRO CUORE;FOND IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO;FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS;MEDITALIA INDUSTRIALE SRL;RESEARCH INSTITUTE AT NATIONWIDE CHILDRENS HOSPITAL;UNIVERSITA DEGLI STUDI DI MILANO BICOCCA;EPISKEY S R L;EPISKEY SRL","16;5;3;2;2;2;2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;40 ENGINEERING;3206 MEDICAL BIOTECHNOLOGY;3215 REPRODUCTIVE MEDICINE;3101 BIOCHEMISTRY AND CELL BIOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;34 CHEMICAL SCIENCES;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3005 FISHERIES SCIENCES","19;5;4;3;3;2;2;2;1;1","BIOENGINEERING;CLINICAL RESEARCH;ACQUIRED COGNITIVE IMPAIRMENT;AGING;ALZHEIMER'S DISEASE;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD);BRAIN DISORDERS;DEMENTIA;HEMATOLOGY;NEURODEGENERATIVE","3;3;2;2;2;2;2;2;2;2","5.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","3;2","A61M1/36;A61M1/02;A61M1/16;A61M1/34;A61P13/12;B01D15/36;C07K14/435;C12N15/87;A61K31/55;A61K35/51","6;4;3;3;3;3;3;3;2;2","A61M1/0209;A61M1/0272;A61M1/3693;A61M2202/0427;A61K45/06;A61K48/005;A61K48/0066;A61M1/0218;A61M1/1698;A61M1/3486","5;5;5;5;3;3;3;3;3;3",5,5783688.67,591836.51,2.75,6.8,5,0.8,4.75,"FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO;BARCELONA INSTITUTE FOR GLOBAL HEALTH;AFRICAN FIELD EPIDEMIOLOGY NETWORK;AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT;ARAB AMERICAN UNIVERSITY;CATHOLIC UNIVERSITY OF THE SACRED HEART;DRUGS FOR NEGLECTED DISEASES INITIATIVE;DÉLÉGATION PARIS 11;HANNOVER MEDICAL SCHOOL;HELMHOLTZ CENTRE FOR INFECTION RESEARCH;HOSPITAL CLÍNIC DE BARCELONA;INSTITUT CATALÀ DE LA SALUT;INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL;IRCCS OSPEDALE SAN RAFFAELE;KAROLINSKA INSTITUTET;LABORATOIRE NATIONAL DE SANTÉ;MANHIÇA HEALTH RESEARCH CENTRE;NIGERIA CENTRE FOR DISEASE CONTROL;NORWEGIAN INSTITUTE OF PUBLIC HEALTH;OSWALDO CRUZ FOUNDATION","5;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;DEUTSCHE FORSCHUNGSGEMEINSCHAFT;ITALIAN ASSOCIATION FOR CANCER RESEARCH","3;1;1","COALITION S;EC & ERC - EUROPEAN UNION;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP","3;3;1","HORIZON-RIA - HORIZON  RESEARCH AND INNOVATION ACTIONS (FUNDING SCHEME);HORIZON.2.1 - HEALTH (PROGRAMME);EU4HEALTH PROGRAMME (EU4H) (PROGRAMME);HORIZON-HLTH-2021-CORONA-01 (CALL FOR PROPOSAL);HORIZON-HLTH-2021-DISEASE-04 (CALL FOR PROPOSAL);RESEARCH GRANTS (DFG PROGRAMME)","2;2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;44 HUMAN SOCIETY;4404 DEVELOPMENT STUDIES","3;2;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CHRONIC LIVER DISEASE AND CIRRHOSIS;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;INFECTIOUS DISEASES;LIVER DISEASE;PREVENTION;RARE DISEASES;GENETICS;HEMATOLOGY;HEPATITIS;HEPATITIS - B;IMMUNIZATION;VACCINE RELATED;CANCER;GENETIC TESTING;HEALTH SERVICES;HEPATITIS - C;HIV/AIDS;HUMAN GENOME","4;3;3;3;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1","INFECTION;CANCER","3;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.3 INFLUENCES AND IMPACT","3;2;2;1","LIVER CANCER;MYELOMA","2;1","1.4 CANCER PROGRESSION AND METASTASIS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY","1;1;1","A01 CLINICAL MEDICINE;A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE","3;2","3 GOOD HEALTH AND WELL BEING","3",165,"FRONTIERS;PUBLIC LIBRARY OF SCIENCE;ZENODO;SPRINGER NATURE;KARGER PUBLISHERS;TAYLOR & FRANCIS GROUP","77;47;20;15;4;2","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;3105 GENETICS;52 PSYCHOLOGY;3207 MEDICAL MICROBIOLOGY;4203 HEALTH SERVICES AND SYSTEMS;3204 IMMUNOLOGY;44 HUMAN SOCIETY;3215 REPRODUCTIVE MEDICINE;5202 BIOLOGICAL PSYCHOLOGY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3009 VETERINARY SCIENCES;3107 MICROBIOLOGY;34 CHEMICAL SCIENCES","165;64;27;25;23;21;13;12;9;8;7;7;6;6;5;4;3;3;3;3","CLINICAL RESEARCH;PREVENTION;GENETICS;NEUROSCIENCES;LUNG;INFECTIOUS DISEASES;VACCINE RELATED;EMERGING INFECTIOUS DISEASES;BIODEFENSE;BRAIN DISORDERS;RARE DISEASES;BIOTECHNOLOGY;PNEUMONIA;PNEUMONIA & INFLUENZA;CANCER;PEDIATRIC;CARDIOVASCULAR;NEURODEGENERATIVE;HUMAN GENOME;PATIENT SAFETY","54;32;27;25;23;22;22;20;18;17;17;14;14;14;12;12;11;11;10;10","INFECTION;NEUROLOGICAL;CANCER;CARDIOVASCULAR;MENTAL HEALTH;REPRODUCTIVE HEALTH AND CHILDBIRTH;INFLAMMATORY AND IMMUNE SYSTEM;MUSCULOSKELETAL;RENAL AND UROGENITAL;RESPIRATORY;GENERIC HEALTH RELEVANCE;ORAL AND GASTROINTESTINAL;SKIN;BLOOD;EYE;STROKE","19;13;10;10;7;5;3;3;3;3;2;2;2;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.1 PHARMACEUTICALS;3.4 VACCINES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.4 SURVEILLANCE AND DISTRIBUTION;5.1 PHARMACEUTICALS;2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);3.3 NUTRITION AND CHEMOPREVENTION;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;7.3 MANAGEMENT AND DECISION MAKING;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.3 PSYCHOLOGICAL, SOCIAL AND ECONOMIC FACTORS;6.6 PSYCHOLOGICAL AND BEHAVIOURAL;6.7 PHYSICAL;7.1 INDIVIDUAL CARE NEEDS","39;7;6;5;4;4;2;2;2;2;1;1;1;1;1","CLINICAL;BIOMEDICAL;POPULATION & SOCIETY;HEALTH SERVICES & SYSTEMS","41;39;6;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH;HEALTH SERVICES RESEARCH","72;22;8;2","COLON AND RECTAL CANCER;BREAST CANCER;LEUKEMIA / LEUKAEMIA;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;LUNG CANCER","4;3;3;2;2;1","3 GOOD HEALTH AND WELL BEING","9",88,2.72,1251.28,26,51.45,5,2,18,4,19,0,4,36,0,66,21,0,0,0,0,0,0,79,7,2,86,1,0,1,0,0,0,0,0,0,"Italy;United States;Germany;Japan;United Kingdom;Austria;Denmark;France;Greece;Malaysia","22;20;4;4;2;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3107 MICROBIOLOGY;3208 MEDICAL PHYSIOLOGY;3215 REPRODUCTIVE MEDICINE;4203 HEALTH SERVICES AND SYSTEMS;3204 IMMUNOLOGY;4206 PUBLIC HEALTH;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3009 VETERINARY SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3105 GENETICS;3205 MEDICAL BIOCHEMISTRY AND METABOLOMICS","82;49;13;11;8;7;6;5;4;3;3;3;3;2;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;LUNG;HEMATOLOGY;PREVENTION;CANCER;NEUROSCIENCES;PATIENT SAFETY;DIGESTIVE DISEASES;CARDIOVASCULAR;NUTRITION;AGING;BRAIN DISORDERS;PEDIATRIC;EMERGING INFECTIOUS DISEASES;MENTAL HEALTH;AUTOIMMUNE DISEASE;CONTRACEPTION/REPRODUCTION;ENDOMETRIOSIS","85;60;30;17;14;14;13;13;13;12;10;9;8;8;8;7;7;6;6;6","CANCER;CARDIOVASCULAR;MENTAL HEALTH;REPRODUCTIVE HEALTH AND CHILDBIRTH;INFECTION;ORAL AND GASTROINTESTINAL;NEUROLOGICAL;RESPIRATORY;CONGENITAL;INFLAMMATORY AND IMMUNE SYSTEM;RENAL AND UROGENITAL;METABOLIC AND ENDOCRINE;SKIN;BLOOD;EYE;GENERIC HEALTH RELEVANCE;MUSCULOSKELETAL;STROKE","9;9;7;7;6;6;5;5;3;3;3;2;2;1;1;1;1;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;7.1 INDIVIDUAL CARE NEEDS;2.4 SURVEILLANCE AND DISTRIBUTION;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;3.4 VACCINES;5.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;6.6 PSYCHOLOGICAL AND BEHAVIOURAL;7.3 MANAGEMENT AND DECISION MAKING","47;10;6;6;2;2;2;1;1;1;1;1;1;1","NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;ENDOMETRIAL CANCER;LEUKEMIA / LEUKAEMIA;LIVER CANCER;MYELOMA;ESOPHAGEAL / OESOPHAGEAL CANCER;LUNG CANCER;OVARIAN CANCER","5;5;4;4;3;3;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;3.1 INTERVENTIONS TO PREVENT CANCER: PERSONAL BEHAVIORS THAT AFFECT CANCER RISK;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","14;3;3;2;2;1"
"IRCCS_CAGRANDA",2023,1816,17.9069383259912,3.04240088105727,0.32868778280543,0.307819383259912,0.329295154185022,0.260462555066079,0.734581497797357,11,804,362,100,116,0.44,0.2,0.06,0.06,4.46,1.01850695014164,0.456497797356828,0.975770925110132,6.29318936877063,0.575572335771747,0.534264059753954,0.533417322219455,0.53675941912001,"FLORA PEYVANDI;FRANCESCO BLASI;ANGELO VALERIO MARZANO;WILMA BARCELLINI;PAOLO BRAMBILLA;ALESSANDRA IURLO;EDGARDO SOMIGLIANA;GIACOMO P. COMI;LUCA VALENTI;DARIO CONSONNI;FABIO MOSCA;GIACOMO GRASSELLI;MASSIMILIANO BUOLI;PIETRO LAMPERTICO;SANTI TRIMARCHI;NICOLA FRACCHIOLLA;ANDREA GRAMEGNA;ALESSANDRA BANDERA;PAOLA VIGANÒ;DANIELA GALIMBERTI","63;56;50;44;43;40;33;32;32;32;32;31;30;30;28;27;27;27;27;27","FLORA PEYVANDI;PIER MANNUCCIO MANNUCCI;FRANCESCO BLASI;ANGELO VALERIO MARZANO;EDGARDO SOMIGLIANA;WILMA BARCELLINI;MASSIMILIANO BUOLI;PAOLA VIGANÒ;DARIO CONSONNI;PAOLO BRAMBILLA;STEFANO CARUGO;BRUNO FATTIZZO;ANDREA GRAMEGNA;SANTI TRIMARCHI;CHIARA MOLTRASIO;STEFANO VERALDI;ALESSIO DI FONZO;GIANFRANCO ALICANDRO;GIACOMO P. COMI;ALESSANDRA BANDERA","7.23;6.15;5.72;5.35;4.45;4.34;4.09;3.74;3.46;3.41;3;2.78;2.77;2.76;2.74;2.73;2.71;2.62;2.59;2.48","FLORA PEYVANDI;FRANCESCO BLASI;ANGELO VALERIO MARZANO;WILMA BARCELLINI;PAOLO BRAMBILLA;ALESSANDRA IURLO;EDGARDO SOMIGLIANA;GIACOMO P. COMI;LUCA VALENTI;DARIO CONSONNI;FABIO MOSCA;GIACOMO GRASSELLI;MASSIMILIANO BUOLI;PIETRO LAMPERTICO;SANTI TRIMARCHI;NICOLA FRACCHIOLLA;ANDREA GRAMEGNA;ALESSANDRA BANDERA;PAOLA VIGANÒ;DANIELA GALIMBERTI","63;56;50;44;43;40;33;32;32;32;32;31;30;30;28;27;27;27;27;27","FLORA PEYVANDI;PIER MANNUCCIO MANNUCCI;FRANCESCO BLASI;ANGELO VALERIO MARZANO;EDGARDO SOMIGLIANA;WILMA BARCELLINI;MASSIMILIANO BUOLI;PAOLA VIGANÒ;DARIO CONSONNI;PAOLO BRAMBILLA;STEFANO CARUGO;BRUNO FATTIZZO;ANDREA GRAMEGNA;SANTI TRIMARCHI;CHIARA MOLTRASIO;STEFANO VERALDI;ALESSIO DI FONZO;GIANFRANCO ALICANDRO;GIACOMO P. COMI;ALESSANDRA BANDERA","7.23;6.15;5.72;5.35;4.45;4.34;4.09;3.74;3.46;3.41;3;2.78;2.77;2.76;2.74;2.73;2.71;2.62;2.59;2.48","GIACOMO GRASSELLI;LISE PIQUILLOUD;GIACOMO BELLANI;JORDI MANCEBO;LAURENT BROCHARD;ANTONIO PESENTI;JOHN G. LAFFEY;LUIGI CAMPOROTA;JEREMY R. BEITLER;HAIBO QIU;ALAIN MERCAT;CLAUDE GUÉRIN;MARCELO B. P. AMATO;MASSIMO ANTONELLI;LUCA VALENTI;JEAN‐PIERRE FRAT;SHEILA NAINAN MYATRA;ÉLIE AZOULAY;DANIEL BRODIE;ALAIN COMBES","622;469;462;449;449;439;413;413;397;388;352;352;352;340;334;332;332;332;330;326","GIACOMO GRASSELLI;LUCA VALENTI;FRANCESCO BLASI;FLORA PEYVANDI;ANGELO VALERIO MARZANO;ALESSANDRA IURLO;PAOLO VERCELLINI;SALVATORE SIENA;ANDREA SCHLEGEL;PIETRO LAMPERTICO;DANIELA GALIMBERTI;NICOLA FRACCHIOLLA;MARCO MAGGIONI;PAOLO MUIESAN;SANTI TRIMARCHI;SILVIA FERRUCCI;MAURIZIO VECCHI;FABIO MOSCA;CAMILLA MENIS;ANTONIO PESENTI","599;280;262;261;252;231;217;198;171;163;161;143;135;132;130;128;127;124;120;118","FLORA PEYVANDI;FRANCESCO BLASI;ANGELO VALERIO MARZANO;WILMA BARCELLINI;ALESSANDRA IURLO;PAOLO BRAMBILLA;DARIO CONSONNI;GIACOMO P. COMI;EDGARDO SOMIGLIANA;LUCA VALENTI;PIETRO LAMPERTICO;FABIO MOSCA;GIACOMO GRASSELLI;NICOLA FRACCHIOLLA;DANIELA GALIMBERTI;PAOLA VIGANÒ;SANTI TRIMARCHI;ALESSANDRA BANDERA;ANDREA GRAMEGNA;STEFANO CARUGO","58;55;47;44;40;38;34;30;29;28;28;27;27;27;26;26;26;25;24;24","MEDICINE;BIOLOGY;PSYCHOLOGY;COMPUTER SCIENCE;PHYSICS;CHEMISTRY;MATHEMATICS;ENGINEERING;ECONOMICS;POLITICAL SCIENCE;SOCIOLOGY;PHILOSOPHY;MATERIALS SCIENCE;BUSINESS;GEOGRAPHY;ART;HISTORY;GEOLOGY;ENVIRONMENTAL SCIENCE","1716;542;164;135;131;129;77;73;65;60;60;34;31;23;10;9;6;4;3","INTERNAL MEDICINE;SURGERY;GENETICS;PATHOLOGY;IMMUNOLOGY;GASTROENTEROLOGY;PEDIATRICS;PSYCHIATRY;ENVIRONMENTAL HEALTH;ONCOLOGY;INTENSIVE CARE MEDICINE;BIOCHEMISTRY;RADIOLOGY;CARDIOLOGY;ENDOCRINOLOGY;DERMATOLOGY;NURSING;FAMILY MEDICINE;VIROLOGY;ANESTHESIA","1310;379;328;313;270;263;233;196;181;168;151;141;131;112;106;96;77;76;75;73","DISEASE;GENE;COHORT;POPULATION;CANCER;PREGNANCY;ADVERSE EFFECT;RETROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;TRANSPLANTATION;CONFIDENCE INTERVAL;ANTIBODY;LUNG;CHEMOTHERAPY;CLINICAL TRIAL;IMMUNE SYSTEM;PROSPECTIVE COHORT STUDY;OBSERVATIONAL STUDY;INCIDENCE (GEOMETRY);ANEMIA","359;219;187;161;149;110;104;101;87;87;85;84;82;79;77;67;67;66;65;64","INFECTIOUS DISEASE (MEDICAL SPECIALTY);CLINICAL ENDPOINT;PHENOTYPE;MUTATION;HAZARD RATIO;PLACEBO;BREAST CANCER;LIVER TRANSPLANTATION;GENE EXPRESSION;DEMENTIA;GESTATIONAL AGE;FATTY LIVER;IMMUNOTHERAPY;TOLERABILITY;2019-20 CORONAVIRUS OUTBREAK;COLORECTAL CANCER;CHRONIC LYMPHOCYTIC LEUKEMIA;FETUS;INFERTILITY;MYELOFIBROSIS","94;54;49;42;41;39;38;37;35;32;32;31;29;28;27;27;26;26;25;25","CORONAVIRUS DISEASE 2019 (COVID-19);FRONTOTEMPORAL DEMENTIA;RUXOLITINIB;DNA METHYLATION;IVACAFTOR;EXOME SEQUENCING;NIVOLUMAB;TRANSCRIPTOME;VENETOCLAX;HBSAG;MISSENSE MUTATION;NONALCOHOLIC FATTY LIVER DISEASE;IBRUTINIB;MACHINE PERFUSION;VON WILLEBRAND DISEASE;PYRUVATE KINASE;COLONOSCOPY;DASATINIB;IGHV@;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;NILOTINIB","94;19;19;17;17;15;15;14;14;12;12;12;11;11;11;10;9;9;9;9;9","HUMANS;;FEMALE;RETROSPECTIVE STUDIES;MALE;COVID-19;ADULT;CHILD;ITALY;PROSPECTIVE STUDIES;TREATMENT OUTCOME;AGED;MIDDLE AGED;SARS-COV-2;INFANT, NEWBORN;PREGNANCY;CROSS-SECTIONAL STUDIES;ADOLESCENT;INFANT;BIOMARKERS","902;894;224;168;149;134;131;96;94;84;84;71;70;56;54;51;50;49;48;46","THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;MANAGEMENT AND TREATMENT OF HEMOPHILIA;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ACUTE MYELOID LEUKEMIA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;DISEASES RELATED TO BLOOD GROUP VARIANTS;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;HEPATOCELLULAR CARCINOMA;ATOPIC DERMATITIS AND SKIN MICROBIOME;EFFICACY AND RESISTANCE IN CML TREATMENT;HEPATITIS B INFECTION AND TREATMENT;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;CORONAVIRUS DISEASE 2019;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;ORGAN TRANSPLANTATION AND REJECTION;CANCER IMMUNOTHERAPY;CORONAVIRUS DISEASE 2019 RESEARCH;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA","45;38;35;30;27;26;25;20;20;19;18;18;17;16;15;15;15;14;14;14","TREATMENT;CLINICAL ENDPOINT;PANDEMIC;DISCONTINUATION;CROSS-SECTIONAL STUDY;REGIMEN;TOLERABILITY;LIVER DISEASE;2019-20 CORONAVIRUS OUTBREAK;CONCOMITANT;INTERQUARTILE RANGE;TRANSFUSION THERAPY;MYELOFIBROSIS;RUXOLITINIB;CLINICAL PRACTICE;CYSTIC FIBROSIS;DEPRESSION (ECONOMICS);NEUROIMAGING DATA ANALYSIS;DELPHI METHOD;DIAGNOSIS","70;56;49;39;31;29;28;23;22;22;22;21;20;19;18;18;18;18;17;17","COHORT STUDY;CYSTIC FIBROSIS;MYELOID LEUKEMIA;OBSERVATIONAL STUDY;HEPATOCELLULAR CARCINOMA;BREAST CANCER;LIVER DISEASE;CROSS-SECTIONAL STUDY;CHRONIC HEPATITIS;PATIENTS TREATED;ACUTE MYELOID;ATOPIC DERMATITIS;CLINICAL TRIAL;RISK FACTORS;CLINICAL PRACTICE;STEM CELL;VON WILLEBRAND;ENDOVASCULAR AORTIC;FRONTOTEMPORAL DEMENTIA;LIVER TRANSPLANTATION;MACHINE LEARNING;RETROSPECTIVE STUDY;BRAIN INJURY;CHRONIC MYELOID;COVID- PANDEMIC;FATTY LIVER;HIDRADENITIS SUPPURATIVA;MULTICENTER STUDY;MULTIPLE MYELOMA;AGGLUTININ DISEASE","44;39;31;29;27;24;23;20;19;19;18;18;16;16;15;15;15;14;14;14;14;14;13;13;13;13;13;13;13;12","RISK FACTORS;ADVERSE EVENTS;HR CI;MEDIAN AGE;PATIENTS TREATED;CLINICAL PRACTICE;PUBMED SCOPUS;PATIENTS RECEIVED;STATISTICALLY SIGNIFICANT;LIVER DISEASE;CONFIDENCE INTERVAL;MEDIAN FOLLOW-UP;LOGISTIC REGRESSION;PATIENTS RECEIVING;BONE MARROW;ADULT PATIENTS;DISEASE PROGRESSION;HB GDL;SIGNIFICANT DIFFERENCES;INCREASED RISK;COHORT STUDY;MEDIAN TIME;CLINICAL TRIALS;MILAN ITALY;INTENSIVE CARE;OBSERVATIONAL STUDY;DISEASE ACTIVITY;HAZARD RATIO;PRIMARY ENDPOINT;SARS-COV- INFECTION","135;131;119;119;114;97;74;69;66;65;63;62;61;61;60;58;57;57;57;56;55;55;54;54;52;52;50;50;50;50",740,0.41,2.2,79.77,8.95,2223.746,54.95,2,1325,1.54,1,10,1.82,1,5,0,0,0,11.96,1,282,0,0,0,1,1,1,1,1,1,66.57,2,1896,2.6,1,6,1,1,1,48.03,1,1312,1.33,1,2,1,1,1,1.99,1,15,7.47,1,169,35.9,1,1038,7.6,1,90,0,0,0,0,0,0,16.6,0,312,16.6,0,312,9,0,0,3,5,3,0,0,0,0,0,0,6,2,3,1,2.72727272727273,1.72727272727273,2,6,6,0,0,2,0,0,5,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,5,2,0,2,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"PESENTI ANTONIO MARIA;PEYVANDI FLORA;SPENA SILVIA;ZANELLA ALBERTO;ARDISSINO GIANLUIGI;CORTI STEFANIA PAOLA;DEBORA LATTUADA;FOUST KEVIN;KASPAR BRIAN K;LIKHITE SHIBI","2;2;2;2;1;1;1;1;1;1","FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO;UNIVERSITA DEGLI STUDI DI MILANO;FOND IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO;EPISKEY S R L;FOND LUIGI VILLA;FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO;FONDAZIONE IRCCS CA'GRANDA OSPEDALE MAGGIORE POLICILINICO;FONDAZIONE LUIGI VILLA;RESEARCH INSTITUTE AT NATIONWIDE CHILDRENS HOSPITAL","8;3;2;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3206 MEDICAL BIOTECHNOLOGY;40 ENGINEERING;3107 MICROBIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3203 DENTISTRY","10;7;2;2;2;2;1;1;1;1","BRAIN DISORDERS;GENETICS;CONDITIONS AFFECTING THE EMBRYONIC AND FETAL PERIODS;DENTAL/ORAL AND CRANIOFACIAL DISEASE;GENE THERAPY;HIV/AIDS;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);PEDIATRIC;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;RARE DISEASES","2;2;1;1;1;1;1;1;1;1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;5.2 CELLULAR AND GENE THERAPIES","2;1","A61M1/36;A61K48/00;A61M1/16;A61M1/34;B01D15/36;G01N33/68;A61B1/24;A61B1/32;A61B5/00;A61B5/026","3;2;2;2;2;2;1;1;1;1","A61K45/06;A61K48/005;A61K48/0066;A61M1/1698;A61M1/3434;A61M1/3468;A61M1/3486;A61M1/3672;B01D15/362;B01D15/363","2;2;2;2;2;2;2;2;2;2",3,7343423,634369.36,3,7.66666666666667,3.66666666666667,0.666666666666667,8.5,"FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO;ACADEMIC MEDICAL CENTER;ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS;CHAMPALIMAUD FOUNDATION;CLAUDE BERNARD UNIVERSITY LYON 1;DÉLÉGATION PARIS 11;EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER (SWITZERLAND);EUROPEAN RESEARCH AND PROJECT OFFICE;FINOVATIS (FRANCE);FRENCH NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;NANION (GERMANY);PARIS 13 UNIVERSITY;SAARLAND UNIVERSITY;SANQUIN;SORBONNE UNIVERSITY;TU DRESDEN;UNIVERSITY MEDICAL CENTER UTRECHT;UNIVERSITY OF MILAN;UNIVERSITÉ LIBRE DE BRUXELLES;UNIVERSITÉ PARIS-CITÉ","3;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;ITALIAN ASSOCIATION FOR CANCER RESEARCH","2;1","COALITION S;EC & ERC - EUROPEAN UNION;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP","2;2;1","HORIZON-MISS-2021-CANCER-02 (CALL FOR PROPOSAL);HORIZON-MSCA-2022-DN-01 (CALL FOR PROPOSAL);HORIZON-RIA - HORIZON  RESEARCH AND INNOVATION ACTIONS (FUNDING SCHEME);HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA DOCTORAL NETWORKS (FUNDING SCHEME);HORIZON.1.2 - MARIE SKŁODOWSKA-CURIE ACTIONS (MSCA) (PROGRAMME);HORIZON.2.1 - HEALTH (PROGRAMME)","1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3208 MEDICAL PHYSIOLOGY;42 HEALTH SCIENCES","3;2;1;1","CANCER;CLINICAL RESEARCH;GENETICS;HEMATOLOGY;RARE DISEASES;ALCOHOLISM, ALCOHOL USE AND HEALTH;CHRONIC LIVER DISEASE AND CIRRHOSIS;DIGESTIVE DISEASES;HEPATITIS;HUMAN GENOME;LIVER CANCER;LIVER DISEASE;NUTRITION;PREVENTION;SUBSTANCE MISUSE","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CANCER","2","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","3;1;1;1;1","LIVER CANCER;MYELOMA","1;1","2.3 INTERACTIONS OF GENES AND/OR GENETIC POLYMORPHISMS WITH EXOGENOUS AND/OR ENDOGENOUS FACTORS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","1;1","A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;A01 CLINICAL MEDICINE","2;1",NA,NA,95,"FRONTIERS;PUBLIC LIBRARY OF SCIENCE;ZENODO;SPRINGER NATURE;KARGER PUBLISHERS;TAYLOR & FRANCIS GROUP;LOUGHBOROUGH UNIVERSITY","39;30;12;8;3;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;51 PHYSICAL SCIENCES;4206 PUBLIC HEALTH;3211 ONCOLOGY AND CARCINOGENESIS;3215 REPRODUCTIVE MEDICINE;44 HUMAN SOCIETY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3105 GENETICS;3204 IMMUNOLOGY;34 CHEMICAL SCIENCES;5105 MEDICAL AND BIOLOGICAL PHYSICS;52 PSYCHOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3208 MEDICAL PHYSIOLOGY;3210 NUTRITION AND DIETETICS;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;40 ENGINEERING","116;31;23;22;9;8;7;7;6;5;5;5;4;4;4;3;2;2;2;2","CLINICAL RESEARCH;GENETICS;PREVENTION;RARE DISEASES;CANCER;PEDIATRIC;AUTOIMMUNE DISEASE;HEMATOLOGY;DIGESTIVE DISEASES;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;NEUROSCIENCES;OBESITY;INFECTIOUS DISEASES;NEURODEGENERATIVE;BIOMEDICAL IMAGING;BIOTECHNOLOGY;BRAIN DISORDERS;BREAST CANCER;EMERGING INFECTIOUS DISEASES;INFANT MORTALITY","36;15;15;15;14;13;8;8;7;6;6;6;5;5;4;4;4;4;4;4","INFLAMMATORY AND IMMUNE SYSTEM;CANCER;ORAL AND GASTROINTESTINAL;CARDIOVASCULAR;NEUROLOGICAL;GENERIC HEALTH RELEVANCE;REPRODUCTIVE HEALTH AND CHILDBIRTH;INFECTION;METABOLIC AND ENDOCRINE;MENTAL HEALTH;MUSCULOSKELETAL;SKIN","10;8;6;5;5;4;4;3;2;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;2.4 SURVEILLANCE AND DISTRIBUTION;7.3 MANAGEMENT AND DECISION MAKING;8.1 ORGANISATION AND DELIVERY OF SERVICES;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","24;13;7;3;2;2;1;1;1","CLINICAL;BIOMEDICAL;POPULATION & SOCIETY;HEALTH SERVICES & SYSTEMS","31;13;4;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","42;7;4","NOT SITE-SPECIFIC CANCER;BREAST CANCER;LEUKEMIA / LEUKAEMIA;HEAD AND NECK CANCER;LARYNGEAL CANCER;ORAL CAVITY AND LIP CANCER;PANCREATIC CANCER;PHARYNGEAL CANCER;COLON AND RECTAL CANCER;LIVER CANCER;LUNG CANCER;OVARIAN CANCER;SKIN CANCER","13;4;4;2;2;2;2;2;1;1;1;1;1","3 GOOD HEALTH AND WELL BEING","8",52,2.69,6489.6,7,56.44,1,0,8,0,13,0,1,29,0,31,21,0,0,0,0,0,0,48,3,1,52,0,0,0,0,0,0,0,0,0,"United States;Italy;Germany;Australia;Sweden;Japan;Austria;Netherlands","13;10;6;3;3;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3213 PAEDIATRICS;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3203 DENTISTRY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;4203 HEALTH SERVICES AND SYSTEMS;3101 BIOCHEMISTRY AND CELL BIOLOGY;3107 MICROBIOLOGY;3204 IMMUNOLOGY;3206 MEDICAL BIOTECHNOLOGY;3207 MEDICAL MICROBIOLOGY;3210 NUTRITION AND DIETETICS;3212 OPHTHALMOLOGY AND OPTOMETRY","49;25;8;7;5;4;3;3;3;2;2;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;RARE DISEASES;PEDIATRIC;PREVENTION;LUNG;BRAIN DISORDERS;DIGESTIVE DISEASES;NEUROSCIENCES;AGING;AUTOIMMUNE DISEASE;CANCER;HEMATOLOGY;CARDIOVASCULAR;INFANT MORTALITY;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;PRETERM, LOW BIRTH WEIGHT AND HEALTH OF THE NEWBORN;HEART DISEASE;HEPATITIS","47;30;15;12;10;10;9;7;7;7;6;6;6;6;5;5;5;5;4;4","CARDIOVASCULAR;REPRODUCTIVE HEALTH AND CHILDBIRTH;CANCER;INFECTION;MUSCULOSKELETAL;NEUROLOGICAL;INFLAMMATORY AND IMMUNE SYSTEM;BLOOD;EYE;GENERIC HEALTH RELEVANCE;METABOLIC AND ENDOCRINE;ORAL AND GASTROINTESTINAL;RENAL AND UROGENITAL;SKIN","5;4;3;3;3;3;2;1;1;1;1;1;1;1","6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;3.4 VACCINES;5.2 CELLULAR AND GENE THERAPIES;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;6.6 PSYCHOLOGICAL AND BEHAVIOURAL","28;5;5;4;3;1;1;1;1;1;1;1","LUNG CANCER;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;BRAIN TUMOR;BREAST CANCER;COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;LIVER CANCER","3;2;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.4 COST ANALYSES AND HEALTH CARE DELIVERY","4;2;1;1;1;1"
"IRCCS_CAGRANDA",2024,1566,18.3837803320562,2.95019157088123,0.338961038961039,0.270114942528736,0.30779054916986,0.188378033205619,0.621328224776501,6,764,299,95,84,0.49,0.19,0.06,0.05,0.95,0.994899690067278,0.450191570881226,0.985312899106003,5.11944727812291,0.559099308445948,0.481610872896971,0.491591521865834,0.487850079744817,"ANGELO VALERIO MARZANO;FRANCESCO BLASI;FLORA PEYVANDI;LUCA VALENTI;PIETRO LAMPERTICO;ANDREA GORI;DARIO CONSONNI;SILVIA FERRUCCI;GIACOMO GRASSELLI;ALESSANDRA BANDERA;FLAVIO CAPRIOLI;EDGARDO SOMIGLIANA;STEFANO CARUGO;GREGORIO P. MILANI;FRANCESCO PASSAMONTI;CARLO ALFIERI;LUCA BOERI;CARLO AGOSTONI;SPINELLO ANTINORI;GIACOMO P. COMI","47;43;42;34;32;31;30;30;28;27;27;24;23;21;20;20;20;20;19;19","ANGELO VALERIO MARZANO;FLORA PEYVANDI;DARIO CONSONNI;CARLO AGOSTONI;FRANCESCO BLASI;SILVIA FERRUCCI;BRUNO FATTIZZO;EDGARDO SOMIGLIANA;STEFANO VERALDI;GIACOMO GRASSELLI;GIANLUCA NAZZARO;LUCA VALENTI;GREGORIO P. MILANI;MICHELE GHIDINI;STEFANO CARUGO;CARLO ALFIERI;PIER MANNUCCIO MANNUCCI;ELISA GHERBESI;PAOLA VIGANÒ;ANDREA GORI","5.01;4.31;3.59;3.23;2.99;2.96;2.85;2.85;2.75;2.69;2.66;2.62;2.61;2.51;2.46;2.37;2.31;2.3;2.28;2.25","ANGELO VALERIO MARZANO;FRANCESCO BLASI;FLORA PEYVANDI;LUCA VALENTI;PIETRO LAMPERTICO;ANDREA GORI;DARIO CONSONNI;SILVIA FERRUCCI;GIACOMO GRASSELLI;ALESSANDRA BANDERA;FLAVIO CAPRIOLI;EDGARDO SOMIGLIANA;STEFANO CARUGO;GREGORIO P. MILANI;FRANCESCO PASSAMONTI;CARLO ALFIERI;LUCA BOERI;CARLO AGOSTONI;GIACOMO P. COMI;LORENZO BERETTA","47;43;42;34;32;31;30;30;28;27;27;24;23;21;20;20;20;20;19;19","ANGELO VALERIO MARZANO;FLORA PEYVANDI;DARIO CONSONNI;CARLO AGOSTONI;FRANCESCO BLASI;SILVIA FERRUCCI;BRUNO FATTIZZO;EDGARDO SOMIGLIANA;STEFANO VERALDI;GIACOMO GRASSELLI;GIANLUCA NAZZARO;LUCA VALENTI;GREGORIO P. MILANI;MICHELE GHIDINI;STEFANO CARUGO;CARLO ALFIERI;PIER MANNUCCIO MANNUCCI;ELISA GHERBESI;PAOLA VIGANÒ;ANDREA GORI","5.01;4.31;3.59;3.23;2.99;2.96;2.85;2.85;2.75;2.69;2.66;2.62;2.61;2.51;2.46;2.37;2.31;2.3;2.28;2.25","LUCA VALENTI;ANGELO VALERIO MARZANO;FRANCESCO BLASI;GIOVANNI TARGHER;SALVATORE PETTA;LUIGI GARGIULO;ALESSANDRA NARCISI;PAOLO DAPAVO;STEFANO CARUGO;ANTONIO COSTANZO;MING‐HUA ZHENG;PIETRO LAMPERTICO;PIERGIORGIO MALAGOLI;ALESSIO AGHEMO;ANNA BALATO;GIANLUCA NAZZARO;LUCIANO IBBA;ALESSANDRA BANDERA;SILVIA FERRUCCI;STEFANO ROMEO","104;88;63;53;49;48;47;47;47;46;44;44;43;41;41;39;39;38;38;38","LUCA VALENTI;ANGELO VALERIO MARZANO;FRANCESCO BLASI;STEFANO CARUGO;PIETRO LAMPERTICO;GIANLUCA NAZZARO;SILVIA FERRUCCI;FLORA PEYVANDI;NICCOLÒ BOLLI;ELISA GHERBESI;ALESSANDRA BANDERA;GIACOMO P. COMI;ANDREA GRAMEGNA;CARLO GIOVANNI CARRERA;GIACOMO GRASSELLI;MARIA DOMENICA CAPPELLINI;CRISTINA SPAZIANI;AMANDA M. LI;AMI J. SHAH;ANTONIS KATTAMIS","100;88;58;47;44;39;38;37;31;30;29;27;26;26;26;26;25;24;24;24","ANGELO VALERIO MARZANO;FLORA PEYVANDI;FRANCESCO BLASI;SILVIA FERRUCCI;LUCA VALENTI;PIETRO LAMPERTICO;DARIO CONSONNI;GIACOMO GRASSELLI;STEFANO CARUGO;EDGARDO SOMIGLIANA;GIUSEPPE CASTELLANO;GREGORIO P. MILANI;LUCA BOERI;ALESSANDRA BANDERA;FLAVIO CAPRIOLI;MICHELE GHIDINI;ANDREA GORI;LORENZO BERETTA;CARLO ALFIERI;CARLO AGOSTONI","56;41;38;32;31;31;30;27;22;22;22;21;20;19;19;19;19;19;19;18","MEDICINE;BIOLOGY;PSYCHOLOGY;COMPUTER SCIENCE;PHYSICS;CHEMISTRY;POLITICAL SCIENCE;ENGINEERING;SOCIOLOGY;MATHEMATICS;ECONOMICS;MATERIALS SCIENCE;PHILOSOPHY;GEOGRAPHY;BUSINESS;ART;ENVIRONMENTAL SCIENCE;HISTORY;GEOLOGY","1473;451;146;136;115;108;73;72;66;65;55;35;31;24;23;10;9;9;7","INTERNAL MEDICINE;SURGERY;PATHOLOGY;GENETICS;INTENSIVE CARE MEDICINE;IMMUNOLOGY;PEDIATRICS;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;BIOCHEMISTRY;CARDIOLOGY;PSYCHIATRY;ONCOLOGY;DERMATOLOGY;RADIOLOGY;FAMILY MEDICINE;VIROLOGY;ENDOCRINOLOGY;LAW;NURSING","1024;274;242;226;212;201;157;154;148;123;123;118;115;108;100;83;79;78;67;66","DISEASE;GENE;CANCER;COHORT;POPULATION;RETROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;PREGNANCY;TRANSPLANTATION;ADVERSE EFFECT;ANTIBODY;LUNG;CLINICAL TRIAL;CONFIDENCE INTERVAL;OBSERVATIONAL STUDY;VIRUS;IMMUNE SYSTEM;COHORT STUDY;ALTERNATIVE MEDICINE;PROSPECTIVE COHORT STUDY","302;148;128;113;109;82;81;78;67;59;53;51;45;45;44;44;41;40;39;39","INFECTIOUS DISEASE (MEDICAL SPECIALTY);BREAST CANCER;2019-20 CORONAVIRUS OUTBREAK;PHENOTYPE;LIVER TRANSPLANTATION;GENE EXPRESSION;FETUS;DEMENTIA;KIDNEY TRANSPLANTATION;MULTICENTER STUDY;COLORECTAL CANCER;PARKINSON'S DISEASE;MUTATION;CLINICAL ENDPOINT;IMMUNOTHERAPY;DUPILUMAB;PLACEBO;MYELOFIBROSIS;GENOTYPE;GESTATIONAL AGE;HAZARD RATIO;INFERTILITY;TOLERABILITY","65;35;30;29;28;25;23;21;21;21;20;20;19;18;18;17;17;16;15;14;14;14;14","CORONAVIRUS DISEASE 2019 (COVID-19);DNA METHYLATION;FRONTOTEMPORAL DEMENTIA;TRANSCRIPTOME;RUXOLITINIB;ANTIRETROVIRAL THERAPY;KIDNEY TRANSPLANT;EXOME SEQUENCING;DEEP BRAIN STIMULATION;MISSENSE MUTATION;STEATOHEPATITIS;VEDOLIZUMAB;CONGENITAL DIAPHRAGMATIC HERNIA;COPY-NUMBER VARIATION;PROBAND;SINGLE-NUCLEOTIDE POLYMORPHISM;ATYPICAL HEMOLYTIC UREMIC SYNDROME;COLD AGGLUTININ DISEASE;COMPLEMENTATION;CROSSOVER STUDY;ENDOVASCULAR ANEURYSM REPAIR;ESTROGEN RECEPTOR;HBSAG;INFLAMMATORY BOWEL DISEASES;IVACAFTOR;MICROVESICLES;NIVOLUMAB;USTEKINUMAB","65;15;12;11;10;9;9;8;7;7;7;7;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5",";HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;RETROSPECTIVE STUDIES;ITALY;TREATMENT OUTCOME;CHILD;ADOLESCENT;YOUNG ADULT;AGED, 80 AND OVER;PROSPECTIVE STUDIES;RISK FACTORS;CHILD, PRESCHOOL;ANIMALS;SURVEYS AND QUESTIONNAIRES;INFANT","928;623;399;368;269;256;205;129;123;84;82;79;73;58;55;55;44;42;42;41","EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;ATOPIC DERMATITIS AND SKIN MICROBIOME;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;MANAGEMENT AND TREATMENT OF HEMOPHILIA;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;ROLE OF COMPLEMENT SYSTEM IN IMMUNE RESPONSE;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;KIDNEY TRANSPLANTATION;SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;CORONAVIRUS DISEASE 2019 RESEARCH;DENTAL IMPLANTOLOGY AND PERI-IMPLANT DISEASES;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;HEPATITIS B INFECTION AND TREATMENT;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;HEPATITIS C INFECTION AND TREATMENT;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;PATHOPHYSIOLOGY AND MANAGEMENT OF PREECLAMPSIA","40;25;25;21;18;17;17;16;13;13;12;12;12;12;12;12;11;11;11;11","TREATMENT;2019-20 CORONAVIRUS OUTBREAK;NEPHROLOGY;LIVER DISEASE;DIAGNOSIS;CLINICAL ENDPOINT;PANDEMIC;DISCONTINUATION;DUPILUMAB;LIVER TRANSPLANTATION;POSITIVE END-EXPIRATORY PRESSURE;PRENATAL DIAGNOSIS;CYSTIC FIBROSIS;ENDOVASCULAR REPAIR;TOLERABILITY;CLINICAL PRACTICE;DEPRESSION (ECONOMICS);INTERQUARTILE RANGE;LIVING DONOR LIVER TRANSPLANTATION;CROSS-SECTIONAL STUDY","61;30;24;23;21;19;19;18;17;17;15;15;14;14;14;13;13;13;13;12","COHORT STUDY;ATOPIC DERMATITIS;RETROSPECTIVE STUDY;OBSERVATIONAL STUDY;LIVER DISEASE;MULTICENTER STUDY;HEPATOCELLULAR CARCINOMA;CYSTIC FIBROSIS;RISK FACTORS;PARKINSONS DISEASE;CHRONIC HEPATITIS;CLINICAL OUTCOMES;LIVER TRANSPLANTATION;BREAST CANCER;STEATOTIC LIVER;CLINICAL PRACTICE;PATIENTS TREATED;SYSTEMIC SCLEROSIS;KIDNEY DISEASE;MAGNETIC RESONANCE;PROSPECTIVE OBSERVATIONAL;PROSPECTIVE STUDY;RANDOMIZED CONTROLLED;RETROSPECTIVE COHORT;SYSTEMATIC REVIEW;DISEASE PATIENTS;ENDOVASCULAR AORTIC;HIDRADENITIS SUPPURATIVA;LEFT VENTRICULAR;NORTHERN ITALY","30;25;23;22;19;18;17;16;16;15;14;14;14;13;13;12;12;12;11;11;11;11;11;11;11;10;10;10;10;10","RISK FACTORS;LIVER DISEASE;ADVERSE EVENTS;CLINICAL PRACTICE;CLINICAL TRIALS;BRIDGEBIO PHARMA;LOGISTIC REGRESSION;MEDIAN AGE;INTENSIVE CARE;RESEARCH INVESTIGATOR;SIGNIFICANT DIFFERENCES;KIDNEY DISEASE;COHORT STUDY;OBSERVATIONAL STUDY;PATIENTS TREATED;ADULT PATIENTS;RETROSPECTIVE STUDY;BLOOD PRESSURE;INCREASED RISK;HR CI;BREAST CANCER;CONFIDENCE INTERVAL;PARKINSONS DISEASE;PRIMARY OUTCOME;SARS-COV- INFECTION;CLINICAL TRIAL;PATIENTS UNDERGOING;STATISTICALLY SIGNIFICANT;CHRONIC KIDNEY;LUNG CANCER","74;63;59;53;43;42;41;40;39;38;37;36;34;34;34;32;32;31;31;28;27;27;26;26;26;25;25;25;24;24",14,0.01,4.225,31.5,10.1,64.65,43.75,14,123,1,1,1,1,1,1,0,0,0,4,4,4,0,0,0,0,0,0,0,0,0,46,14,127,0,0,0,0,0,0,42.25,14,123,0,0,0,0,0,0,2,1,3,7.67,2,17,31.25,6,99,4.25,3,6,0,0,0,0,0,0,1.75,0,3,1.75,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
